



© The Kirby Institute  
for infection and immunity in society

**ISSN 1448-5915**

This publication is available at: <http://www.kirby.unsw.edu.au>

The Kirby Institute  
for infection and immunity in society  
UNSW Sydney  
Sydney NSW 2052  
Australia

Telephone: **02 9385 0900** Facsimile: **02 9385 0920** International prefix: **612** Email: [recpt@kirby.unsw.edu.au](mailto:recpt@kirby.unsw.edu.au)

**Suggested citation:** Memedovic S, Iversen J, Geddes L, and Maher L. Australian Needle Syringe Program Survey National Data Report 2012-2016: Prevalence of HIV, HCV and injecting and sexual behaviour among NSP attendees. Sydney: Kirby Institute, UNSW Sydney; 2017. ISSN: 1448-5915.

**AUSTRALIAN NSP SURVEY**

Prevalence of HIV, HCV and injecting and  
sexual behaviour among NSP attendees

NATIONAL DATA REPORT

2012 - 2016

**Report prepared by**

**Sonja Memedovic, Jenny Iversen, Louise Geddes and Lisa Maher**

**The Kirby Institute**

for infection and immunity in society

UNSW Sydney

Sydney NSW 2052

Australia

May 2017

The Australian Needle and Syringe Program Survey is funded by the Australian Government Department of Health. The Kirby Institute is affiliated with the Faculty of Medicine, UNSW Sydney.

## **ACKNOWLEDGEMENTS**

We would like to acknowledge the many people who assist in the development and conduct of the Australian NSP Survey, particularly the clients, staff and managers at participating NSP services. We also appreciate the dedication and vision of the founding members of the project and the late Dr Margaret MacDonald who was responsible for the development and conduct of the ANSPS until 2003.

Special thanks go to Mr Philip Cunningham, Senior Scientist and Operations Manager and Ms Beth Catlett, DBS Coordinator from the NSW State Reference Laboratory for HIV at St Vincent's Hospital and St Vincent's Centre for Applied Medical Research (AMR). Thanks are also due to Ms Rachel McCleave and Ms Sue Linsen from the Kirby Institute and to Mr Greg Smith and Ashwin Prekesh from Educational Assessment Australia, UNSW Global Pty Limited.

In 2016, the project received support and input from the following members of the Australian NSP Survey National Advisory Group: Ms Tammy Waters and Helene Delany (ACT); Ms Rose Mason (NSW); Mr Shayne Kilford and Katherine Moriarty (NT); Mr Stephen Lymb and Mr Rob Gerrie (SA); Ms Francine Smith (TAS); Ms Cath Williams (VIC); Ms Jude Bevan (WA); Mr Craig Cooper and Ms Angella Duvnjak (Australian Injecting and Illicit Drug Users League); Mr John Ryan (Pennington Institute); and Ms Sonja Memedovic, Dr Jenny Iversen, Professor John Kaldor and Professor Lisa Maher (Kirby Institute). We would particularly like to thank Mr Robert Kemp (QLD) for chairing the National Advisory Group.

Ethical approvals were obtained from Institutional Ethics Committees associated with the investigators and participating NSP sites. The Australian Needle and Syringe Program Survey is funded by the Australian Government Department of Health and Ageing. The Kirby Institute is affiliated with the Faculty of Medicine, UNSW Sydney.

## **ABBREVIATIONS**

ANSPS	Australian Needle and Syringe Program Survey
HCV	Hepatitis C virus
HIV	Human immunodeficiency virus
NSP	Needle syringe program
OST	Opioid substitution therapy
PIEDs	Performance and image-enhancing drugs
RSS	Receptive syringe sharing

## TABLE OF CONTENTS

### Summary

Key Points .....	i
Introduction .....	1
Demographic characteristics.....	1
Injecting behaviour.....	2
Sexual behaviour .....	4
Drug treatment .....	4
HIV antibody prevalence .....	5
HCV antibody prevalence .....	6
HIV and HCV testing .....	8
HCV treatment uptake.....	8

### Tables

1. National .....	9
2. Australian Capital Territory .....	30
3. New South Wales .....	43
4. Northern Territory.....	64
5. Queensland .....	77
6. South Australia .....	98
7. Tasmania .....	119
8. Victoria .....	132
9. Western Australia .....	153

### Appendix

A. Participating NSP services .....	174
B. Methodological notes .....	176
C. List of tables .....	177

## KEY POINTS

- The Australian NSP Survey (ANSPS) functions as a strategic early-warning system designed to monitor blood borne viral infections and associated risk behaviour among people who inject drugs.
- In 2016, 50 Australian Needle and Syringe Programs (NSPs) participated in the ANSPS and 2,210 NSP attendees completed the survey. The response rate was 41%.

### Demographic characteristics:

- Over the period 2012 to 2016, the median age of survey respondents increased from 38 years to 42 years, with a concurrent decrease in the proportion of young injectors (aged <25 years) from 7% in 2012 to 4% in 2016 ( $\chi^2$  trend  $p<0.001$ ).
- The median time since first injection increased from 17 years in 2012 to 21 years in 2016, and the proportion of new initiates (those injecting for less than three years) declined significantly from 7% in 2012 to 5% in 2016 ( $\chi^2$  trend  $p=0.002$ ).
- The proportion of respondents from an Indigenous Australian background increased significantly, from 12% to 18% over the period 2012 to 2016 ( $\chi^2$  trend  $p<0.001$ ).

### Injecting behaviour:

- Daily or more frequent injecting in the month prior to the survey was reported by approximately half of respondents in all survey years 2012 to 2016.
- The proportion of respondents reporting methamphetamine as the last drug injected increased from 26% in 2012 to 43% in 2016 ( $\chi^2$  trend  $p<0.001$ ). Since 2014 methamphetamine has been the most commonly reported drug last injected nationally.
- There was a significant decrease in the proportion of respondents reporting heroin as the last drug injected, from 33% in 2012 to 28% in 2016 ( $\chi^2$  trend  $p=0.020$ ).
- Pharmaceutical opioids were the third most commonly reported class of drugs last injected in all years 2012 to 2016, but prevalence declined from 14% to 8% ( $\chi^2$  trend  $p<0.001$ ) over this period.
- Performance and image enhancing drugs (PIEDs) were reported as the last drug injected by between 4% and 7% of respondents over the period 2012 to 2016.
- Among new initiates to injection (those injecting for less than 3 years) in 2016, one in four reported last injecting PIEDs. Since 2015, methamphetamine has been the most commonly reported last drug injected among new initiates to injection.
- The proportion of respondents reporting reuse of needles and syringes (including reuse of one's own syringes) increased significantly, from 21% in 2012 to 27% in 2016 ( $\chi^2$  trend  $p<0.001$ ). Additionally, there was a significant increase in the proportion of respondents reporting receptive sharing of needles and syringes, from 16% in 2012 to 19% in 2016 ( $\chi^2$  trend  $p=0.018$ ).
- The prevalence of receptive sharing of drug preparation equipment remained stable, ranging from 28% to 32% over the five-year period ( $\chi^2$  trend  $p=0.088$ ).

### **HIV and HCV antibody prevalence:**

- HIV antibody prevalence remained low and stable nationally, ranging from 1.2% to 2.1% over the period 2012 to 2016 ( $\chi^2$  trend  $p=0.943$ ).
- In all years 2012 to 2016, HIV antibody prevalence was higher among homosexual men compared to bisexual or heterosexual men, and compared to women.
- In 2016, HIV antibody prevalence was higher among Aboriginal and Torres Strait Islander respondents compared to non-Indigenous respondents (2.8% vs 1.0% respectively,  $p=0.004$ ). Further, prevalence of HIV infection among Aboriginal and Torres Strait Islander respondents increased from 0.4% in 2012 to 2.8% in 2016 ( $p$ -trend= 0.015).
- Hepatitis C virus (HCV) antibody prevalence was stable over the period 2012 to 2016, ranging from 51% to 57% ( $\chi^2$  trend  $p=0.944$ ).
- Across all survey years 2012 to 2016, prevalence of HCV antibody was higher among older respondents and those with longer injection histories.

### **HCV treatment uptake:**

- The proportion of respondents who reported a lifetime history of HCV antiviral treatment was stable between 2012 and 2015 (range 10-13%,  $\chi^2$  trend  $p=0.251$ ) but increased significantly to 29% in 2016 (five year  $\chi^2$  trend  $p<0.001$ ).
- Similarly, the proportion of respondents who reported recent (last 12 months) HCV treatment was low and stable between 2011 and 2015 (range 1-3%,  $\chi^2$  trend  $p=0.455$ ) but increased significantly to 22% in 2016 (five year  $\chi^2$  trend  $p<0.001$ ).
- An increase in the proportion of respondents who reported recent initiation of HCV treatment was observed in all jurisdictions in 2016.



## INTRODUCTION

The Australian Needle and Syringe Program Survey (ANSPS) provides serial point prevalence estimates of human immunodeficiency virus (HIV) and hepatitis C virus (HCV) antibody prevalence and sexual and injecting risk behaviour among people who inject drugs (PWID) in Australia. Conducted annually over a one-two week period in October, all clients attending participating Needle and Syringe Program (NSP) services are invited to complete a brief, anonymous questionnaire and to provide a capillary blood sample for HIV and HCV antibody testing (see methodological notes [Appendix B] for further details on the ANSPS design and implementation). This report presents national and state/territory findings for the period 2012 to 2016.

In 2016, 50 NSP services participated in the ANSPS. Over the period 2012 to 2016, the number of ANSPS respondents ranged from 2,210 to 2,407 and the annual response rate ranged from 41% to 48% (Table 1.1.1). Of the 2,210 ANSPS respondents in 2016, the majority (87%) were recruited from the 40 NSP services that participated in the ANSPS in all years 2012 to 2016. A list of participating NSP services is provided at Appendix A.

### Demographic Characteristics

Approximately two thirds of survey respondents were male and less than one percent identified as transgender across all survey years 2012 to 2016. In 2016, the majority of respondents identified as heterosexual, while 10% identified as bisexual and 4% as homosexual (Table 1.1.1).

The proportion of respondents from an Indigenous Australian background increased significantly, from 12% to 18% over the period 2012 to 2016 ( $\chi^2$  trend  $p < 0.001$ ). In all survey years, the majority of respondents were born in Australia (ranging between 85% and 87%), with the United Kingdom and Ireland (4%) and New Zealand (3%) the predominant countries of birth outside Australia in 2016. Most respondents also reported that their parents spoke English at home (range 92% to 94% over the period 2012 to 2016).


The median age at survey completion increased from 38 years in 2012 to 42 years in 2016 and there was a concurrent significant decrease in the proportion of young injectors (aged <25 years) from 7% in 2012 to 4% in 2016 ( $\chi^2$  trend  $p < 0.001$ ). The median time since first injection increased from 17 years in 2012 to 21 years in 2016, and concurrently, the proportion of new initiates (those injecting for less than 3 years) declined from 7% in 2012 to 5% in 2016 ( $\chi^2$  trend  $p = 0.002$ ). However, the median age at first drug injection was consistent across the period 2012 to 2016, ranging from 18 to 19 years of age (Table 1.1.1).

The proportion of respondents reporting incarceration in the 12 months prior to survey completion was stable at between 10% to 12% over the five-year period 2012 to 2016 ( $\chi^2$  trend  $p = 0.390$ ). Approximately one in three respondents with a history of recent incarceration reported injecting while in prison (Table 1.1.1).

## Injecting behaviour

Methamphetamine has been the most commonly reported drug last injected nationally since 2014 (Table 1.1.2). Reports of methamphetamine injection increased significantly over the five-year period, from 26% in 2012 to 43% in 2016 ( $\chi^2$  trend  $p < 0.001$ , Figure 1). In 2016, methamphetamine was the most commonly injected drug in the majority of jurisdictions, including New South Wales (36%), Northern Territory (43%), Queensland (39%), South Australia (60%), Tasmania (37%) and Western Australia (60%). Heroin was the second most commonly reported drug last injected nationally in 2016, with a significant decline in the proportion of respondents who reported last injecting heroin observed between 2012 (33%) and 2016 (28%,  $\chi^2$  trend  $p = 0.020$ ). Notwithstanding, heroin remained the most commonly reported drug last injected in the Australian Capital Territory (40%) and Victoria (52%).

**Figure 1. Proportion of respondents (%) reporting last injecting heroin, methamphetamine and all other drugs, 2012–2016**




The third most commonly reported class of drugs last injected nationally was pharmaceutical opioids (including morphine and oxycodone), although prevalence declined from 14% to 8% over the period 2012 to 2016 ( $\chi^2$  trend  $p < 0.001$ , Figure 2). In 2016, pharmaceutical opioids were the second most commonly injected class of drugs last injected in the Northern Territory (34%) and the third most commonly reported class of drugs last injected in Tasmania (20%).

Methadone was reported as the last drug injected by less than ten percent of the ANSPS sample in all years 2012 to 2016 (range 5% to 7%) and prevalence remained stable over this period ( $\chi^2$  trend  $p = 0.067$ ). Buprenorphine and buprenorphine-naloxone injection were reported by a minority of survey respondents. While the prevalence of buprenorphine-naloxone injection remained stable at between 1% and 2% ( $\chi^2$  trend  $p = 0.159$ ) over the period 2012 to 2016, the prevalence of buprenorphine injection declined from 4% to 2% ( $\chi^2$  trend  $p = 0.010$ ).

A minority of survey respondents (1% across all survey years) reported cocaine as the last drug injected. The prevalence of performance and image enhancing drugs (PIEDs) as the last drug injected declined significantly over the period 2012 to 2016 ( $\chi^2$  trend  $p=0.001$ , Figure 2). PIEDS injection in QLD ranged from 6% to 14% over the five-year period, although this variation was not statistically significant ( $p=0.108$ ). Prevalence of PIEDs injection in NSW remained stable at between 10% and 12% ( $\chi^2$  trend  $p=0.587$ ) and was  $\leq 3\%$  in all other jurisdictions. From 2012 to 2014, PIEDs were the most commonly reported last drug injected among new initiates (less than 3 years since first injection) nationally, but since 2015, methamphetamine has been the most commonly reported last drug injected among this group. In 2016, one in four new initiates reported last injecting PIEDs.


**Figure 2. Proportion of respondents (%) reporting last injecting pharmaceutical opioids, methadone and performance and image enhancing drugs, 2012–2016**



Daily or more frequent injection was reported by approximately half of respondents in all of the past five years (Table 1.1.2). Prevalence of at least one public injection (injection in a car, beach, park, street or squat) in the month prior to survey completion increased from 39% in 2012 to 46% in 2016 ( $\chi^2$  trend  $p=0.035$ , Table 1.1.3).

There were significant increases in two of the three key injecting risk behaviours over the five-year period (Figure 3). The proportion of respondents reporting reuse of needles and syringes (including one's own) in the month preceding the survey increased significantly, from 21% in 2012 to 27% in 2016 ( $\chi^2$  trend  $p<0.001$ ). There was also a significant increase in the prevalence of receptive sharing of needles and syringes in the month prior to survey completion, from 16% in 2012 to 19% in 2016 ( $\chi^2$  trend  $p=0.018$ ). Receptive sharing of ancillary equipment was stable over the period 2012 to 2016 (range 28% to 32%,  $\chi^2$  trend  $p=0.088$ ). As in previous years, spoons and water were the most commonly identified receptively shared ancillary items in 2016 (Table 1.1.3).

**Figure 3. Proportion of respondents (%) reporting reuse and receptive sharing of needles and syringes and receptive sharing of ancillary equipment in the last month, 2012–2016**



### Sexual behaviour

Approximately half of respondents reported sex with a regular sex partner in the month prior to survey completion, in all years 2012 to 2016 (range 47% to 48%, Table 1.1.6). Of these, the majority (70% to 77%) reported that they did not use condoms with their regular sex partner. A smaller proportion of respondents (14% to 15%) reported sex with other sex partners in the month preceding survey participation. Condom use was higher among this group, with approximately two thirds reporting use of condoms. The proportion of respondents reporting sex work in the month prior to the survey remained low and stable at 4% to 6% over the last five years ( $\chi^2$  trend  $p=0.474$ ) and use of condoms at last paid sex was relatively high at between 62% and 82% in all years between 2012 and 2016 (Table 1.1.6). Of the respondents who reported sex work in the previous month in 2016 ( $n=121$ ), 54% were women, 41% were men and 4% identified as transgender.

### Drug treatment


Engagement with drug treatment services was high (Table 1.1.4), with nearly three quarters (71%) of 2016 respondents reporting current or previous drug treatment. However, there was a significant decline in the overall proportion of respondents reporting current opioid substitution therapy (OST; methadone, buprenorphine or buprenorphine-naloxone treatment) from 43% in 2012 to 33% in 2016 ( $\chi^2$  trend  $p<0.001$ ). Notwithstanding this overall decline, current OST among respondents who reported last injecting opioids was stable over the period 2012 to 2016 (range 48% to 52%,  $\chi^2$  trend  $p=0.470$ ). In 2016, current methadone maintenance treatment was reported by 24% of respondents, with current buprenorphine treatment reported by 6% of respondents and buprenorphine-naloxone treatment by 7% of respondents.

### HIV antibody prevalence

HIV antibody prevalence remained low and stable nationally over the period 2012 to 2016 (range 1.2% to 2.1%,  $\chi^2$  trend  $p=0.943$ , Table 1.2.1). At the jurisdictional level (Figure 4), there was a significant increase in the overall proportion of HIV antibody positive respondents in Victoria (range 0.2% to 2.2%,  $\chi^2$  trend  $p=0.023$ ), with a significant increase in HIV antibody prevalence observed among Victorian men (Table 8.2.1). Conversely, in South Australia, there was a significant decrease in the overall proportion of HIV antibody positive respondents (range 3.1% to 0.0%,  $\chi^2$  trend  $p=0.001$ ), with a significant decline in HIV antibody prevalence observed among women ( $\chi^2$  trend  $p=0.002$ , Table 6.2.1).

No respondents in Tasmania or the Australian Capital Territory tested positive to HIV antibodies in any of the previous five years, 2012 to 2016.


**Figure 4. HIV antibody prevalence (%) by jurisdiction, 2012–2016**



Nationally, across all survey years, HIV antibody prevalence was consistently higher among homosexual male respondents than among bisexual and heterosexual male respondents or female respondents (Table 1.2.2 and Figure 5). In the last four years (2014 to 2016), HIV prevalence was also higher among men who reported methamphetamine as the last drug injected compared to men who reported last injecting other drugs (Table 1.2.4) and among men who reported sex work in the month preceding the survey compared to men who did not report sex work (Table 1.2.10).

In 2016, respondents from an Aboriginal and/or Torres Strait Islander background were significantly more likely to test HIV antibody positive than non-Indigenous respondents (2.8% vs 1.0% respectively,  $p=0.004$ ). Further, prevalence of HIV infection among Aboriginal and Torres Strait Islander respondents increased from 0.4% in 2012 to 2.8% in 2016 ( $p$ -trend= 0.015). Of the  $n=10$  Indigenous respondents who tested HIV antibody positive in 2016 and who reported their sexual identity ( $n=1$  not reported), one in two ( $n=5$ , 50%) identified as heterosexual.

**Figure 5. HIV antibody prevalence (%) by gender and sexual identity, 2012–2016**




In 2016, the median age of HIV antibody positive respondents was 47 years (range 22-66 years) and respondents first injected a median of 17 years prior to survey participation (range 3-40 years). In 2016, there was no difference in the median age ( $p=0.123$ ) or the median time since first injection ( $p=0.124$ ) among HIV positive and negative respondents.


### HCV antibody prevalence

HCV antibody prevalence remained stable both nationally (range 51% to 57%,  $\chi^2$  trend  $p=0.944$ , Table 1.3.1) and in all jurisdictions over the period 2012 to 2016 (Figure 6). Across all five years of the survey, HCV antibody prevalence was significantly higher among older respondents and those with longer injection histories (Table 1.3.3 and 1.3.5). Figure 7 illustrates the correlation between exposure to HCV and time since first injection among respondents in 2016.

**Figure 6. HCV antibody prevalence (%) by jurisdiction, 2012–2016**




**Figure 7. HCV antibody prevalence (%) by time since first injection, 2016**



In all survey years, prevalence of HCV was also higher among respondents reporting heroin or other opioids as the last drug injected compared to respondents who last injected methamphetamine (Figure 8). HCV antibody prevalence was also consistently higher among respondents who reported imprisonment in the year preceding survey completion compared to those who had not been incarcerated ( $p < 0.001$  in all years 2012 to 2016) and among respondents who reported receptive syringe sharing in the last month compared to respondents who did not report receptive syringe sharing ( $p < 0.05$  in 2012, 2014 and 2015).

**Figure 8. HCV antibody prevalence (%) by drug last injected and gender, 2012–2016**



### HIV and HCV testing


High rates of lifetime HIV diagnostic screening were reported by ANSPS respondents over the period 2012 to 2016, with 82% to 85% of respondents reporting an HIV diagnostic test (Table 1.1.5). In 2016, 51% of respondents reported an HIV diagnostic test in the previous 12 months. Among the 31 respondents who tested HIV antibody positive, the majority (81%) were aware of their HIV positive status, 6% (n=2) reported their status as HIV negative, 6% (n=2) did not know their HIV status and 6% (n=2) did not report their HIV status.

Respondents also reported high rates of lifetime HCV diagnostic screening (range 83% to 88%). In 2016, just over half (54%) of respondents reported having had a HCV test in the previous 12 months.

### HCV treatment uptake

As shown in Figure 9, among respondents who tested HCV antibody positive and after excluding those who self-reported spontaneous HCV clearance, the proportion who reported a lifetime history of HCV antiviral treatment was stable between 2012 and 2015 (range 10-13%,  $\chi^2$  trend p=0.251) but increased significantly to 29% in 2016 (5-year  $\chi^2$  trend p<0.001). Similarly, among respondents who tested HCV antibody positive and after excluding those who reported spontaneous clearance or treatment-induced clearance more than 12 months previously, the proportion who reported recent (last 12 months) HCV treatment was low and stable between 2011 and 2015 (range 1-3%,  $\chi^2$  trend p=0.455) but increased significantly to 22% in 2016 (five year  $\chi^2$  trend p<0.001). An increase in the proportion of respondents who reported recent initiation of HCV treatment was observed in all jurisdictions in 2016.

**Figure 9. Proportion of respondents (%) reporting lifetime and current antiviral treatment among HCV antibody positive respondents, 2012–2016**





## National

Table 1.1.1 Number (percentage) of respondents by demographic characteristics and survey year

National	2012	2013	2014	2015	2016
<b>Number of sites</b>	52	50	50	47	50
<b>N° surveyed</b>	N=2391	N=2407	N=2378	N=2304	N=2210
<b>Response rate (%)</b>	46%	44%	48%	41%	41%
<b>Gender (%)</b>					
Male	1623 (68)	1636 (68)	1635 (69)	1568 (68)	1449 (66)
Female	753 (31)	754 (31)	725 (30)	716 (31)	740 (33)
Transgender	11 (<1)	13 (<1)	16 (<1)	18 (1)	15 (1)
Not reported	4 (<1)	4 (<1)	2 (<1)	2 (<1)	6 (<1)
<b>Sexual identity (%)</b>					
Heterosexual	1949 (82)	1934 (80)	1914 (80)	1900 (82)	1727 (78)
Bisexual	210 (9)	180 (7)	209 (9)	192 (8)	220 (10)
Homosexual	82 (3)	108 (4)	92 (4)	95 (4)	93 (4)
Not reported	150 (6)	185 (8)	163 (7)	117 (5)	170 (8)
<b>Aboriginal and Torres Strait Islander origin (%)</b>					
No	2056 (86)	2003 (83)	2010 (85)	1930 (84)	1738 (79)
Yes	294 (12)	324 (13)	321 (14)	334 (15)	395 (18)
Not reported	41 (2)	80 (3)	47 (2)	40 (2)	77 (3)
<b>Region/country of birth (%)</b>					
Australia	2070 (87)	2070 (86)	2021 (85)	1961 (85)	1904 (86)
Other Oceania	86 (4)	74 (3)	89 (4)	83 (4)	74 (3)
Asia	26 (1)	35 (1)	40 (2)	42 (2)	25 (1)
UK & Ireland	105 (4)	108 (4)	100 (4)	107 (5)	81 (4)
Other	85 (4)	109 (5)	107 (5)	73 (3)	76 (3)
Not reported	19 (<1)	11 (<1)	21 (<1)	38 (2)	50 (2)
<b>Main language spoken at home by parents (%)</b>					
English	2252 (94)	2239 (93)	2195 (92)	2158 (94)	2036 (92)
Non-English	129 (5)	159 (7)	165 (7)	117 (5)	133 (6)
Not reported	10 (<1)	9 (<1)	18 (<1)	29 (1)	41 (2)
<b>Age and time since first injection (years)</b>					
<i>Median age</i>	38	39	39	40	42
<i>Age range</i>	16-71	15-67	14-68	15-70	17-76
<b>Age group (%)</b>					
<25 years	176 (7)	181 (8)	143 (6)	108 (5)	86 (4)
25+ years	2212 (93)	2217 (92)	2226 (94)	2191 (95)	2119 (96)
Not reported	3 (<1)	9 (<1)	9 (<1)	5 (<1)	5 (<1)
<b>Median age first injection</b>					
<i>Median age first injection</i>	18	19	18	19	18
<i>Age range</i>	10-70	10-61	14-68	10-63	10-76
<i>N° not reported</i>	67	91	67	62	83
<b>Median yrs since first injection</b>					
<i>Median yrs since first injection</i>	17	18	19	20	21
<i>Range</i>	<1-53	<1-51	<1-49	<1-52	<1-53
<b>Years since first injection</b>					
<3 years	173 (7)	177 (7)	165 (7)	147 (6)	110 (5)
3+ years	2150 (90)	2139 (89)	2140 (90)	2093 (91)	2016 (91)
Not reported	68 (3)	91 (4)	73 (3)	64 (3)	84 (4)
<b>Imprisonment last year (%)</b>					
No	2037 (85)	1990 (83)	1947 (82)	1958 (85)	1821 (82)
Yes	261 (11)	252 (10)	254 (11)	231 (10)	269 (12)
Not reported	93 (4)	165 (7)	177 (7)	115 (5)	120 (5)
<b>N° in prison</b>					
<i>N° in prison</i>	N=261	N=252	N=254	N=231	N=269
Injected in prison	90 (34)	74 (29)	91 (36)	80 (35)	89 (33)

**Table 1.1.2 Number (percentage) of respondents by last drug injected, frequency of injecting and survey year**

<b>National N° surveyed</b>	<b>2012 N=2391</b>	<b>2013 N=2407</b>	<b>2014 N=2378</b>	<b>2015 N=2304</b>	<b>2016 N=2210</b>
<b>Drug last injected (%)</b>					
Cocaine	21 (1)	31 (1)	29 (1)	20 (1)	17 (1)
Methamphetamine	621 (26)	703 (29)	779 (33)	838 (36)	953 (43)
Heroin	799 (33)	709 (29)	727 (31)	725 (31)	608 (28)
Pharm. opioids	341 (14)	332 (14)	252 (11)	226 (10)	176 (8)
Methadone	159 (7)	163 (7)	139 (6)	139 (6)	121 (5)
Buprenorphine	84 (4)	78 (3)	53 (2)	62 (3)	52 (2)
Buprenorphine/naloxone	46 (2)	46 (2)	42 (2)	26 (1)	38 (2)
PIEDs	162 (7)	157 (7)	156 (7)	148 (6)	86 (4)
More than one	121 (5)	156 (6)	128 (5)	92 (4)	129 (6)
Other	22 (1)	19 (1)	62 (3)	28 (1)	30 (1)
Not reported	15 (1)	13 (1)	11 (<1)	0 (0)	0 (0)
<b>Ever injected opioids</b>					
Yes	-	-	-	-	1757 (80)
No	-	-	-	-	445 (20)
Not reported	-	-	-	-	8 (<1)
<b>Frequency of injection last month (%)</b>					
Not last month	235 (10)	223 (9)	206 (9)	200 (9)	170 (8)
Less than weekly	444 (19)	451 (19)	364 (15)	377 (16)	338 (15)
Weekly not daily	554 (23)	590 (25)	617 (26)	605 (26)	545 (25)
Daily or more	1130 (47)	1070 (44)	1160 (49)	1089 (47)	1110 (50)
Not reported	28 (1)	73 (3)	31 (1)	33 (1)	47 (2)
<b>Present when someone injected for the first time in the last 12 months (%)</b>					
Yes	353 (15)	311 (13)	403 (17)	367 (16)	382 (17)
No	1796 (75)	1730 (72)	1902 (80)	1881 (82)	1771 (80)
Not reported	242 (10)	366 (15)	73 (3)	56 (2)	57 (3)
<b>Overdosed in last 12 months</b>					
Yes	--	279 (12)	367 (15)	328 (14)	403 (18)
No	--	2055 (83)	1935 (81)	1922 (83)	1739 (79)
Not reported	--	73 (3)	76 (3)	54 (2)	68 (3)

**Table 1.1.3 Number (percentage) of respondents by injecting behaviour in the last month and survey year**

<b>National N° injected last month</b>	<b>2012 N=2128</b>	<b>2013 N=2111</b>	<b>2014 N=2141</b>	<b>2015 N=2071</b>	<b>2016 N=1993</b>
<b>Places injected last month (%)</b>					
Any public	836 (39)	828 (39)	781 (36)	774 (37)	915 (46)
All private	1222 (57)	1262 (60)	1346 (63)	1287 (62)	1067 (54)
Not reported	70 (3)	21 (1)	14 (<1)	10 (<1)	11 (1)
<b>Use of new and sterile needles and syringes last month (%)</b>					
All injections	1593 (75)	1586 (75)	1657 (77)	1537 (74)	1424 (71)
Most of the time	366 (17)	420 (20)	381 (18)	426 (21)	442 (22)
Half of the time	36 (2)	34 (2)	33 (2)	55 (3)	49 (2)
Some of the time	21 (1)	31 (1)	20 (1)	23 (1)	33 (2)
Not last month	15 (<1)	9 (<1)	8 (<1)	11 (1)	19 (1)
Not reported	97 (5)	31 (1)	42 (2)	19 (1)	26 (1)
<b>Re-used someone else's used needle &amp; syringe last month (%)</b>					
None	1713 (81)	1770 (84)	1772 (83)	1728 (83)	1597 (80)
Once	148 (7)	105 (5)	129 (6)	104 (5)	114 (6)
Twice	60 (3)	79 (4)	84 (4)	85 (4)	111 (6)
3-5 times	61 (3)	63 (3)	71 (3)	85 (4)	78 (4)
>5 times	67 (3)	67 (3)	48 (2)	58 (3)	73 (4)
Not reported	79 (4)	27 (1)	37 (2)	11 (1)	20 (1)
<b>Number of people needle &amp; syringe was re-used after last month (%)</b>					
None	1713 (81)	1770 (84)	1772 (83)	1728 (83)	1597 (80)
One	158 (7)	139 (7)	136 (6)	142 (7)	152 (8)
Two	23 (1)	31 (1)	27 (1)	36 (2)	37 (2)
Three to five	11 (<1)	13 (1)	12 (<1)	19 (1)	31 (2)
More than five	22 (1)	19 (1)	18 (1)	11 (1)	22 (1)
Don't know	48 (2)	69 (3)	60 (3)	72 (3)	76 (4)
Not reported	153 (7)	70 (3)	116 (5)	63 (3)	78 (4)
<b>Relationship to people needle &amp; syringe was used after last month (%) [more than one could be selected]</b>					
Regular sex partner	113 (5)	131 (6)	132 (6)	117 (6)	155 (8)
Casual sex partner	8 (<1)	19 (1)	10 (<1)	17 (1)	16 (1)
Close friend	96 (5)	88 (4)	62 (3)	94 (5)	98 (5)
Acquaintance	44 (2)	54 (3)	36 (2)	38 (2)	52 (3)
Other	21 (1)	32 (2)	26 (1)	32 (2)	20 (1)
<b>Equipment used after someone else last month (%) [more than one could be selected]</b>					
Spoon	450 (21)	511 (24)	460 (21)	461 (22)	428 (21)
Water	311 (15)	373 (18)	362 (17)	358 (17)	379 (19)
Filter	226 (11)	241 (11)	223 (10)	228 (11)	195 (10)
Drug mix	190 (9)	189 (9)	177 (8)	221 (11)	191 (10)
None	1421 (67)	1436 (68)	1477 (69)	1415 (68)	1354 (68)
<b>Injected by someone after that person injected themselves or others last month (%)</b>					
No	1745 (82)	1754 (83)	1740 (81)	1761 (85)	1638 (82)
Yes	284 (13)	278 (13)	316 (15)	288 (14)	329 (17)
Not reported	99 (5)	79 (4)	85 (4)	22 (1)	26 (1)
<b>Source of needle acquisition</b>					
Needle Syringe Program	1888 (89)	1952 (92)	1916 (89)	1865 (90)	1757 (88)
Chemist/Pharmacy	503 (24)	436 (21)	456 (21)	465 (22)	495 (25)
Personal sources	248 (12)	197 (9)	230 (11)	255 (12)	268 (13)
Dispensing/Vending Machine	255 (12)	240 (11)	279 (13)	280 (14)	324 (16)
Other sources	18 (1)	42 (2)	37 (2)	52 (3)	49 (2)

**Table 1.1.4 Number (percentage) of respondents by treatment for drug use and survey year**

<b>National N° surveyed</b>	<b>2012 N=2391</b>	<b>2013 N=2407</b>	<b>2014 N=2378</b>	<b>2015 N=2304</b>	<b>2016 N=2210</b>
<b>Ever any treatment/therapy for drug use (%)</b>					
No	539 (23)	575 (24)	582 (24)	590 (26)	566 (26)
Yes	1826 (76)	1800 (75)	1750 (74)	1672 (73)	1566 (71)
Not reported	26 (1)	32 (1)	46 (2)	42 (2)	78 (4)
<b>History of methadone maintenance treatment (%)</b>					
Currently	712 (30)	718 (29)	641 (27)	600 (26)	538 (24)
Previously	622 (26)	559 (23)	565 (24)	550 (24)	522 (24)
Never	1041 (44)	1112 (46)	1123 (47)	1105 (48)	1048 (47)
Not reported	16 (1)	18 (1)	49 (2)	49 (2)	102 (5)
<b>History of buprenorphine (Subutex®) treatment (%)</b>					
Currently	241 (10)	193 (8)	197 (8)	177 (8)	143 (6)
Previously	665 (28)	694 (29)	653 (27)	655 (28)	575 (26)
Never	1456 (61)	1475 (61)	1472 (62)	1422 (62)	1408 (64)
Not reported	29 (1)	45 (2)	56 (2)	50 (2)	84 (4)
<b>History of buprenorphine-naloxone (Suboxone®) treatment (%)</b>					
Currently	245 (10)	219 (9)	196 (8)	187 (8)	164 (7)
Previously	469 (20)	529 (22)	526 (22)	533 (23)	482 (22)
Never	1639 (69)	1602 (67)	1597 (67)	1530 (66)	1487 (67)
Not reported	38 (2)	57 (2)	59 (2)	54 (2)	77 (3)

**Table 1.1.5 Number (percentage) of respondents by testing for HIV and HCV, HCV treatment by survey year**

<b>National N° surveyed</b>	<b>2012 N=2391</b>	<b>2013 N=2407</b>	<b>2014 N=2378</b>	<b>2015 N=2304</b>	<b>2016 N=2210</b>
<b>Previous HIV test (%)</b>					
Yes, ever	1997 (83)	2017 (84)	1951 (82)	1950 (85)	1840 (83)
Yes, last year	1157 (48)	1205 (50)	1170 (49)	1151 (50)	1120 (51)
>1 year ago	840 (35)	812 (34)	781 (33)	799 (35)	720 (33)
Never tested	299 (13)	320 (13)	332 (14)	297 (13)	293 (13)
Not reported	95 (4)	70 (3)	95 (4)	57 (2)	77 (3)
<b>Previous HCV test (%)</b>					
Yes, ever	2086 (88)	2013 (83)	2047 (86)	2016 (88)	1825 (83)
Yes, last year	1305 (55)	1235 (51)	1276 (54)	1244 (54)	1203 (54)
>1 year ago	781 (33)	778 (32)	771 (32)	772 (34)	622 (28)
Never tested	181 (8)	196 (8)	214 (9)	187 (8)	185 (8)
Not reported	124 (5)	198 (8)	117 (5)	101 (4)	200 (9)
<b>Lifetime treatment for HCV (%)<sup>#</sup></b>					
<b>N° self-reported HCV diagnosis</b>	<b>N=715</b>	<b>N=746</b>	<b>N=709</b>	<b>N=713</b>	<b>N=643</b>
Antiviral treatment	68 (10)	79 (11)	89 (13)	79 (11)	184 (29)
No antiviral treatment	635 (89)	648 (87)	603 (85)	604 (85)	454 (71)
Not reported	12 (2)	19 (3)	17 (2)	30 (4)	5 (1)
<b>Treatment for HCV in past 12 months (%)<sup>##</sup></b>					
<b>N° self-reported HCV diagnosis</b>	<b>N=692</b>	<b>N=716</b>	<b>N=669</b>	<b>N=685</b>	<b>N=617</b>
Antiviral treatment	14 (2)	21 (3)	7 (1)	14 (2)	137 (22)
No antiviral treatment	666 (96)	676 (94)	645 (96)	641 (94)	475 (77)
Not reported	12 (2)	19 (3)	17 (3)	30 (4)	5 (1)

<sup>#</sup> among people who tested HCV antibody positive and did not report spontaneous clearance

<sup>\*</sup> excludes people who reported treatment induced clearance more than 12 months previously

**Table 1.1.6 Number (percentage) of respondents by sexual behaviour in the month prior to survey and survey year**

<b>National</b>	<b>2012</b>	<b>2013</b>	<b>2014</b>	<b>2015</b>	<b>2016</b>
<b>N° surveyed</b>	N=2391	N=2407	N=2378	N=2304	N=2210
<b>Sex with a regular partner last month (%)</b>					
No	1173 (49)	1176 (49)	1166 (49)	1116 (48)	1089 (49)
Yes	1152 (48)	1151 (48)	1114 (47)	1086 (47)	1039 (47)
Not reported	66 (3)	80 (3)	98 (4)	102 (4)	82 (4)
<b>Condom used with regular partner last month (%)</b>					
<b>N° surveyed</b>	N=1152	N=1151	N=1114	N=1086	N=1039
Never	815 (71)	801 (70)	800 (72)	832 (77)	746 (72)
Sometimes	147 (13)	166 (14)	145 (13)	106 (10)	135 (13)
Every time	127 (11)	113 (10)	110 (10)	113 (10)	105 (10)
Not reported	63 (5)	71 (6)	59 (5)	35 (3)	53 (5)
<b>Sex with other partner(s) last month (%)</b>					
No	1953 (82)	1929 (80)	1895 (80)	1901 (83)	1777 (80)
Yes	336 (14)	364 (15)	357 (15)	319 (14)	331 (15)
Not reported	102 (4)	114 (5)	126 (5)	84 (4)	102 (5)
<b>Condom used with other partner(s) last month (%)</b>					
<b>N° surveyed</b>	N=336	N=364	N=357	N=319	N=331
Never	115 (34)	117 (32)	118 (33)	112 (35)	124 (37)
Sometimes	92 (27)	103 (28)	98 (27)	99 (31)	105 (32)
Every time	109 (32)	128 (35)	101 (28)	95 (30)	95 (29)
Not reported	20 (6)	16 (4)	40 (11)	13 (4)	7 (2)
<b>Sex work last month (%)</b>					
No	2195 (92)	2141 (89)	2050 (86)	2137 (93)	1969 (89)
Yes	119 (5)	98 (4)	133 (6)	96 (4)	121 (5)
Not reported	77 (3)	168 (7)	195 (8)	71 (3)	120 (5)
<b>Condom used at last sex work (%)</b>					
Yes	98 (82)	72 (73)	83 (62)	66 (69)	82 (68)

**Table 1.1.7 Number (percentage) of respondents reporting stigma or discrimination in the last 12 months in 2016**

<b>National<sup>#</sup></b>	<b>Never</b>	<b>Rarely</b>	<b>Sometimes</b>	<b>Often</b>	<b>Always</b>
Use of drugs for injecting	653 (33)	223 (11)	617 (31)	286 (14)	203 (10)
Sexual orientation	1213 (76)	134 (8)	150 (9)	59 (4)	41 (3)
Hepatitis C status	1090 (69)	164 (10)	215 (14)	66 (4)	45 (3)
Hepatitis B status	1200 (90)	53 (4)	49 (4)	18 (1)	13 (1)
HIV status	1178 (91)	36 (3)	46 (4)	12 (1)	16 (1)
Sex work	1082 (85)	47 (4)	76 (6)	42 (3)	29 (2)
Other	442 (75)	18 (3)	54 (9)	48 (8)	30 (5)
Health workers treated me negatively or different to other people	1130 (57)	238 (12)	372 (19)	154 (8)	87 (4)

<sup>#</sup> excludes respondents who indicated 'not applicable' and where data was missing

## HIV antibody prevalence

**Table 1.2.1 HIV antibody prevalence by gender and survey year**

National Survey year	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)
2012	1546	18 (1.2)	718	9 (1.3)	2279	28 (1.2)
2013	1563	41 (2.6)	727	6 (0.8)	2307	48 (2.1)
2014	1558	33 (2.1)	702	3 (0.4)	2273	39 (1.7)
2015	1502	33 (2.2)	696	3 (0.4)	2217	38 (1.7)
2016	1412	24 (1.7)	727	5 (0.7)	2160	31 (1.4)
X <sup>2</sup> p trend		0.544		0.134		0.943

**Table 1.2.2 HIV antibody prevalence by sexual identity, gender and survey year**

National Sexual identity	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)
<b>2012</b>						
Heterosexual	1350	4 (0.3)	506	8 (1.6)	1859	12 (0.7)
Bisexual	69	2 (2.9)	127	0 (0.0)	200	3 (1.5)
Homosexual	42	9 (21.4)	31	0 (0.0)	77	9 (11.7)
p value		<0.001		0.570		<0.001
<b>2013</b>						
Heterosexual	1322	9 (0.7)	519	6 (1.2)	1848	15 (0.8)
Bisexual	59	6 (10.2)	114	0 (0.0)	175	7 (4.0)
Homosexual	73	24 (32.9)	26	0 (0.0)	105	24 (22.9)
p value		<0.001		0.684		<0.001
<b>2014</b>						
Heterosexual	1332	8 (0.6)	497	3 (0.6)	1832	11 (0.6)
Bisexual	58	5 (8.6)	134	0 (0.0)	199	8 (4.0)
Homosexual	64	19 (29.7)	23	0 (0.0)	88	19 (21.6)
p value		<0.001		1.000		<0.001
<b>2015</b>						
Heterosexual	1315	7 (0.5)	514	2 (0.4)	1835	9 (0.5)
Bisexual	69	4 (5.8)	110	1 (0.9)	185	6 (3.2)
Homosexual	53	21 (39.6)	28	0 (0.0)	84	21 (25.0)
p value		<0.001		0.511		<0.001
<b>2016</b>						
Heterosexual	1193	6 (0.5)	492	3 (0.6)	1691	9 (0.5)
Bisexual	61	3 (4.9)	148	1 (0.7)	214	5 (2.3)
Homosexual	58	14 (24.1)	27	0 (0.0)	90	15 (16.7)
p value		<0.001		1.000		<0.001

**Table 1.2.3 HIV antibody prevalence by age group, gender and survey year**

National Age group	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
<b>2012</b>						
<25 years	130	0 (0.0)	38	0 (0.0)	169	0 (0.0)
25-34 years	412	2 (0.5)	241	3 (1.2)	657	5 (0.8)
35-44 years	580	5 (0.9)	266	1 (0.4)	856	7 (0.8)
45+ years	418	11 (2.6)	172	5 (2.9)	595	16 (2.7)
p value		0.022		0.135		0.005
<b>2013</b>						
<25 years	110	2 (1.8)	60	0 (0.0)	170	2 (1.2)
25-34 years	394	6 (1.5)	215	2 (0.9)	616	9 (1.5)
35-44 years	569	15 (2.6)	256	0 (0.0)	828	15 (1.8)
45+ years	483	18 (3.7)	195	4 (2.1)	684	22 (3.2)
p value		0.239		0.097		0.127
<b>2014</b>						
<25 years	98	1 (1.0)	33	0 (0.0)	133	1 (0.8)
25-34 years	363	7 (1.9)	204	0 (0.0)	570	8 (1.4)
35-44 years	596	8 (1.3)	273	2 (0.7)	874	12 (1.4)
45+ years	495	17 (3.4)	190	1 (0.5)	688	18 (2.6)
p value		0.114		0.681		0.224
<b>2015</b>						
<25 years	67	0 (0.0)	32	1 (3.1)	101	1 (1.0)
25-34 years	347	10 (2.9)	187	1 (0.5)	540	13 (2.4)
35-44 years	545	6 (1.1)	248	0 (0.0)	796	6 (0.8)
45+ years	539	17 (3.2)	229	1 (0.4)	776	18 (2.3)
p value		0.055		0.092		0.033
<b>2016</b>						
<25 years	51	1 (2.0)	32	0 (0.0)	86	1 (1.2)
25-34 years	262	7 (2.7)	169	1 (0.6)	433	8 (1.9)
35-44 years	528	3 (0.6)	274	1 (0.4)	808	4 (0.5)
45+ years	568	13 (2.3)	251	3 (1.2)	829	18 (2.2)
p value		0.039		0.64		0.016

**Table 1.2.4 HIV antibody prevalence by last drug injected, gender and survey year**

National Last drug injected	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)
<b>2012</b>						
Heroin	507	2 (0.4)	262	6 (2.3)	773	9 (1.2)
Methamphetamine	355	8 (2.3)	216	2 (0.9)	577	10 (1.7)
Other opioids	416	7 (1.7)	187	1 (0.5)	605	8 (1.3)
PIEDs	146	1 (0.7)	4	0 (0.0)	152	1 (0.7)
Other drugs	111	0 (0.0)	45	0 (0.0)	157	0 (0.0)
p value		0.069		0.423		0.551
<b>2013</b>						
Heroin	449	5 (1.1)	230	4 (1.7)	683	9 (1.3)
Methamphetamine	413	24 (5.8)	249	2 (0.8)	668	26 (3.9)
Other opioids	423	8 (1.9)	177	0 (0.0)	601	8 (1.3)
PIEDs	136	1 (0.7)	3	0 (0.0)	141	1 (0.7)
Other drugs	133	3 (2.3)	65	0 (0.0)	201	4 (2.0)
p value		<0.001		0.340		0.007
<b>2014</b>						
Heroin	460	6 (1.3)	233	1 (0.4)	696	8 (1.2)
Methamphetamine	472	20 (4.2)	265	1 (0.4)	741	21 (2.8)
Other opioids	326	3 (0.9)	145	0 (0.0)	474	3 (0.6)
PIEDs	144	2 (1.4)	5	0 (0.0)	150	2 (1.3)
Other drugs	149	2 (1.3)	52	1 (1.9)	203	5 (2.5)
p value		0.011		0.416		0.024
<b>2015</b>						
Heroin	468	9 (1.9)	230	1 (0.4)	704	11 (1.6)
Methamphetamine	516	21 (4.1)	271	2 (0.7)	798	24 (3.0)
Other opioids	300	2 (0.7)	142	0 (0.0)	444	2 (0.5)
PIEDs	140	1 (0.7)	6	0 (0.0)	146	1 (0.7)
Other drugs	78	0 (0.0)	47	0 (0.0)	125	0 (0.0)
p value		0.008		0.842		0.005
<b>2016</b>						
Heroin	384	5 (1.30)	207	4 (1.9)	595	9 (1.5)
Methamphetamine	582	16 (2.8)	339	1 (0.3)	929	19 (2.1)
Other opioids	254	0 (0.0)	125	0 (0.0)	381	0 (0.0)
PIEDs	80	1 (1.3)	0	0 (0.0)	82	1 (1.2)
Other drugs	112	2 (1.8)	56	0 (0.0)	173	2 (1.2)
p value		0.035		0.146		0.028



**Table 1.2.5 HIV antibody prevalence by years of injection, gender and survey year**

National Years of injection	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)
<b>2012</b>						
<3 years	126	1 (0.8)	35	0 (0.0)	162	1 (0.6)
3 to 10 years	242	3 (1.2)	129	3 (2.3)	373	6 (1.6)
11 + years	1134	14 (1.2)	535	6 (1.1)	1680	21 (1.3)
p value		1.000		0.615		0.701
<b>2013</b>						
<3 years	120	5 (4.2)	38	0 (0.0)	160	5 (3.1)
3 to 10 years	228	10 (4.4)	140	0 (0.0)	369	10 (2.7)
11 + years	1150	25 (2.2)	527	6 (1.1)	1689	32 (1.9)
p value		0.079		0.536		0.323
<b>2014</b>						
<3 years	116	3 (2.6)	41	0 (0.0)	158	3 (1.9)
3 to 10 years	215	10 (4.7)	119	0 (0.0)	335	10 (3.0)
11+ years	1176	19 (1.6)	526	3 (0.6)	1712	24 (1.4)
p value		0.020		1.000		0.097
<b>2015</b>						
<3 years	110	4 (3.6)	32	0 (0.0)	143	4 (2.8)
3 to 10 years	222	10 (4.5)	108	1 (0.9)	337	11 (3.3)
11+ years	1130	18 (1.6)	537	2 (0.4)	1678	22 (1.3)
p value		0.013		0.502		0.020
<b>2016</b>						
<3 years	67	0 (0.0)	39	0 (0.0)	108	0 (0.0)
3 to 10 years	191	10 (5.2)	102	1 (1.0)	296	11 (3.7)
11+ years	1097	12 (1.1)	564	4 (0.7)	1676	18 (1.1)
p value		0.001		0.673		0.003

**Table 1.2.6 HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and survey year**

National Receptively shared syringe last month	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)
<b>2012</b>						
No receptive sharing	1117	12 (1.1)	506	9 (1.8)	1634	22 (1.4)
Receptive sharing	220	0 (0.0)	100	0 (0.0)	320	0 (0.0)
p value		0.234		0.368		0.037
<b>2013</b>						
No receptive sharing	1155	27 (2.3)	534	6 (1.1)	1701	33 (1.9)
Receptive sharing	207	4 (1.9)	98	0 (0.0)	306	5 (1.6)
p value		1.000		0.597		1.000
<b>2014</b>						
No receptive sharing	1163	22 (1.9)	520	2 (0.4)	1693	26 (1.5)
Receptive sharing	213	4 (1.9)	102	1 (1.0)	316	6 (1.9)
p value		1.000		0.416		0.636
<b>2015</b>						
No receptive sharing	1117	29 (2.6)	535	3 (0.6)	1665	34 (2.0)
Receptive sharing	217	3 (1.4)	96	0 (0.0)	315	3 (1.0)
p value		0.464		1.000		0.257
<b>2016</b>						
No receptive sharing	1018	18 (1.8)	527	4 (0.8)	1559	23 (1.5)
Receptive sharing	243	4 (1.7)	124	0 (0.0)	370	4 (1.1)
p value		1.000		1.000		0.805

**Table 1.2.7 HIV antibody prevalence by frequency of drug injection last month, gender and survey year**

National Frequency of injection	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)
<b>2012</b>						
Less than daily	632	8 (1.3)	312	6 (1.9)	953	15 (1.6)
Daily or more	748	6 (0.8)	324	3 (0.9)	1076	9 (0.8)
Not last month	146	4 (2.7)	78	0 (0.0)	225	4 (1.8)
p value		0.111		0.483		0.209
<b>2013</b>						
Less than daily	662	20 (3.0)	334	5 (1.5)	1001	25 (2.5)
Daily or more	713	13 (1.8)	310	1 (0.3)	1031	15 (1.5)
Not last month	146	6 (4.1)	61	0 (0.0)	208	6 (2.9)
p value		0.172		0.339		0.171
<b>2014</b>						
Less than daily	641	11 (1.7)	301	0 (0.0)	946	11 (1.2)
Daily or more	753	16 (2.1)	336	3 (0.9)	1096	22 (2.0)
Not last month	144	6 (4.2)	55	0 (0.0)	201	6 (3.0)
p value		0.186		0.416		0.127
<b>2015</b>						
Less than daily	652	18 (2.8)	276	2 (0.7)	937	21 (2.2)
Daily or more	690	14 (2.0)	357	1 (0.3)	1053	16 (1.5)
Not last month	136	1 (0.7)	54	0 (0.0)	194	1 (0.5)
p value		0.339		0.674		0.215
<b>2016</b>						
Less than daily	559	12 (2.2)	300	1 (0.3)	868	14 (1.6)
Daily or more	715	10 (1.4)	358	3 (0.8)	1081	13 (1.2)
Not last month	110	1 (0.9)	54	1 (1.9)	166	2 (1.2)
p value		0.581		0.347		0.712

**Table 1.2.8 HIV antibody prevalence by imprisonment last year, gender and survey year**

National Imprisonment last year	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)
<b>2012</b>						
No imprisonment	1289	17 (1.3)	639	9 (1.4)	1942	27 (1.4)
Imprisonment	199	1 (0.5)	47	0 (0.0)	247	1 (0.4)
p value		0.496		1.000		0.360
<b>2013</b>						
No imprisonment	1266	36 (2.8)	634	6 (1.0)	1912	43 (2.3)
Imprisonment	189	4 (2.1)	50	0 (0.0)	241	4 (1.7)
p value		0.811		1.000		0.814
<b>2014</b>						
No imprisonment	1260	26 (2.1)	609	3 (0.5)	1874	29 (1.6)
Imprisonment	180	0 (0.0)	51	0 (0.0)	236	3 (1.3)
p value		0.065		1.000		1.000
<b>2015</b>						
No imprisonment	1249	29 (2.3)	625	2 (0.3)	1890	33 (1.8)
Imprisonment	168	1 (0.6)	48	0 (0.0)	219	1 (0.5)
p value		0.247		1.000		0.250
<b>2016</b>						
No imprisonment	1135	16 (1.4)	632	1 (0.2)	1781	18 (1.0)
Imprisonment	200	6 (3.0)	59	2 (3.4)	261	8 (3.1)
p value		0.125		0.020		0.013

**Table 1.2.9 HIV antibody prevalence by condom use at last sex with regular partner, gender and survey year**

National Condom use at last sex	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)
<b>2012</b>						
No condom use	475	2 (0.4)	287	2 (0.7)	767	4 (0.5)
Condom use	173	7 (4.1)	90	2 (2.2)	263	9 (3.4)
p value		0.002		0.242		0.001
<b>2013</b>						
No condom use	448	6 (1.3)	319	1 (0.3)	770	7 (0.9)
Condom use	187	8 (4.3)	76	2 (2.6)	268	11 (4.1)
p value		0.022		0.096		0.001
<b>2014</b>						
No condom use	468	7 (1.5)	302	1 (0.3)	771	8 (1.0)
Condom use	177	5 (2.8)	66	0 (0.0)	246	7 (2.9)
p value		0.265		1.000		0.041
<b>2015</b>						
No condom use	495	9 (1.8)	303	0 (0.0)	802	11 (1.4)
Condom use	139	2 (1.4)	66	1 (1.5)	208	3 (1.4)
p value		1.000		0.179		1.000
<b>2016</b>						
No condom use	429	10 (2.3)	289	1 (0.4)	724	11 (1.5)
Condom use	151	2 (1.3)	83	1 (1.2)	237	4 (1.7)
p value		0.740		0.397		0.771

**Table 1.2.10 HIV antibody prevalence by sex work last month, gender and survey year**

National Sex work last month	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)
<b>2012</b>						
No sex work	1451	17 (1.2)	629	8 (1.3)	2090	25 (1.2)
Sex work	37	1 (2.7)	72	1 (1.4)	114	3 (2.6)
p value		0.366		1.000		0.174
<b>2013</b>						
No sex work	1415	35 (2.5)	624	6 (1.0)	2052	41 (2.0)
Sex work	36	4 (11.1)	56	0 (0.0)	94	5 (5.3)
p value		0.014		1.000		0.048
<b>2014</b>						
No sex work	1364	21 (1.5)	599	3 (0.5)	1969	25 (1.3)
Sex work	58	5 (8.6)	60	0 (0.0)	124	7 (5.7)
p value		<0.001		1.000		<0.001
<b>2015</b>						
No sex work	1415	25 (1.8)	631	3 (0.5)	2059	29 (1.4)
Sex work	34	6 (17.7)	54	0 (0.0)	94	7 (7.5)
p value		<0.001		1.000		<0.001
<b>2016</b>						
No sex work	1286	18 (1.4)	621	3 (0.5)	1921	23 (1.2)
Sex work	50	3 (6.0)	65	1 (1.5)	121	4 (3.3)
p value		0.041		0.329		0.072

**Table 1.2.11 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year**

<b>National</b>	<b>Male</b>		<b>Female</b>		<b>Total</b>	
<b>Aboriginal and Torres Strait Islander origin</b>	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
<b>2012</b>						
Non Indigenous	1349	18 (1.3)	598	8 (1.3)	1959	26 (1.3)
Indigenous	172	0 (0.0)	106	0 (0.0)	281	1 (0.4)
p value		0.251		0.614		0.242
<b>2013</b>						
Non Indigenous	1322	34 (2.6)	587	6 (1.0)	1920	41 (2.1)
Indigenous	184	4 (2.2)	124	0 (0.0)	312	4 (1.3)
p value		1.000		0.597		0.391
<b>2014</b>						
Non Indigenous	1352	26 (1.9)	558	2 (0.4)	1922	30 (1.6)
Indigenous	174	4 (2.3)	132	1 (0.8)	307	6 (2.0)
p value		0.769		0.472		0.612
<b>2015</b>						
Non Indigenous	1282	28 (2.2)	565	1 (0.2)	1864	31 (1.7)
Indigenous	197	5 (2.5)	122	2 (1.6)	319	7 (2.2)
p value		0.754		0.083		0.503
<b>2016</b>						
Non Indigenous	1127	14 (1.2)	555	2 (0.4)	1696	17 (1.0)
Indigenous	233	9 (3.9)	152	2 (1.3)	391	11 (2.8)
p value		0.010		0.204		0.012

**Table 1.2.12 HIV antibody prevalence by main language spoken at home by parents, gender and survey year**

<b>National</b>	<b>Male</b>		<b>Female</b>		<b>Total</b>	
<b>Main language spoken at home by parents</b>	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
<b>2012</b>						
English speaking	1446	15 (1.0)	685	9 (1.3)	2143	25 (1.2)
Non-English speaking	96	3 (3.1)	27	0 (0.0)	126	3 (2.4)
p value		0.097		1.000		0.201
<b>2013</b>						
English speaking	1441	37 (2.6)	689	6 (0.9)	2145	44 (2.1)
Non-English speaking	114	4 (3.5)	38	0 (0.0)	153	4 (2.6)
p value		0.537		1.000		0.557
<b>2014</b>						
English speaking	1426	29 (2.0)	659	2 (0.3)	2096	34 (1.6)
Non-English speaking	120	2 (1.7)	38	1 (2.6)	160	3 (1.9)
p value		1.000		0.155		0.744
<b>2015</b>						
English speaking	1390	31 (2.2)	666	3 (0.5)	2075	36 (1.7)
Non-English speaking	92	2 (2.2)	25	0 (0.0)	117	2 (1.7)
p value		1.000		1.000		1.000
<b>2016</b>						
English speaking	1283	22 (1.7)	688	4 (0.6)	1990	28 (1.4)
Non-English speaking	102	1 (1.0)	26	0 (0.0)	130	1 (0.8)
p value		1.000		1.000		1.000

**Table 1.2.13 HIV antibody prevalence by region/country of birth, gender and survey year**

National Region/country of birth	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
<b>2012</b>						
Australia	1328	12 (0.9)	630	9 (1.4)	1972	22 (1.1)
Other Oceania	49	2 (4.1)	32	0 (0.0)	81	2 (2.5)
Asia	22	0 (0.0)	3	0 (0.0)	26	0 (0.0)
UK & Ireland	73	1 (1.4)	26	0 (0.0)	99	1 (1.0)
Other	58	3 (5.2)	24	0 (0.0)	82	3 (3.7)
p value		0.022		1.000		0.179
<b>2013</b>						
Australia	1329	32 (2.4)	642	6 (0.9)	1983	38 (1.9)
Other Oceania	50	2 (4.0)	20	0 (0.0)	71	3 (4.2)
Asia	30	3 (10.0)	5	0 (0.0)	35	3 (8.6)
UK & Ireland	70	1 (1.4)	31	0 (0.0)	102	1 (1.0)
Other	76	3 (4.0)	27	0 (0.0)	105	3 (2.9)
p value		0.088		1.000		0.048
<b>2014</b>						
Australia	1304	26 (2.0)	620	2 (0.3)	1934	29 (1.5)
Other Oceania	63	1 (1.6)	20	0 (0.0)	85	3 (3.5)
Asia	35	1 (2.9)	4	1 (25)	39	2 (5.1)
UK & Ireland	70	0 (0.0)	28	0 (0.0)	98	0 (0.0)
Other	72	3 (4.2)	26	0 (0.0)	99	3 (3.0)
p value		0.372		0.048		0.056
<b>2015</b>						
Australia	1266	29 (2.3)	606	3 (0.5)	1888	33 (1.8)
Other Oceania	61	1 (1.6)	18	0 (0.0)	80	2 (2.5)
Asia	32	1 (3.1)	9	0 (0.0)	42	1 (2.4)
UK & Ireland	63	1 (1.6)	40	0 (0.0)	104	1 (1.0)
Other	51	0 (0.0)	18	0 (0.0)	69	0 (0.0)
p value		0.878		1.000		0.699
<b>2016</b>						
Australia	1216	22 (1.8)	632	4 (0.6)	1864	27 (1.5)
Other Oceania	46	0 (0.0)	24	0 (0.0)	72	1 (1.4)
Asia	21	0 (0.0)	2	0 (0.0)	24	0 (0.0)
UK & Ireland	47	0 (0.0)	30	0 (0.0)	78	0 (0.0)
Other	50	1 (2.0)	23	0 (0.0)	74	1 (1.4)
p value		0.947		1.000		0.890

## HCV antibody prevalence

**Table 1.3.1 HCV antibody prevalence by gender and survey year**

National Survey year	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2012	1524	794 (52)	713	384 (54)	2252	1184 (53)
2013	1554	831 (53)	726	396 (55)	2296	1235 (54)
2014	1506	802 (53)	684	380 (56)	2203	1188 (54)
2015	1382	790 (57)	654	375 (57)	2054	1173 (57)
2016	1326	695 (52)	672	315 (47)	2016	1019 (51)
X <sup>2</sup> p trend		0.544		0.308		0.944

**Table 1.3.2 HCV antibody prevalence by sexual identity, gender and survey year**

National Sexual identity	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2012</b>						
Heterosexual	1329	703 (53)	501	270 (54)	1833	974 (53)
Bisexual	70	33 (47)	127	71 (56)	201	105 (52)
Homosexual	41	12 (52)	31	14 (45)	76	27 (36)
p value		0.008		0.560		0.011
<b>2013</b>						
Heterosexual	1316	717 (54)	518	283 (55)	1841	1005 (55)
Bisexual	58	29 (50)	114	61 (54)	173	90 (52)
Homosexual	72	19 (26)	26	12 (46)	104	33 (32)
p value		<0.001		0.692		<0.001
<b>2014</b>						
Heterosexual	1286	692 (54)	481	266 (55)	1770	959 (54)
Bisexual	57	28 (49)	133	72 (54)	197	104 (53)
Homosexual	64	22 (34)	23	12 (52)	88	34 (39)
p value		0.008		0.936		0.017
<b>2015</b>						
Heterosexual	1214	698 (58)	481	273 (57)	1701	974 (57)
Bisexual	58	34 (59)	103	63 (61)	167	98 (59)
Homosexual	50	19 (38)	27	15 (56)	80	36 (45)
p value		0.023		0.699		0.085
<b>2016</b>						
Heterosexual	1115	597 (54)	451	207 (46)	1570	806 (51)
Bisexual	58	24 (41)	145	76 (52)	208	103 (50)
Homosexual	57	22 (39)	23	6 (26)	84	30 (36)
p value		0.021		0.051		0.020

**Table 1.3.3 HCV antibody prevalence by age group, gender and survey year**

National Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2012</b>						
<25 years	129	12 (9)	38	12 (32)	168	24 (14)
25-34 years	408	179 (44)	242	132 (55)	654	314 (48)
35-44 years	575	336 (58)	262	140 (53)	842	478 (57)
45+ years	411	266 (65)	170	99 (58)	586	366 (62)
p value		<0.001		0.030		<0.001
<b>2013</b>						
<25 years	109	11 (10)	60	15 (25)	169	26 (15)
25-34 years	392	155 (40)	215	105 (49)	613	263 (43)
35-44 years	565	346 (61)	255	148 (58)	823	494 (60)
45+ years	481	316 (66)	195	127 (65)	682	448 (66)
p value		<0.001		<0.001		<0.001
<b>2014</b>						
<25 years	98	12 (12)	33	8 (24)	133	20 (15)
25-34 years	355	136 (38)	198	109 (55)	556	247 (44)
35-44 years	572	336 (59)	266	144 (54)	843	482 (57)
45+ years	475	315 (66)	185	117 (63)	663	434 (65)
p value		<0.001		<0.001		<0.001
<b>2015</b>						
<25 years	60	11 (18)	29	5 (17)	91	16 (18)
25-34 years	325	127 (39)	176	102 (58)	507	232 (46)
35-44 years	507	302 (60)	232	120 (52)	742	423 (57)
45+ years	486	347 (71)	217	148 (68)	710	499 (70)
p value		<0.001		<0.001		<0.001
<b>2016</b>						
<25 years	50	10 (20)	29	12 (41)	82	24 (29)
25-34 years	248	92 (37)	159	67 (42)	408	160 (39)
35-44 years	502	286 (57)	254	123 (48)	761	410 (54)
45+ years	523	306 (59)	229	113 (49)	761	424 (56)
p value		<0.001		0.459		<0.001

**Table 1.3.4 HCV antibody prevalence by years since first injection, gender and survey year**

National Years of injection	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2012</b>						
<3 years	125	12 (10)	35	10 (29)	161	23 (14)
3 to 10 years	238	79 (33)	126	50 (40)	366	129 (35)
11+ years	1118	681 (61)	533	313 (59)	1662	999 (60)
p value		<0.001		<0.001		<0.001
<b>2013</b>						
<3 years	120	5 (4)	38	9 (24)	160	15 (9)
3 to 10 years	224	58 (26)	140	62 (44)	365	120 (33)
11+ years	1145	723 (63)	526	317 (60)	1682	1046 (62)
p value		<0.001		<0.001		<0.001
<b>2014</b>						
<3 years	116	7 (6)	41	5 (12)	158	12 (8)
3 to 10 years	212	67 (32)	119	54 (45)	332	121 (37)
11+ years	1126	704 (63)	508	311 (61)	1644	1021 (62)
p value		<0.001		<0.001		<0.001
<b>2015</b>						
<3 years	101	14 (14)	27	6 (22)	128	20 (16)
3 to 10 years	206	67 (33)	101	40 (40)	314	108 (34)
11+ years	1040	693 (67)	508	321 (63)	1559	1021 (65)
p value		<0.001		<0.001		<0.001
<b>2016</b>						
<3 years	67	5 (7)	38	8 (21)	107	14 (13)
3 to 10 years	184	55 (30)	93	34 (37)	280	91 (33)
11+ years	1022	601 (59)	522	265 (51)	1556	872 (56)
p value		<0.001		<0.001		<0.001

**Table 1.3.5 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year**

National Receptively shared syringe last month	<3 years		3+ years		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2012</b>						
No receptive sharing	107	19 (18)	1480	808 (55)	1620	843 (52)
Receptive sharing	10	2 (20)	292	192 (66)	315	205 (65)
p value		1.000		<0.001		<0.001
<b>2013</b>						
No receptive sharing	111	8 (7)	1538	869 (57)	1694	910 (54)
Receptive sharing	14	3 (21)	270	162 (60)	303	177 (58)
p value		0.108		0.284		0.131
<b>2014</b>						
No receptive sharing	113	10 (9)	1496	840 (56)	1647	869 (53)
Receptive sharing	9	1 (11)	282	195 (69)	302	205 (68)
p value		0.586		<0.001		<0.001
<b>2015</b>						
No receptive sharing	92	13 (14)	1428	862 (60)	1545	888 (57)
Receptive sharing	13	4 (31)	275	180 (65)	294	190 (65)
p value		0.218		0.113		0.023
<b>2016</b>						
No receptive sharing	75	10 (13)	1341	699 (52)	1460	736 (50)
Receptive sharing	18	2 (11)	318	177 (56)	347	187 (54)
p value		1.000		0.256		0.244



**Table 1.3.6 HCV antibody prevalence by last drug injected, years since first injection and survey year**

National Last drug injected	<3 years		3+ years		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2012</b>						
Heroin	24	5 (21)	727	459 (63)	768	478 (62)
Methamphetamine	27	9 (33)	531	234 (44)	568	249 (44)
Other opioids	14	6 (43)	568	344 (61)	597	358 (60)
PIEDs	87	2 (2)	57	5 (9)	151	7 (5)
Other drugs	8	1 (13)	138	82 (59)	153	87 (57)
p value		<0.001		<0.001		<0.001
<b>2013</b>						
Heroin	13	4 (31)	651	438 (67)	681	453 (67)
Methamphetamine	43	7 (16)	596	281 (47)	662	305 (46)
Other opioids	15	2 (13)	565	338 (60)	599	354 (59)
PIEDs	75	1 (1)	63	1 (1)	141	2 (1)
Other drugs	11	1 (9)	169	105 (62)	200	116 (58)
p value		0.004		<0.001		<0.001
<b>2014</b>						
Heroin	17	4 (24)	639	429 (67)	674	444 (66)
Methamphetamine	46	4 (9)	568	336 (51)	717	347 (48)
Other opioids	11	3 (27)	437	272 (62)	456	279 (61)
PIEDs	68	0 (0)	72	1 (1)	149	2 (1)
Other drugs	15	1 (7)	168	102 (61)	198	113 (57)
p value		0.001		<0.001		<0.001
<b>2015</b>						
Heroin	10	2 (20)	646	475 (74)	663	483 (73)
Methamphetamine	51	10 (20)	665	321 (48)	729	340 (47)
Other opioids	9	3 (33)	388	263 (68)	402	271 (67)
PIEDs	49	1 (2)	69	2 (3)	127	3 (2)
Other drugs	7	3 (43)	90	59 (66)	104	64 (62)
p value		0.007		<0.001		<0.001
<b>2016</b>						
Heroin	7	2 (29)	518	346 (67)	539	354 (66)
Methamphetamine	59	8 (14)	783	336 (43)	870	362 (42)
Other opioids	5	3 (60)	326	192 (59)	340	202 (59)
PIEDs	26	0 (0)	46	0 (0)	75	0 (0)
Other drugs	7	1 (14)	130	68 (52)	152	78 (51)
p value		0.005		<0.001		<0.001

**Table 1.3.7 HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year**

National Frequency of injection last month	<3 years		3+ years		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2012</b>						
Less than daily	67	12 (18)	856	478 (56)	939	501 (53)
Daily or more	52	9 (17)	985	557 (57)	1069	584 (55)
Not last month	40	2 (5)	168	83 (49)	219	88 (40)
p value		0.130		0.224		<0.001
<b>2013</b>						
Less than daily	89	5 (6)	872	489 (56)	996	515 (52)
Daily or more	38	7 (18)	955	554 (58)	1025	587 (57)
Not last month	30	3 (10)	165	84 (51)	208	90 (43)
p value		0.080		0.218		<0.001
<b>2014</b>						
Less than daily	63	3 (5)	840	464 (55)	926	480 (52)
Daily or more	61	8 (13)	966	589 (61)	1055	612 (58)
Not last month	33	1 (3)	147	75 (51)	194	79 (41)
p value		0.165		0.011		<0.001
<b>2015</b>						
Less than daily	65	7 (11)	792	467 (59)	875	483 (55)
Daily or more	41	10 (24)	919	578 (63)	973	598 (61)
Not last month	20	2 (10)	147	75 (51)	177	80 (45)
p value		0.181		0.015		<0.001
<b>2016</b>						
Less than daily	56	7 (13)	743	391 (53)	815	407 (50)
Daily or more	37	5 (14)	933	498 (53)	1010	529 (52)
Not last month	11	2 (18)	127	53 (42)	151	60 (40)
p value		0.840		0.046		0.014

**Table 1.3.8 HCV antibody prevalence by imprisonment last year, years since first injection and survey year**

National Imprisonment last year	<3 years		3+ years		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2012</b>						
No imprisonment	152	23 (15)	1719	913 (53)	1921	962 (50)
Imprisonment	6	0 (0)	228	156 (68)	243	161 (66)
p value		0.594		<0.001		<0.001
<b>2013</b>						
No imprisonment	146	14 (10)	1691	913 (54)	1905	965 (51)
Imprisonment	8	0 (0)	224	166 (74)	238	171 (72)
p value		1.000		<0.001		<0.001
<b>2014</b>						
No imprisonment	143	8 (6)	1618	908 (56)	1814	942 (52)
Imprisonment	7	2 (29)	215	144 (67)	228	149 (65)
p value		0.070		0.003		<0.001
<b>2015</b>						
No imprisonment	113	17 (15)	1590	914 (54)	1750	950 (54)
Imprisonment	7	3 (43)	188	152 (76)	200	152 (76)
p value		0.090		<0.001		<0.001
<b>2016</b>						
No imprisonment	87	9 (10)	1519	760 (50)	1663	801 (48)
Imprisonment	11	2 (18)	222	151 (68)	245	160 (65)
p value		0.607		<0.001		<0.001

**Table 1.3.9 HCV antibody prevalence by sex work last month, years since first injection and survey year**

National Sex work last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2012</b>						
No sex work	150	21 (14)	1857	1024 (55)	2061	1076 (52)
Sex work	6	1 (17)	103	63 (61)	115	65 (57)
p value		1.000		0.231		0.367
<b>2013</b>						
No sex work	142	10 (7)	1833	1030 (56)	2045	1083 (53)
Sex work	8	3 (38)	79	46 (58)	92	53 (58)
p value		0.022		0.721		0.382
<b>2014</b>						
No sex work	139	8 (6)	1712	982 (57)	1903	1016 (53)
Sex work	8	2 (25)	110	72 (65)	123	76 (62)
p value		0.094		0.096		0.070
<b>2015</b>						
No sex work	116	19 (16)	1741	1042 (60)	1905	1080 (57)
Sex work	6	1 (17)	78	56 (72)	87	60 (69)
p value		1.000		0.035		0.024
<b>2016</b>						
No sex work	95	12 (13)	1638	846 (52)	1792	893 (50)
Sex work	3	1 (33)	109	69 (63)	115	71 (62)
p value		0.351		0.018		0.013

**Table 1.3.10 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year**

National Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2012</b>						
Non Indigenous	1330	679 (51)	594	321 (54)	1936	1005 (52)
Indigenous	169	101 (60)	105	54 (51)	277	156 (56)
p value		0.034		0.671		0.177
<b>2013</b>						
Non Indigenous	1314	689 (52)	586	305 (52)	1910	998 (52)
Indigenous	184	111 (60)	124	80 (65)	312	194 (62)
p value		0.044		0.011		0.001
<b>2014</b>						
Non Indigenous	1307	675 (52)	545	293 (54)	1864	974 (52)
Indigenous	169	112 (66)	127	79 (62)	297	191 (64)
p value		<0.001		0.085		<0.001
<b>2015</b>						
Non Indigenous	1190	654 (55)	529	298 (56)	1735	958 (55)
Indigenous	173	129 (75)	116	73 (63)	289	202 (70)
p value		<0.001		0.193		<0.001
<b>2016</b>						
Non Indigenous	1056	544 (52)	513	236 (46)	1580	786 (50)
Indigenous	218	122 (56)	141	68 (48)	365	193 (53)
p value		0.231		0.639		0.281

**Table 1.3.11 HCV antibody prevalence by main language spoken at home by parents, gender and survey year**

National Main language spoken at home by parents	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2012</b>						
English speaking	1425	738 (52)	680	365 (54)	2177	1108 (52)
Non-English speaking	95	55 (58)	27	14 (52)	125	70 (56)
p value		0.249		0.852		0.461
<b>2013</b>						
English speaking	1432	761 (53)	688	373 (54)	2134	1142 (54)
Non-English speaking	114	66 (58)	38	23 (61)	153	89 (58)
p value		0.328		0.447		0.265
<b>2014</b>						
English speaking	1381	732 (53)	641	355 (55)	2033	1092 (54)
Non-English speaking	114	65 (57)	38	21 (55)	154	87 (56)
p value		0.409		0.989		0.505
<b>2015</b>						
English speaking	1275	723 (57)	625	356 (57)	1918	1087 (57)
Non-English speaking	89	56 (63)	24	16 (67)	113	72 (64)
p value		0.252		0.345		0.142
<b>2016</b>						
English speaking	1201	626 (52)	638	294 (46)	1855	928 (50)
Non-English speaking	99	54 (55)	22	14 (64)	123	69 (56)
p value		0.643		0.105		0.192

**Table 1.3.12 HCV antibody prevalence by region/country of birth, gender and survey year**

National Region/Country of birth	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2012</b>						
Australia	1307	672 (51)	627	330 (53)	1948	1008 (52)
Other Oceania	48	21 (44)	31	20 (65)	79	41 (52)
Asia	22	19 (86)	2	2 (100)	25	21 (84)
UK & Ireland	72	41 (57)	26	17 (65)	98	58 (59)
Other	59	33 (56)	24	13 (54)	83	46 (55)
p value		0.011		0.332		0.011
<b>2013</b>						
Australia	1322	708 (54)	641	351 (55)	1975	1067 (54)
Other Oceania	50	24 (48)	20	12 (60)	70	36 (51)
Asia	29	21 (72)	5	4 (80)	34	25 (74)
UK & Ireland	70	37 (53)	31	16 (52)	102	53 (52)
Other	75	37 (49)	27	11 (41)	104	48 (46)
p value		0.257		0.466		0.088
<b>2014</b>						
Australia	1257	687 (55)	602	327 (54)	1869	1018 (54)
Other Oceania	63	26 (41)	19	10 (53)	84	37 (44)
Asia	35	22 (63)	4	3 (75)	39	25 (64)
UK & Ireland	68	35 (51)	29	21 (72)	97	56 (58)
Other	70	28 (40)	26	16 (62)	97	45 (46)
p value		0.027		0.318		0.095
<b>2015</b>						
Australia	1167	674 (58)	571	339 (59)	1753	1020 (58)
Other Oceania	54	26 (48)	15	6 (40)	70	33 (47)
Asia	32	16 (50)	8	3 (38)	41	19 (46)
UK & Ireland	55	31 (56)	37	17 (46)	93	48 (52)
Other	49	28 (57)	18	8 (44)	67	36 (54)
p value		0.619		0.117		0.132
<b>2016</b>						
Australia	1141	596 (52)	588	271 (46)	1743	874 (50)
Other Oceania	45	27 (60)	23	12 (52)	69	40 (58)
Asia	19	11 (58)	2	0 (0)	22	11 (50)
UK & Ireland	44	22 (50)	25	12 (48)	70	35 (50)
Other	49	24 (49)	19	12 (63)	69	36 (52)
p value		0.806		0.422		0.788

## Australian Capital Territory

**Table 2.1.1 Number (percentage) of respondents by demographic characteristics and survey year**

Australian Capital Territory	2012	2013	2014	2015	2016
<b>Number of sites</b>	1	1	1	1	1
<b>N° surveyed</b>	N=78	N=100	N=99	N=110	N=112
<b>Response rate (%)</b>	65%	80%	69%	71%	82%
<b>Gender (%)</b>					
Male	53 (68)	67 (67)	76 (77)	77 (70)	78 (70)
Female	25 (32)	32 (32)	23 (23)	33 (30)	32 (29)
Transgender	0 (0)	1 (1)	0 (0)	0 (0)	2 (2)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
<b>Sexual identity (%)</b>					
Heterosexual	71 (91)	85 (85)	81 (82)	98 (89)	93 (83)
Bisexual	5 (6)	4 (4)	9 (9)	7 (6)	12 (11)
Homosexual	0 (0)	1 (1)	2 (2)	2 (2)	1 (1)
Not reported	2 (3)	10 (10)	7 (7)	3 (3)	6 (5)
<b>Aboriginal and Torres Strait Islander origin (%)</b>					
No	71 (91)	80 (80)	87 (88)	85 (77)	84 (75)
Yes	4 (5)	18 (18)	11 (11)	25 (23)	23 (21)
Not reported	3 (4)	2 (2)	1 (1)	0 (0)	5 (4)
<b>Region/country of birth (%)</b>					
Australia	71 (91)	88 (88)	88 (89)	95 (86)	101 (90)
Other Oceania	1 (1)	0 (0)	3 (3)	1 (1)	1 (1)
Asia	1 (1)	2 (2)	2 (2)	3 (3)	1 (1)
UK & Ireland	5 (6)	5 (5)	4 (4)	5 (5)	6 (5)
Other	0 (0)	4 (4)	1 (1)	4 (4)	2 (2)
Not reported	0 (0)	1 (1)	1 (1)	2 (2)	1 (1)
<b>Main language spoken at home by parents (%)</b>					
English	75 (96)	93 (93)	92 (93)	101 (92)	104 (93)
Non-English	3 (4)	7 (7)	6 (6)	8 (7)	8 (7)
Not reported	0 (0)	0 (0)	1 (1)	1 (1)	0 (0)
<b>Age and time since first injection (years)</b>					
<i>Median age</i>	40	40	41	42	44
<i>Age range</i>	20-66	20-67	19-60	21-61	19-64
<i>Age group (%)</i>					
<25 years	4 (5)	4 (4)	6 (6)	3 (3)	4 (4)
25+ years	74 (95)	96 (96)	92 (93)	106 (96)	107 (96)
Not reported	0 (0)	0 (0)	1 (1)	1 (1)	1 (1)
<i>Median age first injection</i>					
	18	17	17	18	19
<i>Age range</i>	12-41	10-51	12-55	11-45	12-55
<i>N° not reported</i>	0	6	1	2	4
<i>Median yrs since first injection</i>					
	20	20	22	22	24
<i>Range</i>	<1-51	<1-51	1-38	<1-47	<1-48
<i>Years since first injection</i>					
<3 years	2 (3)	1 (1)	5 (5)	3 (3)	2 (2)
3+ years	76 (97)	93 (93)	92 (93)	105 (95)	106 (95)
Not reported	0 (0)	6 (6)	2 (2)	2 (2)	4 (4)
<b>Imprisonment last year (%)</b>					
No	67 (86)	76 (76)	83 (84)	103 (94)	97 (87)
Yes	4 (5)	16 (16)	9 (9)	5 (5)	14 (13)
Not reported	7 (9)	8 (8)	7 (7)	2 (2)	1 (1)
<b>N° in prison</b>					
	N=4	N=16	N=9	N=5	N=14
Injected in prison	3 (75)	4 (25)	3 (33)	2 (40)	4 (29)

**Table 2.1.2 Number (percentage) of respondents by last drug injected, frequency of injecting and survey year**

<b>Australian Capital Territory N° surveyed</b>	<b>2012 N=78</b>	<b>2013 N=100</b>	<b>2014 N=99</b>	<b>2015 N=110</b>	<b>2016 N=112</b>
<b>Drug last injected (%)</b>					
Cocaine	1 (1)	0 (0)	0 (0)	0 (0)	1 (1)
Methamphetamine	23 (29)	30 (30)	31 (31)	45 (41)	41 (37)
Heroin	30 (38)	56 (56)	44 (44)	50 (45)	45 (40)
Pharm. opioids	3 (4)	4 (4)	6 (6)	1 (1)	4 (4)
Methadone	9 (12)	6 (6)	6 (6)	7 (6)	8 (7)
Buprenorphine	3 (4)	0 (0)	2 (2)	2 (2)	5 (4)
Buprenorphine/naloxone	0 (0)	1 (1)	2 (2)	0 (0)	3 (3)
PIEDs	0 (0)	0 (0)	0 (0)	3 (3)	0 (0)
More than one	5 (6)	3 (3)	4 (4)	2 (2)	3 (3)
Other	3 (4)	0 (0)	4 (4)	0 (0)	2 (2)
Not reported	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)
<b>Ever injected opioids</b>					
Yes	-	-	-	-	98 (88)
No	-	-	-	-	13 (12)
Not reported	-	-	-	-	1 (1)
<b>Frequency of injection last month (%)</b>					
Not last month	2 (3)	5 (5)	3 (3)	5 (5)	9 (8)
Less than weekly	10 (13)	17 (17)	13 (13)	11 (10)	14 (13)
Weekly not daily	22 (28)	28 (28)	40 (40)	47 (43)	29 (26)
Daily or more	44 (56)	47 (47)	43 (43)	46 (42)	58 (52)
Not reported	0 (0)	3 (3)	0 (0)	1 (1)	2 (2)
<b>Present when someone injected for the first time in the last 12 months (%)</b>					
Yes	10 (13)	12 (12)	14 (14)	17 (15)	15 (13)
No	65 (83)	76 (76)	82 (83)	92 (84)	96 (86)
Not reported	3 (4)	12 (12)	3 (3)	1 (1)	1 (1)
<b>Overdosed in last 12 months</b>					
Yes	--	10 (10)	18 (18)	13 (12)	24 (21)
No	--	86 (83)	78 (79)	94 (85)	87 (78)
Not reported	--	4 (4)	3 (3)	3 (3)	1 (1)

**Table 2.1.3 Number (percentage) of respondents by injecting behaviour in the last month and survey year**

<b>Australian Capital Territory N° injected last month</b>	<b>2012 N=76</b>	<b>2013 N=92</b>	<b>2014 N=96</b>	<b>2015 N=104</b>	<b>2016 N=101</b>
<b>Places injected last month (%)</b>					
Any public	33 (43)	43 (47)	27 (28)	39 (38)	49 (49)
All private	42 (55)	49 (53)	69 (72)	65 (63)	52 (51)
Not reported	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)
<b>Use of new and sterile needles and syringes last month (%)</b>					
All injections	56 (74)	60 (65)	77 (80)	78 (75)	75 (74)
Most of the time	17 (22)	29 (32)	16 (17)	23 (22)	16 (16)
Half of the time	0 (0)	2 (2)	1 (1)	2 (2)	4 (4)
Some of the time	1 (1)	0 (0)	1 (1)	0 (0)	2 (2)
Not last month	1 (1)	0 (0)	0 (0)	1 (1)	2 (2)
Not reported	1 (1)	1 (1)	1 (1)	0 (0)	2 (2)
<b>Re-used someone else's used needle &amp; syringe last month (%)</b>					
None	60 (79)	74 (80)	82 (85)	88 (85)	81 (80)
Once	6 (8)	9 (10)	6 (6)	4 (4)	5 (5)
Twice	1 (1)	1 (1)	3 (3)	3 (3)	6 (6)
3-5 times	1 (1)	4 (4)	3 (3)	8 (8)	5 (5)
>5 times	5 (7)	3 (3)	0 (0)	1 (1)	3 (3)
Not reported	3 (4)	1 (1)	2 (2)	0 (0)	1 (1)
<b>Number of people needle &amp; syringe was re-used after last month (%)</b>					
None	60 (79)	74 (80)	82 (85)	88 (85)	81 (80)
One	4 (5)	9 (10)	5 (5)	4 (4)	8 (8)
Two	0 (0)	1 (1)	3 (3)	1 (1)	2 (2)
Three to five	0 (0)	1 (1)	0 (0)	1 (1)	3 (3)
More than five	3 (4)	1 (1)	0 (0)	0 (0)	1 (1)
Don't know	4 (5)	3 (3)	2 (2)	6 (6)	2 (2)
Not reported	5 (7)	3 (3)	4 (4)	4 (4)	4 (4)
<b>Relationship to people needle &amp; syringe was used after last month (%) [more than one could be selected]</b>					
Regular sex partner	2 (3)	8 (9)	6 (6)	6 (6)	8 (8)
Casual sex partner	1 (1)	0 (0)	0 (0)	1 (1)	1 (1)
Close friend	3 (4)	8 (9)	1 (1)	3 (3)	5 (5)
Acquaintance	4 (5)	2 (2)	2 (2)	1 (1)	1 (1)
Other	0 (0)	0 (0)	1 (1)	2 (2)	1 (1)
<b>Equipment used after someone else last month (%) [more than one could be selected]</b>					
Spoon	19 (25)	33 (36)	32 (33)	23 (22)	26 (26)
Water	13 (17)	16 (17)	10 (10)	10 (10)	18 (18)
Filter	6 (8)	14 (15)	9 (9)	5 (5)	10 (10)
Drug mix	5 (7)	12 (13)	11 (11)	8 (8)	12 (12)
None	51 (67)	53 (58)	57 (59)	71 (68)	63 (62)
<b>Injected by someone after that person injected themselves or others last month (%)</b>					
No	69 (91)	81 (88)	79 (82)	92 (88)	85 (84)
Yes	6 (8)	9 (10)	14 (15)	12 (12)	16 (16)
Not reported	1 (1)	2 (2)	3 (3)	0 (0)	0 (0)
<b>Source of needle acquisition</b>					
Needle Syringe Program	70 (92)	81 (81)	83 (86)	92 (88)	87 (86)
Chemist/Pharmacy	27 (36)	30 (30)	29 (30)	28 (27)	36 (36)
Personal sources	14 (18)	19 (19)	13 (14)	14 (13)	20 (20)
Dispensing/Vending Machine	22 (29)	24 (24)	23 (24)	20 (19)	23 (23)
Other sources	0 (0)	2 (2)	2 (2)	2 (2)	3 (3)



**Table 2.1.4 Number (percentage) of respondents by treatment for drug use and survey year**

Australian Capital Territory N° surveyed	2012 N=78	2013 N=100	2014 N=99	2015 N=110	2016 N=112
<b>Ever any treatment/therapy for drug use (%)</b>					
No	9 (12)	5 (5)	9 (9)	23 (21)	26 (23)
Yes	69 (88)	94 (94)	90 (91)	87 (79)	86 (77)
Not reported	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)
<b>History of methadone maintenance treatment (%)</b>					
Currently	34 (44)	47 (47)	37 (38)	46 (42)	41 (37)
Previously	27 (35)	31 (31)	29 (29)	31 (28)	23 (21)
Never	17 (22)	21 (21)	32 (32)	31 (28)	46 (41)
Not reported	0 (0)	1 (1)	1 (1)	2 (2)	2 (2)
<b>History of buprenorphine (Subutex®) treatment (%)</b>					
Currently	7 (9)	10 (10)	11 (11)	10 (9)	8 (7)
Previously	20 (26)	35 (35)	27 (27)	27 (25)	24 (21)
Never	49 (63)	51 (51)	59 (60)	72 (65)	76 (68)
Not reported	2 (3)	4 (4)	2 (2)	1 (1)	4 (4)
<b>History of buprenorphine-naloxone (Suboxone®) treatment (%)</b>					
Currently	5 (6)	8 (8)	10 (10)	7 (6)	9 (8)
Previously	13 (17)	27 (27)	25 (25)	18 (16)	23 (21)
Never	60 (77)	63 (63)	63 (64)	84 (76)	77 (69)
Not reported	0 (0)	2 (2)	1 (1)	1 (1)	3 (3)

**Table 2.1.5 Number (percentage) of respondents by testing for HIV and HCV, HCV treatment by survey year**

Australian Capital Territory N° surveyed	2012 N=78	2013 N=100	2014 N=99	2015 N=110	2016 N=112
<b>Previous HIV test (%)</b>					
Yes, ever	72 (92)	88 (88)	82 (83)	91 (83)	98 (88)
Yes, last year	42 (54)	44 (44)	50 (51)	51 (46)	49 (44)
>1 year ago	30 (38)	44 (44)	32 (32)	40 (36)	49 (44)
Never tested	3 (4)	8 (8)	12 (12)	19 (17)	11 (10)
Not reported	3 (4)	4 (4)	5 (5)	0 (0)	3 (3)
<b>Previous HCV test (%)</b>					
Yes, ever	73 (94)	86 (86)	88 (89)	99 (90)	94 (84)
Yes, last year	44 (56)	41 (41)	53 (54)	53 (48)	57 (51)
>1 year ago	29 (37)	45 (45)	35 (35)	46 (42)	37 (33)
Never tested	2 (3)	5 (5)	7 (7)	4 (4)	11 (10)
Not reported	3 (4)	9 (9)	4 (4)	7 (6)	7 (6)
<b>Lifetime treatment for HCV (%)<sup>#</sup></b>					
<b>N° self-reported HCV diagnosis</b>					
Antiviral treatment	0 (0)	4 (9)	4 (10)	4 (8)	8 (24)
No antiviral treatment	34 (100)	39 (91)	36 (88)	46 (90)	26 (76)
Not reported	0 (0)	0 (0)	1 (2)	1 (2)	0 (0)
<b>Treatment for HCV in past 12 months (%)<sup>#*</sup></b>					
<b>N° self-reported HCV diagnosis</b>					
Antiviral treatment	0 (0)	2 (5)	0 (0)	2 (4)	7 (21)
No antiviral treatment	34 (100)	40 (95)	39 (98)	48 (94)	26 (79)
Not reported	0 (0)	0 (0)	1 (3)	0 (0)	0 (0)

<sup>#</sup> among people who tested HCV antibody positive and did not report spontaneous clearance

\* excludes people who reported treatment induced clearance more than 12 months previously

**Table 2.1.6 Number (percentage) of respondents by sexual behaviour in the month prior to survey and survey year**

<b>Australian Capital Territory</b>	<b>2012</b>	<b>2013</b>	<b>2014</b>	<b>2015</b>	<b>2016</b>
<b>N° surveyed</b>	N=78	N=100	N=99	N=110	N=112
<b>Sex with a regular partner last month (%)</b>					
No	53 (68)	59 (59)	58 (59)	61 (55)	73 (65)
Yes	24 (31)	36 (36)	35 (35)	45 (41)	38 (34)
Not reported	1 (1)	5 (5)	6 (6)	4 (4)	1 (1)
<b>Condom used with regular partner last month (%)</b>					
<b>N° surveyed</b>	N=24	N=36	N=35	N=45	N=38
Never	13 (54)	24 (67)	27 (77)	36 (87)	22 (58)
Sometimes	9 (38)	5 (14)	5 (14)	3 (7)	7 (18)
Every time	2 (8)	2 (6)	2 (6)	4 (9)	7 (18)
Not reported	0 (0)	5 (14)	1 (3)	2 (4)	2 (5)
<b>Sex with other partner(s) last month (%)</b>					
No	63 (81)	86 (86)	86 (87)	92 (84)	101 (90)
Yes	11 (14)	11 (11)	8 (8)	14 (13)	8 (7)
Not reported	4 (5)	3 (3)	5 (5)	4 (4)	3 (3)
<b>Condom used with other partner(s) last month (%)</b>					
<b>N° surveyed</b>	N=11	N=11	N=8	N=14	N=8
Never	2 (18)	5 (45)	3 (38)	5 (36)	2 (25)
Sometimes	3 (27)	2 (18)	3 (38)	5 (36)	5 (63)
Every time	6 (55)	4 (36)	2 (25)	3 (21)	1 (13)
Not reported	0 (0)	0 (0)	0 (0)	1 (7)	0 (0)
<b>Sex work last month (%)</b>					
No	72 (92)	92 (92)	89 (90)	106 (96)	105 (94)
Yes	3 (4)	2 (2)	4 (4)	3 (3)	3 (3)
Not reported	3 (4)	6 (6)	6 (6)	1 (1)	4 (4)
<b>Condom used at last sex work (%)</b>					
Yes	2 (67)	1 (50)	3 (75)	1 (33)	1 (33)

**Table 2.1.7 Number (percentage) of respondents reporting stigma or discrimination in the last 12 months in 2016**

<b>Australian Capital Territory<sup>#</sup></b>	<b>Never</b>	<b>Rarely</b>	<b>Sometimes</b>	<b>Often</b>	<b>Always</b>
Use of drugs for injecting	30 (30)	10 (10)	37 (37)	16 (16)	7 (7)
Sexual orientation	66 (73)	10 (11)	9 (10)	3 (3)	2 (2)
Hepatitis C status	51 (56)	11 (12)	22 (24)	4 (4)	3 (3)
Hepatitis B status	63 (84)	3 (4)	8 (11)	0 (0)	1 (1)
HIV status	64 (89)	0 (0)	4 (6)	1 (1)	3 (4)
Sex work	60 (82)	0 (0)	10 (14)	1 (1)	2 (3)
Other	20 (63)	0 (0)	5 (16)	6 (19)	1 (3)
Health workers treated me negatively or different to other people	50 (49)	14 (14)	20 (20)	11 (11)	7 (7)

<sup>#</sup> excludes respondents who indicated 'not applicable' and where data was missing

## HIV antibody prevalence

**Table 2.2.1 HIV antibody prevalence by gender and survey year**

Aust. Capital Territory Survey year	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2012	53	0 (0.0)	25	0 (0.0)	78	0 (0.0)
2013	67	0 (0.0)	32	0 (0.0)	100	0 (0.0)
2014	73	0 (0.0)	23	0 (0.0)	96	0 (0.0)
2015	76	0 (0.0)	33	0 (0.0)	109	0 (0.0)
2016	72	0 (0.0)	31	0 (0.0)	105	0 (0.0)
X <sup>2</sup> p trend		--		--		--

## HCV antibody prevalence

**Table 2.3.1 HCV antibody prevalence by gender and survey year**

Aust. Capital Territory Survey year	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2012	53	34 (64)	25	16 (64)	78	50 (64)
2013	67	49 (73)	32	18 (56)	100	67 (67)
2014	71	49 (69)	23	12 (52)	94	61 (65)
2015	70	54 (77)	29	21 (72)	99	75 (76)
2016	68	39 (57)	27	14 (52)	97	54 (56)
X <sup>2</sup> p trend		0.774		0.920		0.789

**Table 2.3.2 HCV antibody prevalence by sexual identity, gender and survey year**

Aust. Capital Territory Sexual identity	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2012</b>						
Heterosexual	49	31 (63)	22	13 (59)	71	44 (62)
Bisexual	2	1 (50)	3	3 (100)	5	4 (80)
Homosexual	0	0 (0)	0	0 (0)	0	0 (0)
p value		1.000		0.280		0.646
<b>2013</b>						
Heterosexual	60	44 (73)	24	11 (46)	85	55 (65)
Bisexual	1	1 (100)	3	3 (100)	4	4 (100)
Homosexual	1	1 (100)	0	0 (0)	1	1 (100)
p value		1.000		0.222		0.395
<b>2014</b>						
Heterosexual	65	45 (69)	12	5 (42)	77	50 (65)
Bisexual	1	0 (0)	8	5 (63)	9	5 (56)
Homosexual	1	1 (100)	1	0 (0)	2	1 (50)
p value		0.532		0.513		0.755
<b>2015</b>						
Heterosexual	65	50 (77)	24	18 (75)	89	68 (76)
Bisexual	2	2 (100)	3	1 (33)	5	3 (60)
Homosexual	0	0 (0)	2	2 (100)	2	2 (100)
p value		1.000		0.237		0.765
<b>2016</b>						
Heterosexual	60	34 (57)	21	11 (52)	81	45 (56)
Bisexual	5	3 (60)	5	2 (40)	11	6 (55)
Homosexual	1	1 (100)	0	0 (0)	1	1 (100)
p value		1.000		1.000		1.000

**Table 2.3.3 HCV antibody prevalence by age group, gender and survey year**

Aust. Capital Territory Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2012</b>						
<25 years	4	1 (25)	0	0 (0)	4	1 (25)
25-34 years	7	3 (42)	7	3 (43)	14	6 (43)
35-44 years	26	19 (73)	11	7 (64)	37	26 (70)
45+ years	16	11 (69)	7	6 (86)	23	17 (74)
p value		0.174		0.334		0.081
<b>2013</b>						
<25 years	3	1 (33)	1	0 (0)	4	1 (25)
25-34 years	12	7 (58)	15	8 (53)	28	15 (56)
35-44 years	27	21 (78)	10	7 (70)	37	28 (76)
45+ years	25	20 (80)	6	3 (50)	31	23 (74)
p value		0.181		0.600		0.059
<b>2014</b>						
<25 years	4	1 (25)	2	0 (0)	6	1 (17)
25-34 years	11	5 (45)	5	3 (60)	16	8 (50)
35-44 years	29	22 (76)	10	9 (90)	39	31 (79)
45+ years	26	20 (77)	6	0 (0)	32	20 (63)
p value		0.053		<0.001		0.009
<b>2015</b>						
<25 years	1	0 (0)	1	0 (0)	2	0 (0)
25-34 years	14	8 (57)	7	4 (57)	21	12 (57)
35-44 years	28	25 (89)	10	7 (70)	38	32 (84)
45+ years	26	20 (77)	11	10 (91)	37	30 (81)
p value		0.030		0.132		0.010
<b>2016</b>						
<25 years	0	0 (0)	4	3 (75)	4	3 (75)
25-34 years	7	4 (57)	6	2 (33)	13	6 (46)
35-44 years	24	16 (67)	7	4 (57)	33	21 (64)
45+ years	36	19 (53)	10	5 (50)	46	24 (52)
p value		0.592		0.704		0.560

**Table 2.3.4 HCV antibody prevalence by years since first injection, gender and survey year**

Aust. Capital Territory Years of injection	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2012</b>						
<3 years	2	1 (50)	0	0 (0)	2	1 (50)
3 to 10 years	6	2 (33)	3	1 (33)	9	3 (33)
11+ years	45	31 (69)	22	15 (68)	67	46 (69)
p value		0.189		0.530		0.070
<b>2013</b>						
<3 years	0	0 (0)	1	1 (100)	1	1 (100)
3 to 10 years	5	3 (60)	7	1 (14)	12	4 (33)
11+ years	57	43 (75)	23	16 (70)	81	59 (73)
p value		0.597		0.025		0.016
<b>2014</b>						
<3 years	4	1 (25)	1	0 (0)	5	1 (20)
3 to 10 years	8	4 (50)	4	0 (0)	12	4 (33)
11+ years	57	42 (74)	18	12 (52)	75	54 (72)
p value		0.043		0.014		0.003
<b>2015</b>						
<3 years	2	1 (50)	1	0 (0)	3	1 (33)
3 to 10 years	12	6 (50)	4	2 (50)	16	8 (50)
11+ years	54	45 (83)	24	19 (79)	78	64 (82)
p value		0.017		0.112		0.005
<b>2016</b>						
<3 years	1	0 (0)	1	1 (100)	2	1 (50)
3 to 10 years	3	1 (33)	7	3 (43)	10	4 (40)
11+ years	60	36 (60)	19	10 (53)	81	47 (58)
p value		0.384		1.000		0.510

**Table 2.3.5 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year**

Aust. Capital Territory Receptively shared syringe last month	<3 years		3+ years		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2012</b>						
No receptive sharing	1	1 (100)	59	38 (64)	60	39 (65)
Receptive sharing	0	0 (0)	13	9 (69)	13	9 (69)
p value		--		1.000		1.000
<b>2013</b>						
No receptive sharing	0	0 (0)	68	45 (66)	74	48 (65)
Receptive sharing	0	0 (0)	17	13 (76)	17	13 (76)
p value		--		0.564		0.408
<b>2014</b>						
No receptive sharing	4	1 (25)	71	47 (66)	77	50 (65)
Receptive sharing	0	0 (0)	12	8 (67)	12	8 (67)
p value		--		0.975		0.907
<b>2015</b>						
No receptive sharing	3	1 (33)	74	57 (77)	79	60 (76)
Receptive sharing	0	0 (0)	14	11 (79)	14	11 (79)
p value		--		1.000		1.000
<b>2016</b>						
No receptive sharing	2	1 (50)	70	41 (59)	74	44 (59)
Receptive sharing	0	0 (0)	13	6 (46)	13	6 (46)
p value		--		0.407		0.371

**Table 2.3.6 HCV antibody prevalence by last drug injected, years since first injection and survey year**

Aust. Capital Territory Last drug injected	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2012</b>						
Heroin	0	0 (0)	30	22 (73)	30	22 (73)
Methamphetamine	1	1 (100)	22	12 (55)	23	13 (57)
Other opioids	0	0 (0)	15	11 (73)	15	11 (73)
Other drugs	1	0 (0)	8	4 (50)	9	4 (44)
p value		0.157		0.357		0.288
<b>2013</b>						
Heroin	0	0 (0)	54	37 (69)	56	37 (66)
Methamphetamine	1	1 (100)	26	16 (62)	30	19 (63)
Other opioids	0	0 (0)	10	8 (80)	11	9 (82)
Other drugs	0	0 (0)	3	2 (67)	3	2 (67)
p value		--		0.762		0.730
<b>2014</b>						
Heroin	0	0 (0)	40	25 (63)	42	27 (64)
Methamphetamine	2	0 (0)	27	15 (56)	29	15 (52)
Other opioids	2	1 (50)	13	11 (85)	15	12 (80)
Other drugs	1	0 (0)	7	7 (100)	8	7 (88)
p value		0.392		0.066		0.138
<b>2015</b>						
Heroin	1	0 (0)	43	37 (86)	44	37 (84)
Methamphetamine	2	1 (50)	38	26 (68)	41	28 (68)
Other opioids	0	0 (0)	8	6 (75)	9	7 (78)
Other drugs	0	0 (0)	4	3 (75)	4	3 (75)
p value		0.386		0.304		0.397
<b>2016</b>						
Heroin	2	1 (50)	36	26 (72)	40	28 (70)
Methamphetamine	0	0 (0)	34	14 (41)	35	14 (40)
Other opioids	0	0 (0)	15	8 (53)	15	8 (53)
Other drugs	0	0 (0)	4	2 (50)	5	3 (60)
p value		--		0.072		0.076

**Table 2.3.7 HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year**

Aust. Capital Territory Frequency of injection last month	<3 years		3+ years		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2012</b>						
Less than daily	0	0 (0)	32	20 (63)	32	20 (63)
Daily or more	1	1 (100)	43	28 (65)	44	29 (66)
Not last month	1	0 (0)	1	1 (100)	2	1 (50)
p value		1.000		1.000		0.912
<b>2013</b>						
Less than daily	0	0 (0)	40	29 (73)	45	31 (69)
Daily or more	0	0 (0)	46	30 (65)	47	31 (66)
Not last month	1	1 (100)	4	2 (50)	5	3 (60)
p value		--		0.546		0.883
<b>2014</b>						
Less than daily	3	0 (0)	46	30 (65)	50	31 (62)
Daily or more	2	1 (50)	38	26 (68)	41	28 (68)
Not last month	0	0 (0)	3	2 (67)	3	2 (67)
p value		0.400		0.918		0.847
<b>2015</b>						
Less than daily	2	1 (50)	51	38 (75)	55	41 (75)
Daily or more	1	0 (0)	37	30 (81)	38	30 (79)
Not last month	0	0 (0)	5	4 (80)	5	4 (80)
p value		1.000		0.837		0.920
<b>2016</b>						
Less than daily	2	1 (50)	36	23 (64)	39	25 (64)
Daily or more	0	0 (0)	47	24 (51)	49	25 (51)
Not last month	0	0 (0)	6	3 (50)	7	3 (43)
p value		--		0.500		0.425

**Table 2.3.8 HCV antibody prevalence by imprisonment last year, years since first injection and survey year**

Aust. Capital Territory Imprisonment last year	<3 years		3+ years		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2012</b>						
No imprisonment	2	1 (50)	65	42 (65)	67	43 (64)
Imprisonment	0	0 (0)	4	2 (50)	4	2 (50)
p value		--		0.617		0.620
<b>2013</b>						
No imprisonment	1	1 (100)	71	47 (66)	76	49 (64)
Imprisonment	0	0 (0)	16	11 (69)	16	11 (69)
p value		--		0.845		0.744
<b>2014</b>						
No imprisonment	5	1 (20)	72	49 (68)	79	52 (66)
Imprisonment	0	0 (0)	8	5 (63)	8	5 (63)
p value		--		0.750		0.851
<b>2015</b>						
No imprisonment	1	1 (100)	89	68 (76)	92	71 (77)
Imprisonment	1	0 (0)	4	3 (75)	5	3 (60)
p value		--		1.000		0.589
<b>2016</b>						
No imprisonment	2	1 (50)	78	43 (55)	84	46 (55)
Imprisonment	0	0 (0)	12	7 (58)	12	7 (58)
p value		--		0.835		0.816

**Table 2.3.9 HCV antibody prevalence by sex work last month, years since first injection and survey year**

Aust. Capital Territory Sex work last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2012</b>						
No sex work	2	1 (50)	70	44 (63)	72	45 (63)
Sex work	0	0 (0)	3	3 (100)	3	3 (100)
p value		--		0.548		0.549
<b>2013</b>						
No sex work	1	1 (100)	86	58 (67)	92	61 (66)
Sex work	0	0 (0)	2	1 (50)	2	1 (50)
p value		--		1.000		1.000
<b>2014</b>						
No sex work	4	1 (25)	79	54 (68)	85	57 (67)
Sex work	1	0 (0)	2	1 (50)	3	1 (33)
p value		1.000		0.542		0.267
<b>2015</b>						
No sex work	2	1 (50)	91	69 (76)	95	72 (76)
Sex work	0	0 (0)	3	3 (100)	3	3 (100)
p value		--		1.000		1.000
<b>2016</b>						
No sex work	2	1 (50)	85	47 (55)	91	50 (55)
Sex work	0	0 (0)	3	2 (67)	3	2 (67)
p value		--		1.000		1.000

**Table 2.3.10 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year**

Aust. Capital Territory Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2012</b>						
Non Indigenous	46	29 (63)	25	16 (64)	71	45 (63)
Indigenous	4	2 (50)	0	0 (0)	4	2 (50)
p value		0.629		--		0.626
<b>2013</b>						
Non Indigenous	52	38 (73)	27	15 (56)	80	53 (66)
Indigenous	13	9 (69)	5	3 (60)	18	12 (67)
p value		0.743		1.000		0.973
<b>2014</b>						
Non Indigenous	62	41 (66)	21	41 (66)	83	51 (61)
Indigenous	8	7 (88)	8	7 (88)	10	9 (90)
p value		0.220		0.478		0.075
<b>2015</b>						
Non Indigenous	57	42 (74)	20	14 (70)	77	56 (73)
Indigenous	13	12 (93)	9	7 (78)	22	19 (86)
p value		0.272		1.000		0.263
<b>2016</b>						
Non Indigenous	52	31 (60)	18	9 (50)	71	40 (56)
Indigenous	13	5 (38)	7	3 (43)	21	9 (43)
p value		0.170		1.000		0.277



**Table 2.3.11 HCV antibody prevalence by main language spoken at home by parents, gender and survey year**

<b>Aust. Capital Territory</b>	<b>Male</b>		<b>Female</b>		<b>Total</b>	
<b>Main language spoken at home by parents</b>	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2012</b>						
English speaking	52	34 (65)	23	15 (65)	75	49 (65)
Non-English speaking	1	0 (0)	2	1 (50)	3	1 (33)
p value		0.358		1.000		0.291
<b>2013</b>						
English speaking	63	46 (73)	29	16 (55)	93	62 (67)
Non-English speaking	4	3 (75)	3	2 (67)	7	5 (71)
p value		1.000		1.000		1.000
<b>2014</b>						
English speaking	67	48 (72)	20	12 (60)	87	60 (69)
Non-English speaking	3	0 (0)	3	0 (0)	6	0 (0)
p value		0.028		0.093		0.001
<b>2015</b>						
English speaking	62	49 (79)	28	21 (75)	90	70 (78)
Non-English speaking	7	4 (57)	1	0 (0)	8	4 (50)
p value		0.340		0.276		0.098
<b>2016</b>						
English speaking	62	37 (60)	27	14 (52)	91	52 (57)
Non-English speaking	6	2 (33)	0	0 (0)	6	2 (33)
p value		0.390		--		0.401

**Table 2.3.12 HCV antibody prevalence by region/country of birth, gender and survey year**

<b>Aust. Capital Territory</b>	<b>Male</b>		<b>Female</b>		<b>Total</b>	
<b>Region/Country of birth</b>	<b>N° tested</b>	<b>N° with HCV (%)</b>	<b>N° tested</b>	<b>N° with HCV (%)</b>	<b>N° tested</b>	<b>N° with HCV (%)</b>
<b>2012</b>						
Australia	49	31 (63)	22	13 (59)	71	44 (62)
Other Oceania	1	1 (100)	0	0 (0)	1	1 (100)
Asia	1	1 (100)	0	0 (0)	1	1 (100)
UK & Ireland	2	1 (50)	3	3 (100)	5	4 (80)
Other	0	0 (0)	0	0 (0)	0	0 (0)
p value		1.000		0.280		0.856
<b>2013</b>						
Australia	61	45 (74)	27	15 (56)	88	60 (68)
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)
Asia	2	2 (100)	0	0 (0)	2	2 (100)
UK & Ireland	2	1 (50)	3	1 (33)	5	2 (40)
Other	2	1 (50)	1	1 (100)	4	2 (50)
p value		0.516		0.773		0.386
<b>2014</b>						
Australia	62	43 (69)	21	11 (52)	83	54 (65)
Other Oceania	3	3 (100)	0	0 (0)	3	3 (100)
Asia	2	0 (0)	0	0 (0)	2	0 (0)
UK & Ireland	3	2 (67)	1	1 (100)	4	3 (75)
Other	0	0 (0)	0	0 (0)	1	0 (0)
p value		0.128		1.000		0.105
<b>2015</b>						
Australia	59	45 (76)	26	19 (73)	85	64 (75)
Other Oceania	1	1 (100)	0	0 (0)	1	1 (100)
Asia	3	2 (67)	0	0 (0)	3	2 (67)
UK & Ireland	2	1 (50)	2	2 (100)	4	3 (75)
Other	3	3 (100)	1	0 (0)	4	3 (75)
p value		0.681		0.330		1.000
<b>2016</b>						
Australia	64	37 (58)	25	13 (52)	91	51 (56)
Other Oceania	1	1 (100)	0	0 (0)	1	1 (100)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	2	1 (50)	2	1 (50)	4	2 (50)
Other	1	0 (0)	0	0 (0)	1	0 (0)
p value		0.837		1.000		0.884

## New South Wales

Table 3.1.1 Number (percentage) of respondents by demographic characteristics and survey year

New South Wales	2012	2013	2014	2015	2016
<b>Number of sites</b>	20	20	19	16	17
<b>N° surveyed</b>	N=712	N=686	N=761	N=639	N=532
<b>Response rate (%)</b>	47%	38%	45%	35%	36%
<b>Gender (%)</b>					
Male	476 (67)	475 (69)	539 (71)	464 (73)	372 (70)
Female	227 (32)	206 (30)	212 (28)	167 (26)	153 (29)
Transgender	6 (1)	5 (<1)	9 (1)	7 (1)	6 (1)
Not reported	3 (<1)	0 (0)	1 (<1)	1 (<1)	1 (<1)
<b>Sexual identity (%)</b>					
Heterosexual	576 (81)	548 (80)	610 (80)	515 (81)	417 (78)
Bisexual	60 (8)	50 (7)	69 (9)	61 (10)	52 (10)
Homosexual	25 (4)	45 (7)	44 (6)	33 (5)	32 (6)
Not reported	51 (7)	43 (6)	38 (5)	30 (5)	31 (6)
<b>Aboriginal and Torres Strait Islander origin (%)</b>					
No	609 (86)	543 (79)	609 (80)	510 (80)	418 (79)
Yes	90 (13)	124 (18)	136 (18)	117 (18)	99 (19)
Not reported	13 (2)	19 (3)	16 (2)	12 (2)	15 (3)
<b>Region/country of birth (%)</b>					
Australia	621 (87)	602 (88)	646 (85)	548 (86)	455 (86)
Other Oceania	22 (3)	19 (3)	30 (4)	25 (4)	25 (5)
Asia	8 (1)	9 (1)	11 (1)	11 (2)	10 (2)
UK & Ireland	30 (4)	22 (3)	27 (4)	27 (4)	11 (2)
Other	21 (3)	32 (5)	37 (5)	18 (3)	22 (4)
Not reported	10 (1)	2 (<1)	10 (1)	10 (2)	9 (2)
<b>Main language spoken at home by parents (%)</b>					
English	675 (95)	636 (93)	698 (92)	602 (94)	495 (93)
Non-English	32 (4)	48 (7)	56 (7)	32 (5)	31 (6)
Not reported	5 (1)	2 (<1)	7 (1)	5 (1)	6 (1)
<b>Age and time since first injection (years)</b>					
<i>Median age</i>	39	39	40	41	42
<i>Age range</i>	18-64	18-65	17-67	18-70	18-75
<i>Age group (%)</i>					
<25 years	55 (8)	52 (8)	57 (7)	27 (4)	20 (4)
25+ years	657 (92)	634 (92)	702 (92)	612 (96)	512 (96)
Not reported	0 (0)	0 (0)	2 (<1)	0 (0)	0 (0)
<i>Median age first injection</i>					
	19	19	19	19	19
<i>Age range</i>	10-64	10-54	10-47	10-63	10-76
<i>N° not reported</i>	20	25	25	18	16
<i>Median yrs since first injection</i>					
	18	19	19	19	21
<i>Range</i>	<1-46	<1-48	<1-47	<1-52	<1-49
<i>Years since first injection</i>					
<3 years	66 (9)	61 (9)	66 (9)	60 (9)	30 (6)
3+ years	626 (88)	600 (87)	670 (88)	561 (88)	485 (91)
Not reported	20 (3)	25 (4)	25 (3)	18 (3)	17 (3)
<b>Imprisonment last year (%)</b>					
No	603 (85)	569 (83)	601 (79)	531 (83)	430 (81)
Yes	75 (11)	85 (12)	99 (13)	76 (12)	71 (13)
Not reported	34 (5)	32 (5)	61 (8)	32 (5)	31 (6)
<b>N° in prison</b>					
	N=75	N=85	N=99	N=76	N=71
Injected in prison	27 (36)	31 (36)	38 (38)	31 (41)	34 (48)

**Table 3.1.2 Number (percentage) of respondents by last drug injected, frequency of injecting and survey year**

<b>New South Wales N° surveyed</b>	<b>2012 N=712</b>	<b>2013 N=686</b>	<b>2014 N=761</b>	<b>2015 N=639</b>	<b>2016 N=532</b>
<b>Drug last injected (%)</b>					
Cocaine	16 (2)	22 (3)	19 (3)	9 (1)	12 (2)
Methamphetamine	187 (26)	218 (32)	259 (34)	204 (32)	189 (36)
Heroin	216 (30)	178 (26)	216 (28)	194 (30)	170 (32)
Pharm. opioids	80 (11)	57 (8)	40 (5)	48 (8)	16 (3)
Methadone	69 (10)	75 (11)	70 (9)	60 (9)	49 (9)
Buprenorphine	10 (1)	11 (2)	9 (1)	10 (2)	5 (1)
Buprenorphine/naloxone	7 (1)	2 (<1)	3 (<1)	5 (1)	1 (<1)
PIEDs	83 (12)	73 (11)	77 (10)	76 (12)	52 (10)
More than one	33 (5)	33 (5)	33 (4)	25 (4)	33 (6)
Other	4 (<1)	9 (1)	32 (4)	8 (1)	5 (1)
Not reported	7 (1)	8 (1)	3 (<1)	0 (0)	0 (0)
<b>Ever injected opioids</b>					
Yes	-	-	-	-	428 (80)
No	-	-	-	-	103 (19)
Not reported	-	-	-	-	1 (<1)
<b>Frequency of injection last month (%)</b>					
Not last month	110 (15)	102 (15)	89 (12)	71 (11)	46 (9)
Less than weekly	144 (20)	150 (22)	138 (18)	111 (17)	95 (18)
Weekly not daily	178 (25)	161 (23)	186 (24)	159 (25)	140 (26)
Daily or more	271 (38)	251 (37)	339 (44)	286 (45)	240 (45)
Not reported	9 (1)	22 (3)	9 (1)	12 (2)	11 (2)
<b>Present when someone injected for the first time in the last 12 months (%)</b>					
Yes	95 (13)	95 (14)	130 (17)	114 (18)	99 (19)
No	525 (74)	471 (69)	604 (79)	512 (80)	420 (79)
Not reported	92 (13)	120 (17)	27 (4)	13 (2)	13 (2)
<b>Overdosed in last 12 months</b>					
Yes	--	63 (9)	122 (16)	82 (13)	86 (16)
No	--	604 (88)	610 (80)	539 (84)	431 (81)
Not reported	--	19 (3)	29 (4)	19 (3)	15 (3)

**Table 3.1.3 Number (percentage) of respondents by injecting behaviour in the last month and survey year**

<b>New South Wales N° injected last month</b>	<b>2012 N=593</b>	<b>2013 N=562</b>	<b>2014 N=663</b>	<b>2015 N=556</b>	<b>2016 N=475</b>
<b>Places injected last month (%)</b>					
Any public	166 (28)	166 (30)	212 (32)	166 (30)	186 (39)
All private	412 (69)	393 (70)	447 (67)	385 (69)	284 (60)
Not reported	15 (3)	3 (<1)	4 (<1)	5 (1)	5 (1)
<b>Use of new and sterile needles and syringes last month (%)</b>					
All injections	439 (74)	445 (79)	527 (79)	429 (77)	362 (76)
Most of the time	112 (19)	87 (15)	103 (16)	98 (18)	83 (17)
Half of the time	10 (2)	11 (2)	10 (2)	13 (2)	8 (2)
Some of the time	6 (1)	11 (2)	4 (<1)	7 (1)	13 (3)
Not last month	6 (1)	2 (<1)	6 (1)	3 (1)	2 (0)
Not reported	20 (3)	6 (1)	13 (2)	6 (1)	7 (1)
<b>Re-used someone else's used needle &amp; syringe last month (%)</b>					
None	491 (83)	485 (86)	548 (83)	478 (86)	415 (87)
Once	35 (6)	24 (4)	45 (7)	23 (4)	19 (4)
Twice	12 (2)	27 (5)	27 (4)	18 (3)	16 (3)
3-5 times	20 (3)	11 (2)	20 (3)	16 (3)	9 (2)
>5 times	15 (3)	13 (2)	13 (2)	18 (3)	13 (3)
Not reported	20 (3)	2 (<1)	10 (2)	3 (1)	3 (1)
<b>Number of people needle &amp; syringe was re-used after last month (%)</b>					
None	491 (83)	485 (86)	548 (83)	478 (86)	415 (87)
One	41 (7)	28 (5)	45 (7)	24 (4)	22 (5)
Two	9 (2)	8 (1)	8 (1)	11 (2)	5 (1)
Three to five	1 (<1)	2 (<1)	4 (<1)	3 (1)	5 (1)
More than five	4 (<1)	5 (1)	6 (1)	5 (1)	6 (1)
Don't know	9 (2)	16 (3)	18 (3)	18 (3)	11 (2)
Not reported	38 (6)	18 (3)	34 (5)	17 (3)	11 (2)
<b>Relationship to people needle &amp; syringe was used after last month (%) [more than one could be selected]</b>					
Regular sex partner	33 (6)	26 (5)	44 (7)	27 (5)	23 (5)
Casual sex partner	1 (<1)	5 (1)	7 (1)	4 (1)	5 (1)
Close friend	25 (4)	22 (4)	16 (2)	16 (3)	12 (3)
Acquaintance	9 (2)	11 (2)	14 (2)	8 (1)	8 (2)
Other	0 (0)	8 (1)	7 (1)	4 (1)	3 (1)
<b>Equipment used after someone else last month (%) [more than one could be selected]</b>					
Spoon	95 (16)	118 (21)	128 (19)	97 (17)	81 (17)
Water	75 (13)	86 (15)	99 (15)	76 (14)	64 (13)
Filter	47 (8)	51 (9)	63 (10)	42 (8)	36 (8)
Drug mix	34 (6)	47 (8)	47 (7)	60 (11)	35 (7)
None	428 (72)	418 (74)	480 (72)	403 (72)	356 (75)
<b>Injected by someone after that person injected themselves or others last month (%)</b>					
No	486 (82)	487 (87)	544 (82)	491 (88)	419 (88)
Yes	80 (13)	61 (11)	89 (13)	54 (10)	48 (10)
Not reported	27 (5)	14 (2)	30 (5)	11 (2)	8 (2)
<b>Source of needle acquisition</b>					
Needle Syringe Program	527 (89)	518 (92)	585 (88)	494 (89)	427 (90)
Chemist/Pharmacy	101 (17)	96 (17)	132 (20)	103 (19)	93 (20)
Personal sources	56 (9)	55 (10)	70 (11)	65 (12)	59 (12)
Dispensing/Vending Machine	120 (20)	136 (24)	190 (29)	133 (24)	143 (30)
Other sources	3 (<1)	17 (3)	16 (2)	14 (3)	19 (4)

**Table 3.1.4 Number (percentage) of respondents by treatment for drug use and survey year**

<b>New South Wales N° surveyed</b>	<b>2012 N=712</b>	<b>2013 N=686</b>	<b>2014 N=761</b>	<b>2015 N=639</b>	<b>2016 N=532</b>
<b>Ever any treatment/therapy for drug use (%)</b>					
No	174 (24)	162 (24)	200 (26)	158 (25)	121 (23)
Yes	526 (74)	512 (75)	543 (71)	466 (73)	397 (75)
Not reported	12 (2)	12 (2)	18 (2)	15 (2)	14 (3)
<b>History of methadone maintenance treatment (%)</b>					
Currently	289 (41)	263 (38)	251 (33)	225 (35)	196 (37)
Previously	143 (20)	146 (21)	158 (21)	122 (19)	105 (20)
Never	275 (39)	269 (39)	336 (44)	278 (44)	216 (41)
Not reported	5 (<1)	8 (1)	16 (2)	14 (2)	15 (3)
<b>History of buprenorphine (Subutex®) treatment (%)</b>					
Currently	53 (7)	42 (6)	47 (6)	46 (7)	21 (4)
Previously	182 (26)	164 (24)	182 (24)	147 (23)	155 (29)
Never	466 (65)	468 (68)	511 (67)	428 (67)	338 (64)
Not reported	11 (2)	12 (2)	21 (3)	18 (3)	18 (3)
<b>History of buprenorphine-naloxone (Suboxone®) treatment (%)</b>					
Currently	66 (9)	36 (5)	45 (6)	54 (8)	21 (4)
Previously	89 (13)	119 (17)	127 (17)	118 (18)	112 (21)
Never	542 (76)	513 (75)	571 (75)	451 (71)	379 (71)
Not reported	15 (2)	18 (3)	18 (2)	16 (3)	20 (4)

**Table 3.1.5 Number (percentage) of respondents by testing for HIV and HCV, HCV treatment by survey year**

<b>New South Wales N° surveyed</b>	<b>2012 N=712</b>	<b>2013 N=686</b>	<b>2014 N=761</b>	<b>2015 N=639</b>	<b>2016 N=532</b>
<b>Previous HIV test (%)</b>					
Yes, ever	582 (82)	576 (84)	610 (80)	545 (85)	471 (89)
Yes, last year	310 (44)	336 (49)	374 (49)	328 (51)	283 (53)
>1 year ago	272 (38)	240 (35)	236 (31)	217 (34)	188 (35)
Never tested	96 (13)	100 (15)	116 (15)	78 (12)	48 (9)
Not reported	34 (5)	10 (1)	35 (5)	16 (3)	13 (2)
<b>Previous HCV test (%)</b>					
Yes, ever	607 (85)	571 (83)	648 (85)	550 (86)	448 (84)
Yes, last year	364 (51)	342 (50)	389 (51)	339 (53)	282 (53)
>1 year ago	243 (34)	229 (33)	259 (34)	211 (33)	166 (31)
Never tested	64 (9)	62 (9)	80 (11)	60 (9)	36 (7)
Not reported	41 (6)	53 (8)	33 (4)	29 (5)	48 (9)
<b>Lifetime treatment for HCV (%)#</b>					
<b>N° self-reported HCV diagnosis</b>	<b>N=202</b>	<b>N=215</b>	<b>N=231</b>	<b>N=202</b>	<b>N=169</b>
Antiviral treatment	25 (12)	23 (11)	29 (13)	32 (16)	53 (31)
No antiviral treatment	172 (85)	189 (88)	197 (85)	165 (82)	116 (69)
Not reported	5 (2)	3 (1)	5 (2)	5 (2)	0 (0)
<b>Treatment for HCV in past 12 months (%)**</b>					
<b>N° self-reported HCV diagnosis</b>	<b>N=195</b>	<b>N=206</b>	<b>N=218</b>	<b>N=190</b>	<b>N=163</b>
Antiviral treatment	4 (2)	5 (2)	4 (2)	5 (3)	44 (27)
No antiviral treatment	186 (95)	198 (96)	209 (96)	180 (95)	119 (73)
Not reported	5 (3)	3 (1)	5 (2)	5 (3)	0 (0)

# among people who tested HCV antibody positive and did not report spontaneous clearance

\* excludes people who reported treatment induced clearance more than 12 months previously

**Table 3.1.6 Number (percentage) of respondents by sexual behaviour in the month prior to survey and survey year**

<b>New South Wales N° surveyed</b>	<b>2012 N=712</b>	<b>2013 N=686</b>	<b>2014 N=761</b>	<b>2015 N=639</b>	<b>2016 N=532</b>
<b>Sex with a regular partner last month (%)</b>					
No	324 (46)	320 (47)	355 (47)	292 (46)	257 (48)
Yes	360 (51)	348 (51)	377 (50)	319 (50)	257 (48)
Not reported	28 (4)	18 (3)	29 (4)	28 (4)	18 (3)
<b>Condom used with regular partner last month (%)</b>					
<b>N° surveyed</b>	<b>N=360</b>	<b>N=348</b>	<b>N=377</b>	<b>N=319</b>	<b>N=257</b>
Never	254 (71)	232 (67)	265 (70)	250 (78)	186 (72)
Sometimes	47 (13)	62 (18)	49 (13)	28 (9)	28 (11)
Every time	39 (11)	42 (12)	43 (11)	29 (9)	29 (11)
Not reported	20 (6)	12 (3)	20 (5)	12 (4)	14 (5)
<b>Sex with other partner(s) last month (%)</b>					
No	584 (82)	540 (79)	588 (77)	527 (82)	416 (78)
Yes	94 (13)	120 (17)	133 (17)	95 (15)	92 (17)
Not reported	34 (5)	26 (4)	40 (5)	17 (3)	24 (5)
<b>Condom used with other partner(s) last month (%)</b>					
<b>N° surveyed</b>	<b>N=94</b>	<b>N=120</b>	<b>N=133</b>	<b>N=95</b>	<b>N=92</b>
Never	28 (30)	38 (32)	45 (34)	35 (37)	29 (32)
Sometimes	29 (31)	35 (29)	34 (26)	30 (32)	28 (30)
Every time	32 (34)	40 (33)	43 (32)	27 (28)	35 (38)
Not reported	5 (5)	7 (6)	11 (8)	3 (3)	0 (0)
<b>Sex work last month (%)</b>					
No	637 (89)	607 (88)	642 (84)	595 (93)	479 (90)
Yes	42 (6)	33 (5)	51 (7)	29 (5)	29 (5)
Not reported	33 (5)	46 (7)	68 (9)	15 (2)	24 (5)
<b>Condom used at last sex work (%)</b>					
Yes	35 (83)	27 (82)	35 (69)	21 (72)	17 (59)

**Table 3.1.7 Number (percentage) of respondents reporting stigma or discrimination in the last 12 months in 2016**

<b>New South Wales<sup>#</sup></b>	<b>Never</b>	<b>Rarely</b>	<b>Sometimes</b>	<b>Often</b>	<b>Always</b>
Use of drugs for injecting	183 (38)	51 (10)	139 (29)	63 (13)	51 (10)
Sexual orientation	316 (78)	37 (9)	33 (8)	11 (3)	8 (2)
Hepatitis C status	282 (71)	43 (11)	45 (11)	16 (4)	11 (3)
Hepatitis B status	312 (92)	14 (4)	8 (2)	3 (1)	4 (1)
HIV status	296 (90)	7 (2)	15 (5)	3 (1)	7 (2)
Sex work	289 (87)	11 (3)	15 (5)	9 (3)	9 (3)
Other	129 (75)	6 (3)	16 (9)	9 (5)	13 (8)
Health workers treated me negatively or different to other people	320 (66)	47 (10)	81 (17)	26 (5)	13 (3)

<sup>#</sup> excludes respondents who indicated 'not applicable' and where data was missing

## HIV antibody prevalence

**Table 3.2.1 HIV antibody prevalence by gender and survey year**

New South Wales Survey year	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)
2012	465	7 (1.5)	223	0 (0.0)	697	8 (1.2)
2013	456	20 (4.4)	204	0 (0.0)	665	21 (3.2)
2014	505	15 (3.0)	202	0 (0.0)	714	18 (2.5)
2015	436	16 (3.7)	164	2 (1.2)	608	19 (3.1)
2016	354	11 (3.1)	148	1 (0.7)	509	13 (2.6)
X <sup>2</sup> p trend		0.316		0.056		0.130

**Table 3.2.2 HIV antibody prevalence by sexual identity, gender and survey year**

New South Wales Sexual identity	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)
<b>2012</b>						
Heterosexual	410	1 (0.2)	153	0 (0.0)	565	1 (0.2)
Bisexual	14	0 (0.0)	42	0 (0.0)	58	1 (1.7)
Homosexual	15	5 (33.3)	7	0 (0.0)	24	5 (20.8)
p value		0.001		--		<0.001
<b>2013</b>						
Heterosexual	384	2 (0.5)	143	0 (0.0)	528	2 (0.4)
Bisexual	21	1 (4.8)	28	0 (0.0)	50	2 (4.0)
Homosexual	31	16 (51.6)	11	0 (0.0)	45	16 (35.6)
p value		<0.001		--		<0.001
<b>2014</b>						
Heterosexual	434	3 (0.7)	135	0 (0.0)	571	3 (0.5)
Bisexual	17	2 (11.8)	44	0 (0.0)	65	5 (7.7)
Homosexual	31	10 (32.3)	10	0 (0.0)	42	10 (23.8)
p value		<0.001		--		<0.001
<b>2015</b>						
Heterosexual	369	2 (0.5)	125	1 (0.8)	497	3 (0.6)
Bisexual	26	2 (7.7)	28	1 (3.6)	56	4 (7.1)
Homosexual	23	12 (52.2)	2	0 (0.0)	26	12 (46.2)
p value		<0.001		0.351		<0.001
<b>2016</b>						
Heterosexual	293	0 (0.0)	106	0 (0.0)	401	0 (0.0)
Bisexual	16	1 (6.3)	32	1 (3.1)	48	2 (4.2)
Homosexual	25	9 (36.0)	0	0 (0.0)	29	10 (34.5)
p value		<0.001		0.232		<0.001



**Table 3.2.3 HIV antibody prevalence by age group, gender and survey year**

New South Wales Age group	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
<b>2012</b>						
<25 years	42	0 (0.0)	10	0 (0.0)	53	0 (0.0)
25-34 years	117	0 (0.0)	65	0 (0.0)	184	0 (0.0)
35-44 years	157	3 (1.9)	88	0 (0.0)	248	4 (1.6)
45+ years	149	4 (2.7)	60	0 (0.0)	212	4 (1.9)
p value		0.295		--		0.257
<b>2013</b>						
<25 years	38	1 (2.6)	11	0 (0.0)	49	1 (2.0)
25-34 years	105	3 (2.9)	50	0 (0.0)	157	3 (2.6)
35-44 years	173	8 (4.6)	77	0 (0.0)	251	8 (3.2)
45+ years	140	8 (5.7)	66	0 (0.0)	208	8 (3.9)
p value		0.756		--		0.912
<b>2014</b>						
<25 years	42	1 (2.4)	7	0 (0.0)	50	1 (2.0)
25-34 years	105	3 (2.9)	59	0 (0.0)	167	4 (2.4)
35-44 years	187	3 (1.6)	81	0 (0.0)	271	5 (1.9)
45+ years	171	8 (4.7)	53	0 (0.0)	224	8 (3.6)
p value		0.393		--		0.674
<b>2015</b>						
<25 years	21	0 (0.0)	6	1 (16.7)	27	1 (3.7)
25-34 years	101	2 (2.0)	51	1 (2.0)	155	4 (2.6)
35-44 years	138	3 (2.2)	52	0 (0.0)	192	3 (2.6)
45+ years	176	11 (6.3)	55	0 (0.0)	234	11 (4.7)
p value		0.179		0.024		0.249
<b>2016</b>						
<25 years	18	0 (0.0)	2	0 (0.0)	20	0 (0.0)
25-34 years	59	4 (6.8)	32	0 (0.0)	93	4 (4.3)
35-44 years	131	2 (1.5)	54	1 (1.9)	186	3 (1.6)
45+ years	146	5 (3.4)	60	0 (0.0)	210	6 (2.9)
p value		0.249		0.595		0.498

**Table 3.2.4 HIV antibody prevalence by last drug injected, gender and survey year**

New South Wales Last drug injected	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
<b>2012</b>						
Heroin	144	0 (0.0)	67	0 (0.0)	214	1 (0.5)
Methamphetamine	103	4 (3.9)	74	0 (0.0)	181	4 (2.2)
Other opioids	106	2 (1.9)	59	0 (0.0)	165	2 (1.2)
PIEDs	78	1 (1.3)	1	0 (0.0)	81	1 (1.2)
Other drugs	30	0 (0.0)	19	0 (0.0)	49	0 (0.0)
p value		0.133		--		0.545
<b>2013</b>						
Heroin	109	2 (1.8)	61	0 (0.0)	171	2 (1.2)
Methamphetamine	137	10 (7.3)	71	0 (0.0)	211	10 (4.7)
Other opioids	100	4 (4.0)	44	0 (0.0)	144	4 (2.8)
PIEDs	67	1 (1.5)	1	0 (0.0)	68	1 (1.5)
Other drugs	37	3 (8.1)	25	0 (0.0)	63	4 (6.4)
p value		0.128		--		0.141
<b>2014</b>						
Heroin	130	1 (0.8)	70	0 (0.0)	202	2 (1.0)
Methamphetamine	164	9 (5.5)	80	0 (0.0)	245	9 (3.7)
Other opioids	81	2 (2.5)	33	0 (0.0)	115	2 (1.7)
PIEDs	69	1 (1.5)	2	0 (0.0)	72	1 (1.4)
Other drugs	60	2 (3.3)	16	0 (0.0)	78	4 (5.1)
p value		0.173		--		0.187
<b>2015</b>						
Heroin	124	3 (2.4)	60	0 (0.0)	187	4 (2.1)
Methamphetamine	134	10 (7.5)	54	2 (3.7)	191	12 (6.3)
Other opioids	85	2 (2.4)	32	0 (0.0)	119	2 (1.7)
PIEDs	70	1 (1.4)	4	0 (0.0)	74	1 (1.4)
Other drugs	23	0 (0.0)	14	0 (0.0)	37	0 (0.0)
p value		0.165		0.352		0.098
<b>2016</b>						
Heroin	106	1 (0.9)	57	1 (1.8)	165	2 (1.2)
Methamphetamine	121	9 (7.4)	56	0 (0.0)	180	10 (5.6)
Other opioids	47	0 (0.0)	21	0 (0.0)	68	0 (0.0)
PIEDs	48	0 (0.0)	0	0 (0.0)	49	0 (0.0)
Other drugs	32	1 (3.1)	14	0 (0.0)	47	1 (2.1)
p value		0.024		1.000		0.046

**Table 3.2.5 HIV antibody prevalence by years of injection, gender and survey year**

New South Wales Years of injection	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
<b>2012</b>						
<3 years	52	1 (1.9)	11	0 (0.0)	64	1 (1.6)
3 to 10 years	75	1 (1.3)	43	0 (0.0)	119	1 (0.8)
11+ years	324	5 (1.5)	164	0 (0.0)	494	6 (1.2)
p value		0.840		--		0.845
<b>2013</b>						
<3 years	53	4 (7.6)	4	0 (0.0)	57	4 (7.0)
3 to 10 years	61	6 (9.8)	42	0 (0.0)	103	6 (5.8)
11+ years	324	9 (2.8)	151	0 (0.0)	480	10 (2.1)
p value		0.015		--		0.017
<b>2014</b>						
<3 years	53	1 (1.9)	8	0 (0.0)	62	1 (1.6)
3 to 10 years	81	6 (7.4)	39	0 (0.0)	120	6 (5)
11+ years	355	7 (2.0)	149	0 (0.0)	509	9 (1.8)
p value		0.042		--		0.111
<b>2015</b>						
<3 years	45	2 (4.4)	12	0 (0.0)	58	2 (3.5)
3 to 10 years	61	4 (6.6)	21	1 (4.8)	84	5 (6.0)
11+ years	317	9 (2.8)	126	1 (0.8)	448	11 (2.5)
p value		0.287		0.373		0.193
<b>2016</b>						
<3 years	21	0 (0.0)	7	0 (0.0)	29	0 (0.0)
3 to 10 years	59	4 (6.8)	21	0 (0.0)	81	4 (4.9)
11+ years	263	6 (2.3)	116	1 (0.9)	384	8 (2.1)
p value		0.189		1.000		0.349

**Table 3.2.6 HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and survey year**

New South Wales Receptively shared syringe last month	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
<b>2012</b>						
No receptive sharing	327	4 (1.2)	146	0 (0.0)	481	5 (1.0)
Receptive sharing	48	0 (0.0)	32	0 (0.0)	80	0 (0.0)
p value		1.000		--		1.000
<b>2013</b>						
No receptive sharing	328	13 (4.0)	141	0 (0.0)	473	13 (2.8)
Receptive sharing	50	2 (4.0)	21	0 (0.0)	72	3 (4.2)
p value		1.000		--		0.456
<b>2014</b>						
No receptive sharing	362	9 (2.5)	143	0 (0.0)	510	11 (2.2)
Receptive sharing	70	2 (2.9)	28	0 (0.0)	99	3 (3.0)
p value		0.695		--		0.485
<b>2015</b>						
No receptive sharing	329	13 (4.0)	119	2 (1.7)	453	16 (3.5)
Receptive sharing	49	2 (4.1)	20	0 (0.0)	71	2 (2.8)
p value		1.000		1.000		1.000
<b>2016</b>						
No receptive sharing	279	9 (3.2)	114	1 (0.9)	398	10 (2.5)
Receptive sharing	37	0 (0.0)	18	0 (0.0)	55	0 (0.0)
p value		0.606		1.000		0.618

**Table 3.2.7 HIV antibody prevalence by frequency of drug injection last month, gender and survey year**

New South Wales Frequency of injection	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)
<b>2012</b>						
Less than daily	201	3 (1.5)	106	0 (0.0)	313	4 (1.3)
Daily or more	187	2 (1.1)	78	0 (0.0)	268	2 (0.8)
Not last month	70	2 (2.9)	37	0 (0.0)	107	2 (1.9)
p value		0.518		--		0.571
<b>2013</b>						
Less than daily	211	11 (5.2)	92	0 (0.0)	305	11 (3.6)
Daily or more	168	5 (3.0)	71	0 (0.0)	242	6 (2.5)
Not last month	66	3 (4.6)	33	0 (0.0)	99	3 (3.0)
p value		0.592		--		0.750
<b>2014</b>						
Less than daily	221	4 (1.8)	87	0 (0.0)	309	4 (1.3)
Daily or more	218	8 (3.7)	86	0 (0.0)	309	11 (3.6)
Not last month	60	3 (5)	26	0 (0.0)	87	3 (3.4)
p value		0.257		--		0.138
<b>2015</b>						
Less than daily	194	8 (4.1)	55	1 (1.8)	252	9 (3.6)
Daily or more	187	7 (3.7)	84	1 (1.2)	275	9 (3.3)
Not last month	47	1 (2.1)	21	0 (0.0)	69	1 (1.5)
p value		1.000		1.000		0.845
<b>2016</b>						
Less than daily	165	5 (3.0)	60	0 (0.0)	229	5 (2.2)
Daily or more	153	4 (2.6)	73	1 (1.4)	227	5 (2.2)
Not last month	30	1 (3.3)	12	0 (0.0)	43	1 (2.3)
p value		1.000		1.000		1.000

**Table 3.2.8 HIV antibody prevalence by imprisonment last year, gender and survey year**

New South Wales Imprisonment last year	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)
<b>2012</b>						
No imprisonment	397	7 (1.8)	188	0 (0.0)	593	8 (1.4)
Imprisonment	46	0 (0.0)	24	0 (0.0)	71	0 (0.0)
p value		1.000		--		1.000
<b>2013</b>						
No imprisonment	378	17 (4.5)	172	0 (0.0)	553	18 (3.3)
Imprisonment	57	2 (3.5)	22	0 (0.0)	81	2 (2.5)
p value		1.000		--		1.000
<b>2014</b>						
No imprisonment	399	12 (3.0)	167	0 (0.0)	568	12 (2.1)
Imprisonment	65	0 (0.0)	22	0 (0.0)	91	3 (3.3)
p value		0.389		--		0.448
<b>2015</b>						
No imprisonment	355	13 (3.7)	143	2 (1.4)	504	16 (3.2)
Imprisonment	56	1 (1.8)	16	0 (0.0)	74	1 (1.4)
p value		0.703		1.000		0.711
<b>2016</b>						
No imprisonment	278	6 (2.2)	131	0 (0.0)	412	6 (1.5)
Imprisonment	58	3 (5.2)	10	1 (10.0)	68	4 (5.9)
p value		0.190		0.071		0.040

**Table 3.2.9 HIV antibody prevalence by condom use at last sex with regular partner, gender and survey year**

<b>New South Wales</b>	<b>Male</b>		<b>Female</b>		<b>Total</b>	
<b>Condom use at last sex</b>	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)
<b>2012</b>						
No condom use	145	2 (1.4)	102	0 (0.0)	250	2 (0.8)
Condom use	60	2 (3.3)	22	0 (0.0)	82	2 (2.4)
p value		0.582		--		0.256
<b>2013</b>						
No condom use	138	3 (2.2)	87	0 (0.0)	226	3 (1.3)
Condom use	72	2 (2.8)	26	0 (0.0)	101	3 (3.0)
p value		1.000		--		0.378
<b>2014</b>						
No condom use	157	1 (0.6)	96	0 (0.0)	253	1 (0.4)
Condom use	65	2 (3.1)	20	0 (0.0)	88	4 (4.6)
p value		0.206		--		0.017
<b>2015</b>						
No condom use	166	6 (3.6)	73	0 (0.0)	240	7 (2.9)
Condom use	42	1 (2.4)	13	1 (7.7)	55	2 (3.6)
p value		1.000		0.151		0.676
<b>2016</b>						
No condom use	116	5 (4.3)	60	0 (0.0)	176	5 (2.8)
Condom use	35	0 (0.0)	17	1 (5.9)	54	2 (3.7)
p value		0.590		0.221		0.668

**Table 3.2.10 HIV antibody prevalence by sex work last month, gender and survey year**

<b>New South Wales</b>	<b>Male</b>		<b>Female</b>		<b>Total</b>	
<b>Sex work last month</b>	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)
<b>2012</b>						
No sex work	432	6 (1.4)	188	0 (0.0)	625	6 (1.0)
Sex work	10	1 (10.0)	26	0 (0.0)	40	2 (5.0)
p value		0.149		--		0.078
<b>2013</b>						
No sex work	411	15 (3.7)	173	0 (0.0)	588	15 (2.6)
Sex work	12	3 (25.0)	20	0 (0.0)	33	4 (12.1)
p value		0.011		--		0.015
<b>2014</b>						
No sex work	439	8 (1.8)	165	0 (0.0)	606	9 (1.5)
Sex work	17	3 (17.7)	22	0 (0.0)	44	5 (11.4)
p value		0.006		--		<0.001
<b>2015</b>						
No sex work	414	11 (2.7)	147	2 (1.4)	567	13 (2.3)
Sex work	11	3 (27.3)	15	0 (0.0)	28	4 (14.3)
p value		0.004		1.000		0.006
<b>2016</b>						
No sex work	324	6 (1.9)	129	1 (0.8)	457	8 (1.8)
Sex work	15	3 (20.0)	11	0 (0.0)	29	3 (10.3)
p value		0.005		1.000		0.023

**Table 3.2.11 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year**

New South Wales Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
<b>2012</b>						
Non Indigenous	413	7 (1.7)	177	0 (0.0)	597	7 (1.2)
Indigenous	45	0 (0.0)	41	0 (0.0)	88	1 (1.1)
p value		1.000		--		1.000
<b>2013</b>						
Non Indigenous	376	17 (4.5)	147	0 (0.0)	526	18 (3.4)
Indigenous	68	1 (1.5)	51	0 (0.0)	121	1 (0.8)
p value		0.332		--		0.226
<b>2014</b>						
Non Indigenous	421	12 (2.9)	142	0 (0.0)	569	14 (2.5)
Indigenous	73	1 (1.4)	57	0 (0.0)	131	2 (1.5)
p value		0.703		--		0.749
<b>2015</b>						
Non Indigenous	358	15 (4.2)	122	0 (0.0)	486	16 (3.3)
Indigenous	71	1 (1.4)	41	2 (4.9)	112	3 (2.7)
p value		0.489		0.062		1.000
<b>2016</b>						
Non Indigenous	283	7 (2.5)	109	0 (0.0)	399	8 (2.0)
Indigenous	59	3 (5.1)	37	1 (2.7)	96	4 (4.2)
p value		0.386		0.253		0.260

**Table 3.2.12 HIV antibody prevalence by main language spoken at home by parents, gender and survey year**

New South Wales Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
<b>2012</b>						
English speaking	440	6 (1.4)	213	0 (0.0)	660	7 (1.1)
Non-English speaking	23	1 (4.4)	7	0 (0.0)	32	1 (3.1)
p value		0.302		--		0.317
<b>2013</b>						
English speaking	419	19 (4.5)	193	0 (0.0)	616	20 (3.3)
Non-English speaking	35	1 (2.9)	11	0 (0.0)	47	1 (2.1)
p value		1.000		--		1.000
<b>2014</b>						
English speaking	459	13 (2.8)	189	0 (0.0)	654	16 (2.5)
Non-English speaking	41	0 (0.0)	11	0 (0.0)	53	0 (0.0)
p value		0.613		--		0.624
<b>2015</b>						
English speaking	408	15 (3.7)	157	2 (1.3)	573	18 (3.1)
Non-English speaking	25	1 (4.0)	7	0 (0.0)	32	1 (3.1)
p value		1.000		1.000		1.000
<b>2016</b>						
English speaking	324	10 (3.1)	142	1 (0.7)	472	12 (2.5)
Non-English speaking	25	0 (0.0)	5	0 (0.0)	31	0 (0.0)
p value		1.000		1.000		1.000

**Table 3.2.13 HIV antibody prevalence by region/country of birth, gender and survey year**

<b>New South Wales</b>						
<b>Region/country of birth</b>	<b>Male</b>		<b>Female</b>		<b>Total</b>	
	<b>N° tested</b>	<b>N° with HIV (%)</b>	<b>N° tested</b>	<b>N° with HIV (%)</b>	<b>N° tested</b>	<b>N° with HIV (%)</b>
<b>2012</b>						
Australia	402	3 (0.8)	196	0 (0.0)	606	4 (0.7)
Other Oceania	14	2 (14.2)	8	0 (0.0)	22	2 (9.1)
Asia	7	0 (0.0)	0	0 (0.0)	8	0 (0.0)
UK & Ireland	23	0 (0.0)	7	0 (0.0)	30	0 (0.0)
Other	12	2 (16.7)	9	0 (0.0)	21	2 (9.5)
p value		0.001		--		0.003
<b>2013</b>						
Australia	392	15 (3.8)	188	0 (0.0)	582	15 (2.6)
Other Oceania	12	1 (8.3)	6	0 (0.0)	19	2 (10.5)
Asia	8	1 (12.5)	1	0 (0.0)	9	1 (11.1)
UK & Ireland	14	1 (7.1)	7	0 (0.0)	22	1 (4.6)
Other	28	2 (7.1)	2	0 (0.0)	31	2 (6.5)
p value		0.602		--		0.131
<b>2014</b>						
Australia	421	11 (2.6)	179	0 (0.0)	604	12 (2.0)
Other Oceania	20	0 (0.0)	7	0 (0.0)	29	2 (6.9)
Asia	10	0 (0.0)	1	0 (0.0)	11	0 (0.0)
UK & Ireland	19	0 (0.0)	7	0 (0.0)	26	0 (0.0)
Other	28	2 (7.1)	5	0 (0.0)	34	2 (5.9)
p value		0.508		--		0.169
<b>2015</b>						
Australia	373	13 (3.5)	143	2 (1.4)	523	15 (2.9)
Other Oceania	17	1 (5.9)	6	0 (0.0)	24	2 (8.3)
Asia	8	0 (0.0)	3	0 (0.0)	11	0 (0.0)
UK & Ireland	19	1 (5.3)	7	0 (0.0)	26	1 (3.9)
Other	12	0 (0.0)	5	0 (0.0)	17	0 (0.0)
p value		0.704		1.000		0.401
<b>2016</b>						
Australia	304	10 (3.3)	125	1 (0.8)	434	11 (2.5)
Other Oceania	14	0 (0.0)	10	0 (0.0)	25	1 (4.0)
Asia	8	0 (0.0)	1	0 (0.0)	10	0 (0.0)
UK & Ireland	7	0 (0.0)	4	0 (0.0)	11	0 (0.0)
Other	14	0 (0.0)	7	0 (0.0)	21	0 (0.0)
p value		1.000		1.000		0.825

## HCV antibody prevalence

**Table 3.3.1 HCV antibody prevalence by gender and survey year**

New South Wales Survey year	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
2012	453	213 (47)	220	121 (55)	682	338 (50)
2013	453	232 (51)	204	120 (59)	661	354 (54)
2014	502	264 (53)	200	123 (62)	709	390 (55)
2015	371	215 (58)	143	96 (67)	521	316 (61)
2016	331	174 (53)	137	75 (55)	473	252 (53)
X <sup>2</sup> p trend		0.178		0.646		0.179

**Table 3.3.2 HCV antibody prevalence by sexual identity, gender and survey year**

New South Wales Sexual identity	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2012</b>						
Heterosexual	339	195 (49)	152	85 (56)	553	281 (51)
Bisexual	14	4 (29)	41	23 (56)	57	27 (47)
Homosexual	15	3 (20)	6	1 (17)	23	5 (22)
p value		0.033		0.163		0.021
<b>2013</b>						
Heterosexual	383	206 (54)	143	84 (59)	527	291 (55)
Bisexual	21	11 (52)	28	17 (61)	49	28 (57)
Homosexual	30	6 (20)	11	5 (45)	44	12 (27)
p value		0.002		0.720		0.001
<b>2014</b>						
Heterosexual	432	233 (54)	133	80 (60)	567	314 (55)
Bisexual	17	8 (47)	44	27 (61)	65	37 (57)
Homosexual	31	10 (32)	10	6 (60)	42	16 (38)
p value		0.060		0.989		0.087
<b>2015</b>						
Heterosexual	313	185 (59)	108	71 (66)	424	258 (61)
Bisexual	21	12 (57)	25	18 (72)	48	31 (65)
Homosexual	22	9 (41)	2	1 (50)	25	11 (44)
p value		0.247		0.737		0.202
<b>2016</b>						
Heterosexual	271	147 (54)	96	51 (53)	368	199 (54)
Bisexual	16	6 (38)	32	20 (63)	48	26 (54)
Homosexual	25	9 (36)	0	0 (0)	28	11 (39)
p value		0.108		0.355		0.315



**Table 3.3.3 HCV antibody prevalence by age group, gender and survey year**

New South Wales Age group	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2012</b>						
<25 years	41	0 (0)	10	5 (50)	52	5 (10)
25-34 years	114	34 (30)	65	38 (58)	181	74 (41)
35-44 years	153	84 (55)	86	49 (57)	242	134 (55)
45+ years	145	95 (66)	59	29 (49)	207	125 (60)
p value		<0.001		0.713		<0.001
<b>2013</b>						
<25 years	38	2 (5)	11	4 (36)	49	6 (12)
25-34 years	105	38 (36)	50	25 (50)	156	64 (41)
35-44 years	172	102 (59)	77	47 (61)	250	149 (60)
45+ years	138	90 (65)	66	44 (67)	206	135 (66)
p value		<0.001		0.127		<0.001
<b>2014</b>						
<25 years	42	5 (12)	7	2 (29)	50	7 (14)
25-34 years	104	39 (38)	59	38 (64)	166	79 (48)
35-44 years	187	116 (62)	79	44 (56)	269	161 (60)
45+ years	169	104 (62)	53	37 (70)	222	141 (64)
p value		<0.001		0.116		<0.001
<b>2015</b>						
<25 years	16	2 (13)	3	0 (0)	19	2 (11)
25-34 years	87	31 (36)	46	30 (65)	136	63 (46)
35-44 years	126	82 (65)	45	30 (67)	173	113 (65)
45+ years	142	100 (70)	49	36 (73)	193	138 (72)
p value		<0.001		0.089		<0.001
<b>2016</b>						
<25 years	17	4 (24)	2	1 (50)	19	5 (26)
25-34 years	56	14 (25)	31	18 (58)	88	33 (38)
35-44 years	125	74 (59)	49	23 (47)	175	97 (55)
45+ years	133	82 (62)	55	33 (60)	191	117 (61)
p value		<0.001		0.566		<0.001

**Table 3.3.4 HCV antibody prevalence by years since first injection, gender and survey year**

New South Wales Years of injection	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2012</b>						
<3 years	51	3 (6)	11	3 (27)	63	7 (11)
3 to 10 years	73	18 (25)	43	26 (60)	117	44 (38)
11+ years	315	187 (59)	161	91 (57)	482	281 (58)
p value		<0.001		0.134		<0.001
<b>2013</b>						
<3 years	53	0 (0)	4	2 (50)	57	2 (4)
3 to 10 years	61	14 (23)	42	21 (50)	103	35 (34)
11+ years	321	207 (65)	151	94 (62)	476	303 (64)
p value		<0.001		0.334		0
<b>2014</b>						
<3 years	53	1 (20)	8	1 (13)	62	2 (3)
3 to 10 years	80	22 (28)	39	22 (56)	19	44 (37)
11+ years	353	231 (65)	147	96 (65)	505	330 (65)
p value		<0.001		0.009		<0.001
<b>2015</b>						
<3 years	36	5 (14)	8	2 (25)	44	7 (16)
3 to 10 years	50	16 (32)	17	8 (57)	69	25 (36)
11+ years	275	191 (69)	113	84 (74)	393	279 (71)
p value		<0.001		0.002		<0.001
<b>2016</b>						
<3 years	21	2 (10)	7	1 (14)	29	4 (14)
3 to 10 years	55	15 (27)	18	8 (44)	74	23 (31)
11+ years	245	152 (62)	109	65 (60)	357	219 (61)
p value		<0.001		0.048		<0.001

**Table 3.3.5 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year**

New South Wales Receptively shared syringe last month	<3 years		3+ years		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2012</b>						
No receptive sharing	45	6 (13)	417	228 (55)	474	238 (50)
Receptive sharing	5	1 (20)	71	42 (59)	77	44 (57)
p value		0.546		0.520		0.271
<b>2013</b>						
No receptive sharing	33	1 (3)	430	249 (58)	472	256 (54)
Receptive sharing	5	0 (0)	59	34 (58)	69	38 (55)
p value		1.000		0.967		0.896
<b>2014</b>						
No receptive sharing	44	2 (5)	454	259 (57)	507	267 (53)
Receptive sharing	2	0 (0)	90	69 (77)	99	75 (76)
p value		1.000		0.001		<0.001
<b>2015</b>						
No receptive sharing	32	5 (16)	350	232 (66)	389	238 (61)
Receptive sharing	3	1 (33)	56	36 (64)	60	38 (63)
p value		0.442		0.769		0.750
<b>2016</b>						
No receptive sharing	23	4 (17)	337	190 (56)	369	197 (53)
Receptive sharing	3	0 (0)	47	28 (60)	52	30 (58)
p value		1.000		0.679		0.560

**Table 3.3.6 HCV antibody prevalence by last drug injected, years since first injection and survey year**

New South Wales Last drug injected	<3 years		3+ years		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2012</b>						
Heroin	10	2 (20)	198	114 (58)	211	118 (56)
Methamphetamine	7	2 (29)	165	86 (52)	177	91 (51)
Other opioids	4	2 (50)	156	99 (63)	160	101 (63)
PIEDs	39	1 (3)	35	1 (3)	80	2 (3)
Other drugs	3	0 (0)	43	24 (56)	47	25 (53)
p value		0.015		<0.001		<0.001
<b>2013</b>						
Heroin	3	1 (33)	163	116 (71)	171	119 (70)
Methamphetamine	8	1 (13)	198	107 (54)	209	111 (53)
Other opioids	4	0 (0)	137	85 (62)	143	87 (61)
PIEDs	36	0 (0)	30	1 (3)	68	1 (1)
Other drugs	3	0 (0)	50	28 (56)	62	34 (55)
p value		0.029		<0.001		<0.001
<b>2014</b>						
Heroin	4	1 (25)	192	130 (68)	200	133 (67)
Methamphetamine	14	1 (7)	221	130 (59)	243	135 (56)
Other opioids	2	0 (0)	111	73 (66)	114	74 (65)
PIEDs	36	0 (0)	33	1 (3)	72	2 (3)
Other drugs	5	0 (0)	67	40 (60)	78	46 (59)
p value		0.089		<0.001		<0.001
<b>2015</b>						
Heroin	5	1 (20)	158	120 (76)	165	123 (75)
Methamphetamine	12	2 (17)	145	86 (59)	161	90 (56)
Other opioids	3	2 (67)	96	74 (77)	99	76 (77)
PIEDs	20	1 (5)	32	0 (0)	56	1 (2)
Other drugs	3	1 (33)	26	21 (81)	30	22 (73)
p value		0.086		<0.001		<0.001
<b>2016</b>						
Heroin	1	0 (0)	151	94 (62)	156	95 (61)
Methamphetamine	10	3 (30)	148	81 (55)	162	86 (53)
Other opioids	1	1 (100)	60	45 (75)	62	47 (76)
PIEDs	15	0 (0)	28	0 (0)	45	0 (0)
Other drugs	1	0 (0)	37	19 (51)	40	21 (53)
p value		0.028		<0.001		<0.001

**Table 3.3.7 HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year**

New South Wales Frequency of injection last month	<3 years		3+ years		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2012</b>						
Less than daily	27	5 (19)	275	162 (59)	309	170 (55)
Daily or more	23	2 (9)	231	116 (50)	261	121 (46)
Not last month	12	0 (0)	87	44 (51)	103	44 (43)
p value		0.291		0.112		0.036
<b>2013</b>						
Less than daily	28	1 (4)	268	144 (54)	302	150 (50)
Daily or more	11	1 (9)	222	139 (63)	241	145 (60)
Not last month	16	0 (0)	75	44 (59)	99	46 (46)
p value		0.444		0.139		0.018
<b>2014</b>						
Less than daily	26	1 (4)	275	151 (55)	307	157 (51)
Daily or more	20	1 (5)	277	183 (66)	308	191 (62)
Not last month	15	0 (0)	65	35 (54)	85	36 (42)
p value		1.000		0.016		0.001
<b>2015</b>						
Less than daily	22	2 (9)	186	113 (61)	213	115 (54)
Daily or more	13	4 (31)	222	156 (70)	238	162 (68)
Not last month	8	1 (13)	49	32 (65)	60	35 (58)
p value		0.291		0.125		0.008
<b>2016</b>						
Less than daily	15	2 (13)	195	101 (52)	212	104 (49)
Daily or more	11	2 (18)	192	120 (63)	212	126 (59)
Not last month	2	0 (0)	37	18 (49)	41	19 (46)
p value		1.000		0.064		0.063

**Table 3.3.8 HCV antibody prevalence by imprisonment last year, years since first injection and survey year**

New South Wales Imprisonment last year	<3 years		3+ years		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2012</b>						
No imprisonment	61	7 (11)	504	263 (52)	581	274 (47)
Imprisonment	1	0 (0)	66	40 (61)	69	41 (59)
p value		1.000		0.197		0.057
<b>2013</b>						
No imprisonment	52	1 (2)	479	261 (54)	550	272 (49)
Imprisonment	4	0 (0)	74	56 (76)	80	58 (73)
p value		1.000		0.001		<0.001
<b>2014</b>						
No imprisonment	58	1 (2)	492	275 (56)	564	285 (51)
Imprisonment	3	1 (33)	84	67 (80)	91	71 (78)
p value		0.097		<0.001		<0.001
<b>2015</b>						
No imprisonment	38	6 (16)	376	235 (63)	427	244 (57)
Imprisonment	2	1 (50)	64	53 (83)	67	55 (82)
p value		0.323		0.002		<0.001
<b>2016</b>						
No imprisonment	24	2 (8)	349	193 (55)	382	200 (52)
Imprisonment	3	1 (33)	58	36 (62)	64	37 (58)
p value		0.308		0.336		0.418

**Table 3.3.9 HCV antibody prevalence by sex work last month, years since first injection and survey year**

<b>New South Wales</b>	<b>&lt;3 years</b>		<b>3+ years</b>		<b>Total</b>	
<b>Sex work last month</b>	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2012</b>						
No sex work	56	5 (9)	537	290 (54)	610	301 (49)
Sex work	3	1 (33)	35	18 (51)	40	19 (48)
p value		0.279		0.767		0.821
<b>2013</b>						
No sex work	53	1 (2)	514	296 (58)	586	308 (53)
Sex work	1	0 (0)	29	18 (62)	32	20 (63)
p value		1.000		0.634		0.273
<b>2014</b>						
No sex work	57	2 (4)	533	318 (60)	602	327 (54)
Sex work	2	0 (0)	39	31 (79)	44	33 (75)
p value		1.000		0.014		0.008
<b>2015</b>						
No sex work	41	7 (17)	427	276 (65)	483	288 (60)
Sex work	2	0 (0)	23	20 (87)	25	20 (80)
p value		1.000		0.028		0.042
<b>2016</b>						
No sex work	26	3 (12)	389	214 (55)	426	223 (52)
Sex work	1	1 (100)	26	18 (69)	27	19 (70)
p value		0.148		0.157		0.069

**Table 3.3.10 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year**

<b>New South Wales</b>	<b>Male</b>		<b>Female</b>		<b>Total</b>	
<b>Aboriginal and Torres Strait Islander origin</b>	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2012</b>						
Non Indigenous	401	189 (47)	175	95 (54)	583	287 (49)
Indigenous	45	21 (47)	40	24 (60)	87	46 (53)
p value		1.000		0.598		0.566
<b>2013</b>						
Non Indigenous	373	186 (50)	147	83 (56)	522	269 (52)
Indigenous	68	41 (60)	51	33 (65)	121	76 (63)
p value		0.114		0.303		0.025
<b>2014</b>						
Non Indigenous	418	206 (49)	140	84 (60)	564	293 (52)
Indigenous	73	53 (73)	57	36 (63)	131	89 (68)
p value		<0.001		0.680		0.001
<b>2015</b>						
Non Indigenous	311	167 (54)	105	67 (64)	421	237 (56)
Indigenous	55	44 (80)	37	28 (76)	92	72 (78)
p value		<0.001		0.187		<0.001
<b>2016</b>						
Non Indigenous	263	130 (49)	101	55 (54)	369	188 (51)
Indigenous	56	37 (66)	34	19 (56)	90	56 (62)
p value		0.024		0.885		0.055

**Table 3.3.11 HCV antibody prevalence by main language spoken at home by parents, gender and survey year**

<b>New South Wales</b>	<b>Male</b>		<b>Female</b>		<b>Total</b>	
<b>Main language spoken at home by parents</b>	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2012</b>						
English speaking	428	197 (46)	210	118 (56)	645	318 (49)
Non-English speaking	23	15 (65)	7	1 (14)	32	17 (53)
p value		0.087		0.048		0.720
<b>2013</b>						
English speaking	416	216 (52)	193	112 (58)	612	330 (54)
Non-English speaking	35	15 (43)	11	8 (73)	47	23 (49)
p value		0.303		0.531		0.509
<b>2014</b>						
English speaking	456	242 (53)	187	114 (61)	649	358 (55)
Non-English speaking	41	20 (49)	11	7 (64)	53	28 (53)
p value		0.598		0.860		0.743
<b>2015</b>						
English speaking	346	201 (58)	137	93 (68)	490	299 (61)
Non-English speaking	23	13 (57)	6	3 (50)	29	16 (55)
p value		0.883		0.395		0.531
<b>2016</b>						
English speaking	303	164 (54)	132	71 (54)	439	238 (54)
Non-English speaking	23	8 (35)	4	3 (75)	28	11 (39)
p value		0.073		0.625		0.125

**Table 3.3.12 HCV antibody prevalence by region/country of birth, gender and survey year**

<b>New South Wales</b>						
<b>Region/Country of birth</b>	<b>Male</b>		<b>Female</b>		<b>Total</b>	
	<b>N° tested</b>	<b>N° with HCV (%)</b>	<b>N° tested</b>	<b>N° with HCV (%)</b>	<b>N° tested</b>	<b>N° with HCV (%)</b>
<b>2012</b>						
Australia	392	183 (47)	194	105 (54)	594	292 (49)
Other Oceania	13	5 (38)	7	6 (86)	20	11 (55)
Asia	7	5 (71)	0	0 (0)	8	5 (63)
UK & Ireland	22	14 (64)	7	3 (43)	29	17 (59)
Other	12	3 (25)	9	5 (56)	21	8 (38)
p value		0.149		0.361		0.584
<b>2013</b>						
Australia	390	204 (52)	188	110 (59)	580	316 (54)
Other Oceania	12	6 (50)	6	4 (67)	18	10 (56)
Asia	8	3 (38)	1	0 (0)	9	3 (33)
UK & Ireland	14	8 (57)	7	4 (57)	22	12 (55)
Other	27	11 (41)	2	2 (100)	30	13 (43)
p value		0.711		0.724		0.566
<b>2014</b>						
Australia	420	230 (55)	177	108 (61)	601	339 (56)
Other Oceania	20	10 (50)	7	3 (43)	29	14 (48)
Asia	10	5 (50)	1	0 (0)	11	5 (45)
UK & Ireland	18	7 (39)	7	5 (71)	25	12 (48)
Other	27	10 (37)	5	5 (100)	33	16 (49)
p value		0.305		0.179		0.635
<b>2015</b>						
Australia	324	198 (61)	127	89 (70)	457	291 (64)
Other Oceania	11	4 (36)	4	1 (25)	16	6 (38)
Asia	8	1 (13)	2	2 (100)	10	3 (30)
UK & Ireland	14	7 (50)	5	2 (40)	19	9 (47)
Other	10	4 (40)	5	2 (40)	15	6 (40)
p value		0.016		0.057		0.009
<b>2016</b>						
Australia	285	150 (53)	116	62 (53)	405	215 (53)
Other Oceania	14	7 (50)	10	5 (50)	24	12 (50)
Asia	6	2 (33)	1	0 (0)	8	2 (25)
UK & Ireland	7	4 (57)	3	3 (100)	10	7 (70)
Other	13	8 (62)	6	4 (67)	19	12 (63)
p value		0.851		0.440		0.356

## Northern Territory

**Table 4.1.1 Number (percentage) of respondents by demographic characteristics and survey year**

Northern Territory	2012	2013	2014	2015	2016
<b>Number of sites</b>	3	3	3	3	3
<b>N° surveyed</b>	N=50	N=70	N=70	N=60	N=87
<b>Response rate (%)</b>	21%	33%	39%	27%	49%
<b>Gender (%)</b>					
Male	33 (66)	49 (70)	54 (77)	46 (77)	59 (68)
Female	16 (32)	21 (30)	16 (23)	14 (23)	26 (30)
Transgender	1 (2)	0 (0)	0 (0)	0 (0)	2 (2)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
<b>Sexual identity (%)</b>					
Heterosexual	39 (78)	61 (87)	63 (90)	54 (90)	67 (77)
Bisexual	8 (16)	5 (7)	3 (4)	3 (5)	9 (10)
Homosexual	2 (4)	1 (1)	0 (0)	1 (2)	4 (5)
Not reported	1 (2)	3 (4)	4 (6)	2 (3)	7 (8)
<b>Aboriginal and Torres Strait Islander origin (%)</b>					
No	37 (74)	55 (79)	55 (79)	42 (70)	52 (60)
Yes	12 (24)	13 (19)	14 (20)	16 (27)	31 (36)
Not reported	1 (2)	2 (3)	1 (1)	2 (3)	4 (5)
<b>Region/country of birth (%)</b>					
Australia	44 (88)	59 (84)	61 (87)	53 (88)	75 (86)
Other Oceania	1 (2)	1 (1)	2 (3)	3 (5)	1 (1)
Asia	0 (0)	0 (0)	1 (1)	1 (2)	1 (1)
UK & Ireland	2 (4)	7 (10)	3 (4)	2 (3)	0 (0)
Other	3 (6)	3 (4)	3 (4)	0 (0)	5 (6)
Not reported	0 (0)	0 (0)	0 (0)	1 (2)	5 (6)
<b>Main language spoken at home by parents (%)</b>					
English	48 (96)	68 (97)	66 (94)	57 (95)	79 (91)
Non-English	2 (4)	2 (3)	4 (6)	2 (3)	4 (5)
Not reported	0 (0)	0 (0)	0 (0)	1 (2)	4 (5)
<b>Age and time since first injection (years)</b>					
<i>Median age</i>	39	42	42	42	43
<i>Age range</i>	20-59	19-62	21-61	26-57	21-65
<i>Age group (%)</i>					
<25 years	2 (4)	2 (3)	3 (4)	0 (0)	2 (2)
25+ years	48 (96)	68 (97)	67 (96)	60 (100)	85 (98)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
<i>Median age first injection</i>	18	20	20	18	19
<i>Age range</i>	12-40	13-40	10-45	12-43	11-45
<i>N° not reported</i>	3	2	0	2	2
<i>Median yrs since first injection</i>	17	21	21	20	21
<i>Range</i>	1-41	3-46	0-45	2-41	2-46
<i>Years since first injection</i>					
<3 years	3 (6)	0 (0)	4 (6)	1 (2)	4 (5)
3+ years	44 (88)	68 (97)	65 (93)	57 (95)	81 (93)
Not reported	3 (6)	2 (3)	1 (1)	2 (3)	2 (2)
<b>Imprisonment last year (%)</b>					
No	45 (90)	62 (89)	63 (90)	50 (83)	72 (83)
Yes	4 (8)	7 (14)	2 (3)	7 (12)	8 (9)
Not reported	1 (2)	1 (1)	5 (7)	3 (5)	7 (8)
<b>N° in prison</b>					
Injected in prison	0 (0)	1 (14)	0 (0)	0 (0)	1 (13)



**Table 4.1.2 Number (percentage) of respondents by last drug injected, frequency of injecting and survey year**

<b>Northern Territory N° surveyed</b>	<b>2012 N=50</b>	<b>2013 N=70</b>	<b>2014 N=70</b>	<b>2015 N=60</b>	<b>2016 N=87</b>
<b>Drug last injected (%)</b>					
Cocaine	0 (0)	1 (1)	1 (1)	0 (0)	0 (0)
Methamphetamine	9 (18)	8 (11)	19 (27)	21 (35)	37 (43)
Heroin	2 (4)	7 (10)	6 (9)	1 (2)	4 (5)
Pharm. opioids	35 (70)	43 (61)	35 (50)	25 (42)	30 (34)
Methadone	1 (2)	1 (1)	6 (9)	4 (7)	2 (2)
Buprenorphine	0 (0)	1 (1)	1 (1)	5 (8)	2 (2)
Buprenorphine/naloxone	1 (2)	0 (0)	1 (1)	3 (5)	4 (5)
PIEDs	1 (2)	3 (4)	1 (1)	0 (0)	1 (1)
More than one	1 (2)	5 (7)	0 (0)	1 (2)	7 (8)
Other	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
<b>Ever injected opioids</b>					
Yes					
No	-	-	-	-	73 (84)
Not reported	-	-	-	-	13 (15)
<b>Frequency of injection last mon</b>					
Not last month	5 (10)	8 (11)	3 (4)	2 (3)	8 (9)
Less than weekly	3 (6)	11 (16)	9 (13)	7 (12)	10 (11)
Weekly not daily	10 (20)	12 (17)	9 (13)	8 (13)	15 (17)
Daily or more	32 (64)	39 (56)	48 (69)	43 (72)	54 (62)
Not reported	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)
<b>Present when someone injected for the first time in the last 12 months (%)</b>					
Yes	12 (24)	4 (6)	7 (10)	7 (12)	13 (15)
No	37 (74)	54 (77)	63 (90)	50 (83)	69 (79)
Not reported	1 (2)	12 (17)	0 (0)	3 (5)	5 (6)
<b>Overdosed in last 12 months</b>					
Yes	--	10 (14)	2 (3)	9 (15)	13 (15)
No	--	57 (81)	68 (97)	50 (83)	68 (78)
Not reported	--	3 (4)	0 (0)	1 (2)	6 (7)

**Table 4.1.3 Number (percentage) of respondents by injecting behaviour in the last month and survey year**

<b>Northern Territory N° injected last month</b>	<b>2012 N=45</b>	<b>2013 N=62</b>	<b>2014 N=66</b>	<b>2015 N=58</b>	<b>2016 N=79</b>
<b>Places injected last month (%)</b>					
Any public	16 (36)	18 (29)	14 (21)	20 (34)	27 (34)
All private	29 (64)	43 (69)	52 (79)	38 (66)	52 (66)
Not reported	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
<b>Use of new and sterile needles and syringes last month (%)</b>					
All injections	33 (73)	51 (82)	56 (85)	47 (81)	67 (85)
Most of the time	9 (20)	9 (15)	7 (11)	9 (16)	9 (11)
Half of the time	0 (0)	0 (0)	1 (2)	1 (2)	0 (0)
Some of the time	1 (2)	1 (2)	2 (3)	0 (0)	0 (0)
Not last month	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)
Not reported	2 (4)	1 (2)	0 (0)	1 (2)	2 (3)
<b>Re-used someone else's used needle &amp; syringe last month (%)</b>					
None	39 (87)	55 (89)	62 (94)	56 (97)	70 (89)
Once	1 (2)	3 (5)	2 (3)	1 (2)	3 (4)
Twice	4 (9)	2 (3)	1 (2)	1 (2)	3 (4)
3-5 times	1 (2)	0 (0)	1 (2)	0 (0)	1 (1)
>5 times	0 (0)	1 (2)	0 (0)	0 (0)	2 (3)
Not reported	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
<b>Number of people needle &amp; syringe was re-used after last month (%)</b>					
None	39 (87)	55 (89)	62 (94)	56 (97)	70 (89)
One	4 (9)	1 (2)	1 (2)	0 (0)	2 (3)
Two	0 (0)	0 (0)	2 (3)	0 (0)	0 (0)
Three to five	2 (4)	0 (0)	0 (0)	0 (0)	0 (0)
More than five	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)
Don't know	0 (0)	2 (3)	0 (0)	1 (2)	2 (3)
Not reported	0 (0)	4 (6)	1 (2)	1 (2)	4 (5)
<b>Relationship to people needle &amp; syringe was used after last month (%) [more than one could be selected]</b>					
Regular sex partner	5 (11)	1 (2)	0 (0)	1 (2)	2 (3)
Casual sex partner	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)
Close friend	1 (2)	0 (0)	0 (0)	0 (0)	1 (1)
Acquaintance	0 (0)	1 (2)	3 (5)	0 (0)	1 (1)
Other	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)
<b>Equipment used after someone else last month (%) [more than one could be selected]</b>					
Spoon	10 (22)	22 (35)	11 (17)	10 (17)	21 (27)
Water	3 (7)	7 (11)	2 (3)	7 (12)	18 (23)
Filter	4 (9)	7 (11)	9 (14)	4 (7)	7 (9)
Drug mix	3 (7)	3 (5)	1 (2)	4 (7)	9 (11)
None	32 (71)	39 (63)	55 (83)	43 (74)	50 (63)
<b>Injected by someone after that person injected themselves or others last month (%)</b>					
No	36 (80)	58 (94)	57 (86)	54 (93)	67 (85)
Yes	9 (20)	2 (3)	7 (11)	4 (7)	10 (13)
Not reported	0 (0)	2 (3)	2 (3)	0 (0)	2 (3)
<b>Source of needle acquisition</b>					
Needle Syringe Program	43 (96)	58 (94)	62 (94)	57 (98)	75 (95)
Chemist/Pharmacy	9 (20)	6 (10)	7 (11)	9 (16)	9 (11)
Personal sources	12 (27)	7 (11)	9 (14)	5 (9)	12 (15)
Dispensing/Vending Machine	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)
Other sources	0 (0)	0 (0)	3 (5)	1 (2)	1 (1)

**Table 4.1.4 Number (percentage) of respondents by treatment for drug use and survey year**

<b>Northern Territory N° surveyed</b>	<b>2012 N=50</b>	<b>2013 N=70</b>	<b>2014 N=70</b>	<b>2015 N=60</b>	<b>2016 N=87</b>
<b>Ever any treatment/therapy for drug use (%)</b>					
No	14 (28)	29 (41)	24 (34)	18 (30)	37 (43)
Yes	36 (72)	41 (59)	45 (64)	40 (67)	45 (52)
Not reported	0 (0)	0 (0)	1 (1)	2 (3)	5 (6)
<b>History of methadone maintenance treatment (%)</b>					
Currently	6 (12)	11 (16)	2 (3)	5 (8)	1 (1)
Previously	11 (22)	18 (26)	15 (21)	18 (30)	19 (22)
Never	32 (64)	41 (59)	48 (69)	36 (60)	60 (69)
Not reported	1 (2)	0 (0)	5 (7)	1 (2)	7 (8)
<b>History of buprenorphine (Subutex®) treatment (%)</b>					
Currently	6 (12)	3 (4)	3 (4)	2 (3)	9 (10)
Previously	18 (36)	16 (23)	22 (31)	15 (25)	15 (17)
Never	26 (52)	50 (71)	43 (61)	43 (72)	58 (67)
Not reported	0 (0)	1 (1)	2 (3)	0 (0)	5 (6)
<b>History of buprenorphine-naloxone (Suboxone®) treatment (%)</b>					
Currently	6 (12)	9 (13)	5 (7)	4 (7)	12 (14)
Previously	6 (12)	11 (16)	19 (27)	16 (27)	13 (15)
Never	38 (76)	48 (69)	45 (64)	36 (60)	56 (64)
Not reported	0 (0)	2 (3)	1 (1)	4 (7)	6 (7)

**Table 4.1.5 Number (percentage) of respondents by testing for HIV and HCV, HCV treatment by survey year**

<b>Northern Territory N° surveyed</b>	<b>2012 N=50</b>	<b>2013 N=70</b>	<b>2014 N=70</b>	<b>2015 N=60</b>	<b>2016 N=87</b>
<b>Previous HIV test (%)</b>					
Yes, ever	44 (88)	60 (86)	60 (86)	51 (85)	72 (83)
Yes, last year	29 (58)	35 (50)	28 (40)	22 (37)	48 (55)
>1 year ago	15 (30)	25 (36)	32 (46)	29 (48)	24 (28)
Never tested	5 (10)	10 (14)	10 (14)	8 (13)	10 (11)
Not reported	1 (2)	0 (0)	0 (0)	1 (2)	5 (6)
<b>Previous HCV test (%)</b>					
Yes, ever	46 (92)	60 (86)	66 (94)	50 (83)	74 (85)
Yes, last year	30 (60)	36 (51)	31 (44)	26 (43)	49 (56)
>1 year ago	16 (32)	24 (34)	35 (50)	24 (40)	25 (29)
Never tested	3 (6)	7 (10)	4 (6)	5 (8)	5 (6)
Not reported	1 (2)	3 (4)	0 (0)	5 (8)	8 (9)
<b>Lifetime treatment for HCV (%)<sup>#</sup></b>					
<b>N° self-reported HCV diagnosis</b>	<b>N=6</b>	<b>N=20</b>	<b>N=24</b>	<b>N=17</b>	<b>N=21</b>
Antiviral treatment	0 (0)	2 (10)	11 (46)	1 (6)	4 (19)
No antiviral treatment	6 (100)	18 (90)	13 (54)	16 (94)	17 (81)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
<b>Treatment for HCV in past 12 months (%)<sup>#*</sup></b>					
<b>N° self-reported HCV diagnosis</b>	<b>N=6</b>	<b>N=19</b>	<b>N=17</b>	<b>N=17</b>	<b>N=21</b>
Antiviral treatment	0 (0)	0 (0)	0 (0)	0 (0)	4 (19)
No antiviral treatment	6 (100)	19 (100)	17 (100)	17 (100)	17 (81)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

<sup>#</sup> among people who tested HCV antibody positive and did not report spontaneous clearance

\* excludes people who reported treatment induced clearance more than 12 months previously

**Table 4.1.6 Number (percentage) of respondents by sexual behaviour in the month prior to survey and survey year**

<b>Northern Territory N° surveyed</b>	<b>2012 N=50</b>	<b>2013 N=70</b>	<b>2014 N=70</b>	<b>2015 N=60</b>	<b>2016 N=87</b>
<b>Sex with a regular partner last month (%)</b>					
No	30 (60)	43 (61)	41 (59)	40 (67)	52 (60)
Yes	19 (38)	26 (37)	29 (41)	19 (32)	28 (32)
Not reported	1 (2)	1 (1)	0 (0)	1 (2)	7 (8)
<b>Condom used with regular partner last month (%)</b>					
<b>N° surveyed</b>	<b>N=19</b>	<b>N=26</b>	<b>N=29</b>	<b>N=19</b>	<b>N=28</b>
Never	12 (63)	24 (92)	16 (55)	15 (79)	16 (57)
Sometimes	1 (5)	0 (0)	5 (17)	1 (5)	6 (21)
Every time	5 (26)	1 (4)	4 (14)	3 (16)	5 (18)
Not reported	1 (5)	1 (4)	4 (14)	0 (0)	1 (4)
<b>Sex with other partner(s) last month (%)</b>					
No	40 (80)	57 (81)	60 (86)	52 (87)	69 (79)
Yes	10 (20)	13 (19)	10 (14)	6 (10)	15 (17)
Not reported	0 (0)	0 (0)	0 (0)	2 (3)	3 (3)
<b>Condom used with other partner(s) last month (%)</b>					
<b>N° surveyed</b>	<b>N=10</b>	<b>N=13</b>	<b>N=10</b>	<b>N=6</b>	<b>N=15</b>
Never	5 (50)	5 (38)	1 (10)	2 (33)	3 (20)
Sometimes	2 (20)	2 (15)	6 (60)	1 (17)	6 (40)
Every time	3 (30)	5 (38)	3 (30)	3 (50)	5 (33)
Not reported	0 (0)	1 (8)	0 (0)	0 (0)	1 (7)
<b>Sex work last month (%)</b>					
No	46 (92)	64 (91)	64 (91)	56 (93)	70 (80)
Yes	4 (8)	3 (4)	6 (9)	2 (3)	9 (10)
Not reported	0 (0)	3 (4)	0 (0)	2 (3)	8 (9)
<b>Condom used at last sex work (%)</b>					
Yes	3 (75)	2 (67)	4 (67)	1 (50)	8 (90)

**Table 4.1.7 Number (percentage) of respondents reporting stigma or discrimination in the last 12 months in 2016**

<b>Northern Territory<sup>#</sup></b>	<b>Never</b>	<b>Rarely</b>	<b>Sometimes</b>	<b>Often</b>	<b>Always</b>
Use of drugs for injecting	22 (31)	6 (8)	21 (30)	13 (18)	9 (13)
Sexual orientation	49 (82)	2 (3)	3 (5)	4 (7)	2 (3)
Hepatitis C status	41 (68)	6 (10)	8 (13)	3 (5)	2 (3)
Hepatitis B status	47 (89)	3 (6)	2 (4)	0 (0)	1 (2)
HIV status	48 (94)	2 (4)	0 (0)	0 (0)	1 (2)
Sex work	38 (81)	2 (4)	2 (4)	4 (9)	1 (2)
Other	16 (73)	1 (5)	1 (5)	2 (9)	2 (9)
Health workers treated me negatively or different to other people	36 (51)	5 (7)	13 (19)	10 (14)	6 (9)

<sup>#</sup> excludes respondents who indicated 'not applicable' and where data was missing

## HIV antibody prevalence

**Table 4.2.1 HIV antibody prevalence by gender and survey year**

Northern Territory Survey year	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)
2012	30	1 (3.3)	15	0 (0.0)	46	1 (2.2)
2013	47	2 (4.3)	19	0 (0.0)	66	2 (3.0)
2014	54	0 (0.0)	16	0 (0.0)	70	0 (0.0)
2015	45	0 (0.0)	14	0 (0.0)	59	0 (0.0)
2016	59	0 (0.0)	26	0 (0.0)	87	0 (0.0)
X <sup>2</sup> p trend		--		--		--

## HCV antibody prevalence

**Table 4.3.1 HCV antibody prevalence by gender and survey year**

Northern Territory Survey year	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
2012	30	11 (37)	15	5 (33)	46	16 (35)
2013	46	21 (46)	19	12 (63)	65	33 (51)
2014	53	30 (57)	16	8 (50)	69	38 (55)
2015	31	19 (61)	12	7 (58)	43	26 (60)
2016	59	23 (39)	26	12 (46)	87	35 (40)
X <sup>2</sup> p trend		0.925		0.899		0.909

**Table 4.3.2 HCV antibody prevalence by sexual identity, gender and survey year**

Northern Territory Sexual identity	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2012</b>						
Heterosexual	26	11 (42)	10	4 (40)	37	15 (41)
Bisexual	3	0 (0)	3	1 (33)	6	1 (17)
Homosexual	0	0 (0)	2	0 (0)	2	0 (0)
p value		0.268		0.760		0.355
<b>2013</b>						
Heterosexual	40	21 (53)	17	12 (71)	57	33 (58)
Bisexual	4	0 (0)	0	0 (0)	4	0 (0)
Homosexual	1	0 (0)	0	0 (0)	1	0 (0)
p value		0.075		--		0.018
<b>2014</b>						
Heterosexual	50	29 (58)	12	6 (50)	62	35 (56)
Bisexual	2	0 (0)	1	0 (0)	3	0 (0)
Homosexual	0	0 (0)	0	0 (0)	0	0 (0)
p value		0.191		1.000		0.093
<b>2015</b>						
Heterosexual	31	19 (61)	7	5 (71)	38	24 (63)
Bisexual	0	0 (0)	2	1 (50)	2	1 (50)
Homosexual	0	0 (0)	1	1 (100)	1	1 (100)
p value		--		1.000		1.000
<b>2016</b>						
Heterosexual	49	19 (39)	17	9 (53)	67	28 (42)
Bisexual	2	0 (0)	6	1 (17)	9	1 (11)
Homosexual	3	2 (67)	1	1 (100)	4	3 (75)
p value		0.486		0.166		0.071

**Table 4.3.3 HCV antibody prevalence by age group, gender and survey year**

Northern Territory Age group	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2012</b>						
<25 years	2	1 (50)	0	0 (0)	2	1 (50)
25-34 years	5	0 (0)	6	2 (33)	11	2 (18)
35-44 years	16	6 (38)	5	2 (40)	21	8 (38)
45+ years	7	4 (57)	4	1 (25)	11	5 (45)
p value		0.228		1.000		0.521
<b>2013</b>						
<25 years	1	0 (0)	1	0 (0)	2	0 (0)
25-34 years	9	4 (44)	3	0 (0)	12	4 (33)
35-44 years	17	8 (47)	8	7 (88)	25	15 (60)
45+ years	19	9 (47)	7	5 (71)	26	14 (54)
p value		1.000		0.026		0.237
<b>2014</b>						
<25 years	1	0 (0)	2	1 (50)	3	1 (33)
25-34 years	10	4 (40)	3	2 (67)	13	6 (46)
35-44 years	20	11 (55)	5	3 (60)	25	14 (56)
45+ years	22	15 (68)	6	2 (33)	28	17 (61)
p value		0.311		0.814		0.722
<b>2015</b>						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	11	3 (27)	1	0 (0)	12	3 (25)
35-44 years	11	10 (91)	5	3 (60)	16	13 (81)
45+ years	9	6 (67)	6	4 (67)	15	10 (67)
p value		0.010		0.747		0.008
<b>2016</b>						
<25 years	1	0 (0)	0	0 (0)	2	0 (0)
25-34 years	7	4 (57)	2	0 (0)	9	4 (44)
35-44 years	23	3 (13)	10	6 (60)	33	9 (27)
45+ years	28	16 (57)	14	6 (43)	43	22 (51)
p value		0.003		0.443		0.111

**Table 4.3.4 HCV antibody prevalence by years since first injection, gender and survey year**

Northern Territory Years of injection	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2012</b>						
<3 years	2	0 (0)	1	0 (0)	3	0 (0)
3 to 10 years	3	1 (33)	0	0 (0)	3	1 (33)
11+ years	24	10 (42)	12	4 (33)	37	14 (38)
p value		0.773		1.000		0.788
<b>2013</b>						
<3 years	0	0 (0)	0	0 (0)	0	0 (0)
3 to 10 years	6	0 (0)	3	0 (0)	9	0 (0)
11+ years	39	20 (51)	15	12 (80)	54	32 (59)
p value		0.027		0.025		0.001
<b>2014</b>						
<3 years	1	0 (0)	3	0 (0)	4	0 (0)
3 to 10 years	6	3 (50)	2	2 (100)	8	5 (63)
11+ years	45	27 (60)	11	6 (55)	56	33 (59)
p value		0.509		0.097		0.070
<b>2015</b>						
<3 years	0	0 (0)	1	0 (0)	1	0 (0)
3 to 10 years	8	3 (38)	0	0 (0)	8	3 (38)
11+ years	26	16 (70)	9	5 (56)	32	21 (66)
p value		0.206		1.000		0.158
<b>2016</b>						
<3 years	1	0 (0)	2	1 (50)	4	1 (25)
3 to 10 years	4	0 (0)	2	1 (50)	6	1 (17)
11+ years	54	23 (43)	21	9 (43)	75	32 (43)
p value		0.200		1.000		0.507

**Table 4.3.5 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year**

Northern Territory Receptively shared syringe last month	<3 years		3+ years		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2012</b>						
No receptive sharing	1	0 (0)	32	13 (41)	35	13 (37)
Receptive sharing	0	0 (0)	5	2 (40)	6	3 (50)
p value		--		1.000		0.662
<b>2013</b>						
No receptive sharing	0	0 (0)	49	27 (55)	50	28 (56)
Receptive sharing	0	0 (0)	6	4 (67)	6	4 (67)
p value		--		0.686		0.691
<b>2014</b>						
No receptive sharing	3	0 (0)	57	34 (60)	61	34 (56)
Receptive sharing	0	0 (0)	4	3 (75)	4	3 (75)
p value		--		1.000		0.628
<b>2015</b>						
No receptive sharing	1	0 (0)	36	23 (64)	39	25 (64)
Receptive sharing	0	0 (0)	2	0 (0)	2	0 (0)
p value		--		0.149		0.146
<b>2016</b>						
No receptive sharing	4	1 (25)	65	29 (45)	70	31 (44)
Receptive sharing	0	0 (0)	6	3 (50)	7	3 (43)
p value		--		1.000		1.000

**Table 4.3.6 HCV antibody prevalence by last drug injected, years since first injection and survey year**

Northern Territory Last drug injected	<3 years		3+ years		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2012</b>						
Methamphetamine	1	0 (0)	5	1 (20)	7	2 (29)
Pharm. Opioids	1	0 (0)	30	12 (40)	33	12 (36)
OST	0	0 (0)	2	1 (50)	2	1 (50)
Other drugs	1	0 (0)	3	1 (33)	4	1 (25)
p value		--		0.828		0.913
<b>2013</b>						
Methamphetamine	0	0 (0)	6	2 (33)	6	2 (33)
Pharm. Opioids	0	0 (0)	43	24 (56)	43	24 (56)
OST*	0	0 (0)	2	2 (100)	2	2 (100)
Other drugs	0	0 (0)	12	4 (33)	14	5 (36)
p value		--		0.206		0.224
<b>2014</b>						
Methamphetamine	3	0 (0)	16	8 (50)	19	8 (42)
Pharm. Opioids	0	0 (0)	33	25 (76)	34	25 (74)
OST*	1	0 (0)	7	2 (29)	8	2 (25)
Other drugs	0	0 (0)	8	3 (38)	8	3 (38)
p value		--		0.035		0.019
<b>2015</b>						
Methamphetamine	1	0 (0)	14	6 (43)	15	6 (40)
Pharm. Opioids	0	0 (0)	15	10 (67)	17	12 (71)
OST*	0	0 (0)	10	7 (70)	10	7 (70)
Other drugs	0	0 (0)	1	1 (100)	1	1 (100)
p value		--		0.380		0.222
<b>2016</b>						
Methamphetamine	2	1 (50)	35	10 (29)	37	11 (30)
Pharm. Opioids	0	0 (0)	29	14 (48)	30	15 (50)
OST*	1	0 (0)	7	4 (57)	8	4 (50)
Other drugs	1	0 (0)	10	5 (50)	12	5 (42)
p value		0.513		0.265		0.360

\*OST = methadone, buprenorphine & burpenorphine/naloxone



**Table 4.3.7 HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year**

Northern Territory Frequency of injection last month	<3 years		3+ years		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2012</b>						
Less than daily	0	0 (0)	12	6 (50)	12	6 (50)
Daily or more	1	0 (0)	25	9 (36)	29	10 (34)
Not last month	2	0 (0)	3	0 (0)	5	0 (0)
p value		--		0.299		0.170
<b>2013</b>						
Less than daily	0	0 (0)	20	14 (70)	20	14 (70)
Daily or more	0	0 (0)	36	17 (47)	37	18 (49)
Not last month	0	0 (0)	7	1 (14)	8	1 (13)
p value		--		0.037		0.020
<b>2014</b>						
Less than daily	1	0 (0)	17	11 (65)	18	11 (61)
Daily or more	2	0 (0)	44	26 (59)	47	26 (55)
Not last month	1	0 (0)	2	1 (50)	3	1 (33)
p value		--		0.891		0.677
<b>2015</b>						
Less than daily	1	0 (0)	8	5 (63)	11	7 (64)
Daily or more	0	0 (0)	30	18 (60)	30	18 (60)
Not last month	0	0 (0)	2	1 (50)	2	1 (50)
p value		--		1.000		1.000
<b>2016</b>						
Less than daily	2	0 (0)	22	9 (41)	25	10 (40)
Daily or more	2	1 (50)	51	23 (45)	54	24 (44)
Not last month	0	0 (0)	8	1 (13)	8	1 (13)
p value		1.000		0.229		0.248

**Table 4.3.8 HCV antibody prevalence by imprisonment last year, years since first injection and survey year**

Northern Territory Imprisonment last year	<3 years		3+ years		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2012</b>						
No imprisonment	3	0 (0)	35	13 (37)	41	14 (34)
Imprisonment	0	0 (0)	4	2 (50)	4	2 (50)
p value		--		0.631		0.608
<b>2013</b>						
No imprisonment	0	0 (0)	55	25 (45)	57	26 (46)
Imprisonment	0	0 (0)	7	7 (100)	7	7 (100)
p value		--		0.011		0.011
<b>2014</b>						
No imprisonment	2	0 (0)	59	36 (61)	62	36 (58)
Imprisonment	0	0 (0)	2	0 (0)	2	0 (0)
p value		--		0.164		0.187
<b>2015</b>						
No imprisonment	1	0 (0)	32	18 (56)	35	20 (57)
Imprisonment	0	0 (0)	5	4 (80)	5	5 (4)
p value		--		0.629		0.631
<b>2016</b>						
No imprisonment	4	1 (25)	67	29 (43)	72	31 (43)
Imprisonment	0	0 (0)	7	2 (29)	8	2 (25)
p value		--		0.692		0.459

**Table 4.3.9 HCV antibody prevalence by sex work last month, years since first injection and survey year**

Northern Territory Sex work last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2012</b>						
No sex work	3	0 (0)	36	14 (39)	42	15 (36)
Sex work	0	0 (0)	4	1 (25)	4	1 (25)
p value		--		1.000		1.000
<b>2013</b>						
No sex work	0	0 (0)	58	29 (50)	60	30 (50)
Sex work	0	0 (0)	2	0 (0)	2	0 (0)
p value		--		0.492		0.492
<b>2014</b>						
No sex work	4	0 (0)	58	36 (62)	63	36 (57)
Sex work	0	0 (0)	6	2 (33)	6	2 (33)
p value		--		0.213		0.397
<b>2015</b>						
No sex work	1	0 (0)	37	24 (65)	40	26 (65)
Sex work	0	0 (0)	2	0 (0)	2	2 (0)
p value		--		0.142		0.139
<b>2016</b>						
No sex work	3	1 (33)	66	29 (44)	70	31 (44)
Sex work	0	0 (0)	8	4 (50)	9	4 (44)
p value		--		1.000		1.000

**Table 4.3.10 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year**

Northern Territory Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2012</b>						
Non Indigenous	26	9 (35)	10	3 (30)	36	12 (33)
Indigenous	4	2 (50)	4	1 (25)	9	3 (33)
p value		0.611		1.000		1.000
<b>2013</b>						
Non Indigenous	39	18 (46)	11	5 (45)	50	23 (46)
Indigenous	5	2 (40)	8	7 (88)	13	9 (69)
p value		1.000		0.147		0.213
<b>2014</b>						
Non Indigenous	44	24 (55)	11	5 (45)	55	29 (53)
Indigenous	9	6 (67)	4	2 (50)	13	8 (62)
p value		0.504		1.000		0.566
<b>2015</b>						
Non Indigenous	21	16 (76)	7	5 (71)	28	21 (75)
Indigenous	10	3 (30)	4	2 (50)	14	5 (36)
p value		0.021		0.576		0.020
<b>2016</b>						
Non Indigenous	35	19 (54)	17	8 (47)	52	27 (52)
Indigenous	21	4 (19)	8	4 (50)	31	8 (26)
p value		0.012		1.000		0.020

**Table 4.3.11 HCV antibody prevalence by main language spoken at home by parents, gender and survey year**

Northern Territory Main language spoken at home by parents	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2012</b>						
English speaking	30	11 (37)	13	5 (38)	44	16 (36)
Non-English speaking	0	0 (0)	2	0 (0)	2	0 (0)
p value		--		0.524		0.536
<b>2013</b>						
English speaking	44	20 (45)	19	12 (63)	63	32 (51)
Non-English speaking	2	1 (50)	0	0 (0)	2	1 (50)
p value		1.000		--		1.000
<b>2014</b>						
English speaking	49	27 (55)	16	8 (50)	65	35 (54)
Non-English speaking	4	3 (75)	0	0 (0)	4	3 (75)
p value		0.624		--		0.622
<b>2015</b>						
English speaking	30	18 (60)	11	6 (55)	41	24 (59)
Non-English speaking	1	1 (100)	0	0 (0)	1	1 (100)
p value		1.000		--		1.000
<b>2016</b>						
English speaking	52	22 (42)	25	12 (48)	79	34 (43)
Non-English speaking	4	1 (25)	0	0 (0)	4	1 (25)
p value		0.636		--		0.635

**Table 4.3.12 HCV antibody prevalence by region/country of birth, gender and survey year**

Northern Territory		Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
<b>2012</b>							
Australia	25	9 (36)	14	5 (36)	40	14 (35)	
Other Oceania	1	0 (0)	0	0 (0)	1	0 (0)	
Asia	0	0 (0)	0	0 (0)	0	0 (0)	
UK & Ireland	2	1 (50)	0	0 (0)	2	1 (50)	
Other	2	1 (50)	1	0 (0)	3	1 (33)	
p value		1.000		1.000		1.000	
<b>2013</b>							
Australia	41	20 (49)	15	10 (67)	56	30 (54)	
Other Oceania	1	0 (0)	0	0 (0)	1	0 (0)	
Asia	0	0 (0)	0	0 (0)	0	0 (0)	
UK & Ireland	3	1 (33)	2	2 (100)	5	3 (60)	
Other	1	0 (0)	2	0 (0)	3	0 (0)	
p value		1.000		0.237		0.196	
<b>2014</b>							
Australia	47	28 (60)	13	7 (54)	60	35 (58)	
Other Oceania	2	0 (0)	0	0 (0)	2	0 (0)	
Asia	1	1 (100)	0	0 (0)	1	1 (100)	
UK & Ireland	2	0 (0)	1	1 (100)	3	1 (33)	
Other	1	1 (100)	2	0 (0)	3	1 (33)	
p value		0.053		0.467		0.353	
<b>2015</b>							
Australia	28	17 (61)	10	6 (60)	38	23 (61)	
Other Oceania	2	1 (50)	0	0 (0)	2	1 (50)	
Asia	0	0 (0)	1	0 (0)	1	0 (0)	
UK & Ireland	1	1 (100)	0	0 (0)	1	1 (100)	
Other	0	0 (0)	0	0 (0)	0	0 (0)	
p value		1.000		0.455		0.828	
<b>2016</b>							
Australia	51	20 (39)	23	11 (48)	75	31 (41)	
Other Oceania	1	1 (100)	0	0 (0)	1	1 (100)	
Asia	1	1 (100)	0	0 (0)	1	1 (100)	
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)	
Other	3	1 (33)	1	1 (100)	5	2 (40)	
p value		0.527		1.000		0.552	

## Queensland

Table 5.1.1 Number (percentage) of respondents by demographic characteristics and survey year

Queensland	2012	2013	2014	2015	2016
<b>Number of sites</b>	8	8	7	8	8
<b>N° surveyed</b>	N=624	N=565	N=490	N=532	N=349
<b>Response rate (%)</b>	45%	45%	51%	36%	30%
<b>Gender (%)</b>					
Male	454 (73)	397 (70)	356 (73)	386 (73)	230 (66)
Female	168 (27)	167 (30)	133 (27)	144 (27)	117 (34)
Transgender	1 (<1)	1 (<1)	1 (<1)	2 (<1)	1 (<1)
Not reported	1 (<1)	0 (0)	0 (0)	0 (0)	1 (<1)
<b>Sexual identity (%)</b>					
Heterosexual	529 (85)	471 (83)	398 (81)	453 (85)	258 (74)
Bisexual	49 (8)	42 (7)	36 (7)	41 (8)	47 (13)
Homosexual	18 (3)	19 (3)	22 (4)	19 (4)	18 (5)
Not reported	28 (4)	33 (6)	34 (7)	19 (4)	26 (7)
<b>Aboriginal and Torres Strait Islander origin (%)</b>					
No	537 (86)	493 (87)	428 (87)	459 (86)	294 (84)
Yes	78 (13)	58 (10)	49 (10)	67 (13)	44 (13)
Not reported	9 (1)	14 (2)	13 (3)	6 (1)	11 (3)
<b>Region/country of birth (%)</b>					
Australia	549 (88)	504 (89)	421 (86)	467 (88)	304 (87)
Other Oceania	35 (6)	29 (5)	30 (6)	24 (5)	13 (4)
Asia	1 (<1)	0 (0)	2 (<1)	5 (1)	2 (1)
UK & Ireland	22 (4)	13 (2)	15 (3)	17 (3)	16 (5)
Other	14 (2)	17 (3)	17 (3)	9 (2)	5 (1)
Not reported	3 (<1)	2 (<1)	5 (1)	10 (2)	9 (3)
<b>Main language spoken at home by parents (%)</b>					
English	606 (97)	544 (96)	468 (96)	515 (97)	329 (94)
Non-English	16 (3)	19 (3)	17 (3)	9 (2)	12 (3)
Not reported	2 (<1)	2 (<1)	5 (1)	8 (2)	8 (2)
<b>Age and time since first injection (years)</b>					
<i>Median age</i>	36	37	37	38	40
<i>Age range</i>	16-71	16-65	14-64	16-62	17-76
<i>Age group (%)</i>					
<25 years	73 (12)	68 (12)	52 (11)	44 (8)	21 (6)
25+ years	551 (88)	495 (88)	436 (89)	487 (92)	328 (94)
Not reported	0 (0)	2 (<1)	2 (<1)	1 (<1)	0 (0)
<i>Median age first injection</i>					
	18	19	19	19	19
<i>Age range</i>	10-70	11-61	10-49	11-50	11-55
<i>N° not reported</i>	15	15	15	13	16
<i>Median yrs since first injection</i>					
	16	15	16	17	19
<i>Range</i>	<1-53	<1-46	<1-47	<1-44	<1-53
<i>Years since first injection</i>					
<3 years	71 (11)	68 (12)	55 (11)	46 (9)	22 (6)
3+ years	538 (86)	482 (85)	420 (86)	472 (89)	311 (89)
Not reported	15 (2)	15 (3)	15 (3)	14 (3)	16 (5)
<b>Imprisonment last year (%)</b>					
No	543 (88)	497 (88)	415 (85)	468 (88)	299 (86)
Yes	64 (10)	45 (8)	48 (10)	43 (8)	39 (11)
Not reported	17 (3)	23 (4)	27 (6)	21 (4)	11 (3)
<b>N° in prison</b>					
	N=64	N=45	N=48	N=43	N=39
Injected in prison	30 (47)	17 (38)	18 (38)	22 (51)	16 (41)

**Table 5.1.2 Number (percentage) of respondents by last drug injected, frequency of injecting and survey year**

<b>Queensland N° surveyed</b>	<b>2012 N=624</b>	<b>2013 N=565</b>	<b>2014 N=490</b>	<b>2015 N=532</b>	<b>2016 N=349</b>
<b>Drug last injected (%)</b>					
Cocaine	3 (<1)	3 (<1)	3 (<1)	5 (1)	1 (0)
Methamphetamine	165 (26)	162 (29)	155 (31)	183 (34)	136 (39)
Heroin	129 (21)	91 (16)	75 (15)	107 (20)	56 (16)
Pharm. opioids	124 (20)	117 (21)	94 (19)	92 (17)	53 (15)
Methadone	45 (7)	36 (6)	22 (4)	31 (6)	28 (8)
Buprenorphine	41 (7)	32 (6)	20 (4)	21 (4)	11 (3)
Buprenorphine/naloxone	17 (3)	16 (3)	14 (3)	6 (1)	13 (4)
PIEDs	70 (11)	71 (13)	71 (14)	62 (12)	21 (6)
More than one	20 (3)	35 (6)	16 (3)	18 (3)	22 (6)
Other	8 (1)	1 (<1)	16 (3)	7 (1)	8 (2)
Not reported	2 (<1)	1 (<1)	4 (<1)	0 (0)	0 (0)
<b>Ever injected opioids</b>					
Yes	-	-	-	-	274 (79)
No	-	-	-	-	74 (21)
Not reported	-	-	-	-	1 (<1)
<b>Frequency of injection last month (%)</b>					
Not last month	67 (11)	41 (7)	47 (10)	54 (10)	31 (9)
Less than weekly	112 (18)	107 (19)	64 (13)	92 (17)	49 (14)
Weekly not daily	133 (21)	153 (27)	134 (27)	114 (21)	80 (23)
Daily or more	305 (49)	254 (45)	238 (49)	268 (50)	177 (51)
Not reported	7 (1)	10 (2)	7 (1)	4 (1)	12 (3)
<b>Present when someone injected for the first time in the last 12 months (%)</b>					
Yes	105 (17)	82 (15)	88 (18)	80 (15)	57 (16)
No	456 (73)	428 (76)	392 (80)	442 (83)	287 (82)
Not reported	63 (10)	55 (10)	10 (2)	10 (2)	5 (1)
<b>Overdosed in last 12 months</b>					
Yes	--	65 (12)	65 (13)	67 (13)	57 (16)
No	--	493 (87)	415 (85)	458 (86)	285 (82)
Not reported	--	7 (1)	10 (2)	7 (1)	7 (2)

**Table 5.1.3 Number (percentage) of respondents by injecting behaviour in the last month and survey year**

<b>Queensland N° injected last month</b>	<b>2012 N=550</b>	<b>2013 N=514</b>	<b>2014 N=436</b>	<b>2015 N=474</b>	<b>2016 N=306</b>
<b>Places injected last month (%)</b>					
Any public	193 (35)	163 (32)	140 (32)	146 (31)	96 (31)
All private	347 (63)	347 (68)	294 (67)	326 (69)	208 (68)
Not reported	10 (2)	4 (1)	2 (<1)	2 (<1)	2 (1)
<b>Use of new and sterile needles and syringes last month (%)</b>					
All injections	426 (77)	391 (76)	340 (78)	350 (74)	240 (78)
Most of the time	85 (15)	101 (20)	84 (19)	98 (21)	52 (17)
Half of the time	12 (2)	12 (2)	3 (1)	14 (3)	5 (2)
Some of the time	2 (<1)	5 (1)	3 (1)	2 (<1)	3 (1)
Not last month	4 (<1)	1 (<1)	0 (0)	3 (1)	2 (1)
Not reported	21 (4)	4 (1)	6 (1)	7 (1)	4 (1)
<b>Re-used someone else's used needle &amp; syringe last month (%)</b>					
None	463 (84)	437 (85)	361 (83)	400 (84)	245 (80)
Once	31 (6)	21 (4)	24 (6)	26 (5)	14 (5)
Twice	12 (2)	18 (4)	18 (4)	10 (2)	18 (6)
3-5 times	12 (2)	13 (3)	15 (3)	18 (4)	11 (4)
>5 times	21 (4)	19 (4)	11 (3)	17 (4)	15 (5)
Not reported	11 (2)	6 (1)	7 (2)	3 (1)	3 (1)
<b>Number of people needle &amp; syringe was re-used after last month (%)</b>					
None	463 (84)	437 (85)	361 (83)	400 (84)	245 (80)
One	36 (7)	39 (8)	27 (6)	33 (7)	24 (8)
Two	4 (<1)	7 (1)	6 (1)	5 (1)	7 (2)
Three to five	1 (<1)	3 (<1)	4 (1)	6 (1)	1 (0)
More than five	6 (1)	2 (<1)	2 (<1)	3 (1)	3 (1)
Don't know	10 (2)	15 (3)	13 (3)	14 (3)	13 (4)
Not reported	30 (5)	11 (2)	23 (5)	13 (3)	13 (4)
<b>Relationship to people needle &amp; syringe was used after last month (%) [more than one could be selected]</b>					
Regular sex partner	27 (5)	33 (6)	27 (6)	25 (5)	20 (7)
Casual sex partner	1 (<1)	4 (1)	0 (0)	3 (1)	3 (1)
Close friend	19 (3)	20 (4)	10 (2)	21 (4)	14 (5)
Acquaintance	8 (1)	12 (2)	5 (1)	9 (2)	12 (4)
Other	7 (1)	6 (1)	3 (1)	10 (2)	4 (1)
<b>Equipment used after someone else last month (%) [more than one could be selected]</b>					
Spoon	114 (21)	104 (20)	75 (17)	97 (20)	59 (19)
Water	73 (13)	85 (17)	82 (19)	82 (17)	45 (15)
Filter	58 (11)	55 (11)	36 (8)	53 (11)	33 (11)
Drug mix	51 (9)	45 (9)	38 (9)	46 (10)	37 (12)
None	387 (70)	379 (74)	305 (70)	332 (70)	223 (73)
<b>Injected by someone after that person injected themselves or others last month (%)</b>					
No	466 (85)	438 (85)	351 (81)	404 (85)	249 (81)
Yes	73 (13)	65 (13)	72 (17)	68 (14)	51 (17)
Not reported	11 (2)	11 (2)	13 (3)	2 (<1)	6 (2)
<b>Source of needle acquisition</b>					
Needle Syringe Program	500 (91)	487 (95)	394 (90)	437 (92)	274 (90)
Chemist/Pharmacy	159 (29)	109 (21)	107 (25)	122 (26)	88 (29)
Personal sources	50 (9)	34 (7)	36 (8)	38 (8)	27 (9)
Dispensing/Vending Machine	78 (14)	52 (10)	38 (9)	70 (15)	50 (16)
Other sources	6 (1)	3 (1)	6 (1)	9 (2)	6 (2)

**Table 5.1.4 Number (percentage) of respondents by treatment for drug use and survey year**

Queensland N° surveyed	2012 N=624	2013 N=565	2014 N=490	2015 N=532	2016 N=349
<b>Ever any treatment/therapy for drug use (%)</b>					
No	176 (28)	188 (33)	168 (34)	171 (32)	98 (28)
Yes	442 (71)	373 (66)	308 (63)	351 (66)	241 (69)
Not reported	6 (1)	4 (1)	14 (3)	10 (2)	10 (3)
<b>History of methadone maintenance treatment (%)</b>					
Currently	106 (17)	95 (17)	80 (16)	79 (15)	63 (18)
Previously	151 (24)	114 (20)	94 (19)	117 (22)	83 (24)
Never	362 (58)	354 (63)	303 (62)	329 (62)	193 (55)
Not reported	5 (1)	2 (1)	13 (3)	7 (1)	10 (3)
<b>History of buprenorphine (Subutex®) treatment (%)</b>					
Currently	74 (12)	51 (9)	48 (10)	41 (8)	30 (9)
Previously	144 (23)	149 (26)	100 (20)	144 (27)	93 (27)
Never	401 (64)	358 (63)	330 (67)	340 (64)	214 (61)
Not reported	5 (1)	7 (1)	12 (2)	7 (1)	12 (3)
<b>History of buprenorphine-naloxone (Suboxone®) treatment (%)</b>					
Currently	60 (10)	56 (10)	35 (7)	42 (8)	23 (7)
Previously	132 (21)	110 (19)	99 (20)	119 (22)	89 (26)
Never	427 (68)	389 (70)	340 (69)	362 (68)	229 (66)
Not reported	5 (1)	10 (2)	16 (3)	9 (2)	8 (2)

**Table 5.1.5 Number (percentage) of respondents by testing for HIV and HCV, HCV treatment by survey year**

Queensland N° surveyed	2012 N=624	2013 N=565	2014 N=490	2015 N=532	2016 N=349
<b>Previous HIV test (%)</b>					
Yes, ever	517 (83)	477 (84)	408 (83)	437 (82)	292 (84)
Yes, last year	291 (47)	277 (49)	253 (52)	250 (47)	186 (53)
>1 year ago	226 (36)	200 (35)	155 (32)	187 (35)	106 (30)
Never tested	87 (14)	82 (15)	68 (14)	82 (15)	45 (13)
Not reported	20 (3)	6 (1)	14 (3)	13 (2)	12 (3)
<b>Previous HCV test (%)</b>					
Yes, ever	533 (85)	466 (82)	414 (84)	449 (84)	294 (84)
Yes, last year	328 (53)	269 (48)	273 (56)	279 (52)	211 (60)
>1 year ago	205 (33)	197 (35)	141 (29)	170 (32)	83 (24)
Never tested	60 (10)	56 (10)	52 (11)	64 (12)	28 (8)
Not reported	31 (5)	43 (8)	24 (5)	19 (4)	27 (8)
<b>Lifetime treatment for HCV (%)#</b>					
<b>N° self-reported HCV diagnosis</b>					
Antiviral treatment	14 (8)	18 (12)	13 (12)	11 (9)	34 (33)
No antiviral treatment	154 (91)	133 (86)	94 (84)	109 (87)	69 (66)
Not reported	1 (1)	4 (3)	5 (4)	6 (5)	1 (1)
<b>Treatment for HCV in past 12 months (%)**</b>					
<b>N° self-reported HCV diagnosis</b>					
Antiviral treatment	4 (2)	6 (4)	2 (2)	1 (1)	28 (27)
No antiviral treatment	158 (97)	125 (94)	85 (96)	80 (92)	57 (71)
Not reported	1 (1)	2 (2)	2 (2)	6 (7)	1 (1)

# among people who tested HCV antibody positive and did not report spontaneous clearance

\* excludes people who reported treatment induced clearance more than 12 months previously



**Table 5.1.6 Number (percentage) of respondents by sexual behaviour in the month prior to survey and survey year**

<b>Queensland N° surveyed</b>	<b>2012 N=624</b>	<b>2013 N=565</b>	<b>2014 N=490</b>	<b>2015 N=532</b>	<b>2016 N=349</b>
<b>Sex with a regular partner last month (%)</b>					
No	280 (45)	255 (45)	229 (47)	239 (45)	165 (47)
Yes	334 (54)	304 (54)	250 (51)	274 (52)	175 (50)
Not reported	10 (2)	6 (1)	11 (2)	19 (4)	9 (3)
<b>Condom used with regular partner last month (%)</b>					
<b>N° surveyed</b>	<b>N=334</b>	<b>N=304</b>	<b>N=250</b>	<b>N=274</b>	<b>N=175</b>
Never	256 (77)	221 (73)	174 (70)	212 (77)	130 (74)
Sometimes	39 (12)	40 (13)	39 (16)	30 (11)	24 (14)
Every time	31 (9)	27 (9)	25 (10)	26 (9)	15 (9)
Not reported	8 (2)	16 (5)	12 (5)	6 (2)	6 (3)
<b>Sex with other partner(s) last month (%)</b>					
No	526 (84)	461 (82)	398 (81)	440 (83)	294 (84)
Yes	77 (12)	83 (15)	74 (15)	79 (15)	44 (13)
Not reported	21 (3)	21 (4)	18 (4)	13 (2)	11 (3)
<b>Condom used with other partner(s) last month (%)</b>					
<b>N° surveyed</b>	<b>N=77</b>	<b>N=83</b>	<b>N=74</b>	<b>N=79</b>	<b>N=44</b>
Never	24 (31)	26 (31)	23 (31)	26 (33)	21 (48)
Sometimes	20 (26)	22 (37)	25 (34)	25 (32)	11 (25)
Every time	23 (30)	34 (41)	13 (18)	24 (30)	11 (25)
Not reported	10 (13)	1 (1)	13 (18)	4 (5)	1 (2)
<b>Sex work last month (%)</b>					
No	593 (95)	525 (93)	439 (90)	508 (95)	314 (90)
Yes	17 (3)	9 (2)	19 (4)	14 (3)	18 (5)
Not reported	14 (2)	31 (5)	32 (7)	10 (2)	17 (5)
<b>Condom used at last sex work (%)</b>					
Yes	13 (76)	6 (67)	10 (53)	9 (64)	12 (67)

**Table 5.1.7 Number (percentage) of respondents reporting stigma or discrimination in the last 12 months in 2016**

<b>Queensland<sup>#</sup></b>	<b>Never</b>	<b>Rarely</b>	<b>Sometimes</b>	<b>Often</b>	<b>Always</b>
Use of drugs for injecting	123 (42)	37 (13)	76 (26)	35 (12)	23 (8)
Sexual orientation	202 (82)	11 (4)	24 (10)	8 (3)	2 (1)
Hepatitis C status	175 (72)	26 (11)	29 (12)	7 (3)	6 (2)
Hepatitis B status	190 (94)	4 (2)	5 (2)	3 (1)	0 (0)
HIV status	185 (96)	5 (3)	0 (0)	3 (2)	0 (0)
Sex work	169 (90)	4 (2)	7 (4)	5 (3)	2 (1)
Other	78 (88)	1 (1)	3 (3)	4 (4)	3 (3)
Health workers treated me negatively or different to other people	198 (65)	29 (10)	45 (15)	21 (7)	10 (3)

<sup>#</sup> excludes respondents who indicated 'not applicable' and where data was missing

## HIV antibody prevalence

**Table 5.2.1 HIV antibody prevalence by gender and survey year**

Queensland Survey year	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)
2012	415	7 (1.7)	153	2 (1.3)	570	9 (1.6)
2013	372	7 (1.9)	160	0 (0.0)	533	7 (1.3)
2014	349	11 (3.2)	131	0 (0.0)	481	11 (2.3)
2015	382	6 (1.6)	144	0 (0.0)	528	7 (1.3)
2016	224	4 (1.8)	115	0 (0.0)	341	4 (1.2)
X <sup>2</sup> p trend		0.954		0.058		0.740

**Table 5.2.2 HIV antibody prevalence by sexual identity, gender and survey year**

Queensland Sexual identity	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)
<b>2012</b>						
Heterosexual	368	1 (0.3)	112	2 (1.8)	480	3 (0.6)
Bisexual	20	2 (10.0)	27	0 (0.0)	48	2 (4.2)
Homosexual	11	2 (18.2)	6	0 (0.0)	17	2 (11.8)
p value		<0.001		1.000		0.002
<b>2013</b>						
Heterosexual	322	1 (0.3)	119	0 (0.0)	442	1 (0.2)
Bisexual	13	1 (7.7)	28	0 (0.0)	41	1 (2.4)
Homosexual	17	5 (29.4)	2	0 (0.0)	19	5 (26.3)
p value		<0.001		--		<0.001
<b>2014</b>						
Heterosexual	297	1 (0.3)	95	0 (0.0)	392	1 (0.3)
Bisexual	11	1 (9.1)	24	0 (0.0)	35	1 (2.9)
Homosexual	17	8 (47.1)	3	0 (0.0)	20	8 (40.0)
p value		<0.001		--		<0.001
<b>2015</b>						
Heterosexual	339	1 (0.3)	111	0 (0.0)	450	1 (0.2)
Bisexual	18	1 (5.6)	22	0 (0.0)	41	1 (2.4)
Homosexual	14	4 (28.6)	5	0 (0.0)	19	4 (21.1)
p value		<0.001		--		<0.001
<b>2016</b>						
Heterosexual	184	0 (0.0)	67	0 (0.0)	253	0 (0.0)
Bisexual	13	1 (7.7)	33	0 (0.0)	46	1 (2.2)
Homosexual	10	3 (30.0)	8	0 (0.0)	18	3 (16.7)
p value		<0.001		--		<0.001

**Table 5.2.3 HIV antibody prevalence by age group, gender and survey year**

Queensland Age group	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)
<b>2012</b>						
<25 years	56	0 (0.0)	13	0 (0.0)	69	0 (0.0)
25-34 years	128	1 (0.8)	63	0 (0.0)	192	1 (0.5)
35-44 years	144	1 (0.7)	46	1 (2.2)	190	2 (1.0)
45+ years	87	5 (5.8)	31	1 (3.2)	119	6 (5.0)
p value		0.025		0.415		0.015
<b>2013</b>						
<25 years	43	0 (0.0)	20	0 (0.0)	63	0 (0.0)
25-34 years	111	0 (0.0)	49	0 (0.0)	160	0 (0.0)
35-44 years	106	5 (4.7)	52	0 (0.0)	158	5 (3.2)
45+ years	110	2 (1.8)	39	0 (0.0)	150	2 (1.3)
p value		0.074		--		0.084
<b>2014</b>						
<25 years	35	0 (0.0)	16	0 (0.0)	51	0 (0.0)
25-34 years	110	1 (0.9)	45	0 (0.0)	155	1 (0.7)
35-44 years	107	4 (3.7)	45	0 (0.0)	152	4 (2.6)
45+ years	95	6 (6.3)	25	0 (0.0)	121	6 (5.0)
p value		0.119		--		0.091
<b>2015</b>						
<25 years	32	0 (0.0)	12	0 (0.0)	44	0 (0.0)
25-34 years	120	2 (1.7)	44	0 (0.0)	165	3 (1.8)
35-44 years	135	1 (0.7)	47	0 (0.0)	182	1 (0.6)
45+ years	94	3 (3.2)	41	0 (0.0)	136	3 (2.2)
p value		0.489		--		0.529
<b>2016</b>						
<25 years	14	0 (0.0)	7	0 (0.0)	21	0 (0.0)
25-34 years	56	0 (0.0)	29	0 (0.0)	85	0 (0.0)
35-44 years	79	0 (0.0)	41	0 (0.0)	121	0 (0.0)
45+ years	75	4 (5.3)	38	0 (0.0)	114	4 (3.5)
p value		0.060		--		0.060

**Table 5.2.4 HIV antibody prevalence by last drug injected, gender and survey year**

Queensland Last drug injected	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)
<b>2012</b>						
Heroin	70	0 (0.0)	48	1 (2.1)	118	1 (0.9)
Methamphetamine	103	2 (1.9)	46	0 (0.0)	149	2 (1.3)
Other opioids	158	5 (3.2)	50	1 (2.0)	209	6 (2.9)
PIEDs	59	0 (0.0)	3	0 (0.0)	62	0 (0.0)
Other drugs	23	0 (0.0)	6	0 (0.0)	30	0 (0.0)
p value		0.522		1.000		0.601
<b>2013</b>						
Heroin	58	0 (0.0)	30	0 (0.0)	88	0 (0.0)
Methamphetamine	91	6 (6.6)	62	0 (0.0)	153	6 (3.9)
Other opioids	133	1 (0.8)	60	0 (0.0)	194	1 (0.5)
PIEDs	60	0 (0.0)	0	0 (0.0)	60	0 (0.0)
Other drugs	29	0 (0.0)	8	0 (0.0)	37	0 (0.0)
p value		0.020		--		0.065
<b>2014</b>						
Heroin	53	1 (1.9)	21	0 (0.0)	74	1 (1.4)
Methamphetamine	98	8 (8.2)	54	0 (0.0)	152	8 (5.3)
Other opioids	103	1 (1.0)	44	0 (0.0)	148	1 (0.7)
PIEDs	67	1 (1.5)	3	0 (0.0)	70	1 (1.4)
Other drugs	25	0 (0.0)	9	0 (0.0)	34	0 (0.0)
p value		0.051		--		0.106
<b>2015</b>						
Heroin	76	1 (1.3)	31	0 (0.0)	107	1 (0.9)
Methamphetamine	120	5 (4.2)	60	0 (0.0)	182	6 (3.3)
Other opioids	107	0 (0.0)	42	0 (0.0)	149	0 (0.0)
PIEDs	61	0 (0.0)	1	0 (0.0)	62	0 (0.0)
Other drugs	18	0 (0.0)	10	0 (0.0)	28	0 (0.0)
p value		0.126		--		0.108
<b>2016</b>						
Heroin	32	0 (0.0)	22	0 (0.0)	54	0 (0.0)
Methamphetamine	88	3 (3.4)	44	0 (0.0)	133	3 (2.3)
Other opioids	65	0 (0.0)	37	0 (0.0)	103	0 (0.0)
PIEDs	20	1 (5.0)	0	0 (0.0)	20	1 (5.0)
Other drugs	19	0 (0.0)	12	0 (0.0)	31	0 (0.0)
p value		0.313		--		0.199

**Table 5.2.5 HIV antibody prevalence by years of injection, gender and survey year**

Queensland Years of injection	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)
<b>2012</b>						
<3 years	52	0 (0.0)	11	0 (0.0)	63	0 (0.0)
3 to 10 years	77	1 (1.3)	31	0 (0.0)	108	1 (0.9)
11+ years	275	6 (2.2)	109	2 (1.8)	386	8 (2.1)
p value		0.847		1.000		0.653
<b>2013</b>						
<3 years	51	1 (2.0)	10	0 (0.0)	61	1 (1.6)
3 to 10 years	74	1 (1.4)	34	0 (0.0)	108	1 (0.9)
11+ years	237	5 (2.1)	113	0 (0.0)	351	5 (1.4)
p value		1.000		--		1.000
<b>2014</b>						
<3 years	39	2 (5.1)	15	0 (0.0)	54	2 (3.7)
3 to 10 years	59	1 (1.7)	27	0 (0.0)	86	1 (1.2)
11+ years	238	8 (3.4)	88	0 (0.0)	327	8 (2.5)
p value		0.555		--		0.559
<b>2015</b>						
<3 years	41	1 (2.4)	4	0 (0.0)	45	1 (2.2)
3 to 10 years	81	2 (2.5)	28	0 (0.0)	110	2 (1.8)
11+ years	250	3 (1.2)	108	0 (0.0)	359	4 (1.1)
p value		0.526		--		0.533
<b>2016</b>						
<3 years	16	0 (0.0)	5	0 (0.0)	21	0 (0.0)
3 to 10 years	46	3 (6.5)	12	0 (0.0)	58	3 (5.2)
11+ years	151	1 (0.7)	94	0 (0.0)	247	1 (0.4)
p value		0.061		--		0.041

**Table 5.2.6 HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and survey year**

Queensland Receptively shared syringe last month	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)
<b>2012</b>						
No receptive sharing	307	6 (2.0)	115	2 (1.7)	422	8 (1.9)
Receptive sharing	52	0 (0.0)	19	0 (0.0)	71	0 (0.0)
p value		0.599		1.000		0.609
<b>2013</b>						
No receptive sharing	289	2 (0.7)	124	0 (0.0)	414	2 (0.5)
Receptive sharing	45	2 (4.4)	26	0 (0.0)	71	2 (2.8)
p value		0.089		--		0.104
<b>2014</b>						
No receptive sharing	258	8 (3.1)	96	0 (0.0)	355	8 (2.3)
Receptive sharing	46	0 (0.0)	22	0 (0.0)	68	0 (0.0)
p value		0.612		--		0.365
<b>2015</b>						
No receptive sharing	284	5 (1.8)	110	0 (0.0)	396	6 (1.5)
Receptive sharing	49	1 (2.0)	22	0 (0.0)	71	1 (1.4)
p value		1.000		--		1.000
<b>2016</b>						
No receptive sharing	153	3 (2.0)	86	0 (0.0)	239	3 (1.3)
Receptive sharing	41	1 (2.4)	15	0 (0.0)	57	1 (1.8)
p value		1.000		--		0.577

**Table 5.2.7 HIV antibody prevalence by frequency of drug injection last month, gender and survey year**

Queensland Frequency of injection	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)
<b>2012</b>						
Less than daily	163	2 (1.2)	60	0 (0.0)	224	2 (0.9)
Daily or more	201	4 (2.0)	78	2 (2.6)	279	6 (2.2)
Not last month	47	1 (2.1)	14	0 (0.0)	61	1 (1.6)
p value		0.756		0.592		0.484
<b>2013</b>						
Less than daily	173	3 (1.7)	75	0 (0.0)	249	3 (1.2)
Daily or more	164	2 (1.2)	78	0 (0.0)	242	2 (0.8)
Not last month	27	1 (3.7)	6	0 (0.0)	33	1 (3.0)
p value		0.508		--		0.470
<b>2014</b>						
Less than daily	144	5 (3.5)	53	0 (0.0)	197	5 (2.5)
Daily or more	162	3 (1.9)	69	0 (0.0)	232	3 (1.3)
Not last month	38	3 (7.9)	7	0 (0.0)	45	3 (6.7)
p value		0.139		--		0.090
<b>2015</b>						
Less than daily	154	3 (2.0)	48	0 (0.0)	204	4 (2.0)
Daily or more	182	3 (1.7)	84	0 (0.0)	266	3 (1.1)
Not last month	43	0 (0.0)	11	0 (0.0)	54	0 (0.0)
p value		1.000		--		0.532
<b>2016</b>						
Less than daily	82	4 (4.9)	44	0 (0.0)	126	4 (3.2)
Daily or more	113	0 (0.0)	59	0 (0.0)	173	0 (0.0)
Not last month	21	0 (0.0)	10	0 (0.0)	31	0 (0.0)
p value		0.046		--		0.045

**Table 5.2.8 HIV antibody prevalence by imprisonment last year, gender and survey year**

Queensland Imprisonment last year	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)
<b>2012</b>						
No imprisonment	350	6 (1.7)	141	2 (1.4)	493	8 (1.6)
Imprisonment	52	1 (1.9)	9	0 (0.0)	61	1 (1.6)
p value		1.000		1.000		1.000
<b>2013</b>						
No imprisonment	319	7 (2.2)	150	0 (0.0)	470	7 (1.5)
Imprisonment	37	0 (0.0)	6	0 (0.0)	43	0 (0.0)
p value		1.000		--		1.000
<b>2014</b>						
No imprisonment	289	7 (2.4)	118	0 (0.0)	407	7 (1.7)
Imprisonment	38	0 (0.0)	10	0 (0.0)	48	0 (0)
p value		1.000		--		1.000
<b>2015</b>						
No imprisonment	334	6 (1.8)	129	0 (0.0)	465	7 (1.5)
Imprisonment	30	0 (0.0)	12	0 (0.0)	42	0 (0.0)
p value		1.000		--		1.000
<b>2016</b>						
No imprisonment	192	3 (1.6)	98	0 (0.0)	292	3 (1.0)
Imprisonment	27	1 (3.7)	11	0 (0.0)	38	1 (2.6)
p value		0.412		--		0.388

**Table 5.2.9 HIV antibody prevalence by condom use at last sex with regular partner, gender and survey year**

Queensland	Male		Female		Total	
Condom use at last sex	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)
<b>2012</b>						
No condom use	155	0 (0.0)	73	0 (0.0)	229	0 (0.0)
Condom use	48	3 (6.3)	18	1 (5.6)	66	4 (6.1)
p value		0.013		0.198		0.002
<b>2013</b>						
No condom use	132	2 (1.5)	76	0 (0.0)	208	2 (1.0)
Condom use	47	3 (6.4)	15	0 (0.0)	62	3 (4.8)
p value		0.114		--		0.081
<b>2014</b>						
No condom use	121	4 (3.3)	48	0 (0.0)	170	4 (2.4)
Condom use	48	2 (4.2)	16	0 (0.0)	64	2 (3.1)
p value		1.000		--		0.666
<b>2015</b>						
No condom use	140	2 (1.4)	70	0 (0.0)	211	3 (1.4)
Condom use	41	0 (0.0)	14	0 (0.0)	55	0 (0.0)
p value		1.000		--		1.000
<b>2016</b>						
No condom use	77	2 (2.6)	46	0 (0.0)	125	2 (1.6)
Condom use	28	1 (3.6)	11	0 (0.0)	39	1 (2.6)
p value		1.000		--		0.560

**Table 5.2.10 HIV antibody prevalence by sex work last month, gender and survey year**

Queensland	Male		Female		Total	
Sex work last month	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)
<b>2012</b>						
No sex work	399	7 (1.8)	141	1 (0.7)	542	8 (1.5)
Sex work	4	0 (0.0)	11	1 (9.1)	15	1 (6.7)
p value		1.000		0.140		0.219
<b>2013</b>						
No sex work	346	7 (2.0)	148	0 (0.0)	495	7 (1.4)
Sex work	3	0 (0.0)	5	0 (0.0)	8	0 (0.0)
p value		1.000		--		1.000
<b>2014</b>						
No sex work	312	7 (2.2)	118	0 (0.0)	431	7 (1.6)
Sex work	13	2 (15.4)	6	0 (0.0)	19	2 (10.5)
p value		0.045		--		0.051
<b>2015</b>						
No sex work	368	5 (1.4)	135	0 (0.0)	505	6 (1.2)
Sex work	5	1 (20)	9	0 (0.0)	14	1 (7.1)
p value		0.078		--		0.175
<b>2016</b>						
No sex work	208	4 (1.9)	97	0 (0.0)	307	4 (1.3)
Sex work	9	0 (0.0)	9	0 (0.0)	18	0 (0.0)
p value		1.000		--		1.000

**Table 5.2.11 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year**

Queensland Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
<b>2012</b>						
Non Indigenous	357	7 (2.0)	128	1 (0.8)	487	8 (1.6)
Indigenous	52	0 (0.0)	22	0 (0.0)	74	0 (0.0)
p value		0.603		1.000		0.605
<b>2013</b>						
Non Indigenous	330	7 (2.1)	135	0 (0.0)	466	7 (1.5)
Indigenous	33	0 (0.0)	21	0 (0.0)	54	0 (0.0)
p value		1.000		--		1.000
<b>2014</b>						
Non Indigenous	311	10 (3.2)	108	0 (0.0)	420	10 (2.4)
Indigenous	30	0 (0.0)	19	0 (0.0)	49	0 (0.0)
p value		1.000		--		0.609
<b>2015</b>						
Non Indigenous	337	6 (1.8)	118	0 (0.0)	457	7 (1.5)
Indigenous	41	0 (0.0)	21	0 (0.0)	65	0 (0.0)
p value		1.000		--		0.605
<b>2016</b>						
Non Indigenous	193	4 (2.1)	94	0 (0.0)	289	4 (1.4)
Indigenous	25	0 (0.0)	19	0 (0.0)	44	0 (0.0)
p value		1.000		--		1.000

**Table 5.2.12 HIV antibody prevalence by main language spoken at home by parents, gender and survey year**

Queensland Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
<b>2012</b>						
English speaking	405	5 (1.2)	148	2 (1.4)	554	7 (1.3)
Non-English speaking	9	2 (22.2)	4	0 (0.0)	14	2 (14.3)
p value		0.008		1.000		0.018
<b>2013</b>						
English speaking	362	7 (1.9)	154	0 (0.0)	517	7 (1.4)
Non-English speaking	8	0 (0.0)	6	0 (0.0)	14	0 (0.0)
p value		1.000		--		1.000
<b>2014</b>						
English speaking	334	10 (3.0)	125	0 (0.0)	460	10 (2.2)
Non-English speaking	12	1 (8.3)	5	0 (0.0)	17	1 (5.9)
p value		0.326		--		0.332
<b>2015</b>						
English speaking	367	6 (1.6)	142	0 (0.0)	511	7 (1.4)
Non-English speaking	8	0 (0.0)	1	0 (0.0)	9	0 (0.0)
p value		1.000		--		1.000
<b>2016</b>						
English speaking	210	3 (1.4)	111	0 (0.0)	323	3 (0.9)
Non-English speaking	9	1 (11.1)	2	0 (0.0)	11	1 (9.1)
p value		0.156		--		0.126



**Table 5.2.13 HIV antibody prevalence by region/country of birth, gender and survey year**

Queensland						
Region/country of birth	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
<b>2012</b>						
Australia	369	5 (1.4)	134	2 (1.5)	505	7 (1.4)
Other Oceania	19	0 (0.0)	12	0 (0.0)	31	0 (0.0)
Asia	1	0 (0.0)	0	0 (0.0)	1	0 (0.0)
UK & Ireland	14	1 (7.1)	5	0 (0.0)	19	1 (5.3)
Other	9	1 (11.1)	2	0 (0.0)	11	1 (9.1)
p value		0.080		1.000		0.122
<b>2013</b>						
Australia	334	6 (1.8)	141	0 (0.0)	476	6 (1.3)
Other Oceania	21	1 (4.8)	7	0 (0.0)	28	1 (3.6)
Asia	0	0 (0.0)	0	0 (0.0)	0	0 (0.0)
UK & Ireland	8	0 (0.0)	4	0 (0.0)	12	0 (0.0)
Other	8	0 (0.0)	7	0 (0.0)	15	0 (0.0)
p value		0.739		--		0.690
<b>2014</b>						
Australia	298	9 (3.0)	116	0 (0.0)	415	9 (2.2)
Other Oceania	21	1 (4.8)	7	0 (0.0)	28	1 (3.6)
Asia	2	0 (0.0)	0	0 (0.0)	2	0 (0.0)
UK & Ireland	11	0 (0.0)	4	0 (0.0)	15	0 (0.0)
Other	14	1 (7.1)	3	0 (0.0)	17	1 (5.9)
p value		0.480		--		0.441
<b>2015</b>						
Australia	333	6 (1.8)	129	0 (0.0)	464	7 (1.5)
Other Oceania	18	0 (0.0)	6	0 (0.0)	24	0 (0.0)
Asia	4	0 (0.0)	1	0 (0.0)	5	0 (0.0)
UK & Ireland	10	0 (0.0)	6	0 (0.0)	16	0 (0.0)
Other	8	0 (0.0)	1	0 (0.0)	9	0 (0.0)
p value		1.000		--		1.000
<b>2016</b>						
Australia	196	3 (1.5)	101	0 (0.0)	298	3 (1.0)
Other Oceania	8	0 (0.0)	4	0 (0.0)	12	0 (0.0)
Asia	2	0 (0.0)	0	0 (0.0)	2	0 (0.0)
UK & Ireland	7	0 (0.0)	8	0 (0.0)	16	0 (0.0)
Other	5	1 (20.0)	0	0 (0.0)	5	1 (20.0)
p value		0.146		--		0.117

## HCV antibody prevalence

**Table 5.3.1 HCV antibody prevalence by gender and survey year**

Queensland Survey year	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
2012	409	183 (45)	154	83 (54)	565	267 (47)
2013	372	167 (45)	160	79 (49)	533	247 (46)
2014	327	120 (37)	123	49 (40)	451	169 (37)
2015	379	161 (42)	139	64 (46)	520	226 (43)
2016	204	98 (48)	101	54 (53)	306	153 (50)
X <sup>2</sup> p trend		0.959		0.715		0.830

**Table 5.3.2 HCV antibody prevalence by sexual identity, gender and survey year**

Queensland Sexual identity	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2012</b>						
Heterosexual	363	161 (44)	112	59 (53)	474	220 (46)
Bisexual	20	10 (50)	27	16 (59)	48	26 (54)
Homosexual	11	5 (45)	7	3 (43)	18	8 (44)
p value		0.916		0.736		0.604
<b>2013</b>						
Heterosexual	322	142 (44)	119	58 (49)	442	201 (45)
Bisexual	13	6 (46)	28	16 (57)	41	22 (54)
Homosexual	17	6 (35)	2	0 (0)	19	6 (32)
p value		0.763		0.303		0.275
<b>2014</b>						
Heterosexual	275	103 (37)	87	36 (41)	362	139 (38)
Bisexual	11	6 (55)	24	8 (33)	35	14 (40)
Homosexual	18	3 (17)	3	2 (67)	21	5 (24)
p value		0.094		0.565		0.416
<b>2015</b>						
Heterosexual	336	144 (43)	107	47 (44)	443	191 (43)
Bisexual	18	11 (61)	22	12 (55)	41	23 (56)
Homosexual	14	0 (0)	4	2 (50)	18	2 (11)
p value		<0.001		0.655		0.004
<b>2016</b>						
Heterosexual	165	80 (48)	58	31 (53)	224	112 (50)
Bisexual	12	3 (25)	32	19 (59)	44	22 (50)
Homosexual	10	6 (60)	4	1 (25)	14	7 (50)
p value		0.205		0.408		1.000

**Table 5.3.3 HCV antibody prevalence by age group, gender and survey year**

Queensland Age group	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2012</b>						
<25 years	55	6 (11)	13	4 (31)	68	10 (15)
25-34 years	129	49 (38)	64	38 (59)	194	88 (45)
35-44 years	139	73 (52)	46	23 (50)	185	96 (52)
45+ years	86	55 (64)	31	18 (58)	118	73 (62)
p value		<0.001		0.257		<0.001
<b>2013</b>						
<25 years	43	5 (12)	20	5 (25)	63	10 (16)
25-34 years	111	38 (34)	49	24 (49)	160	62 (39)
35-44 years	106	57 (54)	52	24 (46)	158	81 (52)
45+ years	110	66 (60)	39	26 (67)	150	93 (62)
p value		<0.001		0.022		<0.001
<b>2014</b>						
<25 years	35	2 (6)	16	2 (13)	51	4 (8)
25-34 years	105	25 (24)	42	18 (43)	147	43 (29)
35-44 years	97	44 (45)	44	16 (36)	141	60 (43)
45+ years	88	49 (56)	21	13 (62)	110	62 (56)
p value		<0.001		0.020		<0.001
<b>2015</b>						
<25 years	32	7 (22)	12	4 (33)	44	11 (25)
25-34 years	120	37 (31)	43	19 (44)	164	57 (35)
35-44 years	133	56 (42)	46	18 (39)	179	74 (41)
45+ years	93	61 (66)	38	23 (61)	132	84 (64)
p value		<0.001		0.185		<0.001
<b>2016</b>						
<25 years	14	3 (21)	5	2 (40)	19	5 (26)
25-34 years	52	19 (37)	28	14 (50)	80	33 (41)
35-44 years	76	41 (54)	36	21 (58)	112	62 (55)
45+ years	62	35 (56)	32	17 (53)	95	53 (56)
p value		0.023		0.848		0.026

**Table 5.3.4 HCV antibody prevalence by years since first injection, gender and survey year**

Queensland Years of injection	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2012</b>						
<3 years	52	4 (8)	11	3 (27)	63	7 (11)
3 to 10 years	76	17 (22)	31	6 (19)	107	23 (22)
11+ years	271	157 (58)	110	72 (65)	383	230 (60)
p value		<0.001		<0.001		<0.001
<b>2013</b>						
<3 years	51	3 (6)	10	2 (20)	61	5 (8)
3 to 10 years	74	16 (22)	34	15 (44)	108	31 (29)
11+ years	237	139 (59)	113	61 (54)	351	201 (57)
p value		<0.001		0.087		<0.001
<b>2014</b>						
<3 years	39	3 (8)	15	1 (7)	54	4 (7)
3 to 10 years	59	9 (15)	27	7 (26)	86	16 (19)
11+ years	215	106 (49)	80	41 (51)	296	147 (50)
p value		<0.001		0.001		<0.001
<b>2015</b>						
<3 years	42	4 (10)	4	1 (25)	46	5 (11)
3 to 10 years	81	16 (20)	28	10 (36)	110	26 (24)
11+ years	246	138 (56)	103	52 (50)	350	191 (55)
p value		<0.001		0.293		<0.001
<b>2016</b>						
<3 years	16	0 (0)	4	1 (25)	20	1 (5)
3 to 10 years	45	13 (29)	11	3 (27)	56	16 (29)
11+ years	132	77 (58)	82	50 (61)	215	128 (60)
p value		<0.001		0.045		<0.001

**Table 5.3.5 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year**

Queensland Receptively shared syringe last month	<3 years		3+ years		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2012</b>						
No receptive sharing	37	5 (14)	376	184 (49)	417	192 (46)
Receptive sharing	3	0 (0)	64	45 (70)	71	48 (68)
p value		0.002		0.002		0.001
<b>2013</b>						
No receptive sharing	49	3 (6)	356	176 (49)	414	187 (45)
Receptive sharing	5	2 (40)	64	38 (59)	71	41 (58)
p value		0.062		0.143		0.050
<b>2014</b>						
No receptive sharing	38	3 (8)	288	113 (39)	336	118 (35)
Receptive sharing	2	1 (50)	57	38 (67)	59	39 (66)
p value		0.192		<0.001		<0.001
<b>2015</b>						
No receptive sharing	35	4 (11)	349	171 (49)	391	177 (45)
Receptive sharing	4	1 (25)	62	34 (55)	68	37 (54)
p value		0.436		0.397		0.163
<b>2016</b>						
No receptive sharing	10	0 (0)	198	102 (52)	217	107 (49)
Receptive sharing	4	0 (0)	47	27 (57)	52	28 (54)
p value		--		0.464		0.557

**Table 5.3.6 HCV antibody prevalence by last drug injected, years since first injection and survey year**

Queensland Last drug injected	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2012</b>						
Heroin	3	1 (33)	113	72 (64)	118	75 (64)
Methamphetamine	10	3 (30)	134	51 (38)	146	56 (38)
Other opioids	5	2 (40)	198	113 (57)	208	118 (57)
PIEDs	42	1 (2)	19	3 (16)	62	4 (6)
Other drugs	2	0 (0)	25	14 (56)	29	14 (48)
p value		0.013		<0.001		<0.001
<b>2013</b>						
Heroin	3	1 (33)	83	51 (61)	88	53 (60)
Methamphetamine	12	2 (17)	137	56 (41)	153	60 (39)
Other opioids	10	2 (20)	178	102 (57)	194	110 (57)
PIEDs	33	0 (0)	27	0 (0)	60	0 (0)
Other drugs	3	0 (0)	33	22 (67)	37	23 (62)
p value		0.068		<0.001		<0.001
<b>2014</b>						
Heroin	1	1 (100)	64	41 (64)	66	42 (64)
Methamphetamine	17	2 (12)	123	43 (35)	141	46 (33)
Other opioids	4	1 (25)	135	71 (53)	141	72 (51)
PIEDs	27	0 (0)	36	0 (0)	69	0 (0)
Other drugs	5	0 (0)	23	7 (30)	31	7 (23)
p value		0.002		<0.001		<0.001
<b>2015</b>						
Heroin	0	0 (0)	105	64 (61)	106	64 (60)
Methamphetamine	14	3 (21)	162	57 (35)	178	61 (34)
Other opioids	5	1 (20)	140	88 (63)	146	90 (62)
PIEDs	25	0 (0)	33	0 (0)	62	0 (0)
Other drugs	2	1 (50)	19	8 (42)	24	11 (46)
p value		0.041		<0.001		<0.001
<b>2016</b>						
Heroin	1	0 (0)	41	27 (66)	43	27 (63)
Methamphetamine	10	0 (0)	105	51 (49)	120	55 (46)
Other opioids	1	0 (0)	81	49 (60)	85	51 (60)
PIEDs	3	0 (0)	15	0 (0)	19	0 (0)
Other drugs	4	1 (25)	21	11 (52)	30	14 (47)
p value		0.412		<0.001		<0.001

**Table 5.3.7 HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year**

Queensland	<3 years		3+ years		Total	
Frequency of injection last month	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2012</b>						
Less than daily	25	3 (12)	193	94 (49)	219	97 (44)
Daily or more	16	2 (13)	256	138 (54)	279	146 (52)
Not last month	21	2 (10)	37	19 (51)	61	22 (36)
p value		1.000		0.551		0.035
<b>2013</b>						
Less than daily	39	2 (5)	203	97 (48)	249	104 (42)
Daily or more	15	3 (20)	222	121 (55)	242	129 (53)
Not last month	7	0 (0)	25	8 (32)	33	8 (24)
p value		0.185		0.066		0.001
<b>2014</b>						
Less than daily	20	2 (10)	163	59 (36)	189	63 (33)
Daily or more	21	2 (10)	186	94 (51)	212	96 (45)
Not last month	13	0 (0)	27	8 (30)	44	8 (18)
p value		0.663		0.009		0.001
<b>2015</b>						
Less than daily	26	3 (12)	173	81 (47)	202	84 (42)
Daily or more	13	2 (15)	241	124 (51)	260	130 (50)
Not last month	7	0 (0)	45	12 (27)	54	12 (22)
p value		0.827		0.009		0.001
<b>2016</b>						
Less than daily	10	0 (0)	101	54 (53)	116	57 (49)
Daily or more	4	0 (0)	146	77 (53)	155	80 (52)
Not last month	5	1 (20)	16	7 (44)	26	10 (38)
p value		0.474		0.766		0.461

**Table 5.3.8 HCV antibody prevalence by imprisonment last year, years since first injection and survey year**

Queensland	<3 years		3+ years		Total	
Imprisonment last year	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2012</b>						
No imprisonment	58	7 (12)	423	207 (49)	489	219 (45)
Imprisonment	3	0 (0)	37	37 (69)	60	39 (65)
p value		1.000		0.009		0.003
<b>2013</b>						
No imprisonment	58	5 (9)	400	196 (49)	470	210 (45)
Imprisonment	2	0 (0)	41	27 (66)	43	27 (63)
p value		1.000		0.040		0.023
<b>2014</b>						
No imprisonment	49	3 (6)	322	139 (43)	384	144 (38)
Imprisonment	2	0 (0)	39	19 (49)	42	19 (45)
p value		1.000		0.509		0.327
<b>2015</b>						
No imprisonment	42	4 (10)	403	175 (43)	459	183 (40)
Imprisonment	1	1 (100)	39	29 (74)	40	30 (75)
p value		0.116		<0.001		<0.001
<b>2016</b>						
No imprisonment	16	0 (0)	233	115 (49)	263	122 (46)
Imprisonment	1	0 (0)	33	26 (79)	35	27 (77)
p value		--		0.002		0.001

**Table 5.3.9 HCV antibody prevalence by sex work last month, years since first injection and survey year**

Queensland	<3 years		3+ years		Total	
Sex work last month	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2012</b>						
No sex work	61	7 (11)	464	234 (50)	535	248 (46)
Sex work	1	0 (0)	13	9 (69)	16	9 (56)
p value		1.000		0.261		0.457
<b>2013</b>						
No sex work	55	5 (9)	428	214 (50)	495	229 (46)
Sex work	1	0 (0)	7	4 (57)	8	4 (50)
p value		1.000		1.000		1.000
<b>2014</b>						
No sex work	49	3 (6)	340	142 (42)	402	147 (37)
Sex work	1	0 (0)	16	6 (38)	18	6 (33)
p value		1.000		0.735		0.780
<b>2015</b>						
No sex work	42	5 (12)	442	209 (47)	497	217 (44)
Sex work	1	0 (0)	12	6 (50)	14	7 (50)
p value		1.000		0.853		0.637
<b>2016</b>						
No sex work	17	0 (0)	247	128 (52)	276	134 (49)
Sex work	1	0 (0)	15	11 (73)	17	12 (71)
p value		--		0.118		0.078

**Table 5.3.10 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year**

Queensland	Male		Female		Total	
Aboriginal and Torres Strait Islander origin	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2012</b>						
Non Indigenous	352	152 (43)	129	67 (52)	483	220 (46)
Indigenous	51	28 (55)	22	14 (64)	73	42 (58)
p value		0.132		0.360		0.060
<b>2013</b>						
Non Indigenous	330	145 (44)	135	62 (46)	466	208 (45)
Indigenous	33	18 (55)	21	15 (71)	54	33 (61)
p value		0.243		0.030		0.022
<b>2014</b>						
Non Indigenous	293	105 (36)	104	43 (41)	398	148 (37)
Indigenous	27	14 (52)	15	6 (40)	42	20 (48)
p value		0.099		0.921		0.186
<b>2015</b>						
Non Indigenous	334	135 (40)	114	51 (45)	450	187 (42)
Indigenous	41	25 (61)	23	12 (52)	64	37 (59)
p value		0.012		0.514		0.014
<b>2016</b>						
Non Indigenous	176	80 (45)	82	39 (48)	259	120 (46)
Indigenous	22	14 (64)	18	14 (78)	40	28 (70)
p value		0.107		0.035		0.005

**Table 5.3.11 HCV antibody prevalence by main language spoken at home by parents, gender and survey year**

Queensland Main language spoken at home by parents	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2012</b>						
English speaking	400	178 (45)	149	79 (53)	550	258 (47)
Non-English speaking	8	5 (63)	4	3 (75)	13	8 (62)
p value		0.476		0.624		0.401
<b>2013</b>						
English speaking	362	162 (45)	154	76 (49)	517	239 (46)
Non-English speaking	8	5 (63)	6	3 (50)	14	8 (57)
p value		0.476		1.000		0.419
<b>2014</b>						
English speaking	313	115 (37)	117	47 (40)	431	162 (38)
Non-English speaking	12	5 (42)	5	2 (40)	17	7 (41)
p value		0.729		1.000		0.765
<b>2015</b>						
English speaking	364	153 (42)	137	62 (45)	503	216 (43)
Non-English speaking	8	4 (50)	1	1 (100)	9	5 (56)
p value		0.726		0.457		0.449
<b>2016</b>						
English speaking	191	90 (47)	98	51 (52)	290	142 (49)
Non-English speaking	9	5 (56)	2	2 (100)	11	7 (64)
p value		0.738		0.497		0.375



**Table 5.3.12 HCV antibody prevalence by region/country of birth, gender and survey year**

Queensland		Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
<b>2012</b>							
Australia	362	167 (46)	135	73 (54)	499	241 (48)	
Other Oceania	19	5 (26)	12	7 (58)	31	12 (39)	
Asia	1	0 (0)	0	0 (0)	1	0 (0)	
UK & Ireland	14	4 (29)	5	2 (40)	19	6 (32)	
Other	10	5 (50)	2	1 (50)	12	6 (50)	
p value		0.235		0.923		0.406	
<b>2013</b>							
Australia	334	149 (45)	141	71 (50)	476	221 (46)	
Other Oceania	21	11 (52)	7	4 (57)	28	15 (54)	
Asia	0	0 (0)	0	0 (0)	0	0 (0)	
UK & Ireland	8	4 (50)	4	1 (25)	12	5 (42)	
Other	8	3 (38)	7	2 (29)	15	5 (33)	
p value		0.864		0.589		0.646	
<b>2014</b>							
Australia	277	111 (40)	109	42 (39)	387	153 (40)	
Other Oceania	22	5 (23)	6	3 (50)	28	8 (29)	
Asia	2	0 (0)	0	0 (0)	2	0 (0)	
UK & Ireland	10	3 (30)	4	2 (50)	14	5 (36)	
Other	14	1 (7)	3	1 (33)	17	2 (12)	
p value		0.044		0.858		0.095	
<b>2015</b>							
Australia	330	143 (43)	124	62 (50)	456	206 (45)	
Other Oceania	18	7 (39)	6	1 (17)	24	8 (33)	
Asia	4	0 (0)	1	0 (0)	5	0 (0)	
UK & Ireland	10	5 (50)	6	1 (17)	16	6 (38)	
Other	8	2 (25)	1	0 (0)	9	2 (22)	
p value		0.401		0.111		0.132	
<b>2016</b>							
Australia	178	87 (49)	90	47 (52)	268	134 (50)	
Other Oceania	7	3 (43)	3	2 (67)	10	5 (50)	
Asia	2	1 (50)	0	0 (0)	2	1 (50)	
UK & Ireland	7	4 (57)	7	4 (57)	15	9 (60)	
Other	5	1 (20)	0	0 (0)	5	1 (20)	
p value		0.812		1.000		0.682	

## South Australia

**Table 6.1.1 Number (percentage) of respondents by demographic characteristics and survey year**

South Australia	2012	2013	2014	2015	2016
<b>Number of sites</b>	7	7	7	7	7
<b>N° surveyed</b>	N=203	N=248	N=228	N=238	N=247
<b>Response rate (%)</b>	42%	56%	51%	55%	52%
<b>Gender (%)</b>					
Male	127 (63)	169 (68)	143 (63)	137 (58)	151 (61)
Female	75 (37)	78 (31)	83 (36)	98 (41)	95 (38)
Transgender	1 (<1)	1 (<1)	2 (1)	3 (1)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	1 (<1)
<b>Sexual identity (%)</b>					
Heterosexual	155 (76)	193 (78)	177 (78)	187 (79)	196 (79)
Bisexual	18 (9)	26 (10)	28 (12)	26 (11)	20 (8)
Homosexual	12 (6)	8 (3)	5 (2)	12 (5)	10 (4)
Not reported	18 (9)	21 (8)	18 (8)	13 (5)	21 (9)
<b>Aboriginal and Torres Strait Islander origin (%)</b>					
No	183 (90)	201 (81)	197 (86)	210 (88)	192 (78)
Yes	17 (8)	35 (14)	28 (1)	25 (11)	49 (20)
Not reported	3 (1)	12 (5)	3 (1)	3 (1)	6 (2)
<b>Region/country of birth (%)</b>					
Australia	178 (88)	214 (86)	202 (87)	214 (90)	215 (87)
Other Oceania	1 (<1)	4 (2)	4 (2)	0 (0)	9 (4)
Asia	1 (<1)	3 (1)	2 (1)	2 (1)	0 (0)
UK & Ireland	10 (5)	18 (7)	11 (5)	9 (4)	12 (5)
Other	12 (6)	9 (4)	8 (4)	8 (3)	9 (4)
Not reported	1 (<1)	0 (0)	1 (<1)	5 (2)	2 (1)
<b>Main language spoken at home by parents (%)</b>					
English	182 (90)	230 (93)	213 (93)	221 (93)	228 (92)
Non-English	21 (10)	18 (7)	13 (6)	14 (6)	17 (7)
Not reported	0 (0)	0 (0)	2 (1)	3 (1)	2 (1)
<b>Age and time since first injection (years)</b>					
<i>Median age</i>	40	40	40	43	43
<i>Age range</i>	18-60	17-60	18-68	17-70	17-67
<i>Age group (%)</i>					
<25 years	14 (7)	21 (8)	6 (3)	7 (3)	12 (5)
25+ years	189 (93)	225 (91)	222 (97)	231 (97)	235 (95)
Not reported	0 (0)	2 (1)	0 (0)	0 (0)	0 (0)
<i>Median age first injection</i>					
	18	18	18	19	19
<i>Age range</i>	10-55	12-48	10-57	12-51	10-55
<i>N° not reported</i>	3	8	1	5	5
<i>Median yrs since first injection</i>					
	20	18	20	22	21
<i>Range</i>	<1-43	<1-46	<1-41	<1-51	<1-47
<i>Years since first injection</i>					
<3 years	8 (4)	13 (5)	8 (4)	10 (4)	15 (6)
3+ years	192 (95)	227 (92)	218 (96)	223 (94)	227 (92)
Not reported	3 (1)	8 (3)	2 (1)	5 (2)	5 (2)
<b>Imprisonment last year (%)</b>					
No	184 (92)	200 (81)	195 (86)	214 (90)	211 (85)
Yes	15 (8)	25 (10)	19 (8)	13 (5)	24 (10)
Not reported	4 (2)	23 (9)	14 (6)	11 (5)	12 (5)
<b>N° in prison</b>					
Injected in prison	N=15	N=25	N=19	N=13	N=247
	2 (13)	4 (16)	1 (5)	2 (15)	4 (17)

**Table 6.1.2 Number (percentage) of respondents by last drug injected, frequency of injecting and survey year**

<b>South Australia N° surveyed</b>	<b>2012 N=203</b>	<b>2013 N=248</b>	<b>2014 N=228</b>	<b>2015 N=238</b>	<b>2016 N=247</b>
<b>Drug last injected (%)</b>					
Cocaine	0 (0)	1 (<1)	0 (0)	1 (<1)	1 (<1)
Methamphetamine	72 (35)	93 (38)	116 (51)	125 (53)	147 (60)
Heroin	74 (36)	83 (33)	65 (29)	73 (31)	45 (18)
Pharm. opioids	26 (13)	41 (17)	14 (6)	12 (5)	24 (10)
Methadone	9 (4)	8 (3)	9 (4)	11 (5)	11 (4)
Buprenorphine	4 (2)	0 (0)	2 (1)	1 (<1)	3 (1)
Buprenorphine/naloxone	1 (<1)	3 (1)	1 (<1)	1 (<1)	1 (<1)
PIEDs	4 (2)	1 (<1)	1 (<1)	1 (<1)	2 (1)
More than one	11 (5)	16 (6)	18 (8)	10 (4)	13 (5)
Other	1 (<1)	2 (1)	2 (1)	3 (1)	0 (0)
Not reported	1 (<1)	0 (0)	0 (0)	0 (0)	0 (0)
<b>Ever injected opioids</b>					
Yes	-	-	-	-	178 (72)
No	-	-	-	-	67 (27)
Not reported	-	-	-	-	2 (1)
<b>Frequency of injection last month (%)</b>					
Not last month	10 (5)	10 (4)	9 (4)	17 (7)	11 (4)
Less than weekly	41 (20)	41 (17)	42 (18)	48 (20)	40 (16)
Weekly not daily	57 (28)	70 (28)	66 (29)	82 (34)	79 (32)
Daily or more	95 (47)	121 (49)	106 (46)	90 (38)	114 (46)
Not reported	0 (0)	6 (2)	5 (2)	1 (<1)	3 (1)
<b>Present when someone injected for the first time in the last 12 months (%)</b>					
Yes	28 (14)	41 (17)	34 (15)	34 (14)	43 (17)
No	155 (76)	176 (71)	190 (83)	202 (85)	202 (82)
Not reported	20 (10)	31 (13)	4 (2)	2 (1)	2 (1)
<b>Overdosed in last 12 months</b>					
Yes	--	22 (9)	25 (11)	18 (8)	48 (19)
No	--	212 (85)	198 (87)	218 (92)	194 (79)
Not reported	--	14 (6)	5 (2)	2 (1)	5 (2)

**Table 6.1.3 Number (percentage) of respondents by injecting behaviour in the last month and survey year**

South Australia N° injected last month	2012 N=193	2013 N=232	2014 N=214	2015 N=220	2016 N=233
<b>Places injected last month (%)</b>					
Any public	91 (47)	103 (44)	69 (32)	67 (30)	106 (45)
All private	91 (47)	128 (55)	143 (67)	153 (70)	125 (54)
Not reported	11 (6)	1 (<1)	2 (1)	0 (0)	2 (1)
<b>Use of new and sterile needles and syringes last month (%)</b>					
All injections	149 (77)	187 (81)	174 (81)	178 (81)	180 (77)
Most of the time	28 (15)	35 (15)	30 (14)	36 (16)	40 (17)
Half of the time	0 (0)	3 (1)	4 (2)	2 (1)	6 (3)
Some of the time	1 (<1)	2 (1)	2 (1)	1 (<1)	2 (1)
Not last month	1 (<1)	2 (1)	0 (0)	1 (<1)	1 (<1)
Not reported	14 (7)	3 (1)	4 (2)	2 (1)	4 (2)
<b>Re-used someone else's used needle &amp; syringe last month (%)</b>					
None	162 (84)	197 (85)	183 (86)	189 (86)	180 (77)
Once	12 (6)	17 (7)	10 (5)	11 (5)	21 (9)
Twice	5 (3)	6 (3)	12 (6)	13 (6)	14 (6)
3-5 times	0 (0)	5 (2)	4 (2)	4 (2)	11 (5)
>5 times	1 (<1)	6 (3)	3 (1)	3 (1)	5 (2)
Not reported	13 (7)	1 (<1)	2 (1)	0 (0)	2 (1)
<b>Number of people needle &amp; syringe was re-used after last month (%)</b>					
None	162 (84)	197 (85)	183 (86)	189 (86)	180 (77)
One	7 (4)	14 (6)	11 (5)	14 (6)	18 (8)
Two	1 (<1)	3 (1)	1 (<1)	2 (1)	5 (2)
Three to five	1 (<1)	3 (1)	0 (0)	1 (<1)	5 (2)
More than five	0 (0)	3 (1)	2 (1)	0 (0)	2 (1)
Don't know	2 (1)	9 (4)	10 (5)	10 (5)	9 (4)
Not reported	20 (10)	3 (1)	7 (3)	4 (2)	14 (6)
<b>Relationship to people needle &amp; syringe was used after last month (%) [more than one could be selected]</b>					
Regular sex partner	7 (4)	18 (8)	14 (7)	14 (6)	24 (10)
Casual sex partner	0 (0)	2 (1)	1 (<1)	3 (1)	1 (<1)
Close friend	3 (2)	9 (4)	9 (4)	2 (1)	13 (6)
Acquaintance	2 (1)	5 (2)	2 (1)	4 (2)	6 (3)
Other	1 (<1)	5 (2)	3 (1)	4 (2)	1 (<1)
<b>Equipment used after someone else last month (%) [more than one could be selected]</b>					
Spoon	21 (11)	51 (22)	32 (15)	34 (15)	30 (13)
Water	22 (11)	43 (19)	28 (13)	43 (20)	50 (21)
Filter	13 (7)	26 (11)	12 (6)	19 (9)	17 (7)
Drug mix	15 (8)	21 (9)	12 (6)	19 (9)	20 (9)
None	134 (69)	147 (63)	155 (72)	161 (73)	161 (69)
<b>Injected by someone after that person injected themselves or others last month (%)</b>					
No	164 (85)	182 (78)	166 (78)	178 (81)	187 (80)
Yes	15 (8)	39 (17)	40 (19)	42 (19)	43 (18)
Not reported	14 (7)	11 (5)	8 (4)	0 (0)	3 (1)
<b>Source of needle acquisition</b>					
Needle Syringe Program	159 (82)	211 (91)	191 (89)	201 (91)	203 (87)
Chemist/Pharmacy	41 (21)	41 (18)	34 (16)	44 (20)	41 (18)
Personal sources	23 (12)	27 (12)	18 (8)	23 (10)	37 (16)
Dispensing/Vending Machine	27 (14)	20 (9)	22 (10)	37 (17)	47 (20)
Other sources	2 (1)	4 (2)	1 (<1)	4 (2)	3 (1)

**Table 6.1.4 Number (percentage) of respondents by treatment for drug use and survey year**

<b>South Australia</b>	<b>2012</b>	<b>2013</b>	<b>2014</b>	<b>2015</b>	<b>2016</b>
<b>N° surveyed</b>	<b>N=203</b>	<b>N=248</b>	<b>N=228</b>	<b>N=238</b>	<b>N=247</b>
<b>Ever any treatment/therapy for drug use (%)</b>					
No	60 (30)	72 (29)	72 (33)	76 (32)	85 (34)
Yes	142 (70)	170 (69)	153 (67)	161 (68)	153 (62)
Not reported	1 (<1)	6 (2)	3 (1)	1 (<1)	9 (4)
<b>History of methadone maintenance treatment (%)</b>					
Currently	58 (29)	65 (26)	57 (25)	53 (22)	44 (18)
Previously	44 (22)	41 (17)	46 (20)	56 (24)	47 (19)
Never	100 (49)	140 (56)	122 (54)	125 (53)	144 (58)
Not reported	1 (<1)	2 (1)	3 (1)	4 (2)	12 (5)
<b>History of buprenorphine (Subutex®) treatment (%)</b>					
Currently	18 (9)	19 (8)	15 (7)	18 (8)	13 (5)
Previously	46 (23)	64 (26)	54 (24)	74 (31)	54 (22)
Never	139 (68)	158 (64)	157 (69)	143 (60)	170 (69)
Not reported	0 (0)	7 (3)	2 (1)	3 (1)	10 (4)
<b>History of buprenorphine-naloxone (Suboxone®) treatment (%)</b>					
Currently	26 (13)	23 (9)	23 (10)	16 (7)	23 (9)
Previously	29 (14)	57 (23)	37 (16)	48 (20)	36 (15)
Never	144 (71)	163 (66)	164 (72)	170 (71)	180 (73)
Not reported	4 (2)	5 (2)	4 (2)	4 (2)	8 (3)

**Table 6.1.5 Number (percentage) of respondents by testing for HIV and HCV, HCV treatment by survey year**

<b>South Australia</b>	<b>2012</b>	<b>2013</b>	<b>2014</b>	<b>2015</b>	<b>2016</b>
<b>N° surveyed</b>	<b>N=203</b>	<b>N=248</b>	<b>N=228</b>	<b>N=238</b>	<b>N=247</b>
<b>Previous HIV test (%)</b>					
Yes, ever	175 (86)	207 (83)	176 (77)	212 (89)	198 (80)
Yes, last year	101 (50)	132 (53)	98 (43)	127 (53)	112 (45)
>1 year ago	74 (36)	75 (30)	78 (34)	85 (36)	86 (35)
Never tested	21 (10)	34 (14)	45 (20)	22 (9)	45 (18)
Not reported	7 (3)	7 (3)	7 (3)	4 (2)	4 (2)
<b>Previous HCV test (%)</b>					
Yes, ever	182 (90)	214 (86)	183 (80)	211 (89)	201 (81)
Yes, last year	112 (55)	140 (56)	116 (51)	131 (55)	121 (49)
>1 year ago	70 (34)	74 (30)	67 (29)	80 (34)	80 (32)
Never tested	13 (6)	22 (9)	35 (15)	15 (6)	31 (13)
Not reported	8 (4)	12 (5)	10 (4)	12 (5)	15 (6)
<b>Lifetime treatment for HCV (%)#</b>					
<b>N° self-reported HCV diagnosis</b>	<b>N=53</b>	<b>N=65</b>	<b>N=50</b>	<b>N=58</b>	<b>N=48</b>
Antiviral treatment	4 (8)	12 (18)	7 (14)	9 (16)	22 (46)
No antiviral treatment	49 (92)	50 (77)	40 (80)	47 (81)	26 (54)
Not reported	0 (0)	3 (5)	3 (6)	2 (3)	0 (0)
<b>Treatment for HCV in past 12 months (%)**</b>					
<b>N° self-reported HCV diagnosis</b>	<b>N=52</b>	<b>N=59</b>	<b>N=48</b>	<b>N=52</b>	<b>N=42</b>
Antiviral treatment	0 (0)	2 (3)	1 (2)	1 (2)	13 (31)
No antiviral treatment	52 (100)	54 (92)	44 (92)	49 (94)	29 (69)
Not reported	0 (0)	3 (5)	3 (6)	2 (4)	0 (0)

# among people who tested HCV antibody positive and did not report spontaneous clearance

\* excludes people who reported treatment induced clearance more than 12 months previously

**Table 6.1.6 Number (percentage) of respondents by sexual behaviour in the month prior to survey and survey year**

<b>South Australia</b>	<b>2012</b>	<b>2013</b>	<b>2014</b>	<b>2015</b>	<b>2016</b>
<b>N° surveyed</b>	N=203	N=248	N=228	N=238	N=247
<b>Sex with a regular partner last month (%)</b>					
No	91 (45)	124 (50)	102 (45)	108 (45)	94 (38)
Yes	108 (53)	118 (48)	119 (52)	116 (49)	146 (59)
Not reported	4 (2)	6 (2)	7 (3)	14 (6)	7 (3)
<b>Condom used with regular partner last month (%)</b>					
<b>N° surveyed</b>	N=108	N=118	N=119	N=116	N=146
Never	73 (68)	86 (73)	89 (75)	87 (75)	112 (77)
Sometimes	11 (10)	14 (12)	14 (12)	11 (9)	12 (8)
Every time	13 (12)	6 (5)	11 (9)	14 (12)	13 (9)
Not reported	11 (10)	12 (10)	5 (4)	4 (3)	9 (6)
<b>Sex with other partner(s) last month (%)</b>					
No	176 (87)	216 (87)	185 (81)	205 (86)	202 (82)
Yes	22 (11)	23 (9)	34 (15)	21 (9)	39 (16)
Not reported	5 (2)	9 (4)	9 (4)	12 (5)	6 (2)
<b>Condom used with other partner(s) last month (%)</b>					
<b>N° surveyed</b>	N=22	N=23	N=34	N=21	N=39
Never	9 (41)	11 (48)	10 (29)	11 (52)	17 (44)
Sometimes	4 (18)	5 (22)	10 (29)	1 (5)	12 (31)
Every time	8 (36)	6 (26)	11 (32)	9 (43)	9 (23)
Not reported	1 (5)	1 (4)	3 (9)	0 (0)	1 (3)
<b>Sex work last month (%)</b>					
No	192 (95)	217 (88)	207 (91)	221 (93)	228 (92)
Yes	6 (3)	20 (8)	10 (4)	9 (4)	11 (4)
Not reported	5 (2)	11 (4)	11 (5)	8 (3)	8 (3)
<b>Condom used at last sex work (%)</b>					
Yes	6 (100)	14 (70)	8 (80)	6 (67)	9 (82)

**Table 6.1.7 Number (percentage) of respondents reporting stigma or discrimination in the last 12 months in 2016**

<b>South Australia<sup>#</sup></b>	<b>Never</b>	<b>Rarely</b>	<b>Sometimes</b>	<b>Often</b>	<b>Always</b>
Use of drugs for injecting	60 (27)	26 (12)	85 (38)	34 (15)	20 (9)
Sexual orientation	127 (74)	19 (11)	16 (9)	7 (4)	2 (1)
Hepatitis C status	109 (69)	11 (7)	24 (15)	10 (6)	3 (2)
Hepatitis B status	127 (92)	5 (4)	4 (3)	1 (1)	1 (1)
HIV status	123 (93)	3 (2)	6 (5)	0 (0)	0 (0)
Sex work	114 (88)	4 (3)	5 (4)	6 (5)	1 (1)
Other	46 (75)	0 (0)	5 (8)	9 (15)	1 (2)
Health workers treated me negatively or different to other people	119 (54)	29 (13)	49 (22)	13 (6)	10 (5)

<sup>#</sup> excludes respondents who indicated 'not applicable' and where data was missing

## HIV antibody prevalence

**Table 6.2.1 HIV antibody prevalence by gender and survey year**

South Australia Survey year	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)
2012	123	2 (1.6)	73	4 (5.5)	197	6 (3.1)
2013	154	4 (2.6)	74	3 (4.1)	229	7 (3.1)
2014	137	2 (1.5)	82	0 (0.0)	220	2 (0.9)
2015	122	0 (0.0)	88	0 (0.0)	213	0 (0.0)
2016	150	1 (0.7)	94	0 (0.0)	245	1 (0.4)
X <sup>2</sup> p trend		0.140		0.002		0.001

**Table 6.2.2 HIV antibody prevalence by sexual identity, gender and survey year**

South Australia Sexual identity	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)
<b>2012</b>						
Heterosexual	99	0 (0.0)	54	4 (7.4)	153	4 (2.6)
Bisexual	6	0 (0.0)	10	0 (0.0)	16	0 (0.0)
Homosexual	8	2 (25.0)	2	0 (0.0)	11	2 (18.2)
p value		0.007		1.000		0.072
<b>2013</b>						
Heterosexual	127	2 (1.6)	52	3 (5.8)	180	5 (2.8)
Bisexual	6	1 (16.7)	16	0 (0.0)	22	1 (4.6)
Homosexual	5	1 (20.0)	2	0 (0.0)	7	1 (14.3)
p value		0.032		1.000		0.141
<b>2014</b>						
Heterosexual	110	0 (0.0)	61	0 (0.0)	171	0 (0.0)
Bisexual	9	1 (11.1)	16	0 (0.0)	26	1 (3.9)
Homosexual	2	1 (50.0)	3	0 (0.0)	5	1 (20.0)
p value		0.003		--		0.007
<b>2015</b>						
Heterosexual	109	0 (0.0)	55	0 (0.0)	165	0 (0.0)
Bisexual	4	0 (0.0)	18	0 (0.0)	24	0 (0.0)
Homosexual	3	0 (0.0)	8	0 (0.0)	11	0 (0.0)
p value		--		--		--
<b>2016</b>						
Heterosexual	129	1 (0.8)	66	0 (0.0)	195	1 (0.5)
Bisexual	7	0 (0.0)	12	0 (0.0)	19	0 (0.0)
Homosexual	3	0 (0.0)	7	0 (0.0)	10	0 (0.0)
p value		1.000		--		1.000

**Table 6.2.3 HIV antibody prevalence by age group, gender and survey year**

South Australia Age group	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
<b>2012</b>						
<25 years	9	0 (0.0)	5	0 (0.0)	14	0 (0.0)
25-34 years	22	0 (0.0)	18	2 (11.1)	40	2 (5.0)
35-44 years	50	0 (0.0)	26	0 (0.0)	76	0 (0.0)
45+ years	42	2 (4.8)	24	2 (8.3)	67	4 (6.0)
p value		0.287		0.336		0.109
<b>2013</b>						
<25 years	7	0 (0.0)	11	0 (0.0)	18	0 (0.0)
25-34 years	25	0 (0.0)	19	2 (10.5)	44	2 (4.6)
35-44 years	57	1 (1.8)	27	0 (0.0)	84	1 (1.2)
45+ years	63	3 (4.8)	17	1 (5.9)	81	4 (4.9)
p value		0.606		0.218		0.483
<b>2014</b>						
<25 years	5	0 (0.0)	1	0 (0.0)	6	0 (0.0)
25-34 years	22	0 (0.0)	19	0 (0.0)	41	0 (0.0)
35-44 years	62	1 (1.6)	43	0 (0.0)	105	1 (1.0)
45+ years	48	1 (2.1)	19	0 (0.0)	68	1 (1.5)
p value		1.000		--		1.000
<b>2015</b>						
<25 years	1	0 (0.0)	3	0 (0.0)	4	0 (0.0)
25-34 years	14	0 (0.0)	16	0 (0.0)	31	0 (0.0)
35-44 years	43	0 (0.0)	35	0 (0.0)	78	0 (0.0)
45+ years	64	0 (0.0)	34	0 (0.0)	100	0 (0.0)
p value		--		--		--
<b>2016</b>						
<25 years	9	0 (0.0)	3	0 (0.0)	12	0 (0.0)
25-34 years	24	0 (0.0)	20	0 (0.0)	44	0 (0.0)
35-44 years	44	0 (0.0)	36	0 (0.0)	81	0 (0.0)
45+ years	73	1 (1.4)	35	0 (0.0)	108	1 (0.9)
p value		1.000		--		1.000



**Table 6.2.4 HIV antibody prevalence by last drug injected, gender and survey year**

<b>South Australia</b>		<b>Male</b>		<b>Female</b>		<b>Total</b>	
<b>Last drug injected</b>	<b>N° tested</b>	<b>N° with HIV (%)</b>	<b>N° tested</b>	<b>N° with HIV (%)</b>	<b>N° tested</b>	<b>N° with HIV (%)</b>	
<b>2012</b>							
Heroin	42	1 (2.4)	29	2 (6.9)	72	3 (4.2)	
Methamphetamine	42	1 (2.4)	27	2 (7.4)	69	3 (4.4)	
Other opioids	26	0 (0.0)	13	0 (0.0)	39	0 (0.0)	
Other drugs	12	0 (0.0)	4	0 (0.0)	16	0 (0.0)	
p value		1.000		1.000		0.741	
<b>2013</b>							
Heroin	44	0 (0.0)	29	1 (3.5)	73	1 (1.4)	
Methamphetamine	57	3 (5.3)	28	2 (7.1)	85	5 (5.9)	
Other opioids	40	1 (2.5)	11	0 (0.0)	51	1 (2.0)	
Other drugs	13	0 (0.0)	6	0 (0.0)	20	0 (0.0)	
p value		0.456		0.825		0.434	
<b>2014</b>							
Heroin	37	0 (0.0)	27	0 (0.0)	64	0 (0.0)	
Methamphetamine	71	2 (2.8)	39	0 (0.0)	111	2 (1.8)	
Other opioids	14	0 (0.0)	11	0 (0.0)	25	0 (0.0)	
Other drugs	15	0 (0.0)	5	0 (0.0)	20	0 (0.0)	
p value		0.718		--		0.705	
<b>2015</b>							
Heroin	40	0 (0.0)	24	0 (0.0)	65	0 (0.0)	
Methamphetamine	61	0 (0.0)	50	0 (0.0)	113	0 (0.0)	
Other opioids	14	0 (0.0)	9	0 (0.0)	23	0 (0.0)	
Other drugs	7	0 (0.0)	5	0 (0.0)	12	0 (0.0)	
p value		--		--		--	
<b>2016</b>							
Heroin	25	0 (0.0)	18	0 (0.0)	43	0 (0.0)	
Methamphetamine	85	1 (1.2)	61	0 (0.0)	147	1 (0.7)	
Other opioids	28	0 (0.0)	11	0 (0.0)	39	0 (0.0)	
Other drugs	12	0 (0.0)	4	0 (0.0)	16	0 (0.0)	
p value		1.000		--		1.000	

**Table 6.2.5 HIV antibody prevalence by years of injection, gender and survey year**

South Australia Years of injection	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)
<b>2012</b>						
<3 years	6	0 (0.0)	2	0 (0.0)	8	0 (0.0)
3 to 10 years	14	1 (7.1)	17	2 (11.8)	32	3 (9.4)
11+ years	100	1 (1.0)	54	2 (3.7)	154	3 (2.0)
p value		0.307		0.322		0.113
<b>2013</b>						
<3 years	3	0 (0.0)	8	0 (0.0)	11	0 (0.0)
3 to 10 years	21	0 (0.0)	9	0 (0.0)	30	0 (0.0)
11+ years	123	4 (3.3)	56	3 (5.4)	180	7 (3.9)
p value		1.000		1.000		0.719
<b>2014</b>						
<3 years	3	0 (0.0)	4	0 (0.0)	7	0 (0.0)
3 to 10 years	26	1 (4.4)	10	0 (0.0)	33	1 (3.0)
11+ years	109	1 (0.9)	68	0 (0.0)	178	1 (0.6)
p value		0.349		--		0.334
<b>2015</b>						
<3 years	5	0 (0.0)	5	0 (0.0)	10	0 (0.0)
3 to 10 years	10	0 (0.0)	8	0 (0.0)	18	0 (0.0)
11+ years	106	0 (0.0)	74	0 (0.0)	183	0 (0.0)
p value		--		--		--
<b>2016</b>						
<3 years	9	0 (0.0)	6	0 (0.0)	15	0 (0.0)
3 to 10 years	17	0 (0.0)	8	0 (0.0)	25	0 (0.0)
11+ years	120	1 (0.8)	79	0 (0.0)	200	1 (0.5)
p value		1.000		--		1.000

**Table 6.2.6 HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and survey year**

South Australia Receptively shared syringe last month	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)
<b>2012</b>						
No receptive sharing	99	1 (1.0)	56	4 (7.1)	156	5 (3.2)
Receptive sharing	14	0 (0.0)	4	0 (0.0)	18	0 (0.0)
p value		1.000		1.000		1.000
<b>2013</b>						
No receptive sharing	123	3 (2.4)	60	3 (5.0)	184	6 (3.3)
Receptive sharing	20	0 (0.0)	11	0 (0.0)	31	0 (0.0)
p value		1.000		1.000		0.597
<b>2014</b>						
No receptive sharing	109	2 (1.8)	69	0 (0.0)	179	2 (1.1)
Receptive sharing	21	0 (0.0)	7	0 (0.0)	28	0 (0.0)
p value		1.000		--		1.000
<b>2015</b>						
No receptive sharing	95	0 (0.0)	73	0 (0.0)	170	0 (0.0)
Receptive sharing	16	0 (0.0)	11	0 (0.0)	27	0 (0.0)
p value		--		--		--
<b>2016</b>						
No receptive sharing	106	1 (0.9)	71	0 (0.0)	178	1 (0.6)
Receptive sharing	30	0 (0.0)	21	0 (0.0)	51	0 (0.0)
p value		1.000		--		1.000

**Table 6.2.7 HIV antibody prevalence by frequency of drug injection last month, gender and survey year**

South Australia	Male		Female		Total	
Frequency of injection	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)
<b>2012</b>						
Less than daily	60	2 (3.3)	35	4 (11.4)	95	6 (6.3)
Daily or more	60	0 (0.0)	31	0 (0.0)	92	0 (0.0)
Not last month	3	0 (0.0)	7	0 (0.0)	10	0 (0.0)
p value		0.520		0.192		0.067
<b>2013</b>						
Less than daily	63	2 (3.2)	38	3 (7.9)	101	5 (5.0)
Daily or more	80	1 (1.3)	33	0 (0.0)	114	1 (0.9)
Not last month	7	1 (14.3)	2	0 (0.0)	9	1 (11.1)
p value		0.136		0.304		0.061
<b>2014</b>						
Less than daily	58	1 (1.7)	45	0 (0.0)	104	1 (1.0)
Daily or more	72	1 (1.4)	32	0 (0.0)	104	1 (1.0)
Not last month	6	0 (0.0)	2	0 (0.0)	8	0 (0.0)
p value		1.000		--		1.000
<b>2015</b>						
Less than daily	68	0 (0.0)	47	0 (0.0)	116	0 (0.0)
Daily or more	43	0 (0.0)	37	0 (0.0)	81	0 (0.0)
Not last month	10	0 (0.0)	4	0 (0.0)	15	0 (0.0)
p value		--		--		--
<b>2016</b>						
Less than daily	64	1 (1.6)	53	0 (0.0)	118	1 (0.9)
Daily or more	73	0 (0.0)	40	0 (0.0)	113	0 (0.0)
Not last month	11	0 (0.0)	0	0 (0.0)	11	0 (0.0)
p value		0.507		--		1.000

**Table 6.2.8 HIV antibody prevalence by imprisonment last year, gender and survey year**

South Australia	Male		Female		Total	
Imprisonment last year	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)
<b>2012</b>						
No imprisonment	110	2 (1.8)	68	4 (5.9)	179	6 (3.4)
Imprisonment	12	0 (0.0)	2	0 (0.0)	14	0 (0.0)
p value		1.000		1.000		1.000
<b>2013</b>						
No imprisonment	122	3 (2.5)	63	3 (4.8)	186	6 (3.2)
Imprisonment	20	1 (5.0)	1	0 (0.0)	21	1 (4.8)
p value		0.459		1.000		0.533
<b>2014</b>						
No imprisonment	114	2 (1.8)	73	0 (0.0)	188	2 (1.1)
Imprisonment	15	0 (0.0)	4	0 (0.0)	19	0 (0.0)
p value		1.000		--		1.000
<b>2015</b>						
No imprisonment	106	0 (0.0)	84	0 (0.0)	193	0 (0.0)
Imprisonment	9	0 (0.0)	1	0 (0.0)	10	0 (0.0)
p value		--		--		--
<b>2016</b>						
No imprisonment	122	0 (0.0)	87	0 (0.0)	210	0 (0.0)
Imprisonment	18	1 (5.6)	5	0 (0.0)	23	1 (4.4)
p value		0.129		--		0.099

**Table 6.2.9 HIV antibody prevalence by condom use at last sex with regular partner, gender and survey year**

South Australia	Male		Female		Total	
Condom use at last sex	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
<b>2012</b>						
No condom use	42	0 (0.0)	28	2 (7.1)	70	2 (2.9)
Condom use	12	1 (8.3)	11	1 (9.1)	23	2 (8.7)
p value		0.222		1.000		0.255
<b>2013</b>						
No condom use	43	0 (0.0)	38	1 (2.6)	82	1 (1.2)
Condom use	12	0 (0.0)	6	2 (33.3)	18	2 (11.1)
p value		--		0.045		0.083
<b>2014</b>						
No condom use	48	1 (2.1)	39	0 (0.0)	87	1 (1.2)
Condom use	18	0 (0.0)	7	0 (0.0)	25	0 (0.0)
p value		1.000		--		1.000
<b>2015</b>						
No condom use	37	0 (0.0)	41	0 (0.0)	78	0 (0.0)
Condom use	8	0 (0.0)	11	0 (0.0)	21	0 (0.0)
p value		--		--		--
<b>2016</b>						
No condom use	56	0 (0.0)	54	0 (0.0)	111	0 (0.0)
Condom use	17	1 (5.9)	8	0 (0.0)	25	1 (4.0)
p value		0.233		--		0.184

**Table 6.2.10 HIV antibody prevalence by sex work last month, gender and survey year**

South Australia	Male		Female		Total	
Sex work last month	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
<b>2012</b>						
No sex work	118	2 (1.7)	68	4 (5.9)	187	6 (3.2)
Sex work	1	0 (0.0)	4	0 (0.0)	5	0 (0.0)
p value		1.000		1.000		1.000
<b>2013</b>						
No sex work	139	3 (2.2)	60	3 (5.0)	200	6 (3.0)
Sex work	9	1 (11.1)	10	0 (0.0)	19	1 (5.3)
p value		0.224		1.000		0.475
<b>2014</b>						
No sex work	126	2 (1.6)	73	0 (0.0)	200	2 (1.0)
Sex work	2	0 (0.0)	8	0 (0.0)	10	0 (0.0)
p value		1.000		--		1.000
<b>2015</b>						
No sex work	114	0 (0.0)	82	0 (0.0)	197	0 (0.0)
Sex work	4	0 (0.0)	3	0 (0.0)	9	0 (0.0)
p value		--		--		--
<b>2016</b>						
No sex work	139	1 (0.7)	86	0 (0.0)	226	1 (0.4)
Sex work	5	0 (0.0)	6	0 (0.0)	11	0 (0.0)
p value		1.000		--		1.000

**Table 6.2.11 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year**

<b>South Australia</b>	<b>Male</b>		<b>Female</b>		<b>Total</b>	
<b>Aboriginal and Torres Strait Islander origin</b>	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
<b>2012</b>						
Non Indigenous	113	2 (1.8)	64	4 (6.3)	178	6 (3.4)
Indigenous	9	0 (0.0)	7	0 (0.0)	16	0 (0.0)
p value		1.000		1.000		1.000
<b>2013</b>						
Non Indigenous	123	3 (2.4)	62	3 (4.9)	186	6 (3.2)
Indigenous	21	0 (0.0)	10	0 (0.0)	31	0 (0.0)
p value		1.000		1.000		0.597
<b>2014</b>						
Non Indigenous	120	2 (1.7)	68	0 (0.0)	189	2 (1.1)
Indigenous	14	0 (0.0)	14	0 (0.0)	28	0 (0.0)
p value		1.000		--		1.000
<b>2015</b>						
Non Indigenous	109	0 (0.0)	77	0 (0.0)	189	0 (0.0)
Indigenous	11	0 (0.0)	10	0 (0.0)	21	0 (0.0)
p value		--		--		--
<b>2016</b>						
Non Indigenous	116	0 (0.0)	74	0 (0.0)	191	0 (0.0)
Indigenous	29	1 (3.5)	19	0 (0.0)	48	1 (2.1)
p value		0.200		--		0.201

**Table 6.2.12 HIV antibody prevalence by main language spoken at home by parents, gender and survey year**

<b>South Australia</b>	<b>Male</b>		<b>Female</b>		<b>Total</b>	
<b>Main language spoken at home by parents</b>	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
<b>2012</b>						
English speaking	103	2 (1.9)	72	4 (5.6)	176	6 (3.4)
Non-English speaking	20	0 (0.0)	1	0 (0.0)	21	0 (0.0)
p value		1.000		1.000		1.000
<b>2013</b>						
English speaking	140	3 (2.1)	70	3 (4.3)	211	6 (2.8)
Non-English speaking	14	1 (7.1)	4	0 (0.0)	18	1 (5.6)
p value		0.320		1.000		0.441
<b>2014</b>						
English speaking	125	2 (1.6)	79	0 (0.0)	205	2 (1.0)
Non-English speaking	10	0 (0.0)	3	0 (0.0)	13	0 (0.0)
p value		1.000		--		1.000
<b>2015</b>						
English speaking	108	0 (0.0)	85	0 (0.0)	196	0 (0.0)
Non-English speaking	12	0 (0.0)	2	0 (0.0)	14	0 (0.0)
p value		--		--		--
<b>2016</b>						
English speaking	136	1 (0.7)	90	0 (0.0)	227	1 (0.4)
Non-English speaking	13	0 (0.0)	3	0 (0.0)	16	0 (0.0)
p value		1.000		--		1.000

**Table 6.2.13 HIV antibody prevalence by region/country of birth, gender and survey year**

South Australia		Male		Female		Total	
Region/country of birth	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
<b>2012</b>							
Australia	103	2 (1.9)	69	4 (5.8)	173	6 (3.5)	
Other Oceania	0	0 (0.0)	1	0 (0.0)	1	0 (0.0)	
Asia	0	0 (0.0)	1	0 (0.0)	1	0 (0.0)	
UK & Ireland	7	0 (0.0)	2	0 (0.0)	9	0 (0.0)	
Other	12	0 (0.0)	0	0 (0.0)	12	0 (0.0)	
p value		1.000		1.000		1.000	
<b>2013</b>							
Australia	128	4 (3.1)	68	3 (4.4)	197	7 (3.6)	
Other Oceania	2	0 (0.0)	1	0 (0.0)	3	0 (0.0)	
Asia	2	0 (0.0)	1	0 (0.0)	3	0 (0.0)	
UK & Ireland	15	0 (0.0)	2	0 (0.0)	17	0 (0.0)	
Other	7	0 (0.0)	2	0 (0.0)	9	0 (0.0)	
p value		0.934		0.991		0.883	
<b>2014</b>							
Australia	116	2 (1.7)	78	0 (0.0)	195	2 (1.0)	
Other Oceania	4	0 (0.0)	0	0 (0.0)	4	0 (0.0)	
Asia	2	0 (0.0)	0	0 (0.0)	2	0 (0.0)	
UK & Ireland	7	0 (0.0)	4	0 (0.0)	11	0 (0.0)	
Other	7	0 (0.0)	0	0 (0.0)	7	0 (0.0)	
p value		1.000		--		1.000	
<b>2015</b>							
Australia	105	0 (0.0)	82	0 (0.0)	190	0 (0.0)	
Other Oceania	0	0 (0.0)	0	0 (0.0)	0	0 (0.0)	
Asia	2	0 (0.0)	0	0 (0.0)	2	0 (0.0)	
UK & Ireland	5	0 (0.0)	4	0 (0.0)	9	0 (0.0)	
Other	6	0 (0.0)	1	0 (0.0)	7	0 (0.0)	
p value		--		--		--	
<b>2016</b>							
Australia	126	1 (0.8)	86	0 (0.0)	213	1 (0.5)	
Other Oceania	6	0 (0.0)	3	0 (0.0)	9	0 (0.0)	
Asia	0	0 (0.0)	0	0 (0.0)	0	0 (0.0)	
UK & Ireland	9	0 (0.0)	3	0 (0.0)	12	0 (0.0)	
Other	8	0 (0.0)	1	0 (0.0)	9	0 (0.0)	
p value		1.000		--		1.000	

## HCV antibody prevalence

**Table 6.3.1 HCV antibody prevalence by gender and survey year**

South Australia Survey year	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
2012	122	51 (42)	71	28 (39)	194	79 (41)
2013	153	78 (51)	74	32 (43)	228	111 (49)
2014	128	68 (53)	79	40 (51)	208	109 (52)
2015	120	60 (50)	88	40 (45)	211	100 (47)
2016	141	62 (44)	90	27 (30)	232	89 (38)
X <sup>2</sup> p trend		0.958		0.464		0.631

**Table 6.3.2 HCV antibody prevalence by sexual identity, gender and survey year**

South Australia Sexual identity	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2012</b>						
Heterosexual	98	44 (45)	52	19 (37)	150	63 (42)
Bisexual	7	3 (43)	10	5 (50)	17	8 (47)
Homosexual	7	2 (29)	2	1 (50)	10	3 (30)
p value		0.767		0.653		0.692
<b>2013</b>						
Heterosexual	126	65 (52)	52	23 (44)	179	89 (50)
Bisexual	6	1 (17)	16	6 (38)	22	7 (32)
Homosexual	5	0 (0)	2	1 (50)	7	1 (14)
p value		0.021		0.888		0.055
<b>2014</b>						
Heterosexual	103	55 (53)	59	30 (51)	162	85 (52)
Bisexual	8	1 (13)	16	8 (50)	25	10 (40)
Homosexual	1	1 (100)	3	2 (67)	4	3 (75)
p value		0.030		1.000		0.314
<b>2015</b>						
Heterosexual	107	53 (50)	55	25 (45)	163	78 (48)
Bisexual	4	1 (25)	18	10 (56)	24	11 (46)
Homosexual	3	2 (67)	8	2 (25)	11	4 (36)
p value		0.711		0.389		0.812
<b>2016</b>						
Heterosexual	120	52 (43)	62	22 (35)	182	74 (41)
Bisexual	7	3 (43)	12	1 (8)	19	4 (21)
Homosexual	3	1 (33)	7	0 (0)	10	1 (10)
p value		1.000		0.041		0.048

**Table 6.3.3 HCV antibody prevalence by age group, gender and survey year**

South Australia Age group	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2012</b>						
<25 years	9	0 (0)	5	1 (20)	14	1 (7)
25-34 years	22	7 (32)	18	5 (28)	40	12 (30)
35-44 years	50	18 (36)	26	9 (35)	76	27 (36)
45+ years	42	26 (63)	24	13 (59)	67	39 (61)
p value		0.001		0.147		<0.001
<b>2013</b>						
<25 years	7	1 (14)	11	1 (9)	18	2 (11)
25-34 years	25	11 (44)	19	9 (47)	44	20 (45)
35-44 years	57	26 (46)	27	12 (44)	84	38 (46)
45+ years	63	40 (63)	17	10 (59)	81	51 (63)
p value		0.035		0.060		<0.001
<b>2014</b>						
<25 years	5	1 (20)	1	0 (0)	6	1 (17)
25-34 years	22	7 (32)	19	8 (42)	41	15 (37)
35-44 years	56	28 (50)	41	18 (44)	97	46 (47)
45+ years	45	32 (71)	18	14 (78)	64	47 (73)
p value		0.005		0.034		<0.001
<b>2015</b>						
<25 years	1	0 (0)	3	0 (0)	4	0 (0)
25-34 years	14	7 (50)	16	7 (44)	31	14 (45)
35-44 years	43	16 (37)	35	13 (37)	78	29 (37)
45+ years	62	37 (60)	34	20 (59)	98	57 (58)
p value		0.085		0.121		0.007
<b>2016</b>						
<25 years	9	2 (22)	3	0 (0)	12	2 (17)
25-34 years	23	9 (39)	20	5 (25)	43	14 (33)
35-44 years	41	15 (37)	35	11 (31)	77	26 (34)
45+ years	68	36 (53)	32	11 (34)	100	47 (47)
p value		0.178		0.764		0.085



**Table 6.3.4 HCV antibody prevalence by years since first injection, gender and survey year**

South Australia Years of injection	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2012</b>						
<3 years	6	0 (0)	2	1 (50)	8	1 (13)
3 to 10 years	13	3 (23)	16	4 (25)	30	7 (23)
11+ years	100	47 (47)	53	23 (43)	153	70 (46)
p value		0.023		0.361		0.016
<b>2013</b>						
<3 years	3	0 (0)	8	2 (25)	11	2 (18)
3 to 10 years	21	4 (19)	9	3 (33)	30	7 (23)
11+ years	122	71 (58)	56	26 (46)	179	98 (55)
p value		<0.001		0.557		0.001
<b>2014</b>						
<3 years	3	1 (33)	4	0 (0)	7	1 (14)
3 to 10 years	22	8 (36)	10	4 (40)	32	12 (38)
11+ years	101	58 (57)	65	36 (55)	167	95 (57)
p value		0.129		0.074		0.016
<b>2015</b>						
<3 years	5	1 (20)	5	2 (40)	10	3 (30)
3 to 10 years	10	3 (30)	8	1 (13)	18	4 (22)
11+ years	104	55 (53)	75	37 (49)	182	92 (51)
p value		0.177		0.129		0.035
<b>2016</b>						
<3 years	9	0 (0)	6	1 (17)	15	1 (7)
3 to 10 years	17	3 (18)	8	1 (13)	25	4 (16)
11+ years	112	57 (51)	75	25 (33)	188	82 (44)
p value		<0.001		0.509		0.001

**Table 6.3.5 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year**

South Australia Receptively shared syringe last month	<3 years		3+ years		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2012</b>						
No receptive sharing	6	1 (17)	146	61 (42)	155	63 (41)
Receptive sharing	0	0 (0)	17	8 (47)	17	8 (47)
p value		--		0.797		0.614
<b>2013</b>						
No receptive sharing	9	1 (11)	170	83 (49)	183	87 (48)
Receptive sharing	2	1 (50)	27	17 (63)	31	18 (58)
p value		0.345		0.172		0.278
<b>2014</b>						
No receptive sharing	5	1 (20)	163	91 (56)	170	93 (55)
Receptive sharing	1	0 (0)	25	10 (40)	26	10 (38)
p value		1.000		0.139		0.122
<b>2015</b>						
No receptive sharing	8	2 (25)	161	77 (48)	170	80 (47)
Receptive sharing	0	0 (0)	26	14 (54)	26	14 (54)
p value		--		0.569		0.519
<b>2016</b>						
No receptive sharing	11	1 (9)	155	63 (41)	168	64 (38)
Receptive sharing	3	0 (0)	45	17 (38)	49	18 (37)
p value		1.000		0.730		0.863

**Table 6.3.6 HCV antibody prevalence by last drug injected, years since first injection and survey year**

South Australia Last drug injected	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2012</b>						
Heroin	1	0 (0)	68	30 (44)	71	31 (44)
Methamphetamine	2	0 (0)	64	15 (23)	66	15 (23)
Other opioids	1	1 (100)	39	22 (56)	40	23 (58)
Other drugs	4	0 (0)	11	9 (82)	16	9 (56)
p value		0.046		<0.001		0.002
<b>2013</b>						
Heroin	3	1 (33)	70	42 (60)	73	43 (59)
Methamphetamine	7	1 (14)	73	26 (36)	84	30 (36)
Other opioids	0	0 (0)	49	25 (51)	51	26 (51)
Other drugs	1	0 (0)	17	12 (71)	20	12 (60)
p value		0.685		0.008		0.020
<b>2014</b>						
Heroin	2	0 (0)	59	36 (61)	62	36 (58)
Methamphetamine	3	0 (0)	103	52 (50)	106	52 (49)
Other opioids	1	1 (100)	19	9 (47)	21	11 (52)
Other drugs	1	0 (0)	18	10 (56)	19	10 (53)
p value		0.072		0.566		0.736
<b>2015</b>						
Heroin	0	0 (0)	63	45 (71)	64	46 (72)
Methamphetamine	8	2 (25)	104	36 (35)	112	38 (34)
Other opioids	1	0 (0)	22	9 (41)	23	9 (39)
Other drugs	1	1 (100)	10	5 (50)	11	6 (55)
p value		0.240		<0.001		<0.001
<b>2016</b>						
Heroin	0	0 (0)	39	22 (56)	40	22 (55)
Methamphetamine	13	1 (8)	125	40 (32)	140	42 (30)
Other opioids	0	0 (0)	35	18 (51)	35	18 (51)
Other drugs	2	0 (0)	12	5 (42)	14	5 (36)
p value		0.685		0.022		0.010

**Table 6.3.7 HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year**

South Australia	<3 years		3+ years		Total	
Frequency of injection last month	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2012</b>						
Less than daily	5	1 (20)	86	36 (42)	92	38 (41)
Daily or more	1	0 (0)	89	40 (45)	92	40 (43)
Not last month	2	0 (0)	8	1 (13)	10	1 (10)
p value		1.000		0.237		0.127
<b>2013</b>						
Less than daily	7	1 (14)	90	46 (51)	101	50 (50)
Daily or more	4	1 (25)	107	54 (50)	113	55 (49)
Not last month	0	0 (0)	8	3 (38)	9	3 (33)
p value		1.000		0.828		0.687
<b>2014</b>						
Less than daily	3	0 (0)	97	55 (57)	100	55 (55)
Daily or more	3	1 (33)	92	46 (50)	97	48 (49)
Not last month	1	0 (0)	7	3 (43)	8	3 (38)
p value		1.000		0.555		0.529
<b>2015</b>						
Less than daily	4	1 (25)	111	58 (52)	116	60 (52)
Daily or more	4	1 (25)	76	33 (43)	80	34 (43)
Not last month	2	1 (50)	12	4 (33)	14	5 (36)
p value		1.000		0.310		0.301
<b>2016</b>						
Less than daily	8	1 (13)	101	44 (44)	110	45 (41)
Daily or more	6	0 (0)	100	37 (37)	108	38 (35)
Not last month	1	0 (0)	10	4 (40)	11	4 (36)
p value		1.000		0.621		0.659

**Table 6.3.8 HCV antibody prevalence by imprisonment last year, years since first injection and survey year**

South Australia	<3 years		3+ years		Total	
Imprisonment last year	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2012</b>						
No imprisonment	7	1 (14)	169	69 (41)	178	71 (40)
Imprisonment	1	0 (0)	11	5 (45)	13	5 (38)
p value		1.000		0.762		1.000
<b>2013</b>						
No imprisonment	10	2 (20)	169	79 (47)	186	84 (45)
Imprisonment	0	0 (0)	19	13 (68)	20	14 (70)
p value		--		0.073		0.035
<b>2014</b>						
No imprisonment	7	1 (14)	167	91 (54)	176	9 (53)
Imprisonment	0	0 (0)	19	8 (42)	19	8 (42)
p value		--		0.305		0.374
<b>2015</b>						
No imprisonment	8	2 (25)	182	84 (46)	191	87 (46)
Imprisonment	2	1 (50)	8	6 (75)	10	7 (70)
p value		1.000		0.110		0.131
<b>2016</b>						
No imprisonment	11	1 (9)	183	72 (39)	198	75 (38)
Imprisonment	3	0 (0)	19	10 (53)	22	10 (45)
p value		1.000		0.262		0.489

**Table 6.3.9 HCV antibody prevalence by sex work last month, years since first injection and survey year**

South Australia	<3 years		3+ years		Total	
Sex work last month	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2012</b>						
No sex work	8	1 (13)	173	73 (42)	184	75 (41)
Sex work	0	0 (0)	5	0 (0)	5	0 (0)
p value		--		0.790		0.159
<b>2013</b>						
No sex work	9	0 (0)	185	93 (50)	200	97 (49)
Sex work	1	1 (100)	16	8 (50)	18	9 (50)
p value		0.100		0.983		0.903
<b>2014</b>						
No sex work	5	1 (20)	182	101 (55)	188	103 (55)
Sex work	1	0 (0)	9	2 (22)	10	2 (20)
p value		1.000		0.083		0.048
<b>2015</b>						
No sex work	8	2 (25)	186	90 (48)	195	93 (48)
Sex work	2	1 (50)	7	3 (43)	9	4 (44)
p value		1.000		1.000		1.000
<b>2016</b>						
No sex work	13	1 (8)	197	79 (40)	213	81 (38)
Sex work	0	0 (0)	11	4 (36)	11	4 (36)
p value		--		1.000		1.000

**Table 6.3.10 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year**

South Australia	Male		Female		Total	
Aboriginal and Torres Strait Islander origin	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2012</b>						
Non Indigenous	112	47 (42)	62	26 (42)	175	73 (42)
Indigenous	9	4 (44)	7	1 (14)	16	5 (31)
p value		1.000		0.233		0.596
<b>2013</b>						
Non Indigenous	123	59 (48)	62	26 (42)	186	86 (46)
Indigenous	21	16 (76)	10	4 (40)	31	20 (65)
p value		0.017		1.000		0.059
<b>2014</b>						
Non Indigenous	111	55 (50)	66	33 (50)	178	89 (50)
Indigenous	14	11 (79)	13	7 (54)	27	18 (67)
p value		0.040		0.800		0.106
<b>2015</b>						
Non Indigenous	108	55 (51)	77	33 (43)	188	88 (47)
Indigenous	10	5 (50)	10	7 (70)	20	12 (60)
p value		0.955		0.105		0.262
<b>2016</b>						
Non Indigenous	108	40 (37)	71	22 (31)	180	62 (34)
Indigenous	28	19 (68)	18	5 (28)	46	24 (52)
p value		0.003		0.791		0.027

**Table 6.3.11 HCV antibody prevalence by main language spoken at home by parents, gender and survey year**

<b>South Australia</b>	<b>Male</b>		<b>Female</b>		<b>Total</b>	
<b>Main language spoken at home by parents</b>	<b>N° tested</b>	<b>N° with HCV (%)</b>	<b>N° tested</b>	<b>N° with HCV (%)</b>	<b>N° tested</b>	<b>N° with HCV (%)</b>
<b>2012</b>						
English speaking	102	47 (46)	70	28 (40)	173	75 (43)
Non-English speaking	20	4 (20)	1	0 (0)	21	4 (19)
p value		0.046		1.000		0.036
<b>2013</b>						
English speaking	139	73 (53)	70	30 (43)	210	104 (50)
Non-English speaking	14	5 (36)	4	2 (50)	18	7 (39)
p value		0.271		1.000		0.386
<b>2014</b>						
English speaking	119	66 (55)	76	39 (51)	196	106 (54)
Non-English speaking	7	1 (14)	3	1 (33)	10	2 (20)
p value		0.050		0.615		0.050
<b>2015</b>						
English speaking	106	53 (50)	85	39 (46)	194	92 (47)
Non-English speaking	12	5 (42)	2	1 (50)	14	6 (43)
p value		0.584		1.000		0.741
<b>2016</b>						
English speaking	127	53 (42)	87	26 (30)	215	79 (37)
Non-English speaking	13	8 (62)	2	1 (50)	15	9 (60)
p value		0.170		0.517		0.073

**Table 6.3.12 HCV antibody prevalence by region/country of birth, gender and survey year**

South Australia		Male		Female		Total	
Region/Country of birth	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	
<b>2012</b>							
Australia	102	38 (37)	68	26 (38)	171	64 (37)	
Other Oceania	0	0 (0)	1	0 (0)	1	0 (0)	
Asia	0	0 (0)	0	0 (0)	0	0 (0)	
UK & Ireland	7	5 (71)	2	2 (100)	9	7 (78)	
Other	12	7 (58)	0	0 (0)	12	7 (58)	
p value		0.092		0.152		0.030	
<b>2013</b>							
Australia	127	68 (54)	68	30 (44)	196	99 (51)	
Other Oceania	2	1 (50)	1	0 (0)	3	1 (33)	
Asia	2	1 (50)	1	1 (100)	3	2 (67)	
UK & Ireland	15	6 (40)	2	1 (50)	17	7 (41)	
Other	7	2 (29)	2	0 (0)	9	2 (22)	
p value		0.641		0.655		0.445	
<b>2014</b>							
Australia	108	61 (56)	75	37 (49)	184	99 (54)	
Other Oceania	4	2 (50)	0	0 (0)	4	2 (50)	
Asia	2	0 (0)	0	0 (0)	2	0 (0)	
UK & Ireland	7	3 (43)	4	3 (75)	11	6 (55)	
Other	6	2 (33)	0	0 (0)	6	2 (33)	
p value		0.440		0.615		0.583	
<b>2015</b>							
Australia	103	50 (49)	82	36 (44)	188	86 (46)	
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)	
Asia	2	2 (100)	0	0 (0)	2	2 (100)	
UK & Ireland	5	0 (0)	4	3 (75)	9	3 (33)	
Other	6	4 (67)	1	1 (100)	7	5 (71)	
p value		0.046		0.214		0.207	
<b>2016</b>							
Australia	119	51 (43)	83	24 (29)	203	75 (37)	
Other Oceania	6	3 (50)	3	2 (67)	9	5 (56)	
Asia	0	0 (0)	0	0 (0)	0	0 (0)	
UK & Ireland	7	3 (43)	2	1 (50)	9	4 (44)	
Other	8	4 (50)	1	0 (0)	9	4 (44)	
p value		0.975		0.374		0.633	

## Tasmania

**Table 7.1.1 Number (percentage) of respondents by demographic characteristics and survey year**

Tasmania	2012	2013	2014	2015	2016
<b>Number of sites</b>	4	3	4	4	4
<b>N° surveyed</b>	N=75	N=70	N=69	N=48	N=35
<b>Response rate (%)</b>	28%	33%	36%	20%	25%
<b>Gender (%)</b>					
Male	37 (49)	42 (60)	37 (54)	30 (62)	17 (49)
Female	38 (51)	28 (40)	31 (45)	18 (38)	18 (51)
Transgender	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Not reported	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)
<b>Sexual identity (%)</b>					
Heterosexual	62 (83)	61 (87)	52 (75)	39 (81)	31 (89)
Bisexual	7 (9)	3 (4)	3 (4)	2 (4)	2 (6)
Homosexual	4 (5)	2 (3)	2 (3)	3 (6)	1 (3)
Not reported	2 (3)	4 (6)	12 (17)	4 (8)	1 (3)
<b>Aboriginal and Torres Strait Islander origin (%)</b>					
No	64 (85)	60 (86)	56 (81)	39 (81)	31 (89)
Yes	10 (13)	9 (13)	11 (16)	8 (17)	3 (9)
Not reported	1 (1)	1 (1)	2 (3)	1 (2)	1 (3)
<b>Region/country of birth (%)</b>					
Australia	69 (92)	67 (96)	67 (97)	43 (90)	33 (94)
Other Oceania	0 (0)	1 (1)	0 (0)	1 (2)	0 (0)
Asia	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
UK & Ireland	1 (1)	2 (3)	2 (3)	2 (4)	1 (3)
Other	3 (4)	0 (0)	0 (0)	0 (0)	0 (0)
Not reported	2 (3)	0 (0)	0 (0)	2 (4)	1 (3)
<b>Main language spoken at home by parents (%)</b>					
English	73 (97)	70 (100)	69 (100)	47 (98)	33 (94)
Non-English	1 (1)	0 (0)	0 (0)	0 (0)	1 (3)
Not reported	1 (1)	0 (0)	0 (0)	1 (2)	1 (3)
<b>Age and time since first injection (years)</b>					
<i>Median age</i>	38	37	41	42	42
<i>Age range</i>	18-57	21-63	21-60	23-61	29-59
<i>Age group (%)</i>					
<25 years	3 (4)	3 (4)	1 (1)	1 (2)	0 (0)
25+ years	72 (96)	66 (94)	68 (99)	47 (98)	35 (100)
Not reported	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)
<i>Median age first injection</i>					
	18	19	20	20	21
<i>Age range</i>	13-45	12-40	12-53	12-50	14-45
<i>N° not reported</i>	3	3	2	0	1
<i>Median yrs since first injection</i>					
	15	16	18	18	19
<i>Range</i>	<1-38	1-41	1-43	<1-43	7-29
<i>Years since first injection</i>					
<3 years	5 (7)	3 (4)	1 (1)	2 (4)	0 (0)
3+ years	67 (89)	64 (91)	66 (96)	46 (96)	34 (97)
Not reported	3 (4)	3 (4)	2 (3)	0 (0)	1 (3)
<b>Imprisonment last year (%)</b>					
No	68 (91)	54 (77)	56 (81)	41 (85)	33 (94)
Yes	4 (5)	9 (13)	3 (4)	3 (6)	1 (3)
Not reported	3 (4)	7 (10)	10 (14)	4 (8)	1 (3)
<b>N° in prison</b>					
Injected in prison	2 (50)	1 (11)	1 (33)	0 (100)	0 (0)

**Table 7.1.2 Number (percentage) of respondents by last drug injected, frequency of injecting and survey year**

<b>Tasmania</b>	<b>2012</b>	<b>2013</b>	<b>2014</b>	<b>2015</b>	<b>2016</b>
<b>N° surveyed</b>	<b>N=75</b>	<b>N=70</b>	<b>N=69</b>	<b>N=48</b>	<b>N=35</b>
<b>Drug last injected (%)</b>					
Cocaine	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Methamphetamine	24 (32)	17 (24)	23 (33)	20 (42)	13 (37)
Heroin	1 (1)	2 (3)	2 (3)	0 (0)	1 (3)
Pharm. opioids	30 (40)	23 (33)	25 (36)	15 (31)	7 (20)
Methadone	13 (17)	19 (27)	10 (14)	11 (23)	10 (29)
Buprenorphine	2 (3)	3 (4)	1 (1)	1 (2)	1 (3)
Buprenorphine/naloxone	1 (1)	1 (1)	0 (0)	0 (0)	1 (3)
PIEDs	1 (1)	1 (1)	0 (0)	1 (2)	0 (0)
More than one	0 (0)	3 (4)	7 (10)	0 (0)	0 (0)
Other	3 (4)	1 (1)	1 (1)	0 (0)	2 (6)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
<b>Ever injected opioids</b>					
Yes	-	-	-	-	30 (86)
No	-	-	-	-	4 (11)
Not reported	-	-	-	-	1 (3)
<b>Frequency of injection last month (%)</b>					
Not last month	7 (9)	5 (7)	1 (1)	4 (8)	7 (20)
Less than weekly	14 (19)	13 (19)	7 (10)	9 (19)	7 (20)
Weekly not daily	19 (25)	26 (37)	24 (35)	15 (31)	14 (40)
Daily or more	35 (47)	24 (34)	36 (52)	19 (40)	7 (20)
Not reported	0 (0)	2 (3)	1 (1)	1 (2)	0 (0)
<b>Present when someone injected for the first time in the last 12 months (%)</b>					
Yes	9 (12)	6 (9)	7 (10)	6 (13)	2 (6)
No	57 (76)	57 (81)	61 (88)	41 (85)	32 (91)
Not reported	9 (12)	7 (10)	1 (1)	1 (2)	1 (3)
<b>Overdosed in last 12 months</b>					
Yes	--	6 (9)	4 (6)	2 (4)	2 (6)
No	--	62 (89)	63 (91)	45 (94)	32 (91)
Not reported	--	2 (3)	2 (3)	1 (2)	1 (3)



**Table 7.1.3 Number (percentage) of respondents by injecting behaviour in the last month and survey year**

<b>Tasmania</b>	<b>2012</b>	<b>2013</b>	<b>2014</b>	<b>2015</b>	<b>2016</b>
<b>N° injected last month</b>	<b>N=68</b>	<b>N=63</b>	<b>N=67</b>	<b>N=43</b>	<b>N=28</b>
<b>Places injected last month (%)</b>					
Any public	17 (25)	16 (25)	15 (22)	15 (35)	9 (32)
All private	48 (71)	46 (73)	52 (78)	28 (65)	19 (68)
Not reported	3 (4)	1 (2)	0 (0)	0 (0)	0 (0)
<b>Use of new and sterile needles and syringes last month (%)</b>					
All injections	53 (78)	55 (87)	64 (96)	36 (84)	13 (46)
Most of the time	11 (16)	6 (10)	2 (3)	7 (16)	10 (36)
Half of the time	0 (0)	1 (2)	0 (0)	0 (0)	1 (4)
Some of the time	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Not last month	0 (0)	0 (0)	0 (0)	0 (0)	4 (14)
Not reported	4 (6)	1 (2)	1 (1)	0 (0)	0 (0)
<b>Re-used someone else's used needle &amp; syringe last month (%)</b>					
None	54 (79)	61 (97)	61 (91)	40 (93)	24 (86)
Once	5 (7)	1 (2)	4 (6)	1 (2)	2 (7)
Twice	1 (1)	0 (0)	1 (1)	1 (2)	1 (4)
3-5 times	1 (1)	0 (0)	0 (0)	1 (2)	0 (0)
>5 times	3 (4)	1 (2)	0 (0)	0 (0)	1 (4)
Not reported	4 (6)	0 (0)	1 (1)	0 (0)	0 (0)
<b>Number of people needle &amp; syringe was re-used after last month (%)</b>					
None	54 (79)	61 (97)	61 (91)	40 (93)	24 (86)
One	2 (3)	0 (0)	0 (0)	1 (2)	2 (7)
Two	1 (1)	0 (0)	0 (0)	0 (0)	1 (4)
Three to five	0 (0)	0 (0)	0 (0)	0 (0)	1 (4)
More than five	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)
Don't know	2 (3)	0 (0)	0 (0)	1 (2)	0 (0)
Not reported	8 (12)	2 (3)	6 (9)	1 (2)	0 (0)
<b>Relationship to people needle &amp; syringe was used after last month (%) [more than one could be selected]</b>					
Regular sex partner	1 (1)	0 (0)	0 (0)	1 (2)	1 (4)
Casual sex partner	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)
Close friend	3 (4)	0 (0)	0 (0)	0 (0)	3 (11)
Acquaintance	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)
Other	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
<b>Equipment used after someone else last month (%) [more than one could be selected]</b>					
Spoon	9 (13)	6 (10)	7 (10)	2 (5)	4 (14)
Water	5 (7)	10 (16)	14 (21)	2 (5)	4 (14)
Filter	3 (4)	8 (13)	2 (3)	4 (9)	1 (4)
Drug mix	4 (6)	2 (3)	2 (3)	1 (2)	3 (11)
None	54 (79)	46 (73)	46 (69)	36 (84)	21 (75)
<b>Injected by someone after that person injected themselves or others last month (%)</b>					
No	53 (78)	50 (79)	60 (90)	38 (88)	25 (89)
Yes	10 (15)	9 (14)	5 (7)	5 (12)	3 (11)
Not reported	5 (7)	4 (6)	2 (3)	0 (0)	0 (0)
<b>Source of needle acquisition</b>					
Needle Syringe Program	61 (90)	63 (100)	66 (99)	39 (91)	26 (93)
Chemist/Pharmacy	18 (26)	6 (10)	7 (10)	8 (19)	4 (14)
Personal sources	4 (6)	2 (3)	3 (4)	4 (9)	2 (7)
Dispensing/Vending Machine	5 (7)	5 (8)	1 (1)	12 (28)	5 (18)
Other sources	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)

**Table 7.1.4 Number (percentage) of respondents by treatment for drug use and survey year**

Tasmania N° surveyed	2012 N=75	2013 N=70	2014 N=69	2015 N=48	2016 N=35
<b>Ever any treatment/therapy for drug use (%)</b>					
No	19 (25)	13 (19)	17 (25)	14 (29)	6 (17)
Yes	55 (73)	56 (80)	52 (75)	34 (71)	28 (80)
Not reported	1 (1)	1 (1)	0 (0)	0 (0)	1 (3)
<b>History of methadone maintenance treatment (%)</b>					
Currently	22 (29)	27 (39)	21 (30)	14 (29)	17 (49)
Previously	21 (28)	14 (20)	16 (23)	8 (17)	4 (11)
Never	31 (41)	29 (41)	32 (46)	25 (52)	12 (34)
Not reported	1 (1)	0 (0)	0 (0)	1 (2)	2 (6)
<b>History of buprenorphine (Subutex®) treatment (%)</b>					
Currently	7 (9)	5 (7)	9 (13)	5 (10)	3 (9)
Previously	18 (24)	18 (26)	13 (19)	7 (15)	5 (14)
Never	47 (63)	46 (66)	45 (65)	35 (73)	26 (74)
Not reported	3 (4)	1 (1)	2 (3)	1 (2)	1 (3)
<b>History of buprenorphine-naloxone (Suboxone®) treatment (%)</b>					
Currently	6 (8)	3 (4)	5 (7)	2 (4)	1 (3)
Previously	12 (16)	12 (17)	11 (16)	11 (23)	4 (11)
Never	54 (72)	51 (73)	50 (72)	35 (73)	29 (83)
Not reported	3 (4)	4 (6)	3 (4)	0 (0)	1 (3)

**Table 7.1.5 Number (percentage) of respondents by testing for HIV and HCV, HCV treatment by survey year**

Tasmania N° surveyed	2012 N=75	2013 N=70	2014 N=69	2015 N=48	2016 N=35
<b>Previous HIV test (%)</b>					
Yes, ever	55 (73)	61 (87)	56 (81)	45 (94)	26 (74)
Yes, last year	29 (39)	33 (47)	25 (36)	21 (44)	17 (49)
>1 year ago	26 (35)	28 (40)	31 (45)	24 (50)	9 (26)
Never tested	15 (20)	5 (7)	12 (17)	3 (6)	8 (23)
Not reported	5 (7)	4 (6)	1 (1)	0 (0)	1 (3)
<b>Previous HCV test (%)</b>					
Yes, ever	63 (84)	56 (80)	63 (91)	44 (92)	30 (86)
Yes, last year	36 (48)	33 (47)	38 (55)	23 (48)	21 (60)
>1 year ago	27 (36)	23 (33)	25 (36)	21 (44)	9 (26)
Never tested	7 (9)	6 (9)	3 (4)	2 (4)	3 (9)
Not reported	5 (7)	8 (11)	3 (4)	2 (4)	2 (6)
<b>Lifetime treatment for HCV (%)#</b>					
<b>N° self-reported HCV diagnosis</b>					
Antiviral treatment	N=15 4 (27)	N=21 1 (5)	N=13 4 (31)	N=11 2 (18)	N=9 2 (22)
No antiviral treatment	10 (67)	20 (95)	9 (69)	9 (82)	5 (56)
Not reported	1 (7)	0 (0)	0 (0)	0 (0)	2 (22)
<b>Treatment for HCV in past 12 months (%)**</b>					
<b>N° self-reported HCV diagnosis</b>					
Antiviral treatment	N=13 2 (15)	N=21 0 (0)	N=13 0 (0)	N=11 0 (0)	N=9 2 (22)
No antiviral treatment	10 (77)	21 (100)	13 (100)	11 (100)	5 (56)
Not reported	1 (8)	0 (0)	0 (0)	0 (0)	2 (22)

# among people who tested HCV antibody positive and did not report spontaneous clearance

\* excludes people who reported treatment induced clearance more than 12 months previously

**Table 7.1.6 Number (percentage) of respondents by sexual behaviour in the month prior to survey and survey year**

Tasmania	2012	2013	2014	2015	2016
<b>N° surveyed</b>					N=35
<b>Sex with a regular partner last month (%)</b>					
No	34 (45)	23 (33)	28 (41)	16 (33)	17 (49)
Yes	37 (49)	41 (59)	36 (52)	29 (60)	16 (46)
Not reported	4 (5)	6 (9)	5 (7)	3 (6)	2 (6)
<b>Condom used with regular partner last month (%)</b>					
<b>N° surveyed</b>	N=37	N=41	N=36	N=29	N=16
Never	27 (73)	27 (66)	27 (75)	22 (76)	12 (75)
Sometimes	4 (11)	2 (5)	1 (3)	2 (7)	3 (19)
Every time	6 (16)	7 (17)	6 (17)	4 (14)	1 (6)
Not reported	0 (0)	5 (12)	2 (6)	1 (3)	0 (0)
<b>Sex with other partner(s) last month (%)</b>					
No	58 (77)	59 (84)	59 (86)	39 (81)	30 (86)
Yes	8 (11)	5 (7)	4 (6)	6 (13)	1 (3)
Not reported	9 (12)	6 (9)	6 (9)	3 (6)	4 (11)
<b>Condom used with other partner(s) last month (%)</b>					
<b>N° surveyed</b>	N=8	N=5	N=4	N=6	N=1
Never	3 (38)	3 (60)	2 (50)	0 (0)	0 (0)
Sometimes	2 (25)	1 (20)	0 (0)	3 (50)	0 (0)
Every time	2 (25)	1(20)	1 (25)	3 (50)	1 (100)
Not reported	1 (13)	0 (0)	1 (25)	0 (0)	0 (0)
<b>Sex work last month (%)</b>					
No	68 (91)	58 (83)	56 (81)	45 (94)	31 (89)
Yes	2 (3)	1 (1)	1 (1)	0 (0)	1 (3)
Not reported	5 (7)	11 (16)	12 (17)	3 (6)	3 (9)
<b>Condom used at last sex work (%)</b>					
Yes	2 (100)	1 (100)	1 (100)	--	1(100)

**Table 7.1.7 Number (percentage) of respondents reporting stigma or discrimination in the last 12 months in 2016**

Tasmania <sup>#</sup>	Never	Rarely	Sometimes	Often	Always
Use of drugs for injecting	8 (24)	1 (3)	14 (42)	8 (24)	2 (6)
Sexual orientation	10 (77)	1 (8)	1 (8)	0 (0)	1 (8)
Hepatitis C status	12 (80)	0 (0)	3 (20)	0 (0)	0 (0)
Hepatitis B status	10 (91)	0 (0)	1 (9)	0 (0)	0 (0)
HIV status	11 (100)	0 (0)	0 (0)	0 (0)	0 (0)
Sex work	9 (82)	0 (0)	2 (18)	0 (0)	0 (0)
Other	3 (50)	0 (0)	1 (17)	2 (33)	0 (0)
Health workers treated me negatively or different to other people	15 (44)	2 (6)	11 (32)	4 (12)	2 (6)

# excludes respondents who indicated 'not applicable' and where data was missing

## HIV antibody prevalence

**Table 7.2.1 HIV antibody prevalence by gender and survey year**

Tasmania Survey year	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2012	36	0 (0.0)	38	0 (0.0)	74	0 (0.0)
2013	41	0 (0.0)	28	0 (0.0)	69	0 (0.0)
2014	32	0 (0.0)	30	0 (0.0)	63	0 (0.0)
2015	29	0 (0.0)	18	0 (0.0)	47	0 (0.0)
2016	17	0 (0.0)	18	0 (0.0)	35	0 (0.0)
X <sup>2</sup> p trend		--		--		--

## HCV antibody prevalence

**Table 7.3.1 HCV antibody prevalence by gender and survey year**

Tasmania Survey year	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2012	36	17 (47)	37	17 (46)	73	34 (47)
2013	41	19 (46)	28	18 (64)	69	37 (54)
2014	30	16 (53)	30	18 (60)	61	35 (57)
2015	26	16 (62)	18	10 (56)	44	26 (59)
2016	17	7 (41)	18	6 (33)	35	13 (37)
X <sup>2</sup> p trend		0.801		0.730		0.956

**Table 7.3.2 HCV antibody prevalence by sexual identity, gender and survey year**

Tasmania Sexual identity	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2012</b>						
Heterosexual	30	15 (50)	30	16 (53)	60	31 (52)
Bisexual	2	1 (50)	5	1 (20)	7	2 (29)
Homosexual	3	0 (0)	1	0 (0)	4	0 (0)
p value		0.298		0.252		0.100
<b>2013</b>						
Heterosexual	36	17 (47)	24	15 (63)	60	32 (53)
Bisexual	1	1 (100)	2	2 (100)	3	3 (100)
Homosexual	1	0 (0)	1	0 (0)	2	0 (0)
p value		0.730		0.283		0.081
<b>2014</b>						
Heterosexual	24	14 (58)	24	15 (63)	48	29 (60)
Bisexual	0	0 (0)	3	2 (67)	3	2 (67)
Homosexual	1	0 (0)	1	0 (0)	2	0 (0)
p value		0.440		0.726		0.283
<b>2015</b>						
Heterosexual	23	14 (61)	13	7 (54)	36	21 (58)
Bisexual	0	0 (0)	2	1 (50)	2	1 (50)
Homosexual	2	1 (50)	1	1 (100)	3	2 (67)
p value		1.000		1.000		1.000
<b>2016</b>						
Heterosexual	15	7 (47)	16	6 (38)	31	13 (42)
Bisexual	0	0 (0)	2	0 (0)	2	0 (0)
Homosexual	1	0 (0)	0	0 (0)	1	0 (0)
p value		1.000		0.529		0.696

**Table 7.3.3 HCV antibody prevalence by age group, gender and survey year**

Tasmania Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2012</b>						
<25 years	1	0 (0)	2	0 (0)	3	0 (0)
25-34 years	11	5 (45)	13	7 (54)	24	12 (50)
35-44 years	14	8 (57)	17	7 (41)	31	15 (48)
45+ years	10	4 (40)	5	3 (60)	15	7 (47)
p value		0.795		0.605		0.515
<b>2013</b>						
<25 years	2	0 (0)	1	1 (100)	3	1 (33)
25-34 years	11	3 (27)	9	4 (44)	20	7 (35)
35-44 years	17	9 (53)	12	9 (75)	29	18 (62)
45+ years	11	7 (64)	5	3 (60)	16	10 (63)
p value		0.191		0.423		0.188
<b>2014</b>						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	2	1 (50)	8	5 (63)	10	6 (60)
35-44 years	18	9 (50)	12	6 (50)	31	16 (52)
45+ years	10	6 (60)	10	7 (70)	20	13 (65)
p value		0.848		0.651		0.649
<b>2015</b>						
<25 years	1	1 (100)	0	0 (0)	1	1 (100)
25-34 years	4	3 (75)	6	4 (67)	10	7 (70)
35-44 years	12	4 (33)	7	1 (14)	19	5 (26)
45+ years	9	8 (89)	5	5 (100)	14	13 (93)
p value		0.030		0.013		<0.001
<b>2016</b>						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	0	0 (0)	3	1 (33)	3	1 (33)
35-44 years	11	6 (55)	11	5 (45)	22	11 (50)
45+ years	6	1 (17)	4	0 (0)	10	1 (10)
p value		0.304		0.314		0.106

**Table 7.3.4 HCV antibody prevalence by years since first injection, gender and survey year**

Tasmania Years of injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2012</b>						
<3 years	1	0 (0)	4	1 (25)	5	1 (20)
3 to 10 years	5	2 (40)	5	2 (40)	10	4 (40)
11+ years	29	15 (52)	26	14 (54)	55	29 (53)
p value		1.000		0.643		0.356
<b>2013</b>						
<3 years	1	0 (0)	2	0 (0)	3	0 (0)
3 to 10 years	5	2 (40)	8	3 (38)	13	5 (38)
11+ years	34	16 (47)	16	13 (81)	50	29 (58)
p value		1.000		0.022		0.086
<b>2014</b>						
<3 years	0	0 (0)	0	0 (0)	0	0 (0)
3 to 10 years	4	1 (25)	6	4 (67)	10	5 (50)
11+ years	25	15 (60)	23	14 (61)	49	30 (61)
p value		0.299		1.000		0.510
<b>2015</b>						
<3 years	1	0 (0)	1	0 (0)	2	0 (0)
3 to 10 years	6	2 (33)	2	1 (50)	8	3 (38)
11+ years	19	14 (74)	15	9 (60)	34	23 (68)
p value		0.086		0.706		0.078
<b>2016</b>						
<3 years	0	0 (0)	0	0 (0)	0	0 (0)
3 to 10 years	1	0 (0)	1	0 (0)	2	0 (0)
11+ years	16	7 (44)	16	6 (38)	32	13 (41)
p value		1.000		1.000		0.513

**Table 7.3.5 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year**

Tasmania Receptively shared syringe last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2012</b>						
No receptive sharing	3	1 (33)	47	25 (53)	53	26 (49)
Receptive sharing	0	0 (0)	10	5 (50)	10	5 (50)
p value		--		1.000		1.000
<b>2013</b>						
No receptive sharing	2	0 (0)	56	30 (54)	60	32 (53)
Receptive sharing	0	0 (0)	1	0 (0)	2	1 (50)
p value		--		0.474		1.000
<b>2014</b>						
No receptive sharing	0	0 (0)	52	32 (61)	54	32 (59)
Receptive sharing	0	0 (0)	4	1 (25)	4	1 (25)
p value		--		0.295		0.305
<b>2015</b>						
No receptive sharing	2	0 (0)	36	21 (58)	38	21 (55)
Receptive sharing	0	0 (0)	2	2 (100)	2	2 (100)
p value		--		0.509		0.499
<b>2016</b>						
No receptive sharing	0	0 (0)	24	9 (38)	24	9 (38)
Receptive sharing	0	0 (0)	4	3 (75)	4	3 (75)
p value		--		0.285		0.285

**Table 7.3.6 HCV antibody prevalence by last drug injected, years since first injection and survey year**

Tasmania Last drug injected	<3 years		3+ years		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2012</b>						
Methamphetamine	2	1 (50)	19	8 (42)	22	9 (41)
Pharmaceutical opioids	1	0 (0)	28	15 (54)	30	15 (50)
OST	0	0 (0)	15	9 (60)	16	9 (56)
Other drugs	2	0 (0)	3	1 (33)	5	1 (20)
p value		0.392		0.674		0.485
<b>2013</b>						
Methamphetamine	1	0 (0)	14	7 (50)	16	8 (50)
Pharmaceutical opioids	0	0 (0)	23	13 (57)	23	13 (57)
OST	0	0 (0)	21	11 (52)	23	13 (57)
Other drugs	2	0 (0)	5	3 (60)	7	7 (43)
p value		--		0.970		0.904
<b>2014</b>						
Methamphetamine	0	0 (0)	18	10 (56)	18	10 (56)
Pharmaceutical opioids	0	0 (0)	24	13 (54)	25	13 (52)
OST	0	0 (0)	11	9 (82)	11	9 (82)
Other drugs	0	0 (0)	6	3 (50)	7	3 (43)
p value		--		0.408		0.307
<b>2015</b>						
Methamphetamine	1	0 (0)	17	9 (53)	18	9 (50)
Pharmaceutical opioids	0	0 (0)	14	11 (79)	14	11 (79)
OST	0	0 (0)	11	6 (55)	11	6 (55)
Other drugs	1	0 (0)	0	0 (0)	1	0 (0)
p value		--		0.286		0.226
<b>2016</b>						
Methamphetamine	0	0 (0)	13	2 (15)	13	2 (15)
Pharmaceutical opioids	0	0 (0)	7	3 (43)	7	3 (43)
OST	0	0 (0)	12	7 (58)	12	7 (58)
Other drugs	0	0 (0)	2	1 (50)	3	1 (33)
p value		--		0.164		0.167

**Table 7.3.7 HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year**

Tasmania Frequency of injection last month	<3 years		3+ years		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2012</b>						
Less than daily	2	1 (50)	31	14 (45)	33	15 (45)
Daily or more	2	0 (0)	29	16 (55)	34	16 (47)
Not last month	1	0 (0)	5	3 (60)	6	3 (50)
p value		1.000		0.693		1.000
<b>2013</b>						
Less than daily	1	0 (0)	35	19 (54)	38	21 (55)
Daily or more	1	0 (0)	22	11 (50)	24	12 (50)
Not last month	1	0 (0)	4	2 (50)	5	2 (40)
p value		--		0.919		0.804
<b>2014</b>						
Less than daily	0	0 (0)	27	15 (56)	28	15 (54)
Daily or more	0	0 (0)	30	19 (63)	31	19 (61)
Not last month	0	0 (0)	1	0 (0)	1	0 (0)
p value		--		0.414		0.429
<b>2015</b>						
Less than daily	2	0 (0)	20	11 (55)	22	11 (50)
Daily or more	0	0 (0)	18	12 (67)	18	12 (67)
Not last month	0	0 (0)	4	3 (75)	4	3 (75)
p value		--		0.649		0.531
<b>2016</b>						
Less than daily	0	0 (0)	21	10 (48)	21	10 (48)
Daily or more	0	0 (0)	7	2 (29)	7	2 (29)
Not last month	0	0 (0)	6	1 (17)	7	1 (14)
p value		--		0.473		0.310

**Table 7.3.8 HCV antibody prevalence by imprisonment last year, years since first injection and survey year**

Tasmania Imprisonment last year	<3 years		3+ years		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2012</b>						
No imprisonment	5	1 (20)	58	31 (53)	66	32 (48)
Imprisonment	0	0 (0)	4	2 (50)	4	2 (50)
p value		--		1.000		1.000
<b>2013</b>						
No imprisonment	3	0 (0)	49	24 (49)	54	26 (48)
Imprisonment	0	0 (0)	9	8 (89)	9	8 (89)
p value		--		0.033		0.031
<b>2014</b>						
No imprisonment	0	0 (0)	51	27 (53)	53	27 (51)
Imprisonment	0	0 (0)	1	1 (100)	1	1 (100)
p value		--		1.000		1.000
<b>2015</b>						
No imprisonment	2	0 (0)	36	21 (58)	38	21 (55)
Imprisonment	0	0 (0)	2	1 (50)	2	1 (50)
p value		--		1.000		1.000
<b>2016</b>						
No imprisonment	0	0 (0)	32	13 (41)	33	13 (39)
Imprisonment	0	0 (0)	1	0 (0)	1	0 (0)
p value		--		1.000		1.000



**Table 7.3.9 HCV antibody prevalence by sex work last month, years since first injection and survey year**

<b>Tasmania</b>	<b>&lt;3 years</b>		<b>3+ years</b>		<b>Total</b>	
<b>Sex work last month</b>	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2012</b>						
No sex work	5	1 (20)	59	31 (53)	66	32 (48)
Sex work	0	0 (0)	2	1 (50)	2	1 (50)
p value		--		1.000		1.000
<b>2013</b>						
No sex work	3	0 (0)	52	26 (50)	57	28 (49)
Sex work	0	0 (0)	1	1 (100)	1	1 (100)
p value		--		1.000		1.000
<b>2014</b>						
No sex work	0	0 (0)	51	29 (57)	53	29 (55)
Sex work	0	0 (0)	1	0 (0)	1	0 (0)
p value		--		0.442		0.463
<b>2015</b>						
No sex work	2	0 (0)	39	23 (59)	41	23 (56)
Sex work	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
<b>2016</b>						
No sex work	0	0 (0)	30	10 (33)	31	10 (32)
Sex work	0	0 (0)	1	1 (100)	1	1 (100)
p value		--		0.355		0.344

**Table 7.3.10 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year**

<b>Tasmania</b>	<b>Male</b>		<b>Female</b>		<b>Total</b>	
<b>Aboriginal and Torres Strait Islander origin</b>	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2012</b>						
Non Indigenous	33	17 (52)	29	12 (41)	62	29 (47)
Indigenous	2	0 (0)	8	5 (63)	10	5 (50)
p value		0.486		0.428		1.000
<b>2013</b>						
Non Indigenous	36	17 (47)	23	13 (57)	59	30 (51)
Indigenous	5	2 (40)	4	4 (100)	9	6 (67)
p value		1.000		0.264		0.484
<b>2014</b>						
Non Indigenous	26	15 (58)	23	12 (52)	50	28 (56)
Indigenous	3	1 (33)	6	5 (83)	9	6 (67)
p value		0.573		0.168		0.551
<b>2015</b>						
Non Indigenous	22	14 (64)	13	6 (46)	35	20 (57)
Indigenous	3	2 (67)	5	4 (80)	8	6 (75)
p value		1.000		0.314		0.351
<b>2016</b>						
Non Indigenous	16	7 (44)	15	4 (27)	31	11 (35)
Indigenous	0	0 (0)	3	2 (67)	3	2 (67)
p value		--		0.245		0.544

**Table 7.3.11 HCV antibody prevalence by main language spoken at home by parents, gender and survey year**

<b>Tasmania</b>	<b>Male</b>		<b>Female</b>		<b>Total</b>	
<b>Main language spoken at home by parents</b>	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2012</b>						
English speaking	34	16 (47)	37	17 (46)	71	33 (46)
Non-English speaking	1	1 (100)	0	0 (0)	1	1 (100)
p value		0.486		--		0.472
<b>2013</b>						
English speaking	41	19 (46)	28	18 (64)	69	37 (54)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
<b>2014</b>						
English speaking	30	16 (53)	30	18 (60)	61	35 (57)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
<b>2015</b>						
English speaking	25	15 (60)	18	10 (56)	43	25 (58)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
<b>2016</b>						
English speaking	15	7 (47)	18	6 (33)	33	13 (39)
Non-English speaking	1	0 (0)	0	0 (0)	1	0 (0)
p value		1.000		--		1.000

**Table 7.3.12 HCV antibody prevalence by region/country of birth, gender and survey year**

<b>Tasmania</b>		<b>Male</b>		<b>Female</b>		<b>Total</b>	
<b>Region/Country of birth</b>	<b>N° tested</b>	<b>N° with HCV (%)</b>	<b>N° tested</b>	<b>N° with HCV (%)</b>	<b>N° tested</b>	<b>N° with HCV (%)</b>	
<b>2012</b>							
Australia	33	15 (45)	34	15 (44)	67	30 (45)	
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)	
Asia	0	0 (0)	0	0 (0)	0	0 (0)	
UK & Ireland	0	0 (0)	1	1 (100)	1	1 (100)	
Other	1	1 (100)	2	1 (50)	3	2 (67)	
p value		0.471		0.723		0.403	
<b>2013</b>							
Australia	39	17 (44)	27	17 (63)	66	34 (52)	
Other Oceania	0	0 (0)	1	1 (100)	1	1 (100)	
Asia	0	0 (0)	0	0 (0)	0	0 (0)	
UK & Ireland	2	2 (100)	0	0 (0)	2	2 (100)	
Other	0	0 (0)	0	0 (0)	0	0 (0)	
p value		0.209		1.000		0.495	
<b>2014</b>							
Australia	29	15 (52)	29	17 (59)	59	33 (56)	
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)	
Asia	0	0 (0)	0	0 (0)	0	0 (0)	
UK & Ireland	1	1 (100)	1	1 (100)	2	2 (100)	
Other	0	0 (0)	0	0 (0)	0	0 (0)	
p value		1.000		1.000		0.503	
<b>2015</b>							
Australia	22	13 (59)	17	9 (53)	39	22 (56)	
Other Oceania	1	0 (0)	0	0 (0)	1	0 (0)	
Asia	0	0 (0)	0	0 (0)	0	0 (0)	
UK & Ireland	1	1 (100)	1	1 (100)	2	2 (100)	
Other	0	0 (0)	0	0 (0)	0	0 (0)	
p value		0.670		1.000		0.322	
<b>2016</b>							
Australia	16	7 (44)	17	6 (35)	33	13 (39)	
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)	
Asia	0	0 (0)	0	0 (0)	0	0 (0)	
UK & Ireland	0	0 (0)	1	0 (0)	1	0 (0)	
Other	0	0 (0)	0	0 (0)	0	0 (0)	
p value		--		1.000		1.000	

## Victoria

Table 8.1.1 Number (percentage) of respondents by demographic characteristics and survey year

Victoria	2012	2013	2014	2015	2016
<b>Number of sites</b>	6	6	6	6	6
<b>N° surveyed</b>	N=463	N=448	N=436	N=459	N=423
<b>Response rate (%)</b>	52%	61%	41%	62%	70%
<b>Gender (%)</b>					
Male	322 (70)	302 (67)	288 (66)	303 (66)	268 (63)
Female	140 (30)	139 (31)	146 (33)	153 (33)	151 (36)
Transgender	1 (<1)	4 (<1)	2 (<1)	3 (1)	2 (<1)
Not reported	0 (0)	3 (<1)	0 (0)	0 (0)	2 (<1)
<b>Sexual identity (%)</b>					
Heterosexual	367 (79)	338 (75)	349 (81)	381 (83)	329 (78)
Bisexual	46 (10)	31 (7)	36 (8)	36 (8)	45 (11)
Homosexual	17 (4)	25 (6)	11 (3)	17 (4)	13 (3)
Not reported	33 (7)	54 (12)	40 (9)	25 (5)	36 (9)
<b>Aboriginal and Torres Strait Islander origin (%)</b>					
No	389 (84)	380 (85)	378 (87)	401 (87)	341 (81)
Yes	67 (14)	52 (12)	53 (12)	53 (12)	70 (17)
Not reported	7 (2)	16 (4)	5 (1)	5 (1)	12 (3)
<b>Region/country of birth (%)</b>					
Australia	388 (84)	364 (81)	360 (83)	376 (82)	363 (86)
Other Oceania	14 (3)	10 (2)	10 (2)	18 (4)	8 (2)
Asia	14 (3)	20 (4)	20 (5)	16 (3)	7 (2)
UK & Ireland	21 (5)	22 (5)	20 (5)	27 (6)	16 (4)
Other	24 (5)	30 (7)	25 (6)	20 (4)	20 (5)
Not reported	2 (<1)	2 (<1)	1 (<1)	2 (<1)	9 (2)
<b>Main language spoken at home by parents (%)</b>					
English	417 (90)	393 (88)	378 (87)	414 (90)	380 (90)
Non-English	45 (10)	54 (12)	57 (13)	42 (9)	38 (9)
Not reported	1 (<1)	1 (<1)	1 (<1)	3 (1)	5 (1)
<b>Age and time since first injection (years)</b>					
<i>Median age</i>	37	38	39	40	41
<i>Age range</i>	17-64	15-66	16-65	18-64	17-69
<i>Age group (%)</i>					
<25 years	21 (5)	18 (4)	12 (3)	8 (2)	13 (3)
25+ years	440 (95)	429 (96)	422 (97)	450 (98)	409 (97)
Not reported	2 (<1)	1 (<1)	2 (<1)	1 (<1)	1 (<1)
<i>Median age first injection</i>					
	18	18	18	18	18
<i>Age range</i>	10-59	10-52	10-52	11-54	10-48
<i>N° not reported</i>	17	23	6	10	18
<i>Median yrs since first injection</i>					
	18	18	20	20	21
<i>Range</i>	<1-43	<1-40	<1-41	<1-41	<1-49
<i>Years since first injection</i>					
<3 years	14 (3)	13 (3)	17 (4)	19 (4)	12 (3)
3+ years	431 (93)	412 (92)	399 (92)	429 (93)	393 (93)
Not reported	18 (4)	23 (5)	20 (5)	11 (2)	18 (4)
<b>Imprisonment last year (%)</b>					
No	368 (80)	354 (79)	359 (82)	373 (81)	331 (78)
Yes	75 (16)	48 (11)	50 (11)	61 (13)	60 (14)
Not reported	20 (4)	46 (10)	27 (6)	25 (5)	32 (8)
<b>N° in prison</b>					
	N=75	N=48	N=50	N=61	N=60
Injected in prison	22 (29)	14 (29)	19 (38)	15 (25)	17 (28)

**Table 8.1.2 Number (percentage) of respondents by last drug injected, frequency of injecting and survey year**

<b>Victoria N° surveyed</b>	<b>2012 N=463</b>	<b>2013 N=448</b>	<b>2014 N=436</b>	<b>2015 N=459</b>	<b>2016 N=423</b>
<b>Drug last injected (%)</b>					
Cocaine	0 (0)	1 (<1)	6 (1)	5 (1)	2 (<1)
Methamphetamine	82 (18)	96 (21)	98 (22)	142 (31)	134 (32)
Heroin	299 (65)	241 (54)	240 (55)	237 (52)	222 (52)
Pharm. opioids	15 (3)	19 (4)	18 (4)	16 (3)	12 (3)
Methadone	7 (2)	8 (2)	10 (2)	9 (2)	5 (1)
Buprenorphine	13 (3)	22 (5)	14 (3)	16 (3)	11 (3)
Buprenorphine/naloxone	10 (2)	10 (2)	14 (3)	7 (2)	7 (2)
PIEDs	2 (<1)	3 (<1)	0 (0)	4 (1)	1 (<1)
More than one	32 (7)	43 (10)	27 (6)	19 (4)	24 (6)
Other	2 (<1)	4 (<1)	6 (1)	4 (1)	5 (1)
Not reported	1 (<1)	1 (<1)	3 (<1)	0 (0)	0 (0)
<b>Ever injected opioids</b>					
Yes	-	-	-	-	379 (90)
No	-	-	-	-	43 (10)
Not reported	-	-	-	-	1 (<1)
<b>Frequency of injection last month (%)</b>					
Not last month	26 (6)	33 (7)	38 (9)	35 (8)	31 (7)
Less than weekly	93 (20)	84 (19)	68 (16)	74 (16)	58 (14)
Weekly not daily	99 (21)	102 (23)	122 (28)	129 (28)	99 (23)
Daily or more	236 (51)	210 (47)	204 (47)	216 (47)	226 (53)
Not reported	9 (2)	19 (4)	4 (1)	5 (1)	9 (2)
<b>Present when someone injected for the first time in the last 12 months (%)</b>					
Yes	70 (15)	49 (11)	71 (16)	66 (14)	71 (17)
No	356 (77)	318 (71)	349 (80)	379 (83)	339 (80)
Not reported	81 (18)	81 (18)	16 (4)	14 (3)	13 (3)
<b>Overdosed in last 12 months</b>					
Yes	--	78 (17)	82 (19)	97 (21)	112 (27)
No	--	358 (80)	339 (78)	353 (77)	298 (70)
Not reported	--	12 (3)	15 (3)	9 (2)	13 (3)

**Table 8.1.3 Number (percentage) of respondents by injecting behaviour in the last month and survey year**

<b>Victoria</b>	<b>2012</b>	<b>2013</b>	<b>2014</b>	<b>2015</b>	<b>2016</b>
<b>N° injected last month</b>	<b>N=428</b>	<b>N=396</b>	<b>N=394</b>	<b>N=419</b>	<b>N=383</b>
<b>Places injected last month (%)</b>					
Any public	259 (61)	224 (57)	215 (55)	233 (56)	233 (61)
All private	148 (35)	164 (41)	177 (45)	183 (44)	148 (39)
Not reported	21 (5)	8 (2)	2 (<1)	3 (1)	2 (1)
<b>Use of new and sterile needles and syringes last month (%)</b>					
All injections	319 (75)	269 (68)	278 (71)	283 (68)	259 (68)
Most of the time	70 (16)	103 (26)	92 (23)	108 (26)	102 (27)
Half of the time	9 (2)	2 (<1)	10 (3)	15 (4)	9 (2)
Some of the time	4 (1)	8 (2)	3 (1)	9 (2)	7 (2)
Not last month	2 (<1)	2 (<1)	0 (0)	2 (<1)	3 (1)
Not reported	24 (6)	12 (3)	11 (3)	2 (<1)	3 (1)
<b>Re-used someone else's used needle &amp; syringe last month (%)</b>					
None	316 (74)	313 (79)	318 (81)	333 (79)	302 (79)
Once	43 (10)	19 (5)	23 (6)	23 (5)	27 (7)
Twice	18 (4)	18 (5)	15 (4)	27 (6)	20 (5)
3-5 times	17 (4)	20 (5)	17 (4)	21 (5)	17 (4)
>5 times	16 (4)	16 (4)	12 (3)	12 (3)	15 (4)
Not reported	18 (4)	10 (3)	9 (2)	3 (1)	2 (1)
<b>Number of people needle &amp; syringe was re-used after last month (%)</b>					
None	316 (74)	313 (79)	318 (81)	333 (79)	302 (79)
One	50 (12)	30 (8)	31 (8)	42 (10)	35 (9)
Two	5 (1)	8 (2)	6 (2)	9 (2)	7 (2)
Three to five	5 (1)	2 (<1)	1 (<1)	5 (1)	6 (2)
More than five	3 (1)	6 (2)	2 (<1)	2 (<1)	2 (1)
Don't know	16 (4)	18 (5)	11 (3)	15 (4)	17 (4)
Not reported	33 (8)	19 (5)	25 (6)	13 (3)	14 (4)
<b>Relationship to people needle &amp; syringe was used after last month (%) [more than one could be selected]</b>					
Regular sex partner	28 (7)	28 (7)	25 (6)	30 (7)	36 (9)
Casual sex partner	3 (1)	5 (1)	0 (0)	5 (1)	2 (1)
Close friend	29 (7)	18 (5)	17 (4)	28 (7)	20 (5)
Acquaintance	13 (3)	14 (4)	7 (2)	12 (3)	7 (2)
Other	10 (2)	6 (2)	5 (1)	5 (1)	6 (2)
<b>Equipment used after someone else last month (%) [more than one could be selected]</b>					
Spoon	143 (33)	128 (32)	131 (33)	145 (35)	133 (35)
Water	90 (21)	83 (21)	86 (22)	99 (24)	85 (22)
Filter	68 (16)	56 (14)	69 (18)	78 (19)	56 (15)
Drug mix	60 (14)	43 (11)	49 (12)	64 (15)	46 (12)
None	228 (53)	238 (60)	240 (61)	247 (59)	219 (57)
<b>Injected by someone after that person injected themselves or others last month (%)</b>					
No	336 (79)	315 (80)	326 (83)	345 (82)	150 (39)
Yes	65 (15)	58 (15)	53 (13)	67 (16)	219 (57)
Not reported	27 (6)	23 (6)	15 (4)	7 (2)	14 (4)
<b>Source of needle acquisition</b>					
Needle Syringe Program	394 (92)	374 (94)	368 (93)	384 (92)	353 (92)
Chemist/Pharmacy	88 (21)	90 (23)	87 (22)	93 (22)	86 (22)
Personal sources	65 (15)	29 (7)	55 (14)	80 (19)	46 (12)
Dispensing/Vending Machine	0 (0)	1 (<1)	1 (<1)	3 (1)	47 (12)
Other sources	7 (2)	7 (2)	4 (1)	16 (4)	6 (2)

**Table 8.1.4 Number (percentage) of respondents by treatment for drug use and survey year**

Victoria N° surveyed	2012 N=463	2013 N=448	2014 N=436	2015 N=459	2016 N=423
<b>Ever any treatment/therapy for drug use (%)</b>					
No	38 (8)	39 (9)	36 (8)	67 (15)	45 (11)
Yes	423 (91)	406 (91)	396 (91)	388 (85)	367 (87)
Not reported	2 (<1)	3 (<1)	4 (1)	4 (1)	11 (3)
<b>History of methadone maintenance treatment (%)</b>					
Currently	162 (35)	171 (38)	152 (35)	137 (30)	128 (30)
Previously	176 (38)	142 (32)	153 (35)	151 (33)	153 (36)
Never	123 (27)	133 (30)	126 (30)	162 (35)	122 (29)
Not reported	2 (<1)	2 (<1)	5 (1)	9 (2)	20 (5)
<b>History of buprenorphine (Subutex®) treatment (%)</b>					
Currently	55 (12)	44 (10)	48 (11)	40 (9)	45 (11)
Previously	198 (43)	197 (44)	196 (45)	188 (41)	166 (39)
Never	203 (44)	200 (45)	183 (42)	221 (48)	197 (47)
Not reported	7 (2)	7 (2)	9 (2)	10 (2)	15 (4)
<b>History of buprenorphine-naloxone (Suboxone®) treatment (%)</b>					
Currently	53 (11)	61 (14)	50 (11)	48 (10)	55 (13)
Previously	165 (36)	156 (35)	167 (38)	156 (34)	150 (35)
Never	238 (51)	225 (50)	208 (48)	246 (54)	209 (49)
Not reported	7 (2)	6 (1)	11 (3)	9 (2)	9 (2)

**Table 8.1.5 Number (percentage) of respondents by testing for HIV and HCV, HCV treatment by survey year**

Victoria N° surveyed	2012 N=463	2013 N=448	2014 N=436	2015 N=459	2016 N=423
<b>Previous HIV test (%)</b>					
Yes, ever	404 (87)	381 (85)	386 (89)	397 (86)	356 (84)
Yes, last year	274 (59)	253 (56)	244 (56)	243 (53)	222 (52)
>1 year ago	130 (28)	128 (29)	142 (33)	154 (34)	134 (32)
Never tested	44 (10)	42 (9)	33 (8)	48 (10)	51 (12)
Not reported	15 (3)	25 (6)	17 (4)	14 (3)	16 (4)
<b>Previous HCV test (%)</b>					
Yes, ever	417 (90)	393 (88)	395 (91)	429 (93)	362 (86)
Yes, last year	295 (64)	268 (60)	263 (60)	278 (61)	252 (60)
>1 year ago	122 (26)	125 (28)	132 (30)	151 (33)	110 (26)
Never tested	22 (5)	13 (3)	19 (4)	17 (4)	18 (4)
Not reported	24 (5)	42 (9)	22 (5)	13 (3)	43 (10)
<b>Lifetime treatment for HCV (%)#</b>					
<b>N° self-reported HCV diagnosis</b>					
Antiviral treatment	15 (8)	12 (7)	11 (6)	13 (7)	35 (21)
No antiviral treatment	166 (89)	161 (90)	166 (94)	170 (88)	130 (78)
Not reported	5 (3)	5 (3)	0 (0)	11 (6)	1 (1)
<b>Treatment for HCV in past 12 months (%)**</b>					
<b>N° self-reported HCV diagnosis</b>					
Antiviral treatment	2 (1)	2 (1)	0 (0)	4 (2)	25 (16)
No antiviral treatment	174 (96)	165 (96)	172 (100)	176 (92)	135 (84)
Not reported	5 (3)	5 (3)	0 (0)	11 (6)	1 (1)

# among people who tested HCV antibody positive and did not report spontaneous clearance

\* excludes people who reported treatment induced clearance more than 12 months previously

**Table 8.1.6 Number (percentage) of respondents by sexual behaviour in the month prior to survey and survey year**

Victoria N° surveyed	2012 N=463	2013 N=448	2014 N=436	2015 N=459	2016 N=423
<b>Sex with a regular partner last month (%)</b>					
No	256 (55)	244 (54)	240 (55)	260 (57)	223 (53)
Yes	196 (42)	182 (41)	175 (40)	180 (39)	186 (44)
Not reported	11 (2)	22 (5)	21 (5)	19 (4)	14 (3)
<b>Condom used with regular partner last month (%)</b>					
N° surveyed	N=196	N=182	N=175	N=180	N=186
Never	124 (63)	117 (64)	129 (74)	134 (74)	136 (73)
Sometimes	28 (14)	30 (16)	24 (14)	22 (12)	20 (11)
Every time	25 (13)	20 (11)	12 (7)	20 (11)	17 (9)
Not reported	19 (10)	15 (8)	10 (6)	4 (2)	13 (7)
<b>Sex with other partner(s) last month (%)</b>					
No	359 (78)	351 (78)	350 (80)	377 (82)	341 (81)
Yes	86 (19)	70 (16)	60 (14)	64 (14)	60 (14)
Not reported	18 (4)	27 (6)	26 (6)	18 (4)	22 (5)
<b>Condom used with other partner(s) last month (%)</b>					
N° surveyed	N=86	N=70	N=60	N=64	N=60
Never	30 (35)	17 (24)	20 (33)	22 (34)	22 (37)
Sometimes	24 (28)	24 (34)	11 (18)	23 (36)	20 (33)
Every time	30 (35)	24 (34)	21 (35)	16 (25)	18 (30)
Not reported	2 (2)	5 (7)	8 (13)	3 (5)	0 (0)
<b>Sex work last month (%)</b>					
No	418 (90)	390 (87)	372 (85)	416 (91)	370 (87)
Yes	34 (7)	19 (4)	28 (6)	25 (5)	26 (6)
Not reported	11 (2)	39 (9)	36 (8)	18 (4)	27 (6)
<b>Condom used at last sex work (%)</b>					
Yes	29 (85)	12 (63)	16 (57)	18 (72)	16 (62)

**Table 8.1.7 Number (percentage) of respondents reporting stigma or discrimination in the last 12 months in 2016**

Victoria <sup>#</sup>	Never	Rarely	Sometimes	Often	Always
Use of drugs for injecting	116 (30)	44 (11)	117 (30)	65 (17)	47 (12)
Sexual orientation	213 (71)	25 (8)	36 (12)	15 (5)	10 (3)
Hepatitis C status	195 (62)	32 (10)	53 (17)	21 (7)	14 (4)
Hepatitis B status	202 (85)	11 (5)	12 (5)	8 (3)	4 (2)
HIV status	200 (88)	8 (4)	13 (6)	4 (2)	3 (1)
Sex work	180 (79)	14 (6)	17 (7)	10 (4)	8 (3)
Other	61 (63)	5 (5)	15 (15)	9 (9)	7 (7)
Health workers treated me negatively or different to other people	201 (52)	64 (16)	75 (19)	29 (7)	20 (5)

<sup>#</sup> excludes respondents who indicated 'not applicable' and where data was missing



## HIV antibody prevalence

**Table 8.2.1 HIV antibody prevalence by gender and survey year**

Victoria Survey year	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2012	304	1 (0.3)	128	0 (0.0)	433	1 (0.2)
2013	300	5 (1.7)	139	1 (0.7)	446	6 (1.3)
2014	277	4 (1.4)	143	3 (2.1)	421	7 (1.7)
2015	300	10 (3.3)	152	0 (0.0)	455	10 (2.2)
2016	266	6 (2.3)	149	2 (1.3)	419	8 (1.9)
X <sup>2</sup> p trend		0.024		0.461		0.023

**Table 8.2.2 HIV antibody prevalence by sexual identity, gender and survey year**

Victoria Sexual identity	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
<b>2012</b>						
Heterosexual	262	1 (0.4)	82	0 (0.0)	344	1 (0.3)
Bisexual	16	0 (0.0)	27	0 (0.0)	43	0 (0.0)
Homosexual	5	0 (0.0)	9	0 (0.0)	15	0 (0.0)
p value		1.000		--		1.000
<b>2013</b>						
Heterosexual	243	2 (0.8)	91	1 (1.1)	337	3 (0.9)
Bisexual	8	0 (0.0)	22	0 (0.0)	31	0 (0.0)
Homosexual	13	2 (15.4)	8	0 (0.0)	24	2 (8.3)
p value		<0.001		1.000		0.006
<b>2014</b>						
Heterosexual	230	4 (1.7)	106	3 (2.8)	337	7 (2.1)
Bisexual	12	0 (0.0)	23	0 (0.0)	35	0 (0.0)
Homosexual	9	0 (0.0)	2	0 (0.0)	11	0 (0.0)
p value		1.000		1.000		1.000
<b>2015</b>						
Heterosexual	259	4 (1.5)	118	0 (0.0)	377	4 (1.1)
Bisexual	17	1 (5.9)	18	0 (0.0)	36	1 (2.8)
Homosexual	9	4 (44.4)	6	0 (0.0)	17	4 (23.5)
p value		<0.001		--		<0.001
<b>2016</b>						
Heterosexual	232	4 (1.7)	94	1 (1.1)	327	5 (1.5)
Bisexual	10	0 (0.0)	34	0 (0.0)	45	0 (0.0)
Homosexual	6	2 (33.3)	6	0 (0.0)	13	2 (15.4)
p value		0.010		1.000		0.029

**Table 8.2.3 HIV antibody prevalence by age group, gender and survey year**

Victoria Age group	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
<b>2012</b>						
<25 years	13	0 (0.0)	7	0 (0.0)	20	0 (0.0)
25-34 years	93	0 (0.0)	50	0 (0.0)	144	0 (0.0)
35-44 years	133	1 (0.8)	52	0 (0.0)	185	1 (0.5)
45+ years	64	0 (0.0)	19	0 (0.0)	83	0 (0.0)
p value		1.000		--		1.000
<b>2013</b>						
<25 years	8	0 (0.0)	10	0 (0.0)	18	0 (0.0)
25-34 years	80	2 (2.5)	48	0 (0.0)	132	2 (1.5)
35-44 years	135	0 (0.0)	48	0 (0.0)	185	0 (0.0)
45+ years	76	3 (4.0)	33	1 (3.0)	110	4 (3.6)
p value		0.086		0.309		0.054
<b>2014</b>						
<25 years	5	0 (0.0)	5	0 (0.0)	11	0 (0.0)
25-34 years	70	3 (4.3)	51	0 (0.0)	121	3 (2.5)
35-44 years	124	0 (0.0)	51	2 (3.9)	175	2 (1.1)
45+ years	76	1 (1.3)	36	1 (2.8)	112	2 (1.8)
p value		0.098		0.531		0.703
<b>2015</b>						
<25 years	4	0 (0.0)	4	0 (0.0)	8	0 (0.0)
25-34 years	60	6 (10.0)	47	0 (0.0)	108	6 (5.6)
35-44 years	125	2 (1.6)	55	0 (0.0)	181	2 (1.1)
45+ years	110	2 (1.8)	46	0 (0.0)	157	2 (1.3)
p value		0.036		--		0.059
<b>2016</b>						
<25 years	4	1 (25.0)	8	0 (0.0)	13	1 (7.7)
25-34 years	49	3 (6.1)	37	1 (2.7)	86	4 (4.7)
35-44 years	114	0 (0.0)	62	0 (0.0)	177	0 (0.0)
45+ years	99	2 (2.0)	42	1 (2.4)	143	3 (2.1)
p value		0.005		0.384		0.008

**Table 8.2.4 HIV antibody prevalence by last drug injected, gender and survey year**

<b>Victoria</b>						
<b>Last drug injected</b>	<b>Male</b>		<b>Female</b>		<b>Total</b>	
	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)
<b>2012</b>						
Heroin	199	1 (0.5)	89	0 (0.0)	288	1 (0.4)
Methamphetamine	48	0 (0.0)	19	0 (0.0)	68	0 (0.0)
Other opioids	30	0 (0.0)	12	0 (0.0)	42	0 (0.0)
Other drugs	26	0 (0.0)	8	0 (0.0)	34	0 (0.0)
p value		1.000		--		1.000
<b>2013</b>						
Heroin	160	2 (1.3)	76	1 (1.3)	239	3 (1.3)
Methamphetamine	61	3 (4.9)	34	0 (0.0)	96	3 (3.1)
Other opioids	45	0 (0.0)	14	0 (0.0)	59	0 (0.0)
Other drugs	33	0 (0.0)	15	0 (0.0)	51	0 (0.0)
p value		0.258		1.000		0.434
<b>2014</b>						
Heroin	157	4 (2.6)	73	1 (1.4)	230	5 (2.1)
Methamphetamine	55	0 (0.0)	39	1 (2.6)	95	1 (1.1)
Other opioids	40	0 (0.0)	16	0 (0.0)	56	0 (0.0)
Other drugs	23	0 (0.0)	14	1 (7.1)	37	1 (2.7)
p value		0.627		0.344		0.628
<b>2015</b>						
Heroin	155	5 (3.2)	79	0 (0.0)	236	5 (2.1)
Methamphetamine	95	5 (5.3)	44	0 (0.0)	140	5 (3.6)
Other opioids	31	0 (0.0)	17	0 (0.0)	48	0 (0.0)
Other drugs	19	0 (0.0)	12	0 (0.0)	31	0 (0.0)
p value		0.554		--		0.544
<b>2016</b>						
Heroin	150	4 (2.7)	70	2 (2.9)	221	6 (2.7)
Methamphetamine	76	1 (1.3)	55	0 (0.0)	131	1 (0.8)
Other opioids	20	0 (0.0)	14	0 (0.0)	35	0 (0.0)
Other drugs	20	1 (5.0)	10	0 (0.0)	32	1 (3.1)
p value		0.560		0.651		0.434

**Table 8.2.5 HIV antibody prevalence by years of injection, gender and survey year**

Victoria Years of injection	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
<b>2012</b>						
<3 years	9	0 (0.0)	4	0 (0.0)	13	0 (0.0)
3 to 10 years	46	0 (0.0)	18	0 (0.0)	64	0 (0.0)
11+ years	239	1 (0.4)	99	0 (0.0)	339	1 (0.3)
p value		1.000		--		1.000
<b>2013</b>						
<3 years	5	0 (0.0)	6	0 (0.0)	13	0 (0.0)
3 to 10 years	39	2 (5.1)	26	0 (0.0)	66	2 (3.0)
11+ years	239	3 (1.3)	102	1 (1.0)	344	4 (1.2)
p value		0.219		1.000		0.378
<b>2014</b>						
<3 years	8	0 (0.0)	9	0 (0.0)	17	0 (0.0)
3 to 10 years	24	2 (8.3)	22	0 (0.0)	47	2 (4.3)
11+ years	231	2 (0.9)	106	3 (2.8)	337	5 (1.5)
p value		0.074		1.000		0.416
<b>2015</b>						
<3 years	12	0 (0.0)	7	0 (0.0)	19	0 (0.0)
3 to 10 years	32	4 (12.5)	23	0 (0.0)	57	4 (7.0)
11+ years	248	6 (2.4)	119	0 (0.0)	368	6 (1.6)
p value		0.033		--		0.051
<b>2016</b>						
<3 years	5	0 (0.0)	7	0 (0.0)	12	0 (0.0)
3 to 10 years	30	2 (6.7)	26	1 (3.9)	57	3 (5.3)
11+ years	220	4 (1.8)	110	1 (0.9)	333	5 (1.5)
p value		0.250		0.410		0.150

**Table 8.2.6 HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and survey year**

Victoria Receptively shared syringe last month	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
<b>2012</b>						
No receptive sharing	212	1 (0.5)	87	0 (0.0)	300	1 (0.3)
Receptive sharing	61	0 (0.0)	25	0 (0.0)	86	0 (0.0)
p value		1.000		--		1.000
<b>2013</b>						
No receptive sharing	207	4 (1.9)	99	1 (1.0)	311	5 (1.6)
Receptive sharing	55	0 (0.0)	18	0 (0.0)	73	0 (0.0)
p value		0.582		1.000		0.588
<b>2014</b>						
No receptive sharing	206	2 (1.0)	98	2 (2.0)	305	4 (1.3)
Receptive sharing	37	2 (5.4)	28	1 (3.6)	65	3 (4.6)
p value		0.111		0.533		0.107
<b>2015</b>						
No receptive sharing	212	10 (4.7)	114	0 (0.0)	329	10 (3.0)
Receptive sharing	59	0 (0.0)	24	0 (0.0)	83	0 (0.0)
p value		0.125		--		0.223
<b>2016</b>						
No receptive sharing	191	3 (1.6)	103	2 (1.9)	298	5 (1.7)
Receptive sharing	48	3 (6.3)	31	0 (0.0)	79	3 (3.8)
p value		0.097		1.000		0.372

**Table 8.2.7 HIV antibody prevalence by frequency of drug injection last month, gender and survey year**

Victoria	Male		Female		Total	
Frequency of injection	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)
<b>2012</b>						
Less than daily	125	1 (0.8)	56	0 (0.0)	182	1 (0.6)
Daily or more	158	0 (0.0)	61	0 (0.0)	219	0 (0.0)
Not last month	14	0 (0.0)	11	0 (0.0)	25	0 (0.0)
p value		0.468		--		0.486
<b>2013</b>						
Less than daily	119	1 (0.8)	65	1 (1.5)	185	2 (1.1)
Daily or more	147	3 (2.0)	58	0 (0.0)	209	3 (1.5)
Not last month	24	1 (4.2)	9	0 (0.0)	33	1 (3.0)
p value		0.357		1.000		0.520
<b>2014</b>						
Less than daily	119	0 (0.0)	63	0 (0.0)	183	0 (0.0)
Daily or more	129	4 (3.1)	67	3 (4.5)	196	7 (3.6)
Not last month	26	0 (0.0)	12	0 (0.0)	38	0 (0.0)
p value		0.199		0.313		0.031
<b>2015</b>						
Less than daily	126	6 (4.8)	72	0 (0.0)	200	6 (3.0)
Daily or more	146	4 (2.7)	68	0 (0.0)	215	4 (1.9)
Not last month	25	0 (0.0)	10	0 (0.0)	35	0 (0.0)
p value		0.536		--		0.605
<b>2016</b>						
Less than daily	90	1 (1.1)	64	1 (1.6)	156	2 (1.3)
Daily or more	151	5 (3.3)	70	1 (1.4)	223	6 (2.7)
Not last month	18	0 (0.0)	13	0 (0.0)	31	0 (0.0)
p value		0.622		1.000		0.724

**Table 8.2.8 HIV antibody prevalence by imprisonment last year, gender and survey year**

Victoria	Male		Female		Total	
Imprisonment last year	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)
<b>2012</b>						
No imprisonment	230	1 (0.4)	114	0 (0.0)	345	1 (0.3)
Imprisonment	61	0 (0.0)	8	0 (0.0)	69	0 (0.0)
p value		1.000		--		1.000
<b>2013</b>						
No imprisonment	228	4 (1.8)	118	1 (0.9)	352	5 (1.4)
Imprisonment	38	1 (2.6)	10	0 (0.0)	48	1 (2.1)
p value		0.540		1.000		0.538
<b>2014</b>						
No imprisonment	220	4 (1.8)	129	3 (2.3)	350	7 (2.0)
Imprisonment	38	0 (0.0)	8	0 (0.0)	46	0 (0.0)
p value		1.000		1.000		1.000
<b>2015</b>						
No imprisonment	233	9 (3.9)	135	0 (0.0)	371	9 (2.4)
Imprisonment	48	0 (0.0)	11	0 (0.0)	59	0 (0.0)
p value		0.366		--		0.618
<b>2016</b>						
No imprisonment	201	6 (3.0)	124	0 (0.0)	328	6 (1.8)
Imprisonment	42	0 (0.0)	16	1 (6.3)	59	1 (1.7)
p value		0.594		0.114		1.000

**Table 8.2.9 HIV antibody prevalence by condom use at last sex with regular partner, gender and survey year**

<b>Victoria</b>	<b>Male</b>		<b>Female</b>		<b>Total</b>	
<b>Condom use at last sex</b>	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)
<b>2012</b>						
No condom use	72	0 (0.0)	38	0 (0.0)	111	0 (0.0)
Condom use	33	0 (0.0)	18	0 (0.0)	51	0 (0.0)
p value		--		--		--
<b>2013</b>						
No condom use	65	1 (1.6)	51	0 (0.0)	117	1 (0.9)
Condom use	32	2 (6.3)	16	0 (0.0)	50	2 (4.0)
p value		0.252		--		0.214
<b>2014</b>						
No condom use	67	1 (1.5)	57	1 (1.8)	124	2 (1.6)
Condom use	22	0 (0.0)	13	0 (0.0)	35	0 (0.0)
p value		1.000		1.000		1.000
<b>2015</b>						
No condom use	75	1 (1.3)	57	0 (0.0)	133	1 (0.8)
Condom use	25	1 (4.0)	15	0 (0.0)	41	1 (2.4)
p value		0.439		--		0.417
<b>2016</b>						
No condom use	74	2 (2.7)	59	1 (1.7)	134	3 (2.2)
Condom use	24	0 (0.0)	13	0 (0.0)	37	0 (0.0)
p value		1.000		1.000		1.000

**Table 8.2.10 HIV antibody prevalence by sex work last month, gender and survey year**

<b>Victoria</b>	<b>Male</b>		<b>Female</b>		<b>Total</b>	
<b>Sex work last month</b>	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)
<b>2012</b>						
No sex work	282	1 (0.4)	105	0 (0.0)	388	1 (0.3)
Sex work	13	0 (0.0)	21	0 (0.0)	34	0 (0.0)
p value		1.000		--		1.000
<b>2013</b>						
No sex work	268	5 (1.9)	115	1 (0.9)	388	6 (1.6)
Sex work	7	0 (0.0)	11	0 (0.0)	19	0 (0.0)
p value		1.000		1.000		1.000
<b>2014</b>						
No sex work	241	3 (1.2)	119	3 (2.2)	360	6 (1.7)
Sex work	12	0 (0.0)	15	0 (0.0)	28	0 (0.0)
p value		1.000		1.000		1.000
<b>2015</b>						
No sex work	278	8 (2.9)	133	0 (0.0)	412	8 (1.9)
Sex work	6	2 (33.3)	17	0 (0.0)	25	2 (8.0)
p value		0.016		--		0.107
<b>2016</b>						
No sex work	242	5 (2.1)	122	0 (0.0)	366	5 (1.4)
Sex work	8	0 (0.0)	17	1 (5.9)	26	1 (3.9)
p value		1.000		0.122		0.339

**Table 8.2.11 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year**

<b>Victoria</b>	<b>Male</b>		<b>Female</b>		<b>Total</b>	
<b>Aboriginal and Torres Strait Islander origin</b>	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
<b>2012</b>						
Non Indigenous	252	1 (0.4)	110	0 (0.0)	363	1 (0.3)
Indigenous	48	0 (0.0)	16	0 (0.0)	64	0 (0.0)
p value		1.000		--		1.000
<b>2013</b>						
Non Indigenous	256	4 (1.6)	119	1 (0.8)	379	5 (1.3)
Indigenous	32	1 (3.1)	17	0 (0.0)	51	1 (2.0)
p value		0.448		1.000		0.533
<b>2014</b>						
Non Indigenous	245	2 (0.8)	120	2 (1.7)	366	4 (1.1)
Indigenous	30	2 (6.7)	20	1 (5.0)	50	3 (6.0)
p value		0.060		0.373		0.040
<b>2015</b>						
Non Indigenous	261	6 (2.3)	134	0 (0.0)	398	6 (1.5)
Indigenous	34	4 (11.8)	18	0 (0.0)	52	4 (7.7)
p value		0.019		--		0.020
<b>2016</b>						
Non Indigenous	213	2 (0.9)	121	1 (0.8)	337	3 (0.9)
Indigenous	46	4 (8.7)	23	0 (0.0)	70	4 (5.7)
p value		0.010		1.000		0.019

**Table 8.2.12 HIV antibody prevalence by main language spoken at home by parents, gender and survey year**

<b>Victoria</b>	<b>Male</b>		<b>Female</b>		<b>Total</b>	
<b>Main language spoken at home by parents</b>	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
<b>2012</b>						
English speaking	269	1 (0.4)	118	0 (0.0)	388	1 (0.3)
Non-English speaking	35	0 (0.0)	9	0 (0.0)	44	0 (0.0)
p value		1.000		--		1.000
<b>2013</b>						
English speaking	254	4 (1.6)	130	1 (0.8)	391	5 (1.3)
Non-English speaking	45	1 (2.2)	9	0 (0.0)	54	1 (1.9)
p value		0.560		1.000		0.542
<b>2014</b>						
English speaking	235	3 (1.3)	129	2 (1.6)	364	5 (1.4)
Non-English speaking	42	1 (2.4)	13	1 (7.7)	56	2 (3.6)
p value		0.484		0.252		0.237
<b>2015</b>						
English speaking	266	9 (3.4)	141	0 (0.0)	410	9 (2.2)
Non-English speaking	31	1 (3.2)	11	0 (0.0)	42	1 (2.4)
p value		1.000		--		1.000
<b>2016</b>						
English speaking	233	6 (2.6)	139	1 (0.7)	376	7 (1.9)
Non-English speaking	30	0 (0.0)	8	0 (0.0)	38	0 (0.0)
p value		1.000		1.000		1.000

**Table 8.2.13 HIV antibody prevalence by region/country of birth, gender and survey year**

Victoria		Male		Female		Total	
Region/country of birth	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
<b>2012</b>							
Australia	248	1 (0.4)	111	0 (0.0)	360	1 (0.3)	
Other Oceania	9	0 (0.0)	4	0 (0.0)	13	0 (0.0)	
Asia	13	0 (0.0)	1	0 (0.0)	14	0 (0.0)	
UK & Ireland	15	0 (0.0)	5	0 (0.0)	20	0 (0.0)	
Other	17	0 (0.0)	7	0 (0.0)	24	0 (0.0)	
p value		1.000		--		1.000	
<b>2013</b>							
Australia	235	3 (1.3)	121	1 (0.8)	363	4 (1.1)	
Other Oceania	10	0 (0.0)	0	0 (0.0)	10	0 (0.0)	
Asia	17	1 (5.9)	3	0 (0.0)	20	1 (5.0)	
UK & Ireland	14	0 (0.0)	7	0 (0.0)	21	0 (0.0)	
Other	22	1 (4.6)	8	0 (0.0)	30	1 (3.3)	
p value		0.486		1.000		0.258	
<b>2014</b>							
Australia	220	3 (1.4)	127	2 (1.6)	348	5 (1.4)	
Other Oceania	9	0 (0.0)	1	0 (0.0)	10	0 (0.0)	
Asia	17	1 (5.9)	2	1 (50.0)	19	2 (10.5)	
UK & Ireland	14	0 (0.0)	6	0 (0.0)	20	0 (0.0)	
Other	16	0 (0.0)	7	0 (0.0)	26	0 (0.0)	
p value		0.599		0.083		0.121	
<b>2015</b>							
Australia	243	9 (3.7)	128	0 (0.0)	373	9 (2.4)	
Other Oceania	14	0 (0.0)	3	0 (0.0)	17	0 (0.0)	
Asia	13	1 (7.7)	3	0 (0.0)	16	1 (6.3)	
UK & Ireland	13	0 (0.0)	13	0 (0.0)	27	0 (0.0)	
Other	15	0 (0.0)	5	0 (0.0)	20	0 (0.0)	
p value		0.719		--		0.613	
<b>2016</b>							
Australia	225	6 (2.7)	134	1 (0.8)	362	7 (1.9)	
Other Oceania	5	0 (0.0)	1	0 (0.0)	7	0 (0.0)	
Asia	6	0 (0.0)	1	0 (0.0)	7	0 (0.0)	
UK & Ireland	11	0 (0.0)	4	0 (0.0)	15	0 (0.0)	
Other	13	0 (0.0)	6	0 (0.0)	19	0 (0.0)	
p value		1.000		1.000		1.000	



## HCV antibody prevalence

**Table 8.3.1 HCV antibody prevalence by gender and survey year**

Victoria Survey year	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
2012	301	214 (71)	127	83 (65)	429	297 (69)
2013	299	199 (67)	138	94 (68)	444	296 (67)
2014	267	183 (69)	138	90 (65)	406	273 (67)
2015	278	207 (74)	143	98 (69)	424	306 (72)
2016	243	167 (69)	130	85 (65)	377	254 (67)
X <sup>2</sup> p trend		0.865		0.986		0.896

**Table 8.3.2 HCV antibody prevalence by sexual identity, gender and survey year**

Victoria Sexual identity	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2012</b>						
Heterosexual	259	182 (70)	80	50 (63)	339	232 (68)
Bisexual	16	12 (75)	28	19 (68)	44	31 (70)
Homosexual	5	2 (40)	9	7 (78)	15	9 (60)
p value		0.308		0.665		0.717
<b>2013</b>						
Heterosexual	242	166 (69)	90	63 (70)	335	231 (69)
Bisexual	8	6 (75)	22	12 (55)	31	18 (58)
Homosexual	13	4 (31)	8	6 (75)	24	11 (46)
p value		0.019		0.350		0.040
<b>2014</b>						
Heterosexual	221	149 (67)	102	64 (63)	324	213 (66)
Bisexual	12	9 (75)	22	14 (64)	34	23 (68)
Homosexual	9	6 (67)	2	2 (100)	11	8 (73)
p value		0.859		0.750		0.873
<b>2015</b>						
Heterosexual	245	182 (74)	110	75 (68)	355	257 (72)
Bisexual	12	8 (67)	17	11 (65)	30	19 (63)
Homosexual	7	7 (100)	6	5 (83)	15	13 (87)
p value		0.247		0.695		0.281
<b>2016</b>						
Heterosexual	214	153 (72)	81	51 (63)	296	204 (69)
Bisexual	9	5 (56)	32	21 (66)	42	27 (64)
Homosexual	5	0 (0)	6	4 (67)	12	4 (33)
p value		0.001		0.944		0.038

**Table 8.3.3 HCV antibody prevalence by age group, gender and survey year**

Victoria Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2012</b>						
<25 years	14	3 (21)	7	2 (29)	21	5 (24)
25-34 years	91	63 (69)	50	32 (64)	142	95 (67)
35-44 years	132	101 (77)	50	35 (70)	182	136 (75)
45+ years	63	46 (73)	20	14 (70)	83	60 (72)
p value		0.001		0.214		<0.001
<b>2013</b>						
<25 years	8	1 (13)	10	4 (40)	18	5 (28)
25-34 years	79	37 (47)	48	28 (58)	131	67 (51)
35-44 years	135	101 (75)	47	36 (77)	184	137 (74)
45+ years	76	59 (78)	33	26 (79)	110	86 (78)
p value		<0.001		0.030		<0.001
<b>2014</b>						
<25 years	5	2 (40)	5	3 (60)	11	5 (45)
25-34 years	69	42 (61)	48	26 (54)	117	68 (58)
35-44 years	120	80 (67)	49	38 (78)	169	118 (70)
45+ years	71	58 (82)	36	23 (64)	107	81 (76)
p value		0.015		0.093		0.013
<b>2015</b>						
<25 years	4	0 (0)	4	0 (0)	8	0 (0)
25-34 years	54	28 (52)	44	30 (68)	99	58 (59)
35-44 years	117	93 (79)	50	34 (68)	168	127 (76)
45+ years	102	85 (83)	45	34 (76)	148	120 (81)
p value		<0.001		0.030		<0.001
<b>2016</b>						
<25 years	4	1 (25)	8	5 (63)	13	7 (54)
25-34 years	44	26 (59)	31	19 (61)	75	45 (60)
35-44 years	104	78 (75)	55	41 (75)	160	119 (74)
45+ years	91	62 (68)	36	20 (56)	129	83 (64)
p value		0.058		0.258		0.070

**Table 8.3.4 HCV antibody prevalence by years since first injection, gender and survey year**

Victoria Years of injection	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2012</b>						
<3 years	9	2 (22)	4	1 (25)	13	3 (23)
3 to 10 years	46	27 (59)	18	7 (39)	64	34 (53)
11+ years	236	175 (74)	99	70 (71)	336	245 (73)
p value		0.001		0.008		<0.001
<b>2013</b>						
<3 years	5	2 (40)	6	1 (17)	13	4 (31)
3 to 10 years	38	13 (34)	26	18 (69)	65	31 (48)
11+ years	239	170 (71)	101	74 (73)	343	245 (71)
p value		<0.001		<0.001		<0.001
<b>2014</b>						
<3 years	8	1 (13)	9	3 (33)	17	4 (24)
3 to 10 years	24	16 (67)	22	11 (50)	47	27 (57)
11+ years	221	159 (72)	101	71 (70)	322	230 (71)
p value		0.002		0.024		<0.001
<b>2015</b>						
<3 years	11	2 (18)	6	1 (17)	17	3 (18)
3 to 10 years	31	16 (52)	21	11 (52)	54	27 (50)
11+ years	230	183 (80)	113	84 (74)	344	268 (78)
p value		<0.001		0.003		<0.001
<b>2016</b>						
<3 years	5	2 (40)	7	2 (29)	12	4 (33)
3 to 10 years	28	15 (54)	23	15 (65)	52	31 (60)
11+ years	200	142 (71)	96	65 (68)	299	208 (70)
p value		0.050		0.139		0.017

**Table 8.3.5 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year**

Victoria Receptively shared syringe last month	<3 years		3+ years		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2012</b>						
No receptive sharing	10	2 (20)	282	195 (69)	299	203 (68)
Receptive sharing	2	1 (50)	76	57 (75)	84	64 (76)
p value		0.455		0.321		0.179
<b>2013</b>						
No receptive sharing	9	3 (33)	288	192 (67)	309	203 (66)
Receptive sharing	1	0 (0)	65	45 (69)	73	50 (68)
p value		1.000		0.771		0.682
<b>2014</b>						
No receptive sharing	13	3 (23)	273	182 (67)	296	192 (65)
Receptive sharing	3	0 (0)	56	49 (88)	63	52 (83)
p value		1.000		0.002		0.006
<b>2015</b>						
No receptive sharing	9	1 (11)	291	210 (72)	305	216 (71)
Receptive sharing	5	2 (40)	75	61 (81)	81	64 (79)
p value		0.505		0.106		0.142
<b>2016</b>						
No receptive sharing	9	3 (33)	251	171 (68)	269	182 (68)
Receptive sharing	2	0 (0)	66	48 (73)	71	50 (70)
p value		1.000		0.472		0.656

**Table 8.3.6 HCV antibody prevalence by last drug injected, years since first injection and survey year**

Victoria Last drug injected	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2012</b>						
Heroin	9	2 (22)	268	188 (70)	287	199 (69)
Methamphetamine	1	0 (0)	68	45 (66)	69	45 (65)
Other opioids	2	1 (50)	34	28 (82)	39	32 (82)
Other drugs	1	1 (0)	30	18 (60)	33	20 (61)
p value		0.701		0.227		0.197
<b>2013</b>						
Heroin	4	1 (25)	225	161 (72)	237	170 (72)
Methamphetamine	4	1 (25)	86	53 (62)	96	58 (60)
Other opioids	1	0 (0)	54	36 (67)	59	38 (64)
Other drugs	4	2 (50)	43	26 (60)	51	29 (57)
p value		0.738		0.258		0.080
<b>2014</b>						
Heroin	9	2 (22)	204	150 (74)	223	159 (71)
Methamphetamine	4	1 (25)	84	47 (56)	91	50 (55)
Other opioids	1	0 (0)	48	35 (73)	51	37 (73)
Other drugs	3	1 (33)	33	25 (76)	38	27 (71)
p value		0.923		0.021		0.031
<b>2015</b>						
Heroin	4	1 (25)	220	171 (78)	227	175 (77)
Methamphetamine	9	2 (22)	109	73 (67)	122	79 (65)
Other opioids	0	0 (0)	42	29 (69)	42	29 (69)
Other drugs	4	0 (0)	23	18 (78)	28	18 (64)
p value		0.567		0.163		0.070
<b>2016</b>						
Heroin	2	1 (50)	189	138 (73)	195	142 (73)
Methamphetamine	7	1 (14)	105	66 (63)	119	73 (61)
Other opioids	2	2 (100)	27	16 (59)	30	19 (63)
Other drugs	1	0 (0)	23	13 (57)	25	14 (56)
p value		0.117		0.124		0.099

**Table 8.3.7 HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year**

Victoria	<3 years		3+ years		Total	
Frequency of injection last month	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2012</b>						
Less than daily	6	1 (17)	167	116 (69)	179	123 (69)
Daily or more	6	2 (33)	206	146 (71)	219	154 (70)
Not last month	1	0 (0)	21	14 (67)	24	16 (67)
p value		1.000		0.901		0.900
<b>2013</b>						
Less than daily	6	1 (17)	168	117 (70)	185	122 (66)
Daily or more	4	2 (50)	193	126 (65)	207	138 (67)
Not last month	2	1 (50)	30	20 (67)	33	22 (67)
p value		0.414		0.688		0.987
<b>2014</b>						
Less than daily	5	0 (0)	166	112 (67)	178	116 (65)
Daily or more	11	3 (27)	171	125 (73)	189	134 (71)
Not last month	1	1 (100)	30	19 (63)	35	21 (60)
p value		0.168		0.386		0.312
<b>2015</b>						
Less than daily	7	0 (0)	178	125 (70)	188	128 (68)
Daily or more	8	3 (38)	190	148 (78)	201	154 (77)
Not last month	2	0 (0)	26	18 (69)	30	19 (63)
p value		0.300		0.211		0.098
<b>2016</b>						
Less than daily	5	2 (40)	133	90 (68)	140	93 (66)
Daily or more	6	1 (17)	186	131 (70)	202	141 (70)
Not last month	1	1 (100)	25	12 (48)	27	14 (52)
p value		0.343		0.079		0.170

**Table 8.3.8 HCV antibody prevalence by imprisonment last year, years since first injection and survey year**

Victoria	<3 years		3+ years		Total	
Imprisonment last year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2012</b>						
No imprisonment	12	3 (25)	315	210 (67)	341	226 (66)
Imprisonment	1	0 (0)	66	52 (79)	69	54 (78)
p value		1.000		0.058		0.065
<b>2013</b>						
No imprisonment	10	4 (40)	325	212 (65)	351	227 (65)
Imprisonment	1	0 (0)	44	34 (77)	47	35 (74)
p value		1.000		0.127		0.184
<b>2014</b>						
No imprisonment	13	2 (15)	307	206 (67)	336	218 (65)
Imprisonment	2	1 (50)	42	33 (79)	45	34 (76)
p value		0.371		0.133		0.155
<b>2015</b>						
No imprisonment	17	3 (18)	324	233 (72)	348	242 (70)
Imprisonment	0	0 (0)	50	42 (84)	52	44 (85)
p value		--		0.071		0.031
<b>2016</b>						
No imprisonment	11	3 (27)	279	176 (63)	298	185 (62)
Imprisonment	0	0 (0)	49	46 (94)	52	49 (94)
p value		--		<0.001		<0.001

**Table 8.3.9 HCV antibody prevalence by sex work last month, years since first injection and survey year**

Victoria	<3 years		3+ years		Total	
Sex work last month	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2012</b>						
No sex work	11	3 (27)	359	249 (69)	384	265 (69)
Sex work	2	0 (0)	31	24 (77)	34	25 (74)
p value		1.000		0.418		0.584
<b>2013</b>						
No sex work	11	3 (27)	358	237 (66)	386	251 (65)
Sex work	2	1 (50)	16	10 (63)	19	12 (63)
p value		1.000		0.790		1.000
<b>2014</b>						
No sex work	12	1 (8)	317	216 (68)	346	228 (66)
Sex work	3	2 (67)	24	21 (88)	28	23 (82)
p value		0.081		0.047		0.078
<b>2015</b>						
No sex work	15	3 (20)	365	270 (74)	386	278 (72)
Sex work	1	0 (0)	14	14 (74)	21	15 (71)
p value		1.000		0.978		0.953
<b>2016</b>						
No sex work	12	4 (33)	307	205 (67)	329	217 (66)
Sex work	0	0 (0)	23	19 (83)	23	19 (83)
p value		--		0.164		0.113

**Table 8.3.10 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year**

Victoria	Male		Female		Total	
Aboriginal and Torres Strait Islander origin	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2012</b>						
Non Indigenous	251	173 (69)	109	75 (69)	361	248 (69)
Indigenous	46	39 (85)	16	6 (38)	62	45 (73)
p value		0.029		0.014		0.540
<b>2013</b>						
Non Indigenous	255	167 (65)	118	79 (67)	377	247 (66)
Indigenous	32	21 (66)	17	13 (76)	51	35 (69)
p value		0.988		0.431		0.660
<b>2014</b>						
Non Indigenous	236	165 (70)	115	70 (61)	352	235 (67)
Indigenous	29	16 (55)	20	17 (85)	49	33 (67)
p value		0.107		0.037		0.935
<b>2015</b>						
Non Indigenous	242	176 (73)	127	87 (70)	369	264 (72)
Indigenous	31	29 (94)	19	11 (58)	50	40 (80)
p value		0.012		0.284		0.209
<b>2016</b>						
Non Indigenous	197	134 (68)	107	68 (64)	307	204 (66)
Indigenous	39	27 (69)	19	13 (68)	59	40 (68)
p value		0.882		0.683		0.841

**Table 8.3.11 HCV antibody prevalence by main language spoken at home by parents, gender and survey year**

<b>Victoria</b>	<b>Male</b>		<b>Female</b>		<b>Total</b>	
<b>Main language spoken at home by parents</b>	<b>N° tested</b>	<b>N° with HCV (%)</b>	<b>N° tested</b>	<b>N° with HCV (%)</b>	<b>N° tested</b>	<b>N° with HCV (%)</b>
<b>2012</b>						
English speaking	266	186 (70)	117	75 (64)	384	261 (68)
Non-English speaking	35	28 (80)	9	7 (78)	44	35 (80)
p value		0.216		0.493		0.115
<b>2013</b>						
English speaking	253	163 (64)	129	87 (67)	389	253 (65)
Non-English speaking	45	35 (78)	9	7 (78)	54	42 (78)
p value		0.081		0.719		0.063
<b>2014</b>						
English speaking	228	153 (67)	124	80 (65)	352	233 (66)
Non-English speaking	39	30 (77)	13	9 (69)	53	39 (74)
p value		0.222		0.735		0.285
<b>2015</b>						
English speaking	245	181 (74)	132	88 (67)	380	270 (71)
Non-English speaking	31	25 (81)	11	10 (91)	42	35 (83)
p value		0.415		0.096		0.092
<b>2016</b>						
English speaking	211	140 (66)	121	79 (65)	336	221 (66)
Non-English speaking	29	24 (83)	7	4 (57)	36	28 (78)
p value		0.075		0.696		0.146

**Table 8.3.12 HCV antibody prevalence by region/country of birth, gender and survey year**

<b>Victoria</b>	<b>Male</b>		<b>Female</b>		<b>Total</b>	
<b>Region/Country of birth</b>	<b>N° tested</b>	<b>N° with HCV (%)</b>	<b>N° tested</b>	<b>N° with HCV (%)</b>	<b>N° tested</b>	<b>N° with HCV (%)</b>
<b>2012</b>						
Australia	245	169 (69)	110	71 (65)	356	240 (67)
Other Oceania	9	6 (67)	4	2 (50)	13	8 (62)
Asia	13	13 (100)	1	1 (100)	14	14 (100)
UK & Ireland	15	11 (73)	5	4 (80)	20	15 (75)
Other	17	14 (82)	7	5 (71)	24	19 (79)
p value		0.090		0.881		0.042
<b>2013</b>						
Australia	235	154 (66)	120	82 (68)	362	239 (66)
Other Oceania	10	4 (40)	0	0 (0)	10	4 (40)
Asia	16	15 (94)	3	3 (100)	19	18 (95)
UK & Ireland	14	9 (64)	7	4 (57)	21	13 (62)
Other	22	15 (68)	8	5 (63)	30	20 (67)
p value		0.055		0.673		0.022
<b>2014</b>						
Australia	211	142 (67)	122	78 (64)	334	220 (66)
Other Oceania	8	5 (63)	1	1 (100)	9	6 (67)
Asia	17	16 (94)	2	2 (100)	19	18 (95)
UK & Ireland	14	8 (57)	6	4 (67)	20	12 (60)
Other	16	12 (75)	7	5 (71)	23	17 (74)
p value		0.157		0.969		0.101
<b>2015</b>						
Australia	224	167 (75)	119	86 (72)	345	254 (74)
Other Oceania	13	10 (77)	3	3 (100)	16	13 (81)
Asia	13	10 (77)	3	1 (33)	16	11 (69)
UK & Ireland	12	9 (75)	13	5 (38)	26	14 (54)
Other	15	10 (67)	5	3 (60)	20	13 (65)
p value		0.967		0.038		0.202
<b>2016</b>						
Australia	204	138 (68)	118	77 (65)	325	216 (66)
Other Oceania	5	5 (100)	1	1 (100)	7	7 (100)
Asia	6	5 (83)	1	0 (0)	7	5 (71)
UK & Ireland	10	5 (50)	3	1 (33)	13	6 (46)
Other	13	9 (69)	4	3 (75)	17	12 (71)
p value		0.391		0.498		0.179



## Western Australia

**Table 9.1.1 Number (percentage) of respondents by demographic characteristics and survey year**

Western Australia	2012	2013	2014	2015	2016
<b>Number of sites</b>	3	3	3	2	4
<b>N° surveyed</b>	N=186	N=220	N=225	N=218	N=425
<b>Response rate (%)</b>	79%	77%	82%	70%	75%
<b>Gender (%)</b>					
Male	121 (65)	135 (61)	142 (63)	125 (57)	274 (64)
Female	64 (34)	83 (38)	81 (36)	89 (41)	148 (35)
Transgender	1 (<1)	1 (<1)	2 (1)	3 (1)	2 (<1)
Not reported	0 (0)	1 (<1)	0 (0)	1 (<1)	1 (<1)
<b>Sexual identity (%)</b>					
Heterosexual	150 (81)	177 (80)	184 (82)	173 (79)	336 (79)
Bisexual	17 (9)	19 (9)	25 (11)	16 (7)	33 (8)
Homosexual	4 (2)	7 (3)	6 (3)	8 (4)	14 (3)
Not reported	15 (8)	17 (8)	10 (4)	21 (10)	42 (10)
<b>Aboriginal and Torres Strait Islander origin (%)</b>					
No	166 (89)	191 (87)	200 (89)	184 (84)	326 (77)
Yes	16 (9)	15 (7)	19 (8)	23 (11)	76 (18)
Not reported	4 (2)	14 (6)	6 (3)	11 (5)	23 (5)
<b>Region/country of birth (%)</b>					
Australia	150 (95)	172 (78)	176 (78)	165 (76)	358 (84)
Other Oceania	12 (6)	10 (5)	10 (4)	11 (5)	17 (4)
Asia	1 (<1)	1 (<1)	2 (1)	4 (2)	4 (1)
UK & Ireland	14 (8)	19 (9)	18 (8)	18 (8)	19 (4)
Other	8 (4)	14 (6)	16 (7)	14 (6)	13 (3)
Not reported	1 (<1)	4 (2)	3 (1)	6 (3)	14 (3)
<b>Main language spoken at home by parents (%)</b>					
English	176 (95)	205 (93)	211 (94)	201 (92)	388 (91)
Non-English	9 (5)	11 (5)	12 (5)	10 (5)	22 (5)
Not reported	1 (<1)	4 (2)	2 (1)	7 (3)	15 (4)
<b>Age and time since first injection (years)</b>					
<i>Median age</i>	40	39	41	41	41
<i>Age range</i>	20-65	15-66	18-67	15-70	20-68
<i>Age group (%)</i>					
<25 years	4 (2)	13 (6)	6 (3)	18 (8)	14 (3)
25+ years	181 (97)	204 (93)	217 (96)	198 (91)	408 (96)
Not reported	1 (<1)	3 (1)	2 (1)	2 (1)	3 (1)
<i>Median age first injection</i>					
	19	19	18	18	18
<i>Age range</i>	10-53	12-50	11-45	12-57	10-57
<i>N° not reported</i>	6	9	5	12	21
<i>Median yrs since first injection</i>					
	19	17	20	20	21
<i>Range</i>	<1-47	<1-49	<1-49	2-50	<1-51
<i>Years since first injection</i>					
<3 years	4 (2)	18 (8)	9 (4)	6 (3)	25 (6)
3+ years	176 (95)	193 (88)	210 (93)	200 (92)	379 (89)
Not reported	6 (3)	9 (4)	6 (3)	12 (6)	21 (5)
<b>Imprisonment last year (%)</b>					
No	159 (85)	178 (81)	175 (78)	178 (82)	348 (82)
Yes	20 (11)	17 (8)	24 (11)	23 (11)	52 (12)
Not reported	7 (4)	25 (11)	26 (12)	17 (8)	25 (6)
<b>N° in prison</b>					
Injected in prison	4 (20)	2 (12)	11 (46)	8 (35)	13 (25)

**Table 9.1.2 Number (percentage) of respondents by last drug injected, frequency of injecting and survey year**

<b>Western Australia N° surveyed</b>	<b>2012 N=186</b>	<b>2013 N=220</b>	<b>2014 N=225</b>	<b>2015 N=218</b>	<b>2016 N=425</b>
<b>Drug last injected (%)</b>					
Cocaine	1 (<1)	3 (1)	0 (0)	0 (0)	0 (0)
Methamphetamine	59 (32)	79 (36)	78 (35)	98 (45)	256 (60)
Heroin	48 (26)	51 (23)	79 (35)	63 (29)	65 (15)
Pharm. opioids	28 (15)	28 (13)	20 (9)	17 (8)	30 (7)
Methadone	6 (3)	10 (5)	6 (3)	6 (3)	8 (2)
Buprenorphine	11 (6)	9 (4)	4 (2)	6 (3)	14 (3)
Buprenorphine/naloxone	9 (5)	13 (6)	7 (3)	4 (2)	8 (2)
PIEDs	1 (<1)	5 (2)	6 (3)	1 (<1)	9 (2)
More than one	19 (10)	18 (8)	23 (10)	17 (8)	27 (6)
Other	1 (<1)	1 (<1)	1 (<1)	6 (3)	8 (2)
Not reported	3 (2)	3 (1)	1 (<1)	0 (0)	0 (0)
<b>Ever injected opioids</b>					
Yes	-	-	-	-	297 (70)
No	-	-	-	-	128 (30)
Not reported	-	-	-	-	0 (0)
<b>Frequency of injection last month (%)</b>					
Not last month	8 (4)	19 (9)	16 (7)	12 (6)	27 (6)
Less than weekly	27 (15)	28 (13)	23 (10)	25 (11)	65 (15)
Weekly not daily	36 (19)	38 (17)	36 (16)	51 (23)	89 (21)
Daily or more	112 (60)	124 (56)	146 (65)	121 (56)	234 (55)
Not reported	3 (2)	11 (5)	4 (2)	9 (4)	10 (2)
<b>Present when someone injected for the first time in the last 12 months (%)</b>					
Yes	24 (13)	22 (10)	52 (23)	43 (20)	82 (19)
No	145 (78)	150 (68)	161 (72)	163 (75)	326 (77)
Not reported	17 (9)	48 (22)	12 (5)	12 (6)	17 (4)
<b>Overdosed in last 12 months</b>					
Yes	--	25 (11)	49 (22)	40 (18)	61 (14)
No	--	183 (83)	164 (73)	166 (76)	344 (81)
Not reported	--	12 (5)	12 (5)	12 (6)	20 (5)

**Table 9.1.3 Number (percentage) of respondents by injecting behaviour in the last month and survey year**

<b>Western Australia N° injected last month</b>	<b>2012 N=175</b>	<b>2013 N=190</b>	<b>2014 N=205</b>	<b>2015 N=197</b>	<b>2016 N=388</b>
<b>Places injected last month (%)</b>					
Any public	61 (35)	95 (50)	89 (43)	88 (45)	209 (54)
All private	105 (60)	92 (48)	112 (55)	109 (55)	179 (46)
Not reported	9 (5)	3 (2)	4 (2)	0 (0)	0 (0)
<b>Use of new and sterile needles and syringes last month (%)</b>					
All injections	118 (67)	128 (67)	141 (69)	136 (69)	228 (59)
Most of the time	34 (19)	50 (26)	47 (23)	47 (24)	130 (34)
Half of the time	5 (3)	3 (2)	4 (2)	8 (4)	16 (4)
Some of the time	6 (3)	4 (2)	5 (2)	4 (2)	6 (2)
Not last month	1 (<1)	2 (1)	2 (1)	1 (1)	4 (1)
Not reported	11 (6)	3 (2)	6 (3)	1 (1)	4 (1)
<b>Re-used someone else's used needle &amp; syringe last month (%)</b>					
None	128 (73)	148 (78)	157 (77)	144 (73)	280 (72)
Once	15 (9)	11 (6)	15 (7)	15 (8)	23 (6)
Twice	7 (4)	7 (4)	7 (3)	12 (6)	33 (9)
3-5 times	9 (5)	10 (5)	11 (5)	17 (9)	25 (6)
>5 times	6 (3)	8 (4)	9 (4)	7 (4)	20 (5)
Not reported	10 (6)	6 (3)	6 (3)	2 (1)	7 (2)
<b>Number of people needle &amp; syringe was re-used after last month (%)</b>					
None	128 (73)	148 (78)	157 (77)	144 (73)	280 (72)
One	14 (8)	18 (9)	16 (8)	24 (12)	41 (11)
Two	3 (2)	4 (2)	1 (<1)	8 (4)	10 (3)
Three to five	1 (<1)	2 (1)	3 (1)	3 (2)	10 (3)
More than five	5 (3)	2 (1)	6 (3)	1 (1)	7 (2)
Don't know	5 (3)	6 (3)	6 (3)	7 (4)	22 (6)
Not reported	19 (11)	10 (5)	16 (8)	10 (5)	18 (5)
<b>Relationship to people needle &amp; syringe was used after last month (%) [more than one could be selected]</b>					
Regular sex partner	10 (6)	17 (9)	15 (7)	13 (7)	41 (11)
Casual sex partner	1 (<1)	3 (2)	2 (1)	1 (1)	3 (1)
Close friend	13 (7)	11 (6)	9 (4)	24 (12)	30 (8)
Acquaintance	7 (4)	9 (5)	3 (1)	4 (2)	17 (4)
Other	3 (2)	7 (4)	5 (2)	7 (4)	5 (1)
<b>Equipment used after someone else last month (%) [more than one could be selected]</b>					
Spoon	39 (22)	49 (26)	44 (21)	53 (27)	74 (19)
Water	30 (17)	43 (23)	41 (20)	39 (20)	95 (24)
Filter	27 (15)	24 (13)	23 (11)	23 (12)	35 (9)
Drug mix	18 (10)	16 (8)	17 (8)	19 (10)	29 (7)
None	107 (61)	116 (61)	139 (68)	122 (62)	261 (67)
<b>Injected by someone after that person injected themselves or others last month (%)</b>					
No	135 (77)	143 (75)	157 (77)	159 (81)	302 (78)
Yes	26 (15)	35 (18)	36 (18)	36 (18)	83 (21)
Not reported	14 (8)	12 (6)	12 (6)	2 (1)	3 (1)
<b>Source of needle acquisition</b>					
Needle Syringe Program	134 (77)	160 (84)	167 (81)	161 (82)	312 (80)
Chemist/Pharmacy	60 (34)	58 (31)	53 (26)	58 (29)	138 (36)
Personal sources	24 (14)	24 (13)	26 (13)	26 (13)	65 (17)
Dispensing/Vending Machine	3 (2)	2 (1)	3 (1)	5 (3)	9 (2)
Other sources	0 (0)	9 (5)	5 (2)	5 (3)	11 (3)

**Table 9.1.4 Number (percentage) of respondents by treatment for drug use and survey year**

Western Australia N° surveyed	2012 N=186	2013 N=220	2014 N=225	2015 N=218	2016 N=425
<b>Ever any treatment/therapy for drug use (%)</b>					
No	49 (26)	67 (30)	56 (25)	63 (29)	148 (35)
Yes	133 (72)	148 (67)	163 (72)	145 (67)	249 (59)
Not reported	4 (2)	5 (2)	6 (3)	10 (5)	28 (7)
<b>History of methadone maintenance treatment (%)</b>					
Currently	35 (19)	39 (18)	41 (18)	41 (19)	48 (11)
Previously	49 (26)	53 (24)	54 (24)	47 (22)	88 (21)
Never	101 (54)	125 (57)	124 (55)	119 (55)	255 (60)
Not reported	1 (<1)	3 (1)	6 (3)	11 (5)	34 (8)
<b>History of buprenorphine (Subutex®) treatment (%)</b>					
Currently	21 (11)	19 (9)	16 (7)	15 (7)	14 (3)
Previously	39 (21)	51 (23)	59 (26)	53 (24)	63 (15)
Never	125 (67)	144 (65)	144 (64)	140 (64)	329 (77)
Not reported	1 (<1)	6 (3)	6 (3)	10 (5)	19 (4)
<b>History of buprenorphine-naloxone (Suboxone®) treatment (%)</b>					
Currently	23 (12)	23 (10)	23 (10)	14 (6)	20 (5)
Previously	23 (12)	37 (17)	41 (18)	47 (22)	55 (13)
Never	136 (73)	150 (68)	156 (69)	146 (67)	328 (77)
Not reported	4 (2)	10 (5)	5 (2)	11 (5)	22 (5)

**Table 9.1.5 Number (percentage) of respondents by testing for HIV and HCV, HCV treatment by survey year**

Western Australia N° surveyed	2012 N=186	2013 N=220	2014 N=225	2015 N=218	2016 N=425
<b>Previous HIV test (%)</b>					
Yes, ever	148 (80)	167 (76)	173 (77)	172 (79)	327 (77)
Yes, last year	81 (44)	95 (43)	98 (44)	109 (50)	203 (48)
>1 year ago	67 (36)	72 (33)	75 (33)	63 (29)	124 (29)
Never tested	28 (15)	39 (18)	36 (16)	37 (17)	75 (18)
Not reported	10 (5)	14 (6)	16 (7)	9 (4)	23 (5)
<b>Previous HCV test (%)</b>					
Yes, ever	165 (89)	167 (76)	190 (84)	184 (84)	322 (75)
Yes, last year	96 (52)	106 (48)	113 (50)	115 (54)	210 (49)
>1 year ago	69 (37)	61 (28)	77 (34)	69 (32)	112 (26)
Never tested	10 (5)	25 (11)	14 (6)	20 (9)	53 (12)
Not reported	11 (6)	28 (13)	21 (9)	14 (6)	50 (12)
<b>Lifetime treatment for HCV (%)#</b>					
<b>N° self-reported HCV diagnosis</b>					
Antiviral treatment	6 (12)	7 (14)	10 (16)	7 (13)	26 (28)
No antiviral treatment	44 (88)	38 (78)	48 (79)	42 (78)	65 (71)
Not reported	0 (0)	4 (8)	3 (5)	5 (9)	1 (1)
<b>Treatment for HCV in past 12 months (%)**</b>					
<b>N° self-reported HCV diagnosis</b>					
Antiviral treatment	2 (4)	4 (8)	0 (0)	1 (2)	14 (16)
No antiviral treatment	46 (96)	40 (83)	56 (95)	46 (88)	71 (83)
Not reported	0 (0)	4 (8)	3 (5)	5 (10)	1 (1)

# among people who tested HCV antibody positive and did not report spontaneous clearance

\* excludes people who reported treatment induced clearance more than 12 months previously

**Table 9.1.6 Number (percentage) of respondents by sexual behaviour in the month prior to survey and survey year**

<b>Western Australia</b>	<b>2012</b>	<b>2013</b>	<b>2014</b>	<b>2015</b>	<b>2016</b>
<b>N° surveyed</b>	N=186	N=220	N=225	N=218	N=425
<b>Sex with a regular partner last month (%)</b>					
No	105 (56)	108 (49)	113 (50)	100 (46)	208 (49)
Yes	74 (40)	96 (44)	93 (41)	104 (48)	193 (45)
Not reported	7 (4)	16 (7)	19 (8)	14 (6)	24 (6)
<b>Condom used with regular partner last month (%)</b>					
<b>N° surveyed</b>	N=74	N=96	N=93	N=104	N=193
Never	56 (76)	70 (73)	73 (78)	76 (73)	132 (68)
Sometimes	8 (11)	13 (14)	8 (9)	9 (9)	35 (18)
Every time	6 (8)	8 (8)	7 (8)	13 (13)	18 (9)
Not reported	4 (5)	5 (5)	5 (5)	6 (6)	8 (4)
<b>Sex with other partner(s) last month (%)</b>					
No	147 (79)	159 (72)	169 (75)	169 (78)	324 (76)
Yes	28 (15)	39 (18)	34 (15)	34 (16)	72 (17)
Not reported	11 (6)	22 (10)	22 (10)	15 (7)	29 (7)
<b>Condom used with other partner(s) last month (%)</b>					
<b>N° surveyed</b>	N=28	N=39	N=34	N=34	N=72
Never	14 (50)	12 (31)	14 (41)	11 (32)	30 (42)
Sometimes	8 (29)	12 (31)	9 (26)	11 (32)	23 (32)
Every time	5 (18)	14 (36)	7 (21)	10 (30)	15 (21)
Not reported	1 (4)	1 (3)	4 (12)	2 (6)	4 (6)
<b>Sex work last month (%)</b>					
No	169 (91)	188 (85)	181 (80)	190 (87)	372 (88)
Yes	11 (6)	11 (5)	14 (6)	14 (6)	24 (6)
Not reported	6 (3)	21 (10)	30 (13)	14 (6)	29 (7)
<b>Condom used at last sex work (%)</b>					
Yes	8 (73)	9 (80)	6 (43)	10 (71)	18 (75)

**Table 9.1.7 Number (percentage) of respondents reporting stigma or discrimination in the last 12 months in 2016**

<b>Western Australia<sup>#</sup></b>	<b>Never</b>	<b>Rarely</b>	<b>Sometimes</b>	<b>Often</b>	<b>Always</b>
Use of drugs for injecting	111 (29)	48 (13)	128 (33)	52 (14)	44 (11)
Sexual orientation	230 (74)	29 (9)	28 (9)	11 (4)	14 (4)
Hepatitis C status	225 (75)	35 (12)	31 (10)	5 (2)	6 (2)
Hepatitis B status	249 (90)	13 (5)	9 (3)	3 (1)	2 (1)
HIV status	251 (92)	11 (4)	8 (3)	1 (1)	2 (1)
Sex work	223 (84)	12 (5)	18 (7)	7 (3)	6 (2)
Other	89 (79)	5 (4)	8 (7)	7 (6)	3 (3)
Health workers treated me negatively or different to other people	191 (51)	48 (13)	78 (21)	40 (11)	19 (5)

<sup>#</sup> excludes respondents who indicated 'not applicable' and where data was missing

## HIV antibody prevalence

**Table 9.2.1 HIV antibody prevalence by gender and survey year**

Western Australia Survey year	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2012	120	0 (0.0)	63	3 (4.8)	184	3 (1.6)
2013	126	3 (2.4)	71	2 (2.8)	199	5 (2.5)
2014	131	1 (0.8)	75	0 (0.0)	208	1 (0.5)
2015	112	1 (0.9)	83	1 (1.2)	198	2 (1.0)
2016	270	2 (0.7)	146	2 (1.4)	419	5 (1.2)
X <sup>2</sup> p trend		0.872		0.132		0.381

**Table 9.2.2 HIV antibody prevalence by sexual identity, gender and survey year**

Western Australia Sexual identity	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
<b>2012</b>						
Heterosexual	106	0 (0.0)	42	2 (4.8)	148	2 (1.4)
Bisexual	6	0 (0.0)	10	0 (0.0)	17	0 (0.0)
Homosexual	0	0 (0.0)	4	0 (0.0)	4	0 (0.0)
p value		--		1.000		1.000
<b>2013</b>						
Heterosexual	110	2 (1.8)	49	2 (4.1)	159	4 (2.5)
Bisexual	4	1 (25.0)	15	0 (0.0)	19	1 (5.3)
Homosexual	4	0 (0.0)	2	0 (0.0)	6	0 (0.0)
p value		0.191		1.000		0.522
<b>2014</b>						
Heterosexual	118	0 (0.0)	52	0 (0.0)	170	0 (0.0)
Bisexual	6	1 (16.7)	15	0 (0.0)	23	1 (4.4)
Homosexual	3	0 (0.0)	3	0 (0.0)	6	0 (0.0)
p value		0.071		--		0.146
<b>2015</b>						
Heterosexual	99	0 (0.0)	57	1 (1.8)	158	1 (0.6)
Bisexual	1	0 (0.0)	15	0 (0.0)	16	0 (0.0)
Homosexual	2	1 (50.0)	3	0 (0.0)	5	1 (20.0)
p value		0.029		1.000		0.063
<b>2016</b>						
Heterosexual	228	1 (0.4)	103	2 (1.9)	331	3 (0.9)
Bisexual	7	1 (14.3)	24	0 (0.0)	33	2 (6.1)
Homosexual	9	0 (0.0)	5	0 (0.0)	14	0 (0.0)
p value		0.058		1.000		0.118

**Table 9.2.3 HIV antibody prevalence by age group, gender and survey year**

Western Australia Age group	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
<b>2012</b>						
<25 years	3	0 (0.0)	1	0 (0.0)	4	0 (0.0)
25-34 years	29	0 (0.0)	18	1 (5.6)	47	1 (2.1)
35-44 years	45	0 (0.0)	21	0 (0.0)	67	0 (0.0)
45+ years	43	0 (0.0)	22	2 (9.1)	65	2 (3.1)
p value		--		0.530		0.411
<b>2013</b>						
<25 years	8	1 (12.5)	5	0 (0.0)	13	1 (7.7)
25-34 years	41	1 (2.4)	22	0 (0.0)	63	1 (1.6)
35-44 years	36	1 (2.8)	22	0 (0.0)	58	1 (1.7)
45+ years	39	0 (0.0)	22	2 (9.1)	62	2 (3.2)
p value		0.228		0.416		0.518
<b>2014</b>						
<25 years	6	0 (0.0)	0	0 (0.0)	6	0 (0.0)
25-34 years	33	0 (0.0)	14	0 (0.0)	47	0 (0.0)
35-44 years	46	0 (0.0)	26	0 (0.0)	73	0 (0.0)
45+ years	45	1 (2.2)	35	0 (0.0)	81	1 (1.2)
p value		0.646		--		1.000
<b>2015</b>						
<25 years	6	0 (0.0)	6	0 (0.0)	14	0 (0.0)
25-34 years	21	0 (0.0)	14	0 (0.0)	35	0 (0.0)
35-44 years	40	0 (0.0)	34	0 (0.0)	74	0 (0.0)
45+ years	44	1 (2.3)	29	1 (3.5)	74	2 (2.7)
p value		1.000		0.590		0.716
<b>2016</b>						
<25 years	5	0 (0.0)	8	0 (0.0)	14	0 (0.0)
25-34 years	60	0 (0.0)	38	0 (0.0)	98	0 (0.0)
35-44 years	100	1 (1.0)	52	0 (0.0)	152	1 (0.7)
45+ years	103	1 (1.0)	47	2 (4.3)	152	4 (2.6)
p value		1.000		0.279		0.376

**Table 9.2.4 HIV antibody prevalence by last drug injected, gender and survey year**

Western Australia		Male		Female		Total	
Last drug injected	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
<b>2012</b>							
Heroin	31	0 (0.0)	17	3 (17.7)	48	3 (6.3)	
Methamphetamine	31	0 (0.0)	25	0 (0.0)	57	0 (0.0)	
Other opioids	37	0 (0.0)	17	0 (0.0)	54	0 (0.0)	
Other drugs	18	0 (0.0)	4	0 (0.0)	22	0 (0.0)	
p value		--		0.071		0.057	
<b>2013</b>							
Heroin	35	1 (2.9)	14	2 (14.3)	49	3 (6.1)	
Methamphetamine	35	2 (5.7)	34	0 (0.0)	70	2 (2.9)	
Other opioids	36	0 (0.0)	15	0 (0.0)	51	0 (0.0)	
Other drugs	19	0 (0.0)	7	0 (0.0)	26	0 (0.0)	
p value		0.364		0.046		0.265	
<b>2014</b>							
Heroin	47	0 (0.0)	27	0 (0.0)	75	0 (0.0)	
Methamphetamine	39	1 (2.6)	30	0 (0.0)	70	1 (1.4)	
Other opioids	21	0 (0.0)	15	0 (0.0)	36	0 (0.0)	
Other drugs	23	0 (0.0)	3	0 (0.0)	25	0 (0.0)	
p value		0.638		--		0.638	
<b>2015</b>							
Heroin	38	0 (0.0)	21	1 (4.8)	59	1 (1.7)	
Methamphetamine	42	1 (2.4)	42	0 (0.0)	87	1 (1.2)	
Other opioids	17	0 (0.0)	15	0 (0.0)	32	0 (0.0)	
Other drugs	15	0 (0.0)	5	0 (0.0)	20	0 (0.0)	
p value		1.000		0.494		1.000	
<b>2016</b>							
Heroin	43	0 (0.0)	20	1 (5.0)	64	1 (1.6)	
Methamphetamine	148	2 (1.4)	101	1 (1.0)	251	4 (1.6)	
Other opioids	46	0 (0.0)	14	0 (0.0)	60	0 (0.0)	
Other drugs	33	0 (0.0)	11	0 (0.0)	44	0 (0.0)	
p value		1.000		0.523		1.000	



**Table 9.2.5 HIV antibody prevalence by years of injection, gender and survey year**

Western Australia Years of injection	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
<b>2012</b>						
<3 years	2	0 (0.0)	2	0 (0.0)	4	0 (0.0)
3 to 10 years	16	0 (0.0)	10	1 (10.0)	26	1 (3.9)
11+ years	98	0 (0.0)	49	2 (4.1)	148	2 (1.4)
p value		--		0.488		0.427
<b>2013</b>						
<3 years	7	0 (0.0)	7	0 (0.0)	14	0 (0.0)
3 to 10 years	16	1 (6.3)	11	0 (0.0)	27	1 (3.7)
11+ years	97	2 (2.1)	51	2 (3.9)	149	4 (2.7)
p value		0.475		1.000		0.708
<b>2014</b>						
<3 years	8	0 (0.0)	1	0 (0.0)	9	0 (0.0)
3 to 10 years	9	0 (0.0)	9	0 (0.0)	18	0 (0.0)
11+ years	112	1 (0.9)	63	0 (0.0)	177	1 (0.6)
p value		1.000		--		1.000
<b>2015</b>						
<3 years	4	1 (25.0)	1	0 (0.0)	5	1 (20.0)
3 to 10 years	9	0 (0.0)	21	0 (0.0)	32	0 (0.0)
11+ years	93	0 (0.0)	57	1 (1.8)	151	1 (0.7)
p value		0.038		1.000		0.081
<b>2016</b>						
<3 years	14	0 (0.0)	11	0 (0.0)	25	0 (0.0)
3 to 10 years	31	1 (3.2)	24	0 (0.0)	56	1 (1.8)
11 + years	209	0 (0.0)	106	2 (1.9)	317	3 (1.0)
p value		0.177		1.000		0.599

**Table 9.2.6 HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and survey year**

Western Australia Receptively shared syringe last month	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
<b>2012</b>						
No receptive sharing	81	0 (0.0)	44	3 (6.8)	126	3 (2.4)
Receptive sharing	26	0 (0.0)	11	0 (0.0)	37	0 (0.0)
p value		--		1.000		1.000
<b>2013</b>						
No receptive sharing	89	3 (3.4)	45	2 (4.4)	314	5 (3.7)
Receptive sharing	18	0 (0.0)	16	0 (0.0)	34	0 (0.0)
p value		1.000		1.000		0.584
<b>2014</b>						
No receptive sharing	90	1 (1.1)	56	0 (0.0)	147	1 (0.7)
Receptive sharing	25	0 (0.0)	11	0 (0.0)	36	0 (0.0)
p value		1.000		--		1.000
<b>2015</b>						
No receptive sharing	72	1 (1.4)	63	1 (1.6)	136	2 (1.5)
Receptive sharing	28	0 (0.0)	14	0 (0.0)	42	0 (0.0)
p value		1.000		1.000		1.000
<b>2016</b>						
No receptive sharing	176	2 (1.1)	98	1 (1.0)	276	4 (1.5)
Receptive sharing	68	0 (0.0)	31	0 (0.0)	100	0 (0.0)
p value		1.000		1.000		0.577

**Table 9.2.7 HIV antibody prevalence by frequency of drug injection last month, gender and survey year**

Western Australia	Male		Female		Total	
Frequency of injection	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)
<b>2012</b>						
Less than daily	41	0 (0.0)	20	2 (10.0)	62	2 (3.2)
Daily or more	71	0 (0.0)	40	1 (2.5)	111	1 (0.9)
Not last month	6	0 (0.0)	2	0 (0.0)	8	0 (0.0)
p value		--		0.326		0.382
<b>2013</b>						
Less than daily	33	1 (3.0)	25	1 (4.0)	58	2 (3.5)
Daily or more	78	2 (2.6)	37	1 (2.7)	115	3 (2.6)
Not last month	10	0 (0.0)	5	0 (0.0)	16	0 (0.0)
p value		1.000		1.000		1.000
<b>2014</b>						
Less than daily	33	1 (3.0)	23	0 (0.0)	56	1 (1.8)
Daily or more	84	0 (0.0)	47	0 (0.0)	132	0 (0.0)
Not last month	10	0 (0.0)	5	0 (0.0)	16	0 (0.0)
p value		0.339		--		0.353
<b>2015</b>						
Less than daily	44	1 (2.3)	23	1 (4.4)	68	2 (2.9)
Daily or more	57	0 (0.0)	54	0 (0.0)	111	0 (0.0)
Not last month	4	0 (0.0)	4	0 (0.0)	10	0 (0.0)
p value		0.457		0.333		0.232
<b>2016</b>						
Less than daily	101	1 (1.0)	51	0 (0.0)	153	2 (1.3)
Daily or more	148	1 (0.7)	80	1 (1.3)	230	2 (0.9)
Not last month	16	0 (0.0)	10	1 (10.0)	26	1 (3.9)
p value		1.000		0.137		0.398

**Table 9.2.8 HIV antibody prevalence by imprisonment last year, gender and survey year**

Western Australia	Male		Female		Total	
Imprisonment last year	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)
<b>2012</b>						
No imprisonment	102	0 (0.0)	54	3 (5.6)	157	3 (1.9)
Imprisonment	17	0 (0.0)	3	0 (0.0)	20	0 (0.0)
p value		--		1.000		1.000
<b>2013</b>						
No imprisonment	100	3 (3.0)	63	2 (3.2)	163	5 (3.1)
Imprisonment	13	0 (0.0)	3	0 (0.0)	16	0 (0.0)
p value		1.000		1.000		1.000
<b>2014</b>						
No imprisonment	99	1 (1.0)	64	0 (0.0)	163	1 (0.6)
Imprisonment	17	0 (0.0)	3	0 (0.0)	21	0 (0.0)
p value		1.000		--		1.000
<b>2015</b>						
No imprisonment	91	1 (1.1)	72	0 (0.0)	165	1 (0.6)
Imprisonment	13	0 (0.0)	6	0 (0.0)	20	0 (0.0)
p value		1.000		--		1.000
<b>2016</b>						
No imprisonment	218	1 (0.5)	123	1 (0.8)	343	3 (0.9)
Imprisonment	38	1 (2.6)	13	0 (0.0)	51	1 (2.0)
p value		0.275		1.000		0.427

**Table 9.2.9 HIV antibody prevalence by condom use at last sex with regular partner, gender and survey year**

Western Australia	Male		Female		Total	
Condom use at last sex	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
<b>2012</b>						
No condom use	36	0 (0.0)	20	0 (0.0)	56	0 (0.0)
Condom use	8	0 (0.0)	6	0 (0.0)	14	0 (0.0)
p value		--		--		--
<b>2013</b>						
No condom use	29	0 (0.0)	33	0 (0.0)	62	0 (0.0)
Condom use	13	1 (7.7)	7	0 (0.0)	20	1 (5.0)
p value		0.310		---		0.244
<b>2014</b>						
No condom use	36	0 (0.0)	32	0 (0.0)	68	0 (0.0)
Condom use	12	1 (8.3)	2	0 (0.0)	14	1 (7.1)
p value		0.250		--		0.171
<b>2015</b>						
No condom use	33	0 (0.0)	34	0 (0.0)	68	0 (0.0)
Condom use	11	0 (0.0)	8	0 (0.0)	19	0 (0.0)
p value		--		--		--
<b>2016</b>						
No condom use	75	1 (1.3)	53	0 (0.0)	129	1 (0.8)
Condom use	33	0 (0.0)	20	0 (0.0)	53	0 (0.0)
p value		1.000		--		1.000

**Table 9.2.10 HIV antibody prevalence by sex work last month, gender and survey year**

Western Australia	Male		Female		Total	
Sex work last month	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
<b>2012</b>						
No sex work	109	0 (0.0)	58	3 (5.2)	167	3 (1.8)
Sex work	7	0 (0.0)	3	0 (0.0)	11	0 (0.0)
p value		--		1.000		1.000
<b>2013</b>						
No sex work	110	3 (2.7)	60	2 (3.3)	171	5 (2.9)
Sex work	4	0 (0.0)	6	0 (0.0)	10	0 (0.0)
p value		1.000		1.000		1.000
<b>2014</b>						
No sex work	100	1 (1.0)	66	0 (0.0)	167	1 (0.6)
Sex work	10	0 (0.0)	3	0 (0.0)	13	0 (0.0)
p value		1.000		--		1.000
<b>2015</b>						
No sex work	99	1 (1.0)	72	1 (1.4)	174	2 (1.2)
Sex work	6	0 (0.0)	7	0 (0.0)	13	0 (0.0)
p value		1.000		1.000		1.000
<b>2016</b>						
No sex work	239	2 (0.8)	125	2 (1.6)	366	5 (1.4)
Sex work	11	0 (0.0)	12	0 (0.0)	24	0 (0.0)
p value		1.000		1.000		1.000

**Table 9.2.11 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year**

Western Australia	Male		Female		Total	
Aboriginal and Torres Strait Islander origin	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
<b>2012</b>						
Non Indigenous	109	0 (0.0)	55	3 (5.5)	165	3 (1.8)
Indigenous	8	0 (0.0)	7	0 (0.0)	15	0 (0.0)
p value		--		1.000		1.000
<b>2013</b>						
Non Indigenous	109	3 (2.8)	63	2 (3.2)	173	5 (2.9)
Indigenous	7	0 (0.0)	8	0 (0.0)	15	0 (0.0)
p value		1.000		1.000		1.000
<b>2014</b>						
Non Indigenous	119	0 (0.0)	65	0 (0.0)	186	0 (0.0)
Indigenous	6	1 (16.7)	10	0 (0.0)	16	1 (6.3)
p value		0.048		--		0.079
<b>2015</b>						
Non Indigenous	99	1 (1.0)	69	1 (1.5)	171	2 (1.2)
Indigenous	10	0 (0.0)	10	0 (0.0)	20	0 (0.0)
p value		1.000		1.000		1.000
<b>2016</b>						
Non Indigenous	216	1 (0.5)	104	1 (1.0)	320	2 (0.6)
Indigenous	39	1 (2.6)	35	1 (2.9)	76	2 (2.6)
p value		0.283		0.442		0.168

**Table 9.2.12 HIV antibody prevalence by main language spoken at home by parents, gender and survey year**

Western Australia	Male		Female		Total	
Main language spoken at home by parents	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
<b>2012</b>						
English speaking	113	0 (0.0)	60	3 (5.0)	174	3 (1.7)
Non-English speaking	7	0 (0.0)	2	0 (0.0)	9	0 (0.0)
p value		--		1.000		1.000
<b>2013</b>						
English speaking	117	2 (1.7)	66	2 (3.0)	184	4 (2.2)
Non-English speaking	6	1 (16.7)	5	0 (0.0)	11	1 (9.1)
p value		0.140		1.000		0.254
<b>2014</b>						
English speaking	122	1 (0.8)	71	0 (0.0)	195	1 (0.5)
Non-English speaking	8	0 (0.0)	3	0 (0.0)	11	0 (0.0)
p value		1.000		--		1.000
<b>2015</b>						
English speaking	102	1 (1.0)	78	1 (1.3)	183	2 (1.1)
Non-English speaking	7	0 (0.0)	3	0 (0.0)	10	0 (0.0)
p value		1.000		1.000		1.000
<b>2016</b>						
English speaking	247	2 (0.8)	133	2 (1.5)	382	5 (1.3)
Non-English speaking	14	0 (0.0)	7	0 (0.0)	22	0 (0.0)
p value		1.000		1.000		1.000

**Table 9.2.13 HIV antibody prevalence by region/country of birth, gender and survey year**

<b>Western Australia</b>		<b>Male</b>		<b>Female</b>		<b>Total</b>	
<b>Region/country of birth</b>	<b>N° tested</b>	<b>N° with HIV (%)</b>	<b>N° tested</b>	<b>N° with HIV (%)</b>	<b>N° tested</b>	<b>N° with HIV (%)</b>	
<b>2012</b>							
Australia	99	0 (0.0)	49	3 (6.1)	149	3 (2.0)	
Other Oceania	5	0 (0.0)	7	0 (0.0)	12	0 (0.0)	
Asia	0	0 (0.0)	1	0 (0.0)	1	0 (0.0)	
UK & Ireland	10	0 (0.0)	3	0 (0.0)	13	0 (0.0)	
Other	5	0 (0.0)	3	0 (0.0)	8	0 (0.0)	
p value		--		1.000		1.000	
<b>2013</b>							
Australia	98	2 (2.0)	55	2 (3.6)	154	4 (2.6)	
Other Oceania	4	0 (0.0)	5	0 (0.0)	9	0 (0.0)	
Asia	1	1 (100.0)	0	0 (0.0)	1	1 (100.0)	
UK & Ireland	12	0 (0.0)	6	0 (0.0)	18	0 (0.0)	
Other	8	0 (0.0)	5	0 (0.0)	13	0 (0.0)	
p value		0.068		1.000		0.072	
<b>2014</b>							
Australia	106	1 (0.9)	57	0 (0.0)	165	1 (0.6)	
Other Oceania	4	0 (0.0)	5	0 (0.0)	9	0 (0.0)	
Asia	1	0 (0.0)	1	0 (0.0)	2	0 (0.0)	
UK & Ireland	13	0 (0.0)	4	0 (0.0)	17	0 (0.0)	
Other	6	0 (0.0)	8	0 (0.0)	14	0 (0.0)	
p value		1.000		--		1.000	
<b>2015</b>							
Australia	82	1 (1.2)	66	1 (1.5)	150	2 (1.3)	
Other Oceania	8	0 (0.0)	2	0 (0.0)	10	0 (0.0)	
Asia	2	0 (0.0)	1	0 (0.0)	4	0 (0.0)	
UK & Ireland	10	0 (0.0)	7	0 (0.0)	17	0 (0.0)	
Other	7	0 (0.0)	5	0 (0.0)	12	0 (0.0)	
p value		1.000		1.000		1.000	
<b>2016</b>							
Australia	231	2 (0.9)	119	2 (1.7)	353	5 (1.4)	
Other Oceania	11	0 (0.0)	6	0 (0.0)	17	0 (0.0)	
Asia	4	0 (0.0)	0	0 (0.0)	4	0 (0.0)	
UK & Ireland	11	0 (0.0)	7	0 (0.0)	18	0 (0.0)	
Other	6	0 (0.0)	7	0 (0.0)	13	0 (0.0)	
p value		1.000		1.000		1.000	

## HCV antibody prevalence

**Table 9.3.1 HCV antibody prevalence by gender and survey year**

Western Australia Survey year	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
2012	120	71 (59)	64	31 (48)	185	103 (56)
2013	123	66 (54)	71	23 (32)	196	90 (46)
2014	128	72 (56)	75	40 (53)	205	113 (55)
2015	107	58 (54)	82	39 (48)	192	98 (51)
2016	263	125 (48)	143	42 (29)	409	169 (41)
X <sup>2</sup> p trend		0.243		0.184		0.085

**Table 9.3.2 HCV antibody prevalence by sexual identity, gender and survey year**

Western Australia Sexual identity	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2012</b>						
Heterosexual	106	64 (60)	43	24 (56)	149	88 (59)
Bisexual	6	2 (33)	10	3 (30)	17	6 (35)
Homosexual	0	0 (0)	4	2 (50)	4	2 (50)
p value		0.226		0.329		0.151
<b>2013</b>						
Heterosexual	107	56 (52)	49	17 (35)	156	73 (47)
Bisexual	4	3 (75)	15	5 (33)	19	8 (42)
Homosexual	4	2 (50)	2	0 (0)	6	2 (33)
p value		0.857		0.890		0.832
<b>2014</b>						
Heterosexual	116	64 (55)	52	30 (58)	168	94 (56)
Bisexual	6	4 (67)	15	8 (53)	23	13 (57)
Homosexual	3	1 (33)	3	0 (0)	6	1 (17)
p value		0.652		0.171		0.181
<b>2015</b>						
Heterosexual	94	51 (54)	57	25 (44)	153	77 (50)
Bisexual	1	0 (0)	14	9 (64)	15	9 (60)
Homosexual	2	0 (0)	3	1 (33)	5	1 (20)
p value		0.103		0.418		0.306
<b>2016</b>						
Heterosexual	221	105 (48)	100	26 (26)	321	131 (41)
Bisexual	7	4 (57)	24	12 (50)	33	17 (52)
Homosexual	9	3 (33)	5	0 (0)	14	3 (21)
p value		0.673		0.025		0.155

**Table 9.3.3 HCV antibody prevalence by age group, gender and survey year**

Western Australia Age group	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2012</b>						
<25 years	3	1 (33)	1	0 (0)	4	1 (25)
25-34 years	29	18 (62)	19	7 (37)	48	25 (52)
35-44 years	45	27 (60)	21	8 (38)	67	36 (54)
45+ years	43	25 (58)	22	15 (68)	65	40 (62)
p value		0.853		0.079		0.448
<b>2013</b>						
<25 years	7	1 (14)	5	0 (0)	12	1 (8)
25-34 years	40	17 (43)	22	7 (32)	62	24 (39)
35-44 years	35	22 (63)	22	6 (27)	57	28 (49)
45+ years	39	25 (64)	22	10 (45)	62	36 (58)
p value		0.027		0.281		0.006
<b>2014</b>						
<25 years	6	1 (17)	0	0 (0)	6	1 (17)
25-34 years	32	13 (41)	14	9 (64)	46	22 (48)
35-44 years	45	26 (58)	26	10 (38)	72	36 (50)
45+ years	44	31 (70)	35	21 (60)	80	53 (67)
p value		0.013		0.174		0.023
<b>2015</b>						
<25 years	5	1 (20)	6	1 (17)	13	2 (15)
25-34 years	21	10 (48)	13	8 (62)	34	18 (53)
35-44 years	37	16 (43)	34	14 (41)	71	30 (42)
45+ years	43	30 (70)	29	16 (55)	73	47 (64)
p value		0.030		0.218		0.002
<b>2016</b>						
<25 years	5	0 (0)	7	1 (14)	13	2 (15)
25-34 years	59	16 (27)	38	8 (21)	97	24 (25)
35-44 years	98	53 (54)	51	12 (24)	149	65 (44)
45+ years	99	55 (56)	46	21 (46)	147	77 (52)
p value		<0.001		0.040		<0.001

**Table 9.3.4 HCV antibody prevalence by years since first injection, gender and survey year**

Western Australia Years of injection	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2012</b>						
<3 years	2	2 (100)	2	1 (50)	4	3 (75)
3 to 10 years	16	9 (56)	10	4 (40)	26	13 (50)
11+ years	98	59 (60)	50	24 (48)	149	84 (56)
p value		0.640		0.867		0.674
<b>2013</b>						
<3 years	7	0 (0)	7	1 (14)	14	1 (7)
3 to 10 years	14	6 (43)	11	1 (9)	25	7 (28)
11+ years	96	57 (59)	51	21 (41)	148	79 (53)
p value		0.004		0.072		<0.001
<b>2014</b>						
<3 years	8	0 (0)	1	0 (0)	9	0 (0)
3 to 10 years	9	4 (44)	9	4 (44)	18	8 (44)
11+ years	109	66 (61)	63	35 (56)	174	102 (59)
p value		0.002		0.596		0.001
<b>2015</b>						
<3 years	4	1 (25)	1	0 (0)	5	1 (20)
3 to 10 years	8	5 (63)	21	7 (33)	31	12 (39)
11+ years	89	51 (57)	56	31 (55)	146	83 (57)
p value		0.509		0.099		0.064
<b>2016</b>						
<3 years	14	1 (7)	11	1 (9)	25	2 (8)
3 to 10 years	31	8 (26)	23	3 (13)	55	12 (22)
11+ years	203	107 (53)	104	35 (34)	309	143 (46)
p value		<0.001		0.053		<0.001

**Table 9.3.5 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year**

Western Australia Receptively shared syringe last month	<3 years		3+ years		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2012</b>						
No receptive sharing	4	3 (75)	121	64 (53)	127	69 (54)
Receptive sharing	0	0 (0)	36	24 (67)	37	24 (65)
p value		--		0.144		0.255
<b>2013</b>						
No receptive sharing	9	0 (0)	121	67 (55)	132	69 (52)
Receptive sharing	1	0 (0)	31	11 (35)	34	12 (35)
p value		--		0.048		0.077
<b>2014</b>						
No receptive sharing	6	0 (0)	138	82 (59)	146	83 (57)
Receptive sharing	1	0 (0)	34	17 (50)	35	17 (49)
p value		--		0.320		0.376
<b>2015</b>						
No receptive sharing	2	0 (0)	131	71 (54)	134	71 (53)
Receptive sharing	1	0 (0)	38	22 (58)	41	24 (59)
p value		--		0.687		0.532
<b>2016</b>						
No receptive sharing	16	0 (0)	241	94 (39)	269	102 (38)
Receptive sharing	6	2 (33)	90	45 (50)	99	49 (49)
p value		0.065		0.071		0.045



**Table 9.3.6 HCV antibody prevalence by last drug injected, years since first injection and survey year**

Western Australia Last drug injected	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2012</b>						
Heroin	0	0 (0)	48	32 (67)	48	32 (67)
Methamphetamine	3	2 (67)	54	16 (30)	58	18 (31)
Other opioids	0	0 (0)	51	34 (67)	54	36 (67)
Other drugs	1	1 (100)	19	13 (65)	22	15 (68)
p value		0.505		<0.001		<0.001
<b>2013</b>						
Heroin	0	0 (0)	49	29 (59)	49	29 (59)
Methamphetamine	10	1 (10)	56	14 (25)	68	17 (25)
Other opioids	0	0 (0)	48	32 (67)	50	32 (64)
Other drugs	4	0 (0)	19	10 (53)	26	11 (42)
p value		0.512		<0.001		<0.001
<b>2014</b>						
Heroin	1	0 (0)	73	43 (59)	74	43 (58)
Methamphetamine	3	0 (0)	66	31 (47)	70	31 (44)
Other opioids	0	0 (0)	36	24 (67)	36	24 (67)
Other drugs	5	0 (0)	16	11 (69)	24	14 (58)
p value		--		0.165		0.132
<b>2015</b>						
Heroin	0	0 (0)	56	37 (66)	56	37 (66)
Methamphetamine	4	0 (0)	76	28 (37)	82	29 (35)
Other opioids	0	0 (0)	30	23 (77)	31	24 (77)
Other drugs	0	0 (0)	12	6 (50)	15	6 (40)
p value		--		<0.001		<0.001
<b>2016</b>						
Heroin	1	0 (0)	57	37 (65)	60	38 (63)
Methamphetamine	17	2 (12)	218	72 (33)	244	79 (32)
Other opioids	0	0 (0)	53	28 (53)	56	30 (54)
Other drugs	6	0 (0)	29	14 (48)	39	17 (44)
p value		0.638		<0.001		<0.001

**Table 9.3.7 HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year**

Western Australia	<3 years		3+ years		Total	
Frequency of injection last month	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2012</b>						
Less than daily	2	1 (50)	60	30 (50)	63	32 (51)
Daily or more	2	2 (100)	106	64 (60)	111	68 (61)
Not last month	0	0 (0)	6	1 (17)	8	1 (13)
p value		1.000		0.074		0.018
<b>2013</b>						
Less than daily	8	0 (0)	48	23 (48)	56	23 (41)
Daily or more	3	0 (0)	107	56 (52)	114	59 (52)
Not last month	3	1 (33)	12	4 (33)	16	5 (31)
p value		0.429		0.461		0.181
<b>2014</b>						
Less than daily	5	0 (0)	49	31 (63)	56	32 (57)
Daily or more	2	0 (0)	128	70 (55)	130	70 (54)
Not last month	2	0 (0)	12	7 (58)	15	8 (53)
p value		--		0.585		0.912
<b>2015</b>						
Less than daily	1	0 (0)	65	36 (55)	68	37 (54)
Daily or more	2	0 (0)	105	57 (54)	108	58 (54)
Not last month	1	0 (0)	4	1 (25)	8	1 (13)
p value		--		0.560		0.082
<b>2016</b>						
Less than daily	14	1 (7)	134	60 (45)	152	63 (41)
Daily or more	8	1 (13)	204	84 (41)	223	93 (42)
Not last month	2	0 (0)	19	7 (37)	24	8 (33)
p value		1.000		0.714		0.726

**Table 9.3.8 HCV antibody prevalence by imprisonment last year, years since first injection and survey year**

Western Australia	<3 years		3+ years		Total	
Imprisonment last year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2012</b>						
No imprisonment	4	3 (75)	150	78 (52)	158	83 (53)
Imprisonment	0	0 (0)	19	16 (84)	20	16 (80)
p value		--		0.012		0.020
<b>2013</b>						
No imprisonment	12	1 (8)	143	69 (48)	161	71 (44)
Imprisonment	1	0 (0)	14	10 (71)	16	11 (69)
p value		1.000		0.160		0.059
<b>2014</b>						
No imprisonment	9	0 (0)	148	85 (57)	160	87 (54)
Imprisonment	0	0 (0)	20	11 (55)	20	11 (55)
p value		--		0.837		0.958
<b>2015</b>						
No imprisonment	4	1 (25)	148	80 (54)	160	82 (51)
Imprisonment	1	0 (0)	16	7 (44)	19	8 (42)
p value		1.000		0.433		0.451
<b>2016</b>						
No imprisonment	19	1 (5)	298	119 (40)	333	129 (39)
Imprisonment	4	1 (25)	43	24 (56)	51	28 (55)
p value		0.324		0.049		0.029

**Table 9.3.9 HCV antibody prevalence by sex work last month, years since first injection and survey year**

Western Australia	<3 years		3+ years		Total	
Sex work last month	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2012</b>						
No sex work	4	3 (75)	159	89 (56)	168	95 (57)
Sex work	0	0 (0)	10	7 (70)	11	7 (64)
p value		--		0.517		0.760
<b>2013</b>						
No sex work	10	0 (0)	152	77 (51)	169	79 (47)
Sex work	3	1 (33)	6	4 (67)	10	6 (60)
p value		0.231		0.682		0.521
<b>2014</b>						
No sex work	8	0 (0)	152	86 (57)	164	89 (54)
Sex work	0	0 (0)	13	9 (69)	13	9 (69)
p value		--		0.376		0.296
<b>2015</b>						
No sex work	5	0 (0)	154	81 (53)	168	83 (49)
Sex work	0	0 (0)	12	10 (83)	13	11 (85)
p value		--		0.039		0.014
<b>2016</b>						
No sex work	22	2 (9)	317	134 (42)	356	147 (41)
Sex work	1	0 (0)	22	10 (45)	24	10 (42)
p value		1.000		0.770		0.971

**Table 9.3.10 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year**

Western Australia	Male		Female		Total	
Aboriginal and Torres Strait Islander origin	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2012</b>						
Non Indigenous	109	63 (58)	55	27 (49)	165	91 (55)
Indigenous	8	5 (63)	8	3 (38)	16	8 (50)
p value		1.000		0.710		0.795
<b>2013</b>						
Non Indigenous	106	59 (56)	63	22 (35)	170	82 (48)
Indigenous	7	2 (29)	8	1 (13)	15	3 (20)
p value		0.245		0.261		0.056
<b>2014</b>						
Non Indigenous	117	64 (55)	65	36 (55)	184	101 (55)
Indigenous	6	4 (67)	10	4 (40)	16	8 (50)
p value		0.691		0.500		0.706
<b>2015</b>						
Non Indigenous	95	49 (52)	69	35 (51)	167	85 (51)
Indigenous	10	9 (90)	9	2 (22)	19	11 (58)
p value		0.020		0.159		0.563
<b>2016</b>						
Non Indigenous	209	103 (49)	102	31 (30)	311	134 (43)
Indigenous	39	16 (41)	34	8 (24)	75	26 (35)
p value		0.343		0.444		0.184

**Table 9.3.11 HCV antibody prevalence by main language spoken at home by parents, gender and survey year**

<b>Western Australia</b>	<b>Male</b>		<b>Female</b>		<b>Total</b>	
<b>Main language spoken at home by parents</b>	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2012</b>						
English speaking	113	69 (61)	61	28 (46)	175	98 (56)
Non-English speaking	7	2 (29)	2	2 (100)	9	4 (44)
p value		0.120		0.223		0.515
<b>2013</b>						
English speaking	114	62 (54)	66	22 (33)	181	85 (47)
Non-English speaking	6	2 (33)	5	1 (20)	11	3 (27)
p value		0.416		1.000		0.231
<b>2014</b>						
English speaking	119	65 (55)	71	37 (52)	192	103 (54)
Non-English speaking	8	6 (75)	3	2 (67)	11	8 (73)
p value		0.261		1.000		0.216
<b>2015</b>						
English speaking	97	53 (55)	77	37 (48)	177	91 (51)
Non-English speaking	7	4 (57)	3	1 (33)	10	5 (50)
p value		1.000		1.000		1.000
<b>2016</b>						
English speaking	240	113 (47)	130	35 (27)	372	149 (40)
Non-English speaking	14	6 (43)	7	4 (57)	22	11 (50)
p value		0.758		0.101		0.356

**Table 9.3.12 HCV antibody prevalence by region/country of birth, gender and survey year**

<b>Western Australia</b>		<b>Male</b>		<b>Female</b>		<b>Total</b>	
<b>Region/Country of birth</b>	<b>N° tested</b>	<b>N° with HCV (%)</b>	<b>N° tested</b>	<b>N° with HCV (%)</b>	<b>N° tested</b>	<b>N° with HCV (%)</b>	
<b>2012</b>							
Australia	99	60 (61)	50	22 (44)	150	83 (55)	
Other Oceania	5	4 (80)	7	5 (71)	12	9 (75)	
Asia	0	0 (0)	1	1 (100)	1	1 (100)	
UK & Ireland	10	5 (50)	3	2 (67)	13	7 (54)	
Other	5	2 (40)	3	1 (33)	8	3 (38)	
p value		0.543		0.516		0.453	
<b>2013</b>							
Australia	95	51 (54)	55	16 (29)	151	68 (45)	
Other Oceania	4	2 (50)	5	3 (60)	9	5 (56)	
Asia	1	0 (0)	0	0 (0)	1	0 (0)	
UK & Ireland	12	6 (50)	6	3 (50)	18	9 (50)	
Other	8	5 (63)	5	1 (20)	13	6 (46)	
p value		0.929		0.395		0.956	
<b>2014</b>							
Australia	103	57 (55)	56	27 (48)	161	85 (53)	
Other Oceania	4	1 (25)	5	3 (60)	9	4 (44)	
Asia	1	0 (0)	1	1 (100)	2	1 (50)	
UK & Ireland	13	11 (85)	5	4 (80)	18	15 (83)	
Other	6	2 (33)	8	5 (63)	14	7 (50)	
p value		0.044		0.590		0.097	
<b>2015</b>							
Australia	77	41 (53)	66	32 (48)	145	74 (51)	
Other Oceania	8	3 (38)	2	1 (50)	10	4 (40)	
Asia	2	1 (50)	4	0 (0)	4	1 (25)	
UK & Ireland	10	7 (70)	6	3 (50)	16	10 (63)	
Other	7	5 (71)	5	2 (40)	12	7 (58)	
p value		0.624		1.000		0.644	
<b>2016</b>							
Australia	224	106 (47)	116	31 (27)	343	139 (41)	
Other Oceania	11	7 (64)	6	2 (33)	17	9 (53)	
Asia	4	2 (50)	0	0 (0)	4	2 (50)	
UK & Ireland	11	5 (45)	7	2 (29)	18	7 (39)	
Other	6	1 (17)	7	4 (57)	13	5 (38)	
p value		0.506		0.382		0.856	

## Appendix A: Participating NSP services

<b>Year</b>		<b>'12</b>	<b>'13</b>	<b>'14</b>	<b>'15</b>	<b>'16</b>
Number of NSP sites		52	50	50	47	50
<b>Australian Capital Territory</b>		<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>
Canberra	Directions ACT	✓	✓	✓	✓	✓
<b>New South Wales</b>		<b>20</b>	<b>19</b>	<b>19</b>	<b>16</b>	<b>17</b>
Albury	Albury Community Health Centre	✓	✓	✓		
Ballina	Harm Reduction Services	✓	✓	✓	✓	✓
Blacktown	HIV/Hepatitis C Prevention Service	✓	✓	✓	✓	✓
Byron/Tweed	Harm Reduction Services	✓	✓	✓	✓	✓
Coffs Harbour/Grafton	Harm Reduction Services	✓	✓	✓	✓	✓
Camperdown	Royal Prince Alfred Hospital					✓
Canterbury	Harm Minimisation Program				✓	✓
Central Coast	Gosford, Long Jetty and Woy Woy Harm Reduction	✓	✓	✓		
Liverpool	Health ConneXions	✓	✓			
Kings Cross	Clinic 180	✓	✓	✓	✓	✓
Kings Cross	Kirketon Road Centre	✓	✓	✓	✓	✓
Kogarah/Sutherland	Central Access Service	✓	✓	✓		
Mt Druitt	Kelly Close Needle Syringe Program	✓	✓	✓	✓	✓
Kingswood	South Court Primary Care NSP	✓		✓	✓	✓
Newcastle	Hunter Harm Reduction Services	✓	✓	✓	✓	✓
Newcastle	AIDS Council of NSW Hunter	✓	✓	✓	✓	✓
Nimbin/Lismore	Harm Reduction Services	✓	✓	✓	✓	✓
Parramatta	HIV/Hepatitis C Prevention Service	✓	✓	✓	✓	✓
Port Kembla	First Step Program	✓	✓	✓	✓	✓
Redfern	Harm Minimisation Program	✓	✓	✓	✓	✓
Surry Hills	NSW Users and AIDS Association	✓	✓	✓	✓	✓
Wagga Wagga	Wagga Wagga Community Health Centre	✓	✓	✓		
<b>Northern Territory</b>		<b>3</b>	<b>3</b>	<b>3</b>	<b>3</b>	<b>3</b>
Alice Springs	Northern Territory AIDS & Hepatitis Council	✓	✓	✓	✓	✓
Darwin	Northern Territory AIDS & Hepatitis Council	✓	✓	✓	✓	✓
Palmerston	Northern Territory AIDS & Hepatitis Council	✓	✓	✓	✓	✓
<b>Queensland</b>		<b>8</b>	<b>8</b>	<b>7</b>	<b>8</b>	<b>8</b>
Brisbane	Biala Community Alcohol and Drug Services	✓	✓	✓	✓	✓
Brisbane	Queensland Injectors Health Network	✓	✓	✓	✓	✓
Cairns	Cairns ATODS NSP	✓	✓	✓	✓	✓
Gold Coast	Queensland Injectors Health Network	✓	✓	✓	✓	✓
Ipswich	West Moreton Sexual Health Service	✓	✓		✓	✓
Sunshine Coast	Queensland Injectors Health Network	✓	✓	✓	✓	✓
Toowoomba	Kobi House	✓	✓	✓	✓	✓
Townsville	Townsville ATODS NSP	✓	✓	✓	✓	✓

<b>Year</b>		<b>'12</b>	<b>'13</b>	<b>'14</b>	<b>'15</b>	<b>'16</b>
Number of NSP sites		52	52	51	47	50
<b>South Australia</b>		<b>7</b>	<b>7</b>	<b>7</b>	<b>7</b>	<b>7</b>
Adelaide	Nunkuwarrin Yunti Community Health Centre	✓	✓	✓	✓	✓
Adelaide	Streetlink Youth Services		✓	✓	✓	✓
Angle Park	SAVIVE - Central Northern Adelaide Health Service	✓	✓	✓		
Hindmarsh	Hindmarsh Centre	✓	✓	✓	✓	✓
Norwood	SAVIVE, Clean Needle Program	✓				
Noarlunga	Noarlunga Primary Health	✓	✓	✓	✓	✓
Port Adelaide	SAVIVE, Central Northern Adelaide Health Service	✓	✓	✓	✓	✓
Salisbury	Anglicare SA Salisbury	✓	✓	✓	✓	✓
Warradale	Drug Arm Australasia				✓	✓
<b>Tasmania</b>		<b>4</b>	<b>3</b>	<b>4</b>	<b>4</b>	<b>4</b>
Burnie	Burnie NSP Service					✓
Clarence	Clarence Community Health Centre	✓	✓	✓	✓	✓
Glenorchy	Glenorchy NSP Service	✓	✓	✓	✓	✓
Hobart	Hobart NSP Service	✓		✓	✓	✓
Launceston	Salvation Army Launceston	✓	✓	✓	✓	
<b>Victoria</b>		<b>6</b>	<b>6</b>	<b>6</b>	<b>6</b>	<b>6</b>
Barwon	Barwon Health Drug and Alcohol Services	✓	✓	✓	✓	✓
Collingwood	Inner Space	✓	✓	✓	✓	✓
Footscray	Health Works	✓	✓	✓	✓	✓
Frankston	Southern Hepatitis/HIV/AIDS Resource & Prevention Service	✓	✓	✓	✓	✓
North Richmond	North Richmond NSP Services	✓	✓	✓	✓	✓
St Kilda	Health Information Exchange	✓	✓	✓	✓	✓
<b>Western Australia</b>		<b>3</b>	<b>3</b>	<b>3</b>	<b>2</b>	<b>4</b>
Bunbury	Western Australia Substance Users Association (WASUA)	✓	✓	✓		✓
Northbridge	Hepatitis Council of Western Australia					✓
Perth	Western Australia Substance Users Association (WASUA)	✓	✓	✓	✓	✓
Perth	WA AIDS Council Mobile Exchange	✓	✓	✓	✓	✓

## Appendix B: Methodological notes

Capillary blood was obtained by finger-prick using disposable lancets and cotton-fibre blotting paper. Dried blood samples were kept at room temperature at the survey sites and couriered to a central laboratory every second or third day. HIV antibody was detected using the Murex 1.2.0 ELISA (Diasorin). Repeatedly reactive specimens were subjected to Western blot confirmatory testing (Bio-Rad New LAV blot 1, France). A modified third generation enzyme immunoassay (Monalisa anti-HCV Plus Version 3 EIA, Biorad, France) was used to test for HCV antibody. A modified cut off value for optical density was calculated to capture greater than 95% of the seronegative population. Specimens were considered positive for HCV antibody if the optical density to cut off ratio was greater than or equal to one on initial and subsequent testing.

Data presented in this report were analysed using Stata, Version 14 (Stata Corporation, College Station TX). Changes in HIV and HCV antibody prevalence overtime were assessed using the  $X^2$  test for linear trend. Associations between demographic and behavioural variables and HIV and HCV antibody prevalence were assessed using the  $X^2$  test or Fisher's exact test where expected frequencies were less than five.

Percentage values in tables may not add to 100 due to rounding. Totals in HIV and HCV antibody prevalence tables stratified by gender include people whose gender was not reported or reported as transgender. Time since first injection was calculated by subtracting age at first injection from age at survey completion. Totals in HIV and HCV antibody prevalence tables stratified by time since first injection include people who did not report age at survey completion or age at first injection.

Tables reporting HIV antibody prevalence stratified by demographic and drug use characteristics are not included in this report for states and territories or survey years where the number of HIV antibody positive participants was less than 5 in all years. Where data were collected but no participants endorsed a particular response, results are presented as "0 (0)". The symbol "--" shown in some tables denotes missing data; and is used to identify circumstances where data were not collected in the reported format. The vast majority of survey questions were consistent over all survey years.

NSP staff recorded sex, age group and survey participation for all clients at the NSP during the survey period and this data was used to assess response rates. Some clients visited the site more than once during the survey week, and only one attendance per person was included in the response rate denominator. Ethical approvals for the study were obtained from Human Research Ethics Committees associated with the investigators and participating sites. Verbal rather than written informed consent was obtained to assure the anonymity of participants.



## Appendix C: List of Tables

### 1. Demographic characteristics and drug use

Table 1.1.1	Number (percentage) of respondents by demographic characteristics and survey year
Table 1.1.2	Number (percentage) of respondents by last drug injected, frequency of injecting and survey year
Table 1.1.3	Number (percentage) of respondents by injecting behaviour in the last month and survey year
Table 1.1.4	Number (percentage) of respondents by treatment for drug use and survey year
Table 1.1.5	Number (percentage) of respondents by testing for HIV and HCV, HCV treatment by survey year
Table 1.1.6	Number (percentage) of respondents by sexual behaviour in the month prior to survey and survey year
Table 1.1.7	Number (percentage) of respondents reporting stigma or discrimination in the last 12 months in 2016

### 2. HIV antibody prevalence

Table 1.2.1	HIV antibody prevalence by gender and survey year
Table 1.2.2	HIV antibody prevalence by sexual identity, gender and survey year
Table 1.2.3	HIV antibody prevalence by age group, gender and survey year
Table 1.2.4	HIV antibody prevalence by last drug injected, gender and survey year
Table 1.2.5	HIV antibody prevalence by years of injection, gender and survey year
Table 1.2.6	HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and survey year
Table 1.2.7	HIV antibody prevalence by frequency of drug injection last month, gender and survey year
Table 1.2.8	HIV antibody prevalence by imprisonment last year, gender and survey year
Table 1.2.9	HIV antibody prevalence by condom use at last sex with regular partner, gender and survey year
Table 1.2.10	HIV antibody prevalence by sex work last month, gender and survey year
Table 1.2.11	HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year
Table 1.2.12	HIV antibody prevalence by main language spoken at home by parents, gender and survey year
Table 1.2.13	HIV antibody prevalence by region/country of birth, gender and survey year

### 3. HCV antibody prevalence

Table 1.3.1	HCV antibody prevalence by gender and survey year
Table 1.3.2	HCV antibody prevalence by sexual identity, gender and survey year
Table 1.3.3	HCV antibody prevalence by age group, gender and survey year
Table 1.3.4	HCV antibody prevalence by years since first injection, gender and survey year
Table 1.3.5	HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year
Table 1.3.6	HCV antibody prevalence by last drug injected, years since first injection and survey year
Table 1.3.7	HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year
Table 1.3.8	HCV antibody prevalence by imprisonment last year, years since first injection and survey year
Table 1.3.9	HCV antibody prevalence by sex work last month, years since first injection and survey year
Table 1.3.10	HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year
Table 1.3.11	HCV antibody prevalence by main language spoken at home by parents, gender and survey year
Table 1.3.12	HCV antibody prevalence by region/country of birth, gender and survey year

